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Abstract 
Duchenne muscular dystrophy (DMD), the most common lethal neuromuscular 
disease in  chi ldhood, arises from protein-truncating mutations in  the dystrophin gene. 
A deficiency in dystrophin l eads to loss of the dystrophin associated protein complex 
(DAPC), which in turn� renders muscle fibres vulnerable to inj ury, and eventually leads 
to muscle loss� necros is  and fibrosis. 
A lthough, the dystrophfn gene was identified nearly two decades ago, and 
extensive research has been directed at finding a therapy for DMD, to date, there is sti ll 
no effective treatment avai lable. One promising molecular approach to treat DNID is 
antisense ol igomer (AO) induced spl ice intervention. AOs were most widely used to 
induce RNaseH-mediated gene transcript degradation, however, the development of 
different backbone chemistries heralds a new generation of AOs that can modifY gene 
transcript splicing patterns. Appl icat ion of AOs to the dystrophin pre-mRNA to 
influence exon selection and induce shortened, in-frame dystrophin isoforms i s  being 
vigorously pursued. 
The majority of the work presented here explores the concept of personal ised 
therapies for DMD, whereby o�igomers are designed to specifical ly target individual 
mutations. The impOliance of AO-optimisation to obtain AOs capable of inducing 
efficient dual exon skipping in  an established animal model of muscu lar dystrophy (4CV 
lllouse), which carries a DMD-causing mutation in  exon 53, is demonstrated. Removal 
of both exons 52 and 53 was required to by-pass the mutation, maintain the reading 
frame and restore dystrophin expression. 
One of the major challenges of AO-induced spl ice intervention for therapeutic 
purposes will be the design and development of c l inically relevant oligomers for many 
different mutations. Various models ,  including cells transfected with artificial 
constructs and mice carrying a human dystrophin transgene, have been proposed as 
tools to facilitate o l igomel' design for spl ice manipulat ion. This thesis investigates the 
relevance of us ing mouse models to design AOs for human appl ication, and also 
explores the use of cultured human myoblasts, from both unaffected humans and a 
DMD patient, as a means of establ ishing the most effect ive therapeutic compound. 
In addition to induction of exon skipping, the appl icabi lity of AOs to promote 
exon inclusion, by masking possible intronic si lencing motifs of survival motor neuron 
(SMN) pre�mRNA in cultured· fibroblasts from a spinal muscular atrophy (SMA) 
v i  
patient, is investigated. Th is 
'
study provides additional information about a novel 
o l igomer target site that could be used in combination with previously identified splice 
s i lencing motifs for a molecular therapeutic approach to SMA, and may perhaps open 
up new avenues of treatment for other geneti c  d isorders, where oI igomers could be used 
to induce exon inclusion. 
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Introduction 
1.1 Muscle biology and the role of dystropbin 
Skeletal musc le, which accounts for approximately  30-40% of human bodymass, 1 
is composed of myofibres wrapped wi th in a cell membrane termed the sarcolemma. 
Myofibres comprise several hundreds of myo fibri ls, which are surrounded by the h i ghly 
organi sed sarcotubular system ; mitochondria , and sarcoplasm (cytoplasm) (Fig 1). 
Stratified l ayers of act in an d myosin filaments and other proteins (including 
t ropOJnyosin, members of the troponin family, calpain-3, and titin) form the myo fibri l s, 
which are subdivided by the Z plate ( Z- l ine) i nto 2Jlm-lon g contracti le units cal l ed 
sarcomeres. 
Figure 1 i l lustrates the st i 'ucture of myofibres and the process whereby muscle 
contraction is stimulated . Muscle contraction begins a fter the transmission o f  a stimulus 
from the motor neuron to the motor end plate embedded in skele tal musc le (Fig la). 
Muscle-membrane action potentia Is, which are generated by acetylchol ine-s tim ulated 
cation channels on the sarcolemma, excite volta ge-sensitive dihydropyridine receptors 
(D HPR s) located in the "triad ". region (Fig Ib). Once activated, D HPRs a l ter t he ir 
conforma tion resultin g in the release of calcium ions fi'om ryanod ine receptors ( R  YRs) 
residin g on the sarcop lasmic membrane. 
The presence of calcium ions in conjunction with A TP activates the myosin 
calcium-dependent ATPase. Detachme nt of i norganic phosphate frOln t he complex 
lea ds to a conformational change in the head of the myosin molecule, increasin g  the 
affinity between actin and myosin filaments, caus in g the s l id in g movement of myosi n 
a lon g the acti n filaments . Release of ADP brin gs the myosin  head into i ts final position . 
Subsequently, the recruitment of a new AT P lnolecule loosens the actin- myosin  
association and as  a consequence the myosin head moves back to its erect position. 
Contrac tile forces on each sarcomere lead to muscle contraction \vith the assistance o f  
Z-plates , M- p lates (to stabi lise act in and myosin fi laments i n  sin gle myofibres) and, 
important in the contex t of th is t hesis , dystrophin, wh ich stabi l ises t he at tachment of 
cytoskeletal ac tin to extrace l lular matr ices in the muscle fascicle durin g contractio n and 
relaxa tion, throu gh the dys trophin-assoc iated protein complex (D APC). 
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Figure 1: Muscle contraction and ttHt role of dystrophln. 
Trjoos/ ..... A} 
The phases of contraction shown are (a) neuronal stimuli from anterior horn cells are transmitted to the neuromuscular junction; (b) 
action pofenllals (APs) on Ihe sarcolemma generated I7f the release of the acetylcholine from the presynaptic membrane. are dissipated 
throughout the myofibre through Ihe sarcotubular system (T system); and APs activate the discharge of calcium Ions from the sarcoplasm 
(SR); and (c) release of calcium ions Induce contracllon of the sarcomeres, which are prlmarily composed of two major contraclile 
proleins, sclin and myoslo; (d) inset B shows tholocaltsalion of dyst ro ph In In the myofibr8 and its positional relationship to the aclin 
cytoskelelon and extracellular matrices (modified from Despopoulos et al. 2003,2 Kapsa et al 20033 ). 
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1.2 Dystrophin, its role in muscle biology and its molecular and genetic 
complexity 
The dystrophin gene has an exceptionally l arge 2 . 5  Mb genomic sequence,4 
encoding a 1 4  kb full-length transcriptS derived from a tota1 of 79 exons�6 (Fig 2) which 
in  turn translates into a 427 kDa protein. At least seven, possibly eight promoters� 
spanning the dystrophin gene are kno'wn to regulate tissue-specific expression of 
dystrophin (Fig 3a). The structural features of the various dystrophin isoforms are 
i llustrated in Figure 3b. Four ful l- length 427 kDa isoforms are present in muscle� 
Iymphocytes, brain (neurons), and Purkinje cells .  
Dystrophin has been identified as having four major domains, an amino terminal 
domain, a 24 helical spectrin-l ike repeat rod domain containing four hinge reg ions, a 
cysteine-rich domain, and the carboxy terminal domain (Fig 2). The amino terminal 
domain of dystrophin interacts with the actin filament of myofibrils. The hinged 
structure of the spectrin-rich 2,839 amino acid rod domain, 'which contains a secondary 
actin  binding site, provides structural flexibility and a l lows the dystrophin molecule to 
retain functional integrity in the face of the sheer forces associated with the contractile 
process in muscle.1 The cysteine rich domain, compris ing a WW domain,8 EF hand- l ike 
moti fs,9 and ZZ domains,lO binds to J3-dystroglycan, forming the DAPC (Fig Id). The 
carboxy terminal d01nain  is responsible for the docking of O'.-syntrophin and 
dystrobrevin  with in  the sarcoplasm. The a-syntrophin associated with neuronal n itric 
oxide synthase (nNOS) functions in anchoring ion channels and signall ing molecules. 
1.3 Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD), the most common neuromuscular d isorder 
of young adults affecting 1 in' 3,500 boys, is caused by the ablation of functional 
dystrophin, rendering muscle lnore susceptible to membrane damage. During infancy, 
affected DMD patients appear normal but show delayed 'walking and experience 
difficulties in running and climbing in early chi ldhood. As the d isease progresses, 
weakness in  the knee and h ip extensor muscles becomes conspicuous and results in a 
waddling gate and d ifficult ies in  ris ing from the floor (Gowerls manoeuvre). DMD 
patients thereafter lose their ambulation around the age of 12. Although, the use of 
assisted ventilation reduces hospital isation time and prolongs the l ife expectancy of 
affected DMD boys by approximate1y 10 years,1 1 , 12 by their late twenties, patients 
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Figure 2: Layout of dystrophJn cDNA and the encoded functional domains of dystroptlln protein. 
The figure sllows the alignment of the four functional domains of dystrophin separated by vertical lines. (viZ. amino terminal (red cylinder), 2 .... spectrin repeat rod domain (blue cylinders) with four hinges 
(teal rings). cysteine-rich domain (green cylinder). and the c-terminal domain (orange cylinder» to the cDNAencoded by the 79 axons oUhe dystrophin gene. The size ofthe exons and the triplet codons 
on either side of the axon junctions are indicated (not shown to scale) (modified from van Oeutekom et al. 200311 ). 
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Flgur.3: Organisation of tha dystrophin gene. protein and homotogues. 
(8) The struclure of tha dystrophin gena and the location of its eight promoters. vlhlch lead to the expression of multiple isoforms (viz. 
0p427�L. Dp421-B Dp427-M Dp427-P. Dp260. Op116. Op140, Dp40, Op71) In different cell types. depending on which promoters are 
operational, and (b) the structure of fIVe major lsoforms of dysfrophln. miero-dystrophin. minl-dystmphin and the dystfophin homologue. 
utrophln. The (our functiona I domains of the protein and the reg ions • .... hero dysfrophin interacts ",nth other proteins are illustrated 
(mooifUld from Sadoulet-pucclo et a1.199611 and van Deutelcom et al. 200(12). 
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typical ly succumb to respiratory failure or cardiac complications. 
The absence of dystrophin leads to a fai lure to assemble the DAPC, resulting in 
chronic membrane injuries promoting calcium ion leakage. After exercise, more 
calcium ions are pumped into the cytosolic space through mechano-sensitive cationic 
receptors and store operative calcium channels (SOCS).1 5- 1 7 Calcium influx induces 
calcium release from the sarcoplasmic ret iculum1 8  and also activates the protease 
calpain, causing protein degradation. A sustained surge of cytosol ic calcium increases 
i ntra-mitochondrial calcium levels, thus opening the mitochondrial permeability 
transit ion pore (MPTP) , which,- in turn, d issipates the electrochemical mitochondrial 
membrane potential (Ll\jJ) and pH gradient. The consequent loss of the proton motive 
force leads not only to disrupted A TP production because of impaired oxidative 
phosphorylation, but also pr01notes cytosolic A TP breakdown. In addition, the rise in 
i ntra-mitochondrial calcium stimulates reactive oxygen species (ROS) production 
through inhibi tion of electron tr�nsport. These pathological changes eventual ly lead to 
necrotic cell death through the activation of phospholipases, nuc]eases, and proteases 
and to muscle cell death, inflammation, and fibrosi s  (for review seeI9-25) .  
1.4 Becker muscula r  dystrophy and the reading frame rule 
A mi lder allel ic variant, Becker muscular dystrophy (BMD), has a broader and 
commonly less severe spectrum of cl inical symptoms, depending on the s ize and 
location of the mutation. There is no s imple correlation between the extent of the 
genetic  lesion and phenotypi c  severity. Indeed, although both DMD and BMD carry 
mutations of the same gene, it is the d isruption of the dystrophin reading frame in DMD 
that is respons ible for the severity of the symptoms in DMD. These observations have 
primarily led to the reading frame rule, which states that the severity of symptoms in 
DMD as opposed to BMD is  the direct result of d isruption of the reading frame?6 
Koen ig27 ( 1989) has reported that the rule holds in 90 to 95% of dystrophinopathy 
cases . 
DMD patients with in-frame mutations usually carry Jarge delet ions in the 5' 
region, which presumably causes compromised actin binding.2&-31 Although the in­
frame deletions in the repeat rod domain  are usually ben ign,32, 33 this is not the case in 
patients \vho have lost more than 35 exons from the dystrophin gene.3D 
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Some deletions at the genomic DNA l evel can affect pl'e-mRNA spli c ing, 
inducing naturally occurring exon skipping. RT-PCR analysis of RNA from patient 
myoblasts has detected in-frame " alternatively spl iced transcripts missing exons 2-7 (�2-
7) and exons 3-8/9 (�3_8/9) .34 This  may explai n  why pat ients carrying a deletion of 
exons 3-7 (�3-7) have a mi lder phenotype. Another possible reason for the milder than 
expected phenotypes of BMD patients is  the use of an a lternative translat ion initi ation 
codon located in exon 8.35-37 
It i s  important to recognise that most studies, until late 90s, have involved 
diagnosis at the genomic DNA level, which can lead to diagnostic confusion. In fact, 
over 99. 5% of dystroph inopathy pati ents fit the reading frame rule  if diagnosis involves 
ana1ysis at the DNA, RNA and protein level s .38 For this reason ,  it is now recommended 
that diagnosis based on genomic DNA is confirmed ideal ly by diagnosi s  at the RNA 
and protein l evels,38 
1.5 Approaches to the treatnlent of DM D 
During the more than twenty years since the mapping and isolation of the 
dystrophin  gene, various approaches have been explored to ameliorate the symptoms of 
DMD or forestaU their onset. . There are three basi c  therapeutic approaches to the 
treatment of DMD, indirect therapies, d irect therapies and personal ised therapies. 
1.5.1. Indirect therapies 
Indi rect therapies involve the modulation of other genes or proteins involved in  
the pathogenesis of DMD. Therapies i nc lude enhancement of utrophin expression, 
chronic steroid  administrat ion, use ofTNF-a inhibitor and use of a myostatin  inhibitor. 
Upregulation of the dystrophin homologue, utrophin, a foetal form of dystrophin  
encoded by  a separate gene, whose expression is abundant only at neuromuscular and 
myotend inous junctions after birth,39-42 creates a s ituat ion where utrophin i s  abl e  to 
partially assume the function .of dystrophin. The A isoform of utrophin� whose 
expression is under the control of promoter A, has been observed at the sarcolemma of 
md" mice and DMD patients. Molecu lar characterisation of promote I' A has been 
undertaken, with the goal of identifying transcriptional motifs which may potent ia l ly be 
targets for utrophin upregulation.43 The nerve gro\vth factor, heregu lin, stimulates 
utroph in expression through its binding to a transcriptional motif.44 Increasi ng levels of 
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utrophin protein three-fo ld i s  reportedly sufficient to ame liorate the dystrophic 
phenotype after intraperi tonea l  injection of recombinant heregul in in mdx mice. 
Mattei et al.45 (2007) produced VP- 1 6  jazz zinc finget' protein transgenic mice 
with upregulated utrophin express ion via promoter A enhancement and sho\ved that 
increased utrophin level s  led to �tabi l i sation of the DAPC .  Increasing utrop hin leve ls by 
systemic del ivery viral constructs expressing thi s  zinc finger protein as opposed to 
transgenes is and app lying the technique to larger animals are issues that need to be 
resolved before the tec hnique can be app lied more broadly. 
A second indirect t herapy� c hronic systemi c  steroid administration has been 
shown to increase muscle functionality, improve respiratory function and decrease 
respiratory comp lications in DMD patients.46, 47 Althoug h c learly providing benefit to 
DMD patients, chronic oral steroid use a l so leads to adverse effects, including excessive 
weight gain, be havioura l prob lems, insomnia, reduction in bone density and 
compromised immunity. An anti-inflammatory effect48 coupled with promotion of 
pro liferat ion and/or fus ion of musc le precursor ceI Js49 is thought to be the mechanism 
underlying the amel ioration of muscle functionality in mdx mice by steroids. 
Whi le steroid administration improves t he pat hology of DMD through severa l 
mechanisms, b locking the activ ity of the imp0l1ant pro-inflammatory cytokine, tumour 
necrosis factor-a (TNF-a), provides another option. Treatment wit h Infliximab, the 
neutra lising antibody of TNF�a, has bee n shown to reduce musc le necrosis in young 
mdx mice50, 5 1  and exercised adult m ice.52 
Administrat ion of a myostat in inhi bitor in combinat ion with steroids or direct 
therapy provides a mechanism to boost genera l muscle mass and enhance musc le 
d ifferentiation. Long-term inhib ition of myostatin might however accelerate the 
depletion of muscle regenerative capacity in t he sett ing of a c hronic muscle disease.53 
1.5.2. Direct therapies 
Dystrophin replacement therapy, \vhich involves d irect administration of 
dystrophin (or dystrophin homologue) cDNAs or cells expressing dystrop hin, has been 
extensive ly studied using both g�ne rep lacement and ce ll therapy tec hniques. Both viral 
and non-viral approaches have been uti l ised as tools for the de livery of dystrophin 
cDNA. Analysis of Inutations in BMD patients suggests that a major pali of the gene 
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can be excluded with m in imal effect on function. cDNAs of mini-dystrophin (6.3kb) 
and m icro-dystrophin (4.8kb) (Fig 3b) have been characterised and successful ly uti l i sed 
as a dystrophin replacement therapy for DMD patients, although thei r  use is severely 
l imited by the associated adverse immune response to the viral vectors. 
P lasmid DNA i nducing ful l  length dystrophin has been demonstrated to be 
present and part ial ly restore dystrophin protein levels in  rodent, can ine and non-human 
primate model s  of musculal' dystrophy after its systemic administration, with a minimal 
adverse immune response. However, the comparatively low efficiency of thi s  technique 
i s  a major drawback. 54, 55 
Treatment \vi th the adeno-associated virus (AA V) constructs) l inked to micro­
dystrophin cDNA� has been shown to lead to systemically increased levels of dystrophin 
expression in  md\ mice.56, 57 However, this approach i s  problematical because it 
provokes an immune response l imit ing the option for subsequent treatment. T\vo 
different laboratories using similar approaches have reported adverse i mmune responses 
against vira l  constructs of AA V2 and AA V 6 carrying e ither a reporter gene or micro� 
dystrophin.58• 59 In addition to an adverse immune response ,  viral approaches may 
potential 1y lead to ITIultiple integrationsJ insel1ional mutagenesis, or prol iferative 
d isorders.6o 
Cel l  therapy involves the adm inistration to patients of adult stem cel ls ,  such as 
muscle  precursor cel l s  (MP Cs) or mesangioblasts carrying a normal  dystrophin  gene. 
These stem cel l s  can come from human donors \vith norma l dystrophin (heterologous 
stem ceJ J s) or involve the use of the patient's own stem cells (autologous stem cells) 
treated to augment dystrophin protein levels. Quennevil le et al.6 1  (2007) have reported 
successfu l  i ntramuscular autologous transplantation of lentiviral vector 
microdystroph in-treated NfPCs in mdx mice and non-human primates in a protocol  
i ncorporati ng immunosuppressant therapy. Recently, use of a high densi ty injection 
protocol of MPCs was shown to enhance dystrophin  expression and lead to functional 
improvement 1 8  months after intramuscular injection in mdx mice.62 
Another ce l l  type, heterologous mesangioblasts intra-arterially administered  to 
immunosuppressed dystrophic  dogs, has been shown to improve muscle functionality.63 
The maj or challenges of cel l  therapy are avoiding susta ined immunosuppression and 
ensuring the systemic delivery of stem cell s .  The transplant of autoJogous stem cells 
genetica lly corrected by v iral constructs \vould i nevitably share simi lar l imitat ions to 
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viral gene replacement strategy. 
1 .5.3 . Personalised therapies 
Mutation-specific therapies, a form of personal i sed medicine, provide an 
alternative approach to DMD mo lecular therapy. A prerequi site is that patient 
mutations must first be characterised. The d ifferent targets for correction include gene 
editing or tnRNA modulation. Gene editing could theoretically correct both nonsense 
and frameshift mutations, however� on ly nonsense mutations of md--c and mdx5cv mice 
have been proven to restore read ing frame functionality.64, 65 Gene ed iting could a lso be 
used in genetical ly-modified autologous stem cell therapy.66 
High concentrations of aminoglycoside antibiotics, such as gentamycin, under 
some circumstances are known t� force the translational machinery to read through stop 
codons. Up to twenty percent of dystrophin transcripts were restored after gentamycin 
treatment in mdx mice.67 A subsequent study using gentamycin in DMD and BMD 
patients, however, did not produce such an encouraging resu lt�68 possibly because 
multiple i soforms of gentamycin cause variations in potency. Identification of small 
molecules, which specifically suppress UGA nonsense codons,  has been examined 
using high-throughput drug screening. PTC 124 was demonstrated to read through UGA 
'with minimal adverse effects, and to partia lly restore dystrophin levels  (as determined 
by immuno-staining) and delay d isease progression in mdt. mice fol lowing a 
combination of oral and intraperitoneal administration.69 Both gene ed it ing and PTC 
1 24 treatment in theory could be applied in the 1 0- 1 5% of DMD patients who carry a 
nonsense mutation. 
1.6 Principles underlying the antisense oligomer induced exon skipping 
approach 
Unti l  no\v, because many different approaches to develop molecular therapies 
for DMD all have some l imitations, there has been a lack of consensus as to the best 
therapeutic strategy. Pre-mRNA splice intervention using antisense oligomers (AOs) 
potentially offers a personal ised approach to therapy where AOs can efficiently induce 
functional dystrophin w ith minimally provoked adverse immune responses, and 
theoretically be app lied to the majority ofDMD patients . 
1 0  
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The AO-induced exon skipping concept was init ially put forward because some 
l arge deletions of the dystrophin gene cause only m i ld symptoms in some cases of 
BMD. In addition, rare dystrophin-positive revertant fibres have been shown to arise by 
a natural ly occurring exon skipping mechanism, At the molecular level, the significant 
differences between DMD and BMD are due to the d ifferent extents of reading-frame 
d isruption.26 Consequently, it ha's been proposed that AOs could help DMD patients by 
dislodging some exons to circumvent read ing-frame d isruption, thus restoring functional 
dystrophin expression and re-establish ing the sarcolemmal protein complex. 
Although the u lthnate goal of using o l igomers i s  to interfere with pre-mRNA 
spl icing by preventing exon recognition and seiection,7o, 7 1  the chal lenge is that spl ic ing 
is tightly linked to transcr iption', Understanding the flo\v of genetic information (viz.  
transcript ion, spl icing, S' capping, 3' polyadenylation, mRNA export and trans lation) 
could potentially improve oligomer design for exon removal both in DMD and other 
genetic d iseases and broaden the app lication of o l igomers to other processes in gene 
expression. 
1.7 Gene expression and splicing 
1 .7.1 The complexity of gene expression and pre-mRNA splicing 
Transcription is the synthesis  of RNA from a DNA template. For a protein­
coding gene, RNA polymerase II (RNAP IT) initial ly  synthesises a ful l - length 
complementary RNA molecule: described as a nascent tra nscript or precursor mRNA 
(pre-mRNA) fro m  the template strand. Eukaryotes exhibit  greater genomic complexity 
than prokaryotes because intronic sequences are inserted between the coding sequences 
(exons). Consequently, the pre-mRNA needs to be modified by intron removal, before 
its commitment to the protein translational machinery .  After RNA processing, the 
mature mRNA acts as a template for protein transl ation using groups of three 
nucleotides (triplet codons). 72 
Differential spl icing of 5' or 3' spl ice sites either within the original exon or at 
cryptic spl ice junctions potential l y  al lows ind ividual genes to express mU ltiple mRNAs 
that encode proteins with d iverse functions. Seven types of a lternative spl icing 
mechanisms are recognised as · shown in Figure 4. On the basis of conservative 
analyses of expressed sequence tags (ESTs) and cDNA datasets, alternative spli cing has 
been reported to occur in some 40% to 60% of human genes, a figure that increases to 
1 1  
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73% when spl icing data is combined with information derived from alternative splicing 
microarray analysis .73 
1 .7.2 Splicing motifs and trans-factors 
Pre-mRNA splicing i s  control led by a battery of proteins (trans-acting factors), 
which act in combination to recognise specific sequence motifs (eis-acting e lements) on 
pre-mRNA.74 Both smal l  nuclear ribonucleoproteins (snRNPs) and non-small nuclear 
r ibonucleoproteins (non-snRNPs) cooperatively define the exon/intron border. SnRNPs 
are proteins tightly bound to a s i'ngle uridine-rich smal l nuclear RNA (snRNA) and five 
snRNPs are i nvolved in spli ci ng (viz. U1 > U2� U4} US, and U6).75 Non-snRNP splicing 
factors comprise an assoliment of functional ly d iverse proteins that play a pivotal part 
in a lternative spl ic ing.76 Non-snRNPs, which are specifically attached to pre-mRNA or 
to one another to enhance exon inc1usion or exon repression, comprise two groups of 
protei ns, serine-arginine-rich � (SR) proteins and heterogeneous nuclear 
ribonucleoproteins (hnRNPs). 
Many members of the SR protein family have been demonstrated to possess an 
exon inclusion function.77, 78 SR proteins contain one or two RNA recognition motifs 
(RRMs), which bind to pre-mRNA on the exonic sequence enhancer (ESE) .  They have 
a d ist inctive carboxy terminal domain that is rich in arginine/serine dipeptides (the RS 
domain) . The RRMs determine substrate specificity via the ESE, whereas the RS 
domain is mainly involved in protein-protein  interaction by d irectly recruiting the 
splicing machinery.78 
Whereas SR proteins act by enhancing exon inclusion, hnRNPs act by inducing 
exon repression. The hnRNPs contain RRMs and protein  K homology RNA binding 
motifs (KH domains), and RGG (Arg-Gly�Gly) boxes.79 HnRNPs not only exhibit 
RNA-b inding propeliies but also contain one or more protein-protein interacting 
domains.76 Moreover, HnRNPs take patt in various nucleat' events, such as 
transcriptional regulation, pre-ribosomal RNA processing, 3' end processing, and 
nucleat'�cytoplasmic mRNA tra�sport.76 In summary, the aggregations of non-snRNP 
proteins attached to a e is-acting element i n  a spl iceosome (see Section 1 .8 .2) define the 
exoniintron border and determine whether the exon is incorporated i nto transcript, vvith 
the snRNPs signall ing the precise locat ions for spl icing. 
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1 .7.3 SpIiceosome 
Spl icing was first discovered when Berget et al. 80 ( 1977) identified a spl ice 
segment in adenovirus. Shortly thereafter, a number of cel lu lar genes in a variety of 
organisms were discovered to contain int1'ons, includ ing the rabbit and mouse globin 
genes,81 , 8 2  and mouse immunoglobul in .83 Evolutionary analysis revealed a l imi ted set 
of conserved sequences at each intron boundary . 84 These conserved sequences were 
shown to be common across vertebrates, plants, and yeasts.85 
It is no\v recognised that the process of gene spl icing involves an assembly of 
prote ins, the spl iceosome. The components of spliceosomes and their specific roles in 
spl icing have been progressively identified in h igher eukaryotes since the discovery of 
splicing in t he 1 970s. 
The components of the spliceosome vary between different genes and even 
within the same cell  type at different phases of gene expression, a lthough there are five 
common snRNPs in every spl iceosome. Both s nRNPs and non-snRNPs perform an 
i ntroniexon defining function, and snRNP complexes are responsi bl e  for excis ing 
interven ing sequences . Non-s!1RNPs are extensively involved in determin ing the 
existence of exons in certain transcripts.78 Many methods have been uti l i sed to 
determine the human spliceosome components/5, 86 and a proteomi c  analysis of the 
human spl iceosome has revealed the presence of 145 distinct proteins.87 For this 
reason, the spl iceosome is regarded as one of the largest and Inost complex 
macromolecular assembl ies present in cel ls ,8s 
1 .7.4 Spliceosome asselnbly and the fidelity of pre-mRNA splicing 
Spliceosomes form the dynamic complex responsible for spl icing, a process 
which involves two successive esterification reactions (Fig 5). With a s ingle catalytic 
core, dynamic conformation and multiple re arrangements are required to enabl e  the hvo 
consecutive reactions to procee& More than a decade ago, RNA helicases and members 
of the DExHfD-box ATPase family were proposed to have roles in spl iceosome 
function and determine the fidelity of spl icing, and have been directly demonstrated to 
un\vind duplex RNA,89 d issociate protein from RNA90 and bind protein  to RNA,9 1 in an 
ATP-dependent manner. Subsequently, various RNA he licases, includ ing prp28 , prp 1 6, 
prp5 , prp 8, prp22, prp 1 9  and prp43 , have been suggested to control the reposition ing of 
the spl iceosomal catalytic core by inducing a conformational sh ift during the hvo 
1 3  
Chapter 1 Introduction 
Cassette exon 
< . 
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Figure 4: Patterns of aHernatlve gene splldng. 
The S8'len different types of eHematwe gene transcript sptk:lng are illustrated. The coloured reclangles represent exonic regions, and 
the bold lines Indicate the Inironlc regions. The blue lines represent Ihe regions which are spliced out 10 produce the mature transcripts 
resulting from the seven different types of pre-mRNA splicing. 
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catalytic reactions, which a llows spl iceosomes to kinetic a l ly proofread the spl ice motif 
during pre-mRNA spl ic ing (for review see 92). Figure 6 i llustrates the conformational 
changes in the spl iceosome during the two successive esterification reactions. 
As illustrated in Figure 5, during assembly the U 1 snRNP complex binds to the 
51 splice s i te via 6-7 base pairing between the spl ice s ite and UI snRNA.93 A branch 
point binding protein, SF l binds to a branch point and the 65-kDa subunit  of the U2/AF 
protei n  recognises a pyrimidine tract. The 35kDa subunit of U2/AF then attaches to the 
3 '  spl ice s ite.93 Either d irect RS-RS domain interaction or indirect interaction through 
spl icing co-activators i s  required to ensure the recruitment  of the spl ic ing factor 
U2/ AF65-kDa, especially i n  those cases in which recognition of a \veak pyrimidine tract 
is a rate-l imiting step.77, 94 
At thi s  stage, the assembly of proteins i s  referred to as complex E (Fig 5). 
Subsequently, U2 snRNPs are recruited to interact with compl ex E. U2 snRNPs attach 
to a branch site via U2 snRNA, which forms a stem I Ia structureJ thereby forming 
complex A.93, 95 The A complex i s  joined by the U4/5/6 tri-snRNP to form the B 
complex. Brr2 , a helicase protein, faciJ itates unwinding of the U4/U6 duplex, allowing 
U6 to d isplace U l  snRNA.96 The coupling reaction of UI d isplacement and U6 base­
pairing to the 5' spl ice s i te is mediated by phosphorylated prp28.97-99 In conjunction 
with rearrangement of U2snRNA from stem lIa to stem lIc through prp5p and cus2p 
interaction, U6snRNA anneals to a region of U2snRNA that is near to the branch s ite 
duplex bUlging 21 hydroxyl group of adenosine. 1 00- 103 Bulging of the 21 hydroxyl group 
at the branch point base leads to nucleophi lic attack at the 5' spl ice site, and causes the 
first esterification. 
After the first esterification, a prp 1 6-dependent interaction coupled with ATP 
hydrolysis juxtaposes the 3 '  splice s ite and the 5 '  spl ice s i te, a l lowing progression to the 
second esterification step. This causes the intronic RNA to be bent i nto a loop or lariate 
structure. Releasing the intermediate lariate (Fig 6) weakens binding to the spl iceosome 
and is important in  the context of fidelity of spl ic ing. It permits kinetic competition and 
determ ines whether the second esterification proceeds or whether the spl iceosome 
disassembles. Efficient repositioning involves binding of the 3' sp lice s i te and the 
lariate intermedi ate to the cata l ytic core for the second esterification. Failure of the 3 '  
and 5 '  spl ice sites t o  become juxtaposed i s  thought to lead t o  d isassemb ly of the 
spHceosome and unspl iced transcripts containing spl ice mutations are subjected to 
1 5  
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degradation (Fig 6) .92, 104 The U5snRNP has been shown to undergo base pairing to 
both exons and i s  believed to a lign the ends of the two exons for the second 
esterification to proceed . The two exons join and the l igated product is released from 
the spl iceosome by Prp22} after the second esterificat ion has been completed (Fig 5) . 105, 
106 
1.7.5 Transcription-coupled pre-mRNA splicing 
Pre-mRNA spl ic ing occurs e ither soon after RNA transcription, or co� 
transcriptionally, during the expression of large or complex genes. to7 The flow of 
geneti c  i nformation i s  t ightly coupled and control led  by a highly complex network of 
functi onal interactions between the transcription machi nery and pre-mRNA processing 
factors. Whi le  usua lly taking more than 20 minutes in vitro (where processing is 
uncoupled from transcripti on), post-transcriptional modification in vivo can be 
processed within 30 seconds under circumstances where the transcript ional apparatus 
and spli c ing factors are coupled . lo8 
The C-terminal domain of RNAP II (CTD), comprising 25 to 52 tandem copies 
of the consensus repeat heptad y, S2P3T4SSP6S7, 109 functions as a platform where 
transcription is coupled and able to interact \vith the proteins responsib le for post­
transcriptional modification (viz. capping, spl ic ing and polyadenylation). Mobi l isation 
of the trans-spl ic ing factor to the spl ice s ites and the kinetics of transcription are thought 
to be the mechani sm influencing pre-mRNA splicing. 1 08 Reversible modifications of 
the CTD of RNAP II (viz. phosphorylation, gIycosylation, and prol i ne isomerisation) 
provide the basis for what is termed the CTD code. The CTD code refers to the 
moleculal' diversity that is introduced to the s imple heptad sequence structure by the 
process of covalent modification (viz. phosphorylat ion, glycosylat ion, and pro l i ne 
i someri sation)) which gives greater d iversity to the processes that regulate transcription 
in i tiat ion and post-transcriptional modification processes. Components of U l snRNPs 
(viz. U1 70K, UIA, U I C, TIAR, TIA- 1 ,  and the Srn core proteins) and some othet' SR 
proteins, such as U2AF65 and SF21 ASF, have recently been reported to be associated 
w ith the RNAP II immunoprec ipitate. 1 1 0, 1 1 1  After the transcription in i tiation step, 
proteins associated with RNAP II enhance the capping process and recruitment of  other 
SR proteins (Fig 7). 1 1 2 These proteins, i n  turn, stabi lise the transcription elongation 
complex during the process of polymerisation along the DNA template. 1 1 3, 1 14 I n  1 988, 
i t  was hypothesised that the rate of RNA synthesis may affect the secondary structure of 
1 6  
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Comptex A 
u s  
Complex B 
us nJL5?i, U4 
Figure 5 :  Structure and function of the  spllceosome. 
The figure Illustrates how the spllceosome Is thought to carry out the process of pre--mRNA splicIng. The complex E contains three essential 
protein complexes (viz. U1  snRNPs, a branch point binding protein and U2IAF protein). The U1  snRNP complex binds to Ihe 5' splice site via 6-7 
base pairing and the branch point binding protein (SF1) beoomes located al the branch point. The U2IAF protein recognises a pyrimidine fracf. 
Either serine arglnlne-Jlch (SR) proteins or heterogeneous nuclear ribonucleoprotelns (hnRNPs) may inHuence splice site selecllon through direct 
interaction with U2IAF or IndIrect Interaction through splicing co-activators. The U2snRNPs attach 10 a branch site via U2snRNA, Vlhlch forms a 
slem Ita structure, thereby forming the A complex The A complex Is Joined to the U4fSI6 Ir1-snRNP to form the B oomplex. In conjunction with 
rearrangement of U2snRNA from stem I/a to stem lie through prpSp and cus2p Interaction, U6snRNA anneals to a region of U2 snRNA that is near 
to the branch site duplex bulging 2' hydroxyl group of adenosine. This leads to nuoleophlllo attack at the 5' splice sUe, and causes the firsl 
esterification reaction. The U5 snRNP undergoes base pairing 10 both exons and aligns the ends of the two el(ons for the second esterification 
reaction 10 proceed. The two exons join and the ligaled product is reteased from the spliceosome (modiHed from Palet et al. 20031(4 ). 
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Figure 6: Regulatory me<:hanlsm whereby the spllc:eosome maintains the fidelity of pre-mRNA splh;lng. 
The hellcases delermlne whether pre-mRNA splicing proceeds 10 completion or abor1$ through disassembly 
of the $pI�some comple)( thereby ensuring Ihe fidelity 0( pre-mRNA splicing. (a) The process of determining 
the fidelity of pre-mRNA splicing involves all lhree of the consecutive stages (viz. spliceosome assembly, the 
calatytlc phase and product release). (b) The conformational alterations In Ihe s.pllceosome occur after Ihe tlrsl 
esterification reaction fo shifl lhe product of the reaction 10 the calatytic COle of the second esterification and this 
Is regulated by interaction between Prp16 and ifs counterpart, isv1-deJla. (modified from Konarska &t aJ. 20051» 
and Querry et al. 20081(5). 
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nascent transcripts, which i n  turn increase spl ic ing.  1 1 6  Evidence supporting this concept 
came l ater \vhen the e longation rate of a mutant form of RNAP II� C4, was shown to be 
increased 3-fold by changing the conformation of the nascent transcript by inclusion of 
the fibronectin EDI exon in the transcript. I 1 7, 1 1 8 Mutated RNAP II was found to 
partial ly prevent exon skipping in yeast. 1 1 9 The inhibition of specific proteins in the 
elongation complex; such as topoisomerase I can also affect the spl icing process. A 
reduced number of spliced transcripts and accumulation of spl ic ing factors \vas reported 
after treatment with camptothecin, a topoisomerase inhibitor. I 1 I 
1 .8 AO-induced exon skipP'ing intervention and choice of chemistry 
In 1978, AOs \vere demonstrated to have the potential for gene downregulation by 
causing the inhibition of both Rous sarcoma viral translation in  a cel l -free system and 
v iral rep l ication in  chick fibroblast tissue culture. 120, 121 Subsequently, AOs have 
become of increasing interest to scientists, both as therapeuti c  agents and as tools to 
study gene function. During the past two decades, anti sense technologies have been 
continually deve loped to overcome the practical problems associated with AO usage, 
including cel lular uptake, AO stabil ity (viz. binding capaci ty of AOs to RNA target), 
and spec ificity. 122.1 24 
The first generation of oligomers, ol igodeoxynucleotides on phosphorothioate 
backbones (ODN), were used to' knockdown mature transcripts of various target genes, 
including the gamma-aminobutyric acid (GABA(A)) receptor, 1 25 bcl_2, 126 c_myc, 1 27 
transforming growth factor-p (TGF -P), 128 and others. The basic principle of 
conventional AO duwnregulation is dependent on anneal ing of the AO to target mRNA 
and subsequent RNaseH activation to destroy the message. 
The second generation o ligomers, 2' -O-methyl modified (20Me) and 2' -0-
methyl and 2'-O-methoxy ethyl (MOB) modified oIigomers on phosphorothi oate 
backbones, were devised to minimise nuclease d igestion; h owever 2' modification, in  
turn, was shown to compromise RNaseH activation. The concept of using chimeric 
oligomers (gapmers), in which 8 to 1 0  nucleotides of DNA are flanked by 5 oligomers 
of the RNA analogue (20MeAOs 01' MOEs), has emerged as a means of maintaining 
the positive attributes of ODNs (high affinity of AO to RNA molecule and l on g  half­
l ife) without compromising RNaseH activation. 
1 9  
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Modification has successful ly produced the third generation of oligomers, 
including phosphorodiamidate morpholino oligomers (PMOs), peptide nucleic acids 
(PNAs), and locked nucleic acids (LNAs). These third generation oligomers have been 
used to interfere with the translational process of various gene tal'gets. 129. 1 32 
Immed iately after the discovery that synthetic d ouble stranded RNA (RNAi) can induce 
gene inactivation at high potency in mammalian cultures, 1 33 an explosion of research 
into therapeutic applications of RNAi has to some extent overshadowed the use of 
antisense-induced gene inactivat�on by RNaseH (for review see 1 34, 1 35), 
The use of AOs to redirect or modulate the pre-mRNA splicing process is 
widely recognised as having broad applicability, where second and third generation 
AOs can be used to sterical ly mask recognition of splice motifs, and a l ter the 
proportions of different products of gene spJicing (spl iceoforms) without degrading 
targeted transcripts. Pioneering work on AO-induced splice intervention \vas init ial ly 
undertaken in Hela cells, where 20MeAOs were shown to mask the cryptic spl ice site 
of the mutant f3-globin at1ificial gene construct and normalise the splicing pattern. 1 36 
AO-induced exon skipping was first demonstrated to remove human dystrophin exon 1 9  
in Ebstein-Barr virus (EBV) transformed human lymphocytes. 1 37 S ince then, AO­
induced exon skipping has been widely studied in relation to the dystrophin gene and 
provides an example of constitutive splicing manipulation to overcome genetic lesions 
in both cell culture and animal models. 138- I 43 
Although possessing greater nuclease resistance, the third generation oligomers, 
PMOs and PNAs, have low transfection efficiency in cultured cells. 144 To overcome 
this problem, conjugation with cell penetrating peptides (CPPs) has been used to 
facilitate oligomer uptake. Systemic administration of peptide-tagged PMOs has led to 
improved biodistribution and increased exon removal and dystrophin protein restoration 
in vivo. 1 45, 1 46 More recently, a carbohydrate-modified peptide-conj ugated PMO has 
been sho\vn to increase dystrophin protein levels by ten to thirty precent in c ardiac 
tissue following systemic treatment in mdx mice. 147-149 
1 .9 AO-induced exon skipping intervention in the 4cV mouse 
In this thesis, the bulk of the work has focused on AO-induced exon skipping in 
a model of muscu1ar dystrophy, the 4cV mouse, which carries a protein-truncating 
mutation of dystrophin exon 53.  Because removal of both exons 52 and 53 is required 
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(a) 
(e) 
(d) 
(e) 
Figure 7: Transcr!ptlon-coupled pre-mRNA splicing. 
The steps in transcription-coupled pre-mRNA splicing are (a) RNA polymerase 11 (RNAP 11) associated with other proteins (ellipsoids attached 
to the spiral tall of RNA? 11) engages the DNA template. As a result, S' cappIng enzymes assocIated with eTD modify the 5' end of the nascent 
transcript. The ' string of beads' shovm represents Ihe mRNA slrand containing exonlc (light green) a nd inlronic (pale blue) regions; (b) as 
RNAP U proceeds along t he DNAtemplale, protei ns associaled with CTD mobilise Irans-factors la the splice silos , thereby facililating 
recognition of splice motifs and Initiatfng pre-mRNA splicing; (c) spliced mRNA is recognised by the axon Junction comptex (EJC) responsible 
for mRNA quality control (dark purple proteins); (d) once the RNA? 11 finishes polymerisation, the proteins associated with the CTD of RNA? 11 
(orange ellipsoid) activate the cleavage of Ihe 3' end of m RNA and recruit the enzyme responsible for polyadenylalion. AI this slage. the 
Iranscrlpt is released and the residual sequence still attached to RNA? Il ls degraded by 5' to 3' exonuclease 10 promole RNA? 11 dissociation 
from the DNA; and finally (0) the complex disassembles allO'w'ling the mature transcript to be transported 10 the nuclear pore. 
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to maintain the reading frame, the 4cV model offers an opportunity to i nvestigate dual 
exon skipping in a region that corresponds to the major mutation hot spot in  the human 
dystrophin gene. 
1 . 1 0  AO-induced exon inclusion in SMN2 gene transcript 
Although the major focus of the research descri bed here involves exon removal in 
the 4cv mouse model of muscular dystrophy, the thesis also reports attempts to restore 
gene expression by the inclusion of selected exons into other mature transcripts. These 
studies were undetiaken on the premise that it may be possible to affect change by 
masking s i lencing e lements 01' - by adding AOs which reinforce exon selection and 
inclusion. By comparison with exon skipping, only l imi ted numbers of AO-induced 
exon inclusion experiments are reported in the l iterature, a lthough this is now starting to 
increase. The survival motor neuron gene is one of the best characterised models . 1 50- 152 
Spinal muscular atrophy (SMA) i s  characterised by degeneration of the anterior 
horn cells leading to four main symptoms, hypotonia, symmetrical muscle weakness 
and atrophy, tremor of finger and hand, and fasciculation of the tongue muscles. A 
defect in the survivor motor neuron gene (SMN) has been identified as the cause of 
SMA. In humans, there are two copies of the SMN gene, SNINl (telOlneric SMN) and 
SMN 2 (centromeric SMN). SMN2 differs from SMNl by one nucleotide in the splice 
motif of exon 7, which leads to production of a transcript l acking exon 7 � while the full 
l ength protein  is  almost exclusively produced by SMN I .  SMN l  is m issing or altered in 
SMA pati ents, but SMN2, which mainly encodes a truncated protein, can also produce 
I imited amounts of the fuU Jength transcript. 
One of the most promising genetic treatments for this d isease i s  enhancement of 
the number of transcripts inc lud ing exon 7, "vhere modified antisense o ligomers have 
been shown to reinforce exon inclus ion in human cultured fibroblasts. 153- 1 55 Studies 
reported in this thesis aim at identifying potentia l  sites for AO binding as a ne\v avenue 
for AO-induced exon i nclusion therapy for SMN patients� a technique that may have 
broader appl icabi l ity to other diseases . 
1 . 1 1  The goals of the thesis and their significance 
DMD is  a re lentlessJy progressive neufOlnuscular disease which affects one i n  
3 ,500 newborn males. Because, to date, no  effective treatment for DMD i s  cl inically 
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avai lable, patients usual ly lose ambulation and d ie from respiratory and cardiac 
compl ications i n  t heir late twenties . The use of antisense oligomer-induced exon 
skipping has already been the subject of cl inical trials in DMD patients. 156, (57 The 
novelty of the \vorks presented here i s  that it explores the concept of personalised 
therapy for DMD, whereby ol igomers are constructed to specifically target individual 
mutations . These studies use a proven ani mal model of DMD, the 4cV mouse, which 
carries a protein-truncating mutation of exon 53. Importantly, exon 53 corresponds to a 
mutation hot-spot in human dystrophin (exons 45-53), thereby making the 4cV mouse a 
pa11icularly relevant model of DMD in humans. The model also offers an opportunity to 
investigate dual exon skipping, which i n  theory, has the potentia l  to extend the range of 
mutations that may be treatable by use of antisense o ligomers . 
For personalised ol igomer therapy to be effective in ind ividua l DMD patients, a 
method to optim ise the therapeutic o ligomers in appropriate cultured cel ls is required. 
The thesis explores the use of cultured human myoblasts, from both unaffected humans 
and a DMD patient with a mutation in exon 1 6, as a means of establishing the most 
effective oHgomers to induce exon 1 6  skipping in a range of patients w ith mutations that 
are treatable by removal of exon 16.  
The thesis a lso investigates the use of antisense o l igomers to induce exon 
i nclusion in SMA patients using cultured patient fibroblasts, with the goal of exploring 
the appl icabi l ity of antisense ol igomers in the treatment of other neuromuscular 
d isorders . 
1 . 12 Purpose 
The a ims of this project are to explore the fol lowing issues :  
1 .  How efficiently can AOs modify spl icing patterns? 
2.  Can dual exon skipping be efficiently induced in the B6Ros.Cg-Dmdlld-c-.JCl'j J mouse 
model of muscular dystrophy? 
3 .  Does the choice o f  o l igomer chemistry influence exon skipping efficiency in vivo? 
4 .  Do combinations of AOs that induce exon removal lead to increased dystrophin 
levels and improve musc le functional ity? 
23 
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5 .  Can the use of ol igomers . for exon remova1 be d irectly extrapolated between 
species? 
6 . Does the use of AO-induced exon skipping in  norma1 human myoblasts provi de a 
means of optimis ing the AOs to be used cl inically in DMD patients? 
7 .  Can appropriately designed ADs promote exon i nclusion in fibroblast cultures from 
an SMA pat ient and, if so, what combination of o l igomers i s  most optimal? 
24 
Chapter 1 Introduction 
1 .13 References 
1. Janssen I, Heymsfield SB, Wang ZM, Ross R. Ske letal muscle  mass and 
d istribution in  468 men and women aged 1 8-88 yr. J Appl Physiol 2000; 89(1) :  
8 1 -88.  
2.  Despopoulos AS� S .  Color Atlas of Physiology, 5th edition edn .  Thieme medical 
publishers: Basel, Switzerland, 2003,  369pp. 
3 .  Kapsa R ,  Kornberg AJ, Byrne E.  Novel therapies for Duchenne muscular 
dystrophy. Lancet Neuro1 2003 ; 2(5): 299-3 1 0. 
4. Monaco AP, Walker AP, Mi l lwood I, Larin Z, Lehrach H. A yeast artificial 
chromosome contig containing the complete Duchenne muscular dystrophy 
gene. Genomics 1 992; 12(3) : 465-473. 
5. Koenig M, Hoffman EP, Berte lson CJ, Monaco AP, Feener C, Kunkel LM. 
Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and 
preliminary genomic organization of the DMD gene in normal and affected 
individuals. Cell 1 987; 50(3) :  5 09-5 1 7. 
6. Robet1s RG, Coffey AJ, Bobrow M, Bentley DR. Exon structure of the human 
dystrophin gene. Genomics 1 993;  16(2): 536-53 8. 
7. Koenig M, Kunkel LM. Detailed analysis of the repeat domain of dystrophin 
reveals four potential hinge segments that may confer flexibi l ity. J Bioi Chem 
1 990; 265(8) : 4560-4566. 
8. Bork P, Sudol M. The WW domain : a signall ing site in  dystroph in? Trends 
Biochem Sci 1 994; 19(1 2): 53 1 -533 .  
9. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin 
predicts a rod-shaped cytoskeletal protein. Cel/ 1 9 88;  53 (2) : 2 1 9-228. 
10. Pont ing CP, B lake DJ, Davies KE, Kendrick-Jones J, Winder SJ . and TAZ: 
new putative zinc fingers in dystrophin and other proteins . Trends Biochem Sci 
1 996; 21( 1 ) :  1 1 - 1 3 .  
11 .  Bach JR, Ishikawa Y,  K im H. Prevention of pulmonary morbidity for patients 
with Duchenne muscular dystrophy. Chest 1 997;  112(4): 1 024- 1 028.  
12. Bushby K, Bourke J, . Bul lock R, Eagle M, Gibson M, Quinby J .  The 
multid isciplinary management of Duchenne muscular dystrophy. Current 
Paediatrics 2005;  1 5(4): 292-300. 
13. van Deutekom JC, van Ommen GJ. Advances in Duchenne muscular dystrophy 
gene therapy. Nat Rev Genet 2003 ; 4(1 0) : 774-783.  
25 
Chapter 1 - Introduction 
14. Sadoulet-Puccio HM, Kunkel LM. Dystroph in  and its isoforms. Brain Pa/ho! 
1 996; 6(1 ) :  25-3 5 .  
15.  Boittin FX, Petermann 0, HiI'n C,  Mittaud P, Dorch ies OM, Roulet E et al. 
Ca2+-independent phosphol ipase A2 enhances store-operated Ca2+ entry in 
dystrophic skeletal muscle fibers. J Cell Sci 2006; 1 19(Pt 1 8) :  3 733·3742. 
16. Dietrich A, Kalwa H, Storch U, Mederos y Schnitzler M, Salanova B ,  
Pinkenburg 0 et al. Pressure- induced and store-operated cation influx in  
vascular smooth muscle cel ls  i s  independent of  TRPCl .  Pflugers Arch 2007; 
455(3) : 465 -477 . 
17. Lansman IB, Franco-Obregon A. Mechanosensitive ion channels in skeleta1 
muscle :  a l ink in the membrane patho logy of muscular dystrophy. Clin Exp 
Pharmacal Physiol 2006� 33(7): 649-656. 
18. Marx SO, Ondrias K, Marks AR. Coupled gating between individual ske letal 
muscle Ca2+ release channels (ryanodine receptors). Science 1 998;  281 (5378): 
8 ]  8-82 1 .  
19. B lake Dl, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin 
and dystrophin-related proteins in muscle.  Physiol Rev 2002; 82(2) : 291 -329. 
20. Emery AE. Muscular dystrophy into the new m i llennium. Neuromuscul Disord 
2002; 12(4) :  343-349. 
21 . Emery AE. The muscular dystrophies . Lancet 2002; 359(9307) : 687- 695 . 
22. GunteI' TB, Buntinas L, Sparagna G, Eliseev R, Gunter K.  Mitochondrial 
calcium transport: mechanisms and functions. Cell Calcium 2000; 28(5 -6) : 285-
296.  
23.  Gunter TE} Yule  DI,  Gunter KK} Eliseev RA, Salter ID. Calcium and 
m itochondria. FEBS Left 2004; 567( 1 ) : 96- 1 02. 
24. Leung A W, Halestrap AP. Recent progress in elucidating the molecular 
mechanism of the mitochondrial permeability transition pore. Biochim Biophys 
Acta 2008; 1 777(7-8): 9�6w952. 
25. Zamzami N, Kroemer O. The mitochondrion in  apoptosis :  how Pandora's box 
opens. Nat Rev Mol Cell Bio/ 200 1 ;  2(1 ) :  67-7 1 .  
26. Monaco AP, Bet1elson Cl, Liechti-Gallati S ,  Moser H, Kunkel LM. An 
exp lanation for the phenotypic d ifferences between patients bearing pa11ial 
deletions of the DMD locus. Genomics 1 988 ;  2( 1 ) : 90-95 .  
27. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T et al. The 
molecular basis for Duchenne versus Becker muscular dystrophy: correlation  of 
26 
Chapter 1 Introduction 
severity with type of deletion. Am J Hum Gene! 1 989; 45(4): 498-506. 
28. Vainzof M, Passos-Bueno MR, Takata RI, Pavanello Rde C, Zatz M. 
Intrafamilial  variabil ity in dystrophin abundance correlated with d ifference in 
the severity of the phenotype. J Neurol Sci 1 993 ; 119( 1 ) :  38-42. 
29. Arikawa-Hirasawa E, Koga R, Tsukahara T, Nonaka I,  Mitsudome A, Ooto K et 
al. A severe muscular dystrophy patient \vith an internal ly deleted very ShOlt 
(1 1 0  kD) dystrophin:  presence of the binding site for dystrophin-associated 
glycoprotein (DAG) may not be enough for physiological function of 
dystrophin. Neuromuscu� Disord 1 995; 5(5): 429-438 .  
30.  Fanin M, Freda MP, VitieIlo L,  Daniel i GA, Pegoraro E, Ange l ini C. Duchenne 
phenotype with in-frame deletion removing major portion of dystrophin rod: 
threshold effect for deletion s ize? Muscle Nerve 1 996; 19(9) : 1 154- 1 1 60. 
31. Norwood FL) Sutherland-Smith AJ, Keep NH, Kendrick-Jones J. The structure 
of the N-terminal actin�binding domain of human dystrophin and how mutations 
in thi s  dOlnain may cause Duchenne or Becker muscular dystrophy. Structure 
2000; 8(5) :  48 1 -49 1 . 
32. England SB, Nicholson LV, Johnson MA, Forrest SM, Love OR, Zubrzycka­
Gaal'n EE et al. Very m i ld muscular dystrophy associated with the deletion of 
46% of dystrophin. Nature 1 990; 343(6254) : 1 80- 1 82. 
33. Mirabella M, Gal luzzi G, Manfredi  G, Bertini E, Ricci E, De Leo R et al. Giant 
dystrophin de letion associated with congenital cataract and mi ld muscular 
dystrophy. Neurology 1 998;  51 (2) : 592-595 .  
34. Chelly J, Oilgenkrantz H, Lambert M, Hamard G, Chafey P, Recan D et al. 
Effect of dystrophin gene deletions on mRNA levels and processing in 
Duchenne and Becker muscular dystl'ophies. Cell 1 990; 63(6) : 1 239- 1248 . 
35. Gangopadhyay SB, Sherratt TO, Heckmatt JZ, Dubowitz V, Mil ler G, Shokeir 
M et al. Dystrophin in frameshift deletion patients with Becker muscu lar 
dystrophy. Am J Hum Gene! 1 992; 51(3) :  562-570. 
36. Winnard AV, Klein CJ, Coovert DD, Prior T, Papp A, Snyder P et al. 
Characterization of translational frame exception patients in Duchenne/Becker 
muscular dystrophy. Hum Mol Gene! 1 993; 2(6) : 737-744. 
37. Winnard AV, Mendell JR, Prior TW, Florence J, Burghes AH. Frameshift 
deletions of exons 3-7 and reveltant tibers in Duchenne muscular dystrophy: 
mechanisms of dystrophin production . Am J Hum Genet 1 995 ; 56( 1 ) :  158 - 1 66.  
38. Aattsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen 
27 
Chapter 1 - Introduction 
IT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an 
overview of mutation types and paradoxica l cases that confirm the read ing­
frame rule. Muscle Nerve 2006; 34(2) : 1 35 - 1 44.  
39. Ohlendieck K, Ervasti JM, Matsumura K, Kahl SD, Levei l le CJ, Campbel1 KP. 
Dystrophin-related protein i s  localized to neuromuscular junctions of adult 
skeletal muscle. Neuron ] 991 ;  7(3) :  499-508. 
40. Khurana TS, Davies KE. Pharmacological strategies for muscular dystrophy. 
Nat Rev Drug Discov 2003 ; 2(5) : 379-390.  
41 .  Takemitsu M, Ishim'a S ,  Koga R,  Kamakura K, Arahata K, Nonaka I et al. 
Dystrophin-related protein  in the feta l and denervated skeletal muscles of norma l 
and mdx m ice. Biochem Biophys Res Commun 1 99 1 ;  180(3) :  1 1 79-1 1 86. 
42. Rafael lA, Brown SC. Dystroph in  and utrophin: genetic analyses of their role  in 
skeletal muscle. Microsc Res Tech 2000; 48(3 -4): 1 55 - 1 66 . 
43 . Weir AP, Burton EA, Harrod G, Davies KE. A- and B-utrophin  have d ifferent 
expression patterns and are d ifferential ly up-regUlated in mdx muscle. J BioI 
Chem 2002; 277(47) : 45285 -45290 . 
44. Koike S ,  Schaeffer L, Changeux JP. Identification of a DNA e lement 
determining synaptic expression of the mouse acetyJcholine receptor delta­
subunit gene. Proc Natl Acad Sci U S A  1995 ; 92(23) :  1 0624- 1 0628 .  
45. Mattei E, Corbi N, Di  Certo MG, Strimpakos G, Severini  C, Onori A et al. 
Utrophin up-regulation by an aliificial transcription factor in transgenic  mice. 
PLoS ONE 2007; 2: e774. 
46. B iggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort 
treatment for boys with Duchenne muscular dystrophy in the i r  second decade. 
Neuromuscul Disord 2006; 16(4) :  249-255.  
47.  B iggar WD, Pol itano L, Hart'is  VA, Passamano L, Vajsar J ,  Alman B et al. 
Deflazacort in Duchenne  muscular dystrophy: a comparison of two d ifferent 
protocols. Neuromuscul Disord 2004; 14(8-9) : 476·482. 
48. Kissel JT, Burrow KL, Rammohan KW, Mendel l  JR. Mononuclear cel l  analysis 
of muscle biopsies in prednisone-treated and untreated Duchenne Jnuscular 
dystrophy. CIDD Study Group. Neurology 1 991 ;  41(5) : 667-672. 
49. Anderson JE, Mclntosh LM, Poettcker R. Deflazacort but not prednisone 
i mproves both muscle repair and fib er growth i n  d iaphragm and l imb muscle in 
vivo in the mdx dystrophic mouse. Muscle fileI've 1 996; 19( 1 2) :  1 576- 1 585 .  
50. Grounds MD, Torl'isi J. Anti-TNFalpha (Remicade) therapy protects dystrophic 
28 
Chapter 1 Introduction 
skeletal musc le from necrosis. Faseb J 2004; 18(6) : 676-682. 
51. Pierno S, D idonna MP, Cippone V, De Luca A, Pison i  M, Frigeri A et al. 
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle :  a 
biochemicat histological. and e lectrophysiologicaI study. Br J Pharmacol 2006; 
149(7) : 909-9 1 9 . 
52. Hodgetts S, Radley H, Davies M, Grounds MD. Reduced necrosis of dystrophic 
muscle by depletion of host neutrophi ls, or blocking TNFalpha function with 
Etanercept in mdx mice. Neuromuscul Disord 2006; 16(9- 1 0) :  59 1 -602. 
53. Carnac G, Ricaud S, Vernus B, Bonnieu A. Myostatin :  biology and clin ical 
relevance. Mini Rev Afed Chem 2006; 6(7): 765-770. 
54. Zhang G, Ludtke JJ, Thioudellet C, Kleinpeter p� Antoniou M, Henveijer H et 
al. Intraarterial delivery of naked plasmid DNA expressing ful l-length mouse 
dystrophin in the mdx mouse model of duchenne muscular dystrophy. Hum 
Gene Ther 2004; 15(8): 770-782. 
55. Hagstrom JE, Hegge J, Zhang G, Noble M, Budker V, Lewis DL et al. A facile 
nonviral method for del ivering genes and siRNAs to skeletal muscle of 
mammalian l imbs. Mol Ther 2004; 10(2) : 386-398. 
56. Gregorevic P, Allen JM, Minami E, B lankinship MJ, Haraguchi M, Meuse L et 
a1. rAA V6-micl'odystrophin preserves muscle function and extends lifespan in 
severely dystrophic mice. Nat Med 2006; 12(7): 787-789. 
57. Gregorev ic P, B lankinship MJ� AlIen JM� Crawford RW, Meuse L, Mil 1er DG et 
al. Systemic delivery of genes to striated muscles using adeno-associated v iral 
vectors . Nat Med 2004; 10(8): 828-834. 
58. Wang Z, Al ien JM, Riddel l SR, Gregorevic P, Storb R, Tapscott SJ et af. 
Immunity to adeno-assoc iated virus-mediated gene transfer in a random-bred 
canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007; 18( 1 ): 
1 8-26 . 
59. Yuasa K, Yoshimura M, Urasawa N, Ohshima S, Howel l  JM, Nakamura A et al. 
Injection of a recombinant AA V serotype 2 into canine skeletal muscles evokes 
strong immune responses against transgene products. Gene Ther 2007; 14( 1 7) :  
1249- 1 260. 
60. Hacein-Bey-Abina S, von KaI le  C, Schmidt M, Le Deist F, Wulffraat N, 
Mclntyre E et af. A serious adverse event after successful gene therapy for X­
l inked severe combined immunodeficiency. N Eng/ J A1ed 2003 ; 348(3): 255-
256. 
29 
Chapter 1 - Introduction 
61. Quennevi l le SP, Chapdel aine P, Skuk D, Parad is M, Goulet M, Rousseau J et al. 
Autologous transplantation of muscle precursor cells modified with a l entivirus 
for muscular dystrophy: human cells and primate models. Mol Ther 2007; 15(2) : 
43 1 ¥43 8 . 
62. Skuk D, Goulet M, Roy B} P iette V, Cote CH} Chapdelaine P et al. F irst test of a 
I Ihigh-dens ity injection" protocol for myogenic  cell transplantation throughout 
large volumes of muscl �s in a Duchenne muscul ar dystrophy patient : eighteen 
months fol low-up. Neuromuscul Disord 2007; 17( 1):  3 8-46. 
63. Sampaolesi M, B lot S, D'Antona G, GrangeI' N, Tonlorenzi R, Innocenzi A et al. 
Mesoangiob l ast stem cel ls ameliorate muscle function in dystrophic dogs. 
Nature 2006; 444(7 1 1 9) : 574-579. 
64. Belion i C, Lau C, Rando TA. Restoration of dystrophin expression in mdx 
muscl e  cel l s  by ch imeniplast-mediated exon skipping. Hum Mol Genet 2003 ; 
12( 1 0) :  1 087¥ 1 099. 
65. Be110ni C, Morris GE, Rando TA. Strand bias in oligonucleotide-mediated 
dystrophin gene ed iting. Hum Mol Gene! 2005; 14(2): 221 -233 .  
66. Bertoni C, Rando TA. Oystrophin gene repair in mdx muscl e  precursor cells in 
v itro and in vivo mediated by RNA-DNA chimeric o ligonucl eotides. Hum Gene 
Ther 2002; 13(6) : 707-7 1 8. 
67. Barton-Davis ER, Cordier L, Shotunna 01, Leland SE, Sweeney HL. 
Aminoglycoside antibiotics restore dystrophin function to skeletal muscles  of 
mdx mice. J Clin Inves/ 1 999; 104(4) : 375-3 8 1 .  
68. Wagner KR, Hamed S, Had ley DW, Gropman AL, Burstein AH, Escolal' OM et 
al. Gentamicin treatment of Duchenne and Becker muscul ar dystrophy due to 
nonsense mutations. Ann Neurol 200 1 ;  49(6): 706-7 1 1 .  
69. Welch EM, Ba110n ER, Zhuo J, Tomizawa Y, Friesen WJ, TrifiI1i s  P et a1. 
PTC 124 targets genetic d isorders caused by nonsense mutations . Nature 2007; 
447(7 140) : 87-9 1 .  
70. Aartsma-Rus A, van Ommen GJ. Antisense�mediated exon skipping:  A versatile 
tool with therapeutic and research appl ications. Rna 2007. 
71 .  WiJton SO, F letcher S .  RNA sp l ic ing manipulation: strategies to  modify gene 
expression for a variety of therapeutic outcomes. Curl' Gene Ther 2005 ; 5(5): 
467-483 . 
72. Strachan T, Read, A .P . Human Molecular Genetics 3, 3 edn, voL 1 .  Garland 
science publisher: London and New York, 2004, 674pp . 
30 
Chapter 1 - Introduct ion 
73. Kampa D, Cheng J, Kapranov P, Yamanaka M, Brubaker S ,  Cawley S et al. 
Novel RNAs identified from an in-depth analysi s  of the transcriptome of human 
chromosomes 2 1  and 22. Genome Res 2004; 14(3) :  3 3 1 -342. 
74. Smith CW, Valcarcel 1 .  Alternative pre-mRNA spl icing: the logic of 
combinatorial control .  Trends Biochem Sd 2000; 25(8):  38 1 -388 .  
75. Matlin  AJ, Clark F, Smith CW. Understanding alternative spJ icing: towards a 
cellu1ar code. Nat Rev Mol Cell Biol 2005; 6(5) :  386-398 .  
76. Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the 
messages they carry. Nat Rev Mol Cell BioI 2002;  3(3) :  1 95-205 . 
77. B lencowe BJ. Exonic spl ic ing enhancers : mechanism of action, d iversity and 
role in human genetic diseases. Trends Biochem Sd 2000; 25(3) :  1 06- 1 1 0 . 
78. Cartegni L, Chew SL, Krainer AR. Listening to si lence and understanding 
nonsense: exonic mutations that affect spl icing. Nat Rev Genet 2002; 3(4) : 285-
298.  
79. Burd CG, Dreyfuss G. Conserved structures and diversity of functions of RNA­
bind ing proteins .  Sdence' 1 994; 265(5 1 72): 6 1 5�62 1 . 
80. Berget SM, Moore C, Sharp P A. Spliced segments at the 5' terminus of 
adenovirus 2 late mRNA. Proc Natl Acad Set U S A  1 977; 74(8) : 3 1 7 1 -3 1 75 .  
8 1 .  Jeffreys AJ, Flavell RA. The rabbit beta�globin gene contains a large large insert 
i n  the coding sequence. Cell 1 977; 12(4) : 1 097- 1 1 08 .  
82. Tilghman SM, Tiemeiel' .DC, Seidman JO, PeterHn BM, Sull ivan M, Maizel JV 
et al. Intervening sequence of DNA identified in the structural portion of a 
mouse beta-globin gene . Proc Nat! A cad Sci U S A  1 978; 75(2) : 725-729. 
83. Bernard 0, Hozumi N, Tonegawa S. Sequences of mouse immunoglobu l in l ight 
chain genes before and after somatic changes.  Cell 1 978; 15(4) : 1 1 33 - 1 1 44.  
84.  Breathnach R, Chambon P.  Organization and expression of eucaryotic  spl it 
genes coding for proteins. Annu Rev Biochem 1 98 1 ;  50: 349-383 .  
85. Padgett RA, Grabowski PJ, Konarska MM, Sei ler S, Sharp PA. Splicing of 
messenger RNA precursors. Annu Rev Bioehem 1 986; 55: 1 1 1 9- 1 1 50. 
86. Jurica MS, Moore MJ. Pre-mRNA spl icing: awash in a sea of proteins. Mol Cell 
2003 ; 12( 1 ) : 5w 1 4 . 
87. Zhou Z, Lickl ider LJ, Gygi SP, Reed R. Comprehensive proteomic analysis of 
the human spliceosome. Nature 2002; 419(6903) : 1 82 .. 1 85 .  
88. Jurica MS, Sousa D, Moore MJ, Grigorieff N. Three-dimensional structure of C 
complex spl iceosomes by electron microscopy. Nat Struet Mol Bioi 2004; 1 1(3) :  
3 ]  
Chapter 1 - Introducti on 
265-269. 
89. Tanner NK� Linder P.  DExDIH box RNA hel icases: from generic motors to 
specific d issociation funCtions . Mol Cell 200 1 ;  8(2) : 25 ] �262. 
90. Jankowsky E, Bo\vers H. Remodel ing of ribonucleoprotei n  complexes with 
DExHID RNA helicases. Nucleic Acids Res 2006; 34( 1 5): 4 1 8 1 -4 1 88 .  
91.  Ballut L,  Marchadier B, Baguet A, Tomasetto C,  Seraphin B ,  Le Hir H. The 
exon j unction core complex is locked onto RNA by inhibition of eIF4AIlI 
ATPase activity. Not Strucf Mol Bio/ 2005;  12( 1 0) : 86 1 �869. 
92. Konarska MM, Query CC. Insights into the mechanisms of spl icing: more 
lessons from the ribosome. Genes Dev 2005; 19( 1 9): 2255-2260. 
93. B lack DL. Mechanisms of a lternative pre-messengel' RNA spl icing. Annu Rev 
Biochem 2003 ; 72: 291 -336. 
94. Birney E, Kumal' S,  Krainer AR. Analysi s  of the RNA-recognition motif and RS 
and RGG domains: conservation in metazoan pre-mRNA spl icing factors. 
Nucleic Acids Res 1 993; 21(25): 5 803-58 1 6. 
95. Perriman RJ, Ares M, Jr. Rearrangement of competing U2 RNA hel i ces within 
the spl iceosome promotes multiple steps in spl ic ing. Genes Dev 2007; 21(7) : 
8 1 1 -820. 
96. Bellare P, Smal l EC, Huang X, Wohlschlegel JA, Staley JP., Sontheimer El A 
role for ubiqu it in in the spl iceosome assembly pathway. Nat Strucf Mol Bioi 
2008; 15(5): 444-45 1 .  
97. Wassarman DA, Steitz JA. Interactions of small nuclear RNA's with precursor 
messenger RNA during in vitro splicing. Science 1 992; 257(5078): 1 9 1 8- 1 925. 
98. Mathew R> Hat1muth K, Mohlmann S ,  Urlaub H, Ficner R, Lubrmann R. 
Phosphorylation of human PRP28 by SRPK2 is required for integration of the 
U4/U6-U5 tri-snRNP into the spl iceosome.  Not Slruct Mol Bioi 2008; 15(5): 
435-443 . 
99. Staley JP, Guthrie C. An RNA switch at the 5' splice s ite requires ATP and the 
DEAD box protein Prp28p. Mol Cell 1 999; 3( 1 ) : 5 5-64. 
100. Datta B ,  Weiner AM. Genetic evidence for base pairi ng behveen U2 and U6 
snRNA in mammal ian mRNA spl icing. Nature 1 99 1 ;  352(633 8) :  82 1 -824. 
101 .  Hausner TP, Giglio LM, Weiner AM. Evidence for base-pairing between 
mammal ian U2 and U6 smal l  nuclear ribonucleoprotein  pat1icles. Genes Dev 
1 990; 4(l 2A) : 2 146�2 1 56. 
1 02. Madhani lID, Guthrie C .  A novel base-pairing interaction between U2 and U6 
32 
-Chapter 1 - Introduction 
snRNAs suggests a mechanism for the catalytic activation of the spliceosome. 
Cell 1 992; 71 (5): 803-8 1 7. 
103. Wu lA, Manley JL. B ase pairing between U2 and U6 snRNAs is necessary for 
spl icing of a mammal ian pre-mRNA. Nature 1 99 1 ;  352(633 8) : 8 1 8-82 L 
104. Konarska MM, Vilardell J, Query CC. Repositioning of the reaction 
intermediate \vithi n  the
' 
cata lytic center of the spI iceosome. Mol Cell 2006; 
2 1 (4) :  543-553 .  
1 05.  Schwer B. A conformational l'earrangement in  the spI iceosome sets the stage for 
Prp22-dependent mRNA release. Mol Cell 2008; 30(6): 743-754.  
106. Patel AA, Steitz lA. Splicing double: ins ights from the second spliceosome. Nat 
Rev Mol Cell BioI 2003 ; 4(1 2) :  960-970. 
1 07. Kornblihtt AR� de la Mata M, Fededa JP, Munoz MJ, Nogues G. Multiple l inks 
between transcription and spl icing. Rna 2004; 1 0( 1 0) :  1 4 89- 1 498.  
108.  Bentley DL. Rules of engagement: co-transcriptional recruitment of pre-mRNA 
processing factors. Curl' Opin Cell Biol 2005;  17(3) :  25 1 -256 . 
1 09. Corden JL. Tai ls of RNA polymerase n. Trends Biochem Sci 1 990; 1 5( 1 0) :  3 83 -
3 87 . 
1 10. Das R, Yu J, Zhang Z, Gygi MP, Krainer AR, Gygi SP et al. SR proteins 
function in coupling  RNAP II transcription to pre-mRNA spl ic ing. Mol Cell 
2007; 26(6): 867-88 1 .  
1 1 1 .  Listerman I, Sapra AK, Neugebauer KM .  Cotranscriptional coupl ing of spl icing 
factor recruitment and precursor messenger RNA spl icing in mammalian cel ls .  
Nat Strllct Mol BioI 2006; 13(9): 8 1 5 -822. 
1 12.  Gornemann J,  Kotovic KM, Hujer K, Neugebauer KM. Cotranscriptional 
spl iceosome assembly occurs in a stepwise fashion and requires the cap b ind ing 
complex. Mol Cell 2005;  19(1 ) :  5 3-63 . 
1 13 .  Fong YW, Zhou Q. Sti.mulatory effect of spl icing factors on transcriptional 
elongation. Nature 200 1 ; 4 1 4(6866) : 929-933 .  
1 14. Lin S, Coutinho-Mansfield G, Wang D, Pandit S, Fu XD. The splicing factor 
SC35 has an active role in transcriptional elongation. Nat Struct Mol Bio/ 200S; 
1 5(8) : 8 1 9-826. 
1 15. Query CC, Konarska MM. Spl ic ing fidelity rev is ited . Nat Struct Mol BioI 2006; 
13(6): 472-474. 
1 16. Eperon LP, Graham IR, Griffiths AD, Eperon lC. Effects of RNA secondary 
structure on alternative spl icing of pre-mRNA: is folding l imited to a region 
33 
Chapter 1 - Introduction 
behind the transcribing RNA polymerase? Cell 1 988;  54(3):  393-40 1 . 
1 17. Chen Y, Chafin D) Price DH, Greenleaf AL. Drosophi l a  RNA polYlnerase II 
mutants that affect transcription elongation. J Bioi Chem 1 996; 271 ( 1 1 ) :  5 993-
5999. 
118. de la Mata M, Alonso CR, Kadener S, Fededa JP, B laustein M, Pelisch F et al. 
A slo\v RNA polymerase II affects alternative splicing in vivo. Mol Cell 2003; 
12(2): 525-532. 
1 19. Howe KJ, Kane CM, Ares M, Jr. Perturbation of transcription elongation 
influences the fidel ity of internal exon inclus ion in Saccharomyces cerevisi ae. 
Rna 2003 ; 9(8): 993 - 1006. 
120. Stephenson ML, Zamecnik  PC. Inhibition of Rous sarcoma viral RNA 
transl ation by a specific ol igodeoxyribonucleotide. Proc Notl Acad Sct U S A  
] 978; 75( 1 ) :  285-288 .  
121 .  Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and 
cel l  transformation by a specific ol igodeoxynucleotide. Proc Natl Acad Sci U S 
A 1 978; 75(1 ): 280-284. 
122. Dias N, Stein CA. Antisense ol igonucleotides: basic  concepts and mechani sms. 
Mol Cancer Ther 2002; 1 (5): 347-355 .  
123. KUl'reck 1 .  Antisense technologies. Improvement through novel chemical 
modifications. Eur J Biochem 2003 ; 270(8): 1 628- 1 644. 
124. Opalinska JB, Gewirtz AM. Nucleic .. acid therapeutics: basic  principles and 
recent applicat ions. Nat Rev Drug Discov 2002; 1(7): 503-5 1 4. 
125. Kal'le J, Laudrup P, Sams-Dodd F, Mikke lsen ID, Nielsen M. Differential 
changes in induced seizures after hippocampal treatment of rats with an 
antisense o l igodeoxynucleotide to the GABA(A) receptor gamma2 subunit. ElIr 
J Pharmacol 1 997; 340(2-3): 1 53- 1 60. 
126. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister­
Wittke U. Induction of apoptosis in smaI l-ceI l  lung cancer cells by an antisense 
o l igodeoxynuc leotide targeting the Bcl-2 coding sequence. J Natl Cancer Ins! 
1 997; 89(1 4):  1 027- 1 036 .  
127. McManaway ME, Neckers LM, Loke SL, al-Nasser AA, Redner RL, Sh iramizu 
BT et al. TUlnour-specific inhibit ion of lymphoma gro\vth by an antisense 
ol igodeoxynuc leotide. Lancet 1 990; 335(8693) :  808-8 1 1 .  
128. Zhao J, Bu D, Lee M, S lavki n  HC, Hall FL, Warburton D.  Abrogation of 
transfonning growth factor-beta type II receptor stimulates embryonic mouse 
34 
Chapter 1 - Introduction 
lung branching morphogenes is in culture. Dev Bioi 1 996; 180( 1 ) :  242-257 .  
129 .  Drysel ius R,  Nikravesh A, Kulyte A� Goh S, Good L .  Variable  coord ination of 
cotranscribed genes in Escherichia coli fol lowing anti sense repression. BMC 
Microbiol 2006; 6 :  97. 
130. Holden KL, Stein DA, Pierson TC, Ahmed AA, C lyde K, Iversen PL et af. 
Inh ib it ion of dengue virus translation and RNA synthesis by a morpholino 
oligomer targeted to the top of the terminal 3' stem-loop structure. Virology 
2006; 344(2): 439-452. 
131 .  Nikravesh A,  DryseI ius R, Faridani OR, Goh S ,  Sadeghizadeh M, Behmanesh M 
et al. Antisense PNA accumulates in Escherich ia col i  and mediates a long post­
antibiotic  effect. Mol The,. 2007; 15(8) : 1 537-1 542 . 
132. Yuan J, Stein DA, Lim T, Q iu D, Coughl in S,  Liu Z et af. Inhibition of 
coxsackievirus B3 in cell cultures and in mice by peptide-conjugated 
morphol ino ol igomers target ing the internal ribosome entry s ite. J Virol 2006; 
80(23) :  1 1 5 1 0- 1 1 5 1 9 . 
133. Elbashir SM, Harborth J, Lendecke l  W, Yalcin A, Weber K, TuschJ T. Dup lexes 
of 2 1  �nucleotide RNAs mediate RNA interference in cultured mamma lian cel ls .  
Nature 200 1 ;  41 1(6836):- 494-498. 
134. Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of 
mRNA. Nat Biotechnol 2003 ; 21( 12): 1 457- 1 465. 
135. Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and 
appJ icat ions . Drug Discov Today 2008; 13(1 9-20) : 842-855.  
136.  Dominski Z, Kole R. R�storation of correct splicing in  thalassemic pre-tnRNA 
by anti sense ol igonucleotides. Proc Natl Acad Set U S A 1 993; 90( 1 8) :  8673-
8677. 
137. Pramono ZA, Takeshima Y, Al imsardjono H, Ish i i  A, Takeda S, Matsuo M. 
Induction of exon skipping of the dystrophin  transcript in lymphoblastoid  cell s  
by transfecting an  ant isense ol igodeoxynucleotide complementary to  an exon 
recognition sequence. Biochem Biophys Res COJnmun 1 996; 226(2) : 445-449. 
138. Errington SJ, Mann CJ, F letcher S,  WHton SD. Target selection for antisense 
ol igonucleotide induced exon skipping in the dystrophin gene. J Gene Med 
2003;  5(6) : 5 1 8-527. 
139. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, F letcher S et al. Ant isense­
induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl 
A cad Sci USA 200 1 ;  98( 1 ) :  42-47. 
3 S  
Chapter 1 - Introduction 
140. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD. Improved 
anti sense o l igonucleotide induced exon skipping in the mdx mouse model of 
muscular dystrophy. J Gene Med 2002; 4(6) : 644-654. 
14 1 .  Aat1sma-Rus A ,  Bremmer-Bout M ,  Janson AA ,  den Dunnen JT, van Ommen 
OJ, van Deutekom JC. Targeted exon skipping as a potential gene correction 
therapy for Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12 Suppl 
1 :  S7 1 -77. 
142. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den 
Dunnen JT et al. Ant isense-induced exon skipping restores dystrophin 
expression in DMD pati�nt derived muscle cells. Hum Mol Gene! 200 1 ;  10(1 5) : 
1 547- 1 554 .  
1 43. Wilton SD, L loyd F ,  Carvil le K, Fletcher S,  Honeyman K, Agrawal S et al. 
Specific removal of the nonsense mutation from the mdx dystrophin mRNA 
using antisense o l igonucleotides. Neuromuscul Disord 1 999; 9(5) : 330-338 .  
144. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen IT, 
van Ommen OJ et al. Comparative analysis of antisense o l igonucleotide analogs 
for targeted DMD exon 46 skipping in muscle cells. Gene Ther 2004; 1 1 ( 1 8) : 
1 39 1 - 1 398 .  
1 45. Alter J, Lou F, Rabino\vitz A, Yin H, Rosenfeld J, Wilton SD et al. Systemic 
delivery of morpholino ol igonucleotide restores dystrophin expression bodywide 
and improves dystrophic .pathology. Nat Med 2006; 12(2) : 1 75- 1 77. 
146. Fletcher S, Honeyman K, Fall AM, Hard ing PL, Johnsen RD, Steinhaus JP et al. 
Morpholino Ol igomer-Mediated Exon Skipping Averts the Onset of Dystrophic  
Pathology in the mdx Mouse. Mol Ther 2007 ; 15(9) : 1 587- 1 592. 
147. Jearawiriyapaisarn N, Moulton HM, Buckley B ,  Roberts J, Sazani P,  Fucharoen 
S et al. Sustained dystrophin expression induced by peptide-conjugated 
morphol i no o ligomers in "the muscles of mdx mice. Mol Ther 2008; 16(9) : 1 624-
1 629.  
1 48. Wu B, Moulton HM, Iversen PL, Jiang J, Li  J, Li J et al. Effective rescue of 
dystrophin improves cardiac function in dystrophin-deficient mice by a modified 
morphol ino ol igomer. Proc Natf Acad Sci U S A  2008 ;  105(39) : 1 48 14 - 148 1 9 . 
149. Yin H, Moulton HM, Seow Y, Boyd C, Bouti l ier J, Iverson P et al. Cell­
penetrat ing peptide-conjugated antisense ol igonuc leotides restore systemic 
musc le and cardiac dystrophin expression and function. Hum Mol Genet 2008. 
1 50. Miyaj ima H,  Miyaso H, Okumura M, Kurisu J, Imaizumi K. Identification of a 
36 
Chapter 1 - Introduction 
eis-acting element for the regulation of SMN exon 7 splicing. J Biol Chem 2002; 
277(26) : 23271 -23277. 
151. Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of 
human survival motor neuron is  regulated by a unique si lencer e lement located 
in the last i ntron. Mol Cell Bioi 2006; 26(4): 1333- 1346. 
152. Singh NN, Androphy EJ, Singh RN. An extended inhibitOlY context causes 
skipp ing of exon 7 of SMN2 in spinal muscular atrophy . Biochem Biophys Res 
Commlln 2004; 315(2): 38 1 -3 88. 
153. Lim SR, HerteI KJ. Modulation of survival motor neuron pre-mRNA spl icing by 
inh ib ition of alternative 3' spl ice site pairing. J BioI Chem 2001 ;  276(48) : 
45476-45483. 
154. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ. Correction of SMN2 Pre­
mRNA spl icing by antisense U7 small nuclear RNAs. Mol Ther 2005 ; 12(6): 
1 0 1 3- 1 022. 
155. Skordis  LA, Dunckley MG, Vue B,  Eperon IC, Muntoni F. Bifunctional 
antisense o l igonucleotides provide a trans-acting spl ic ing enhancer that 
stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S 
A 2003 ; 100(7): 4 1 1 4-4 1 19. 
156. van Deutekom JC, Jans<?n AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, 
Bremmel'-Bout M et 01. Local dystrophin restoration with anti sense 
o l igonucleotide PR005 1 .  N Engl J Med 2007; 357(26): 2677-2686. 
1 57. Muntoni F, Bushby K, van Ommen G. 1 28th ENMC International Workshop on 
'Precl inical optimizat ion and Phase Illl Cl in ical Trials Using Antisense 
Ol igonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, 
Naarden, The Netherlands. Neuromuscul Disord 2005 ; 15(6): 450w457. 
37 
Chapter 2 - Personalised genetic i ntervention for DMD: Antisense oligomers and exon skipping 
CHAPTER 2 
Personalised genetic intervention for Duchenne muscular dystrophy: 
Antisense oligomers and e�on skipping 
Chalermchai Mitrpant 1. 2, J, Sue Fletcher1,  Steve D. Wilton 1 ,  *. 
I Molecular Genetic Therapy Group, Centre for Neuromuscular and Neurological 
Diseases, The University of Western Australia, QEII Medical Centre, Nedlands, 
Western Austral ia, Austral ia 
2Centre for Human Genetics, Edith Cowan University, 1 00 100ndalup Drive, Perth W A 
6027, Austra l ia  
3DepaI1ment of B iochemistry, Faculty of Medicine, S iriraj Hospital, Mahidol 
University, Bangkok 1 0700, Thai land 
* Correspondence to: 
Steve D Wilton, Centre for Neuromuscular and Neurological Disorders, The University of 
Western Austral ia, QE II Medical Centre, Nedlands, Western Australia, 6009, Austra l ia. 
Email :  swi l ton@meddent.uwa.edu.au 
Telephone: +6 1 8 9346 3 967 
Facsimile: +6 1 8 9346 3487 
3 8  
Chapter 2 - Personalised genetic intervention for DMD :  Antisense oligomers and exon skipping 
2.1  Abstract 
Duchenne muscular dystrophy (DMD) arises from protein-truncat ing mutations 
in  the large dystrophin gene that precl ude synthesis of a functional protein that primarily 
stabil izes muscle fibre membranes. The absence of dystrophin leads to this most 
common and serious form of childhood muscle-wasting. S ince the identification of the 
dystrophin gene in 1 987, cell and gene repair or repJacement therapies have been 
evaluated for DMD treatment and one genetic i ntervention, exon skipping, is now in  
cl inica1 trials .  Antisense ol igomers have been designed to  redirect dystrophin  spl icing 
patterns so that targeted exons may be removed from a defective dystrophin pre-mRNA 
to e i ther restore the reading frame of a delet ion, or excise an in-frame exon corrupted by 
a nonsense mutation 01' micro-insertion/deletion. This review discusses the evolution of 
ol igomer i nduced exon skipping? including in vitro appl icat ions, evaluation of different 
o l igomer chemistries, the treatment of animal model s  and alternative exon skipping 
strategies involving viral expression cassettes and ex vivo manipulation of stem cel ls .  
The discussion culminates with the current cl inica l trials and the great chal lenges that 
l ie ahead. The major obstacle to the i mplementation of persona l i sed genetic treatments 
to address the many different mutations that can lead to DMD, are considered to be 
establ ish ing effective del ivery regimens for the d ifferent patients and thei r  mutations. 
Furthermore, the vie\v of regulatory authorities in assessing prec lin ical data on 
potential ly scores of d ifferent but  class-specific compounds wil l  be of paramount 
impOltance in expediting the c l inical appl icat ion of exon skipping therapy fOl' th i s  
serious and relentlessly progressive muscle wasting disease. 
KeY\" ords: Antisense Oligonuc leotides, Exon skipping� Duchenne muscular dystrophy, 
Morpho l ino, c l in ical trials, dystroph in, personal ized medic ine, pre-mRNA spl icing 
Abbreviations : AO: antisense o l igomer, B MD: Becker muscular dystrophy, cDNA: 
complementary DNA, DMD: Duchenne muscular dystrophy, DNA: deoxyribonucleic 
acid, ENAs: 4' -C-ethylene bridge nucleic acids, ESE: exon splicing enhancer, GRMD: 
Golden retriever muscu lar dystrophy, kDa: kilodalton, LNAs: locked nucleic acids, 
MOE: 2'-O-methoxy-ethoxy AO, NMD: nonsense mediated decay, ODN: 
oligodeoxynucleotide, PMO:  Phosphorodiamidate Morphol ino Ol igomer, PNAs: 
peptide nucleic acids, pre-mRNA: precursor messenger ribonucleic acid, RNA : 
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ribonucleic acid, SCID : severe combined immunodeficiency, 20Me: 2'-O-methyl 
modified. 
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2.2 Introduction 
When considered indiv�dual ly, serious monogenic d isorders are fortunately 
rel at ively rare, especial ly when compared to complex traits such as Alzheimer's, 
asthma, d iabetes, or acquired conditions,  including pathogenic infections and cancer. 
The most common human autosomal recessive d i sorder, cyst ic fibrosis, is reported to 
occur at a frequency of about 1 in 2 1 00 in  the Caucasian population. } Ho\vever, 'when 
viewed col lectively, single gene disorders are an enormous burden to those affected, 
thei r  fami l ies� communities, and "the health care system. 
It i s  no l onger appropriate to consider single gene d isorders as "simple", 
particularly s ince i t  is apparent that different lesions i n  a particular gene can result in a 
variety of clin ically d istinguishab le  conditions, w ith either recessive or dominant modes 
of transmission .  Although the dF508 mutat ion defect accounts for about 75% of cystic 
fibrosi s  cases,2, 3 over 1 ,000 different mutations have been reported and the cl i nical 
presentation can vary considerably from severe, with extensive lung involvement, to a 
very mi ld phenotype with reduced fert i l i ty as the predominant symptom. S imilarly, 
d ifferent mutations in the huge dystrophi n  gene can lead to the al lelic conditions� 
Duchenne muscul ar dystrophy (DMD), Becker muscular dystrophy (BMD), and X­
l inked d ilated cardiomyopathy,4 . 
Restoration of expression of a single  component to address a miss ing or 
defective gene product is  the bas is of gene replacement (viral and non-vira l  systems) or 
cell-based therapies. A lthough great advances are being made in the treatment of some 
conditions, for example, gene replacement in chi ldren w ith X- l inked severe combined 
immune deficiency (SCID),s· 6 there have also been serious adverse events and progress 
has not been as rapid as anticipated. 7 Chal lenges to gene and ce]] replacement therapy 
for DMD ari se from the s ize of the gene product and/or nature of the gene expression. 
Dystrophin, the affected gene product in DMD} is encoded by the l argest known gene 
and is expressed as mu ltiple isoforms in different t issues, with the 427 kDa skeletal 
muscle protein produced at low amounts i n  about 30% of the human body mass.s 
Such chal lenges in  gene and ce l l  replacement for DMD have prompted the 
examination of other possible therapeutic i nterventions} including up-regulation of a 
homologous protein  or redirecting expression, processing, or translat ion of the defective 
gene product.9- I 1  This review ,viH consider the use of antisense o l igomers (AOs) to 
4 1  
Chapter 2 - Personalised genetic intervention for DMD: Antisense oligomers and exon skipping 
reduce the severity of DMD, through specific redirection of dystrophin pre-mRNA 
processing to by-pass protein-truncating mutations during mRNA maturation. The 
nature of this genetic therapy is such that specific AOs and exon skipp ing strategies 
must be tai lored to address different mutations. Although this may sound daunting� 
development of personalized treatments should not be considered unrealistic. Many 
compounds have now been optimised to address different dystrophin mutations in vitro, 
and two compounds are currently in cl inical testing to restore the reading frame of a 
common type of dystrophin mutation. Demonstration of dystl'ophin expression in these 
trials should faci l itate implementation of other AO strategies for different DMD 
patients, particularly if exon skipping could be regarded as a generic therapy. 
2.3 Duchenne and Becker Muscular Dystrophy 
DMD and BMD are al lelic X-linked recessive conditions arising from mutations 
in the dystrophin gene. One third of cases are de novo and germ-line mosaicism has 
been reported to be as high as 1 4%. 12 The tremendous s ize of the dystrophin gene and 
organization of repeated elements within some introns in excess of 200kB, are thought 
to contribute to the high spontaneous mutation rate. DMD occurs at a c ited incidence of 
1 in 3 ,500 l ive male births, and is the most common severe muscular d isorder in 
childhood . 13 DMD individuals appear norma] at b irth, but present with musc le 
weakness bet\veen the ages of 3-5 years . Muscle degeneration gradually ovelwhehns 
regenerative capacity in a relentlessly progressive and predictable manner. As muscle 
degeneration progresses, affected ind ividuals exhibit difficu lties arising from the floor, 
climbing stairs and running} and eventual ly lose ambulation before the age of 1 2  years. 
The most common causes of death are cardiac or respiratory compl ications, but 
improvements in heath care, the use of steroids and assisted venti lat ion have extended 
the l ife span of DMD patients by up to 50% over the last two decades. 1 4  
BMD is estimated to oc�ur at  one tenth the  frequency of DMD. 15 Presenting 
with a spectrum of severities, BMD is  c l inically classified as an individual becoming 
wheelchair bound by age 1 6  years or later, whi le some are apparently asymptomatic and 
may only be diagnosed later in I ife. 1 6 Examples of gross dystt'ophin gene deletions that 
have been identified in mild ly affected BMD patients are shown in Ta ble 1, where i t  
can be seen that over 50 dystrophin exons may be deleted, in various combinat ions, with 
relatively minor clinical consequences . It seems probable that the low incidence of 
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BMD, compared to DMD, may be due to the inabi l i ty to identify cases that do not 
present with overt symptoms. A mutation in the dystrophin gene was recently rep011ed 
where the loss of exon 1 6  did not raise the serum creatine kinase levels , 17 a sensitive 
lnarker of muscle damage. 
The molecular distinction between DMD and BMD depends upon the quantity 
and qual ity of dystrophin that can be synthesized as a consequence of the gene lesion. I S  
Genomic delet ions of one or more exons, found to  cluster i n  2 hotspots near huge 
introns, are the most common type of dystrophin mutation and account for about 60% of 
cases. Duplications, typically involving m ultiple exons� are generally found in the 
proximal third of the gene and are seen in 8- 1 5% of DMD cases. 1 9-22 D isruption of the 
reading frame that leads to premature termination of dystrophin synthesis  resu lts in 
DMD, whi le  in-frame gene re-arrangements typical ly al low the generation of internally 
truncated dystrophin that retains some biological function. The variable manifestation 
of BMD, £l'om border-l ine DMD to asymptomatic, reflects the qual ity and/or quantity of 
the internally shortened dystrophi n  (for review see 23.25) . 
The dystrophin gene contains 79 exons spanning approximately 2.4 mil lion base 
pairs and encodes 3 major isoforms, which are expressed primari ly in muscle, heart and 
brain. The reading frame organization of the 79 exons is shown in Figure I. In 
addition, there are 4 i nternal promoters, \vhich encode shOlter isoforms expressed in 
other tissues. Due to the catastrophic consequences of dystrophin loss on muscle 
function and integrity, it is presumed that the 427 kDa ske letal muscle isoform is  most 
important, hence this has been the focus of the gene repair or replacement studies (for 
review see 26, 27) . 
Dystrophin is thought to act much l ike a shock absorber linking the actin 
cytoskeleton to a complex of proteins embedded in the sal'colemma. The primary actin 
binding domain involves dystrophin exons 2-8, a lthough secondary actin binding s ites 
have been identified,28, 29 suppOlted by the identification of mildly affected BMD 
individuals missing exons 3_9. 1 6  Dystrophin exons 62-69 encode the cysteine rich 
domain, which i s  pivotal in the . linkage of dystrophin to J3-dystroglycan, and hence to 
the dystrophin associated proteins and glycoproteins embedded in the sarcolemma. In 
add ition to the primary structural role linking the actin cytoskeleton and the 
sarcolemma, dystrophin also anchors syntrophin, dystrobrevin, and localizes nNos.25 
As well  as the major 427 kDa isoforms expressed in musc le, hea11 and brain, inte rnal 
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promoters located within introns 3 0} 45, 56 and 63 are responsible for the production of 
the shol1er isoforms, DP260, DP l 1 6, DP 1 40, and DP7 1 ,  respectively. In non-muscle 
tissue, DP1 1 6  associates with the sarcoglycan complex and is  implicated in myel in 
stabi l i ty in schwann cel ls.3o Transient expression of DP1 40 in embryonic kidney i s  
involved in  rena l  tubulogenesis.3 1  The carboxy (C)-termina l  domain of DP71  isoforms 
plays an important role in neuronal d ifferentiation.32 
The act in and p-dystroglycan binding domains are separated by 24 spectrin-li ke 
repeats, and this rod domain is encoded by about two thirds of the dystrophin gene 
transcript .33 Pot1ions of the rod domain appear to be somewhat redundant i n  that 
substantial in-frame deleti ons of rod domain general ly lead only to a mi ld BMD 
phenotype (Table 1)?4 
2.4 Natural precedents for exon exclusion during dystrophin processing 
There are two precedents to support the hypothes is that i nduced exon skipping 
could minimise the consequences of protein-truncating mutat ions in the dystrophin 
gene. Revertant fibres are dystrophin-positive fibres that occur naturally and have been 
detected in mdy mouse model of muscular dystrophy,35, 36 the dystrophin-deficient 
muscular dystrophy can ine model ,37-39 and at least 60% of aU DMD cases.40-43 Another 
can ine model, a German short-hai red pointer,44 in which the entire dystrophin gene was 
missing, did not contain any revertant fibres, suggesting that the mechanism responsib le 
for restoring some dystrophin expression required the retention of sufficient coding 
sequences of the dystrophin gene.  
Although revertant fibres are regularly detected in many dystrophic t issues, the 
frequency is insufficient to be of any substantial c l in ical benefit.42 RNA analysis and 
epitope mapping indicated the presence of multiple revertant dystrophin isoforms in 
human and mouse muscle. This suggested some natura l exon skipping event led to re­
arrangements,36. 45 general 1y exc �uding 20 or more exons.46 In situ hybridization studies 
in the mdx mouse using exon 23 and flanking intronic  sequences as a genomic  probe, 
indicated that the dystrophin gene in the majority of revet1ant fibres was structurally 
i ntact, thereby excluding secondary somatic deletions in the dystrophin gene as the 
primary possib le mechanism.46 The underlying basis of revertant fibres is believed to 
involve some form of alternative spl ic ing,36, 47 although it i s  d ifficult to conceptual ize a 
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mechanism whereby 20 exons spanning hundreds of kilobases of pre-mRNA are 
consi stently excluded in one muscle fibre and not another. 
BMD patients typically have genomic deletions in the dystrophin gene that do 
not d isrupt the reading frame. A few point mutations that lead to BMD have been 
identified, i ncluding missense mutations in the actin binding domain, 1 5  and splice motif 
lnutations that either lead to excision of an in-frame exon, or reduce the amount of 
normal dystrophin mRNA.48 Some nonsense mutations  in the dystrophin gene have 
also been found to lead to BMD,49, 50 in apparent conflict with the reading frame 
hypothesis, which predicts that protein-truncating mutations should resul t  in DMD.5 1  
However in  these milder than expected BMD cases, it  was found that the nonsense 
mutation influenced splicing patterns such that natural exon skipping excluded the exon 
containing the nonsense mutations. 50 Comprehensive screening of genomic DNA has 
been repOlied to confirm diagnosis of over 96% of DMD cases, whereas only 60% of 
BMD mutations were identified .52, S3 Analysis and sequencing of dystrophin cDNA 
frOln muscle is often essential to identify the consequences of less obvious gene 
mutations� where a nonsense or missense mutation/polymorphism may lead to exon 
skipping or activation of a cryptic spl ice s ite . Similarly, deep intronic DNA changes, 
sometimes kilobases away from the nearest dystrophin exon, can lead to the 
incorporation of pseudo-exons it'! the mature gene transcript. 54 
2.5 Antisense Oligomers and Modes of Action 
An o l igodeoxyribonucleotide was reported to inhibit Rous sarcoma virus 
repl ication in cell culture near1y three decades ago.55, 56 Antisense technologies became 
synonymous with gene down-regulation studies, most commonly through the induction 
of RNaseH degradation of the RNA strand in the AO:RNA duplex. Inadequate controls 
confounded results of some early experiments, where apparent gene suppression arose 
from non-sequence specific effects, in particular the sequestration of 
transcription/translation proteins by the phosphorothioate backbone. Despite these early 
setbacks, which saw anti sense technology regarded with a great deal of skepticism, 
there has since been great progress in terms of new chemistry development and 
identifying d i stinct mechan isms of altering gene expression . 
New oligomer chemistries, with modified bases andlor backbones, generated 
compounds with greatly increased anneal ing affinity and/or enhanced resistance to 
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nuclease degradation. Vitravene (fomi virsen) was the first anti sense drug to achieve 
marketing clearance in the USA to treat cytomegalovirus retinitis in people with 
AIDS .57 In addition, new ol igomer chemistries were abl e  to influence gene expression 
throu gh mechanisms other than RNaseH-induced degradation. Chemically synthesised 
RNA ol igomers are routinely used i n  gene s i lencing studies in nematodes, plants and 
human cells .5S.6 1 Some second .or thi rd generation o1 igomers, which were not able to 
activate si lencing pathways� can modify gene expression at d ifferent stages .  Depending 
upon the target sequence design, some mod ified ol igomers can suppress translation by 
masking motifs essential for ribosomal i nitiation and elongation, wh ile other o l igomers 
can anneal to motifs i nvolved in exon recognition and intron removal, thereby 
redirecting pre-InRNA processing. 
2 .. 6 Early splice intervention studies 
Kole and colleagues fi rst reported the use of AOs to correct aberrant �-globin 
pre-mRNA spl icing fifteen years ago.62 Intronic mutations in this  gene activated cryptic 
spl ice sites and account for nearly 30% of f3-thalassemia cases. Despite the presence of 
i ntact splice donor and acceptOl: s ites� the selection of cryptic spl ice s ites led to some 
i ntron retention in the mutant f3-globi n  mRNA. ADs consisting of 21-O-methyl 
modified bases on a phosphorothioate backbone (20Me) were designed to anneal to the 
cryptic splice s ites, rendering them inaccessible to the spl icing mach inery, which in turn 
defaulted to the selection of the normal spl ice s ites. A few years later, Matsuo and 
colleagues were able to induce an abnormal dystrophin  gene transcript by targeting an 
o ligodeoxynucleotide on a phosphorothioate backbone (ODN) to an internal domain 
within  dystrophin exon 1 9.63 The lIKobe" DMD mutation was found to arise from a 52 
bp deletion withi n  dystrophin exon 1 9  that, whi le  leaving the donor and acceptor sites 
i ntact, resulted in  the excis ion of the entire exon from the gene transcript.64, 65 Matsuo 
and colleagues  hypothesized that the smal l  intra-exonic deletion removed crucial  exon 
recognit ion motifs and resu lted . in complete exon removal .  An AO was designed to 
i nduce dystrophin exon 19 skipping in  normal IYlnphobJastoid cel ls  transformed with 
Epstein-Barr viruS .63 Hence, the first demonstration of exon skipping in the dystrophin 
gene did not rescue defective gene expression, but induced abnormal spl icing and 
disrupted the readi ng frame. Neveltheless these experiments confirmed the principle of 
targeted exon skipping and proposed th i s  approach as a potential therapy for DMD. 
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2.7 Animal Models 
The most commonly studied animal models of dystrophin mutations are the mdx 
mouse, which carries a nonsense mutation in exon 23,35 and the Golden retriever 
muscular dystrophy model (GRMD), which was found to h ave a spl ice site mutation 
that leads to exon 7 exclusion and a subsequent mRNA frame-sh ift.39 The mdx mouse 
model is  readily ava ilable, inexpensive, but suffers from the l imitation that the 
dystrophin deficiency does not induce an overt severe dystrophic phenotype. 
Nevertheless, detailed examinations show raised serum creatine kinase levels and 
muscle weakness, and some muscles, in  particular the diaphragm, show extensive 
fibrosi s  and dystrophic pathology,66 As these animals age, the consequences of the 
dystrophinopathy become more obvious, but these animals can voluntarily run in a 
Inanner simi lar to wild type animals.  Another mouse model, which does show a very 
severe phenotype is the utrophinldystrophin double knockout mouse,67 aJthough no 
exon skipping studies in  this model have been reported to date . 
The canine GRMD model is much more severely affected, perhaps more so than 
the human condition, and provides a more relevant model in which to assess any 
therapies. Limitations of the canine model include substantial variat ion in severity, 
excessive costs involved in maintenance and care, limited numbers available from each 
l i tter, and the emotive issues associated \vith working on companion animals. 
2.8 AO Design and Target Selection 
The rescue of dystrophi n  expression using AO-induced exon ski pping in the md� 
mouse was fi rst reported by Dunkley and colleagues, who described a 20Me AO 1 2mer 
directed at the exon 23 acceptor spl ice s ite that generated a transcript in which exons  23 
to 29 had been skipped . 20Me AOs directed at the branch point or the donor spl ice site 
of exon 23 were not found to ha�e any effect on the dystrophin mRNA processing.68 In 
contrast, the follo\ving year we demonstrated that targeting the exon 23 donor spl ice site 
with a 20Me AO 20mer was able to induce precise and consistent exon 23 skipping, 
whereas a 20mer directed at the acceptor site was found to be ineffective .69 Subsequent 
refinements in AOs targeting the dystrophin exon 23 donor spl ice site \vere reported and 
found to further enhance the -capacity of the AO to induce exon 23 skipping.7o 
Additional AO refinement at the acceptor spl ice s ite consistently failed to induce any 
detectable skipping.70 
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Studies describing the applicat ion of AOs d irected to exons flanking frame­
shifting genomic delet ions i n  DMD patient cell l ines were repOlted by van Deutekom 
and colleagues,?1 The Leiden muscular dystrophy database (http://www .dmd .nll) l ists 
exon 45  as one of the most commonly deleted exons in  DMD, whereas the in-frame 
deletion of exons 45  and 46 is associated with a mild form of BMD. van Deutekom and 
colleagues designed a 20Me AO to motifs withi n  exon 46 and conc lusively 
demonstrated restoration of the reading frame in cells from DMD individuals carrying a 
dystrophin genomic deletion of exon 45 .7 1  These studies were then extended to a 
variety of other mutations in the dystrophin gene.72-74 
It has been proposed that only 1 2  different AOs would be able to restore the 
reading frame in the majority of DMD deletion patients, particularly since this type of 
mutation i s  c lustered in the minor and major dystrophin delet ion hotspots.75 Indeed} the 
most commonly deleted exons lie between exons 45 and 55 ,  and Beroud and 
col leagues,76 repotted that mUltiple exon skipping across those exons could restore some 
functional dystrophin expression in almost two thirds of al l DMD patients . 
However, more than one-third of DMD cases do not arise from genomic 
deletions and these patients sho.uld not be excluded from any potential exon skipping 
therapy. Nonsense mutations, spl icing defects and micro�insertionldeletions have the 
potential  to lead to premature termination of translation, and these defects appear evenly 
distri buted across the entire gene. As d iscussed previously, an apparent catastrophic  
DNA change such as  a nonsense mutation, does not necessarily lead to premature 
termination of translat ion, if the DNA variant compromises exon recognition and results 
i n  variable levels of natural exon skipping. S ince the excluded exon is in-frame, a 
protein  typical of BMD is generated,49. 50 again provid ing evidence that exon skipping 
has the potential to ame liorate DMD progression. 
FUl1hermore, unlike many genomic delet ions involving multiple exons, the 
entire dystrophin coding region is present in the non-delet ion DMD patients . The 
removal of one or two exons to by-pass a prote in-truncating mutation is unl ikely to 
seriously compromise the function of the induced dystrophin, unless the exons code for 
a crucial functional domain. Aartsma-Rus and colleagues,77 described 1 1 4 AOs that 
target 35 exons for removal. In 2007, we released the first draft of AOs targeting every 
exon in the dystrophin pre-mRNA for excis ion, excluding the first and last exons .78 
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It has been suggested that directing AOs to dystrophin  donor or acceptor spJ ice 
sites may lead to off-target effects on other splice sites,79 a possibility which cannot be 
discounted . However, the invariant bases of the acceptor and donor spl ice sites are only 
2 nucleotides long, and occur at �he end and beginning of each i ntron flanking the target 
exon (---ag[EXON]gu---). We took the approach that any motif involved in splicing 
must be regarded as a potentially amenable target and evaluated the effici ency of AOs 
d i rected at acceptor and donor splice s ites, as well as Exon Splicing Enhancers (ESE's) 
as predi cted by ESEFinder.8o, 81 Although the IIag" and "gu" motifs are almost invariant 
at the acceptor and donor splice sites respectively, these two nucleotides would  on ly 
constitute a minor proportion o{the AO anneal ing site. It may be argued that targeting 
ESE's, where 6 or 8 consensus nucleotide motifs are recognised by SRp55 or SC35 
respectively, offers a greater chance of cross-transcript targeting. 
Remarkably from these two extensive reports on AO design to induce 
dystrophin exon skipping,77, 78 about two thirds of AOs designed and evaluated were 
able to induce some level of targeted exon exclusion. This is consistent with the 
observation that many changes in  the protein coding region can disrupt spl ic ing,82 and 
impl ies that many Inotifs are involved in exon recognition and splicing. However, there 
are substantial variations in exon skipping efficiencies, as clearly some AOs targeted 
more amenable or responsive sites for i nduced exon skipping than others. Some exons 
\vere readily and efficiently rem9ved at what was arbitrarily chosen an acceptable level 
in vitro, greater than 30% exon removal compared to the intact transcript after 
transfection at 1 00 nM AO:lipoplex,78 while other exons were more difficult to 
dis lodge. Aartsma-Rus and colleagues,83 noted that the effective AOs targeted 
significantly higher numbers of SF2/ASF, SC35  and SRp40 motifs than the ineffective 
AOs.77 
Our strategy for AO design has been more empirically based. An init ial panel of 
AOs was designed to target spl ice site junctions for each exon, as wel l  as predicted ESE 
motifs .  Normal myogenic cultures were transfected and the test compounds exhibiting 
the most pronounced exon skipping efficiency \vere used as a template to design a 
subsequent series of overlapping AOs. The most efficient AO was defined as the 
compound that induced maximal exon excision in vitro, after transfection at 
concentrations over the range 1 0  to 1 00 nM. Although the AOs designed to i nduce 
specific exon skipping will u ltimately be applied to cells expressing a defective 
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dystrophin gene, AO development was undertaken in normal human primary myogenic 
cell cultures . Designing AOs to target the normal  dystrophin gene transcript places 
extra demands on evaluation. Unl ike cells express ing a defective dystrophin mRNA 
sUbjected to increased turn-over through nonsense mediated decay,84 removal of 
approximately half of the exons from a normal dystl'ophin transcript may lead to a 
disruption of the reading frame. Hence, the normal gene transcript wil l  be expressed at 
wUd-type levels, and the induced exon deleted transcript wil l  be subj ected to faster turn­
over though nonsense mediated decay. Consequently, when the appropriate therapeutic 
ol igomer is applied to dystrophic cel l s, the effect on exon skipping should be more 
pronounced, as the reading frame will have been restored and the induced transcript no 
longer subjected to nonsense mediated decay (NMD). This feature was evident in 
evaluating AOs to excise exon 19 from the dystrophin gene transcript expressed i n  
normal and mdx murine myogenic cel ls .  The mdx dystrophin  transcript would be 
subjected to NMD, as would any dystrophin  transcripts missing exon 1 9 .  Despite the 
same nucleotide sequence and spl ic ing machinery, exon 1 9  removal was induced in md'C 
cel l s  at concentrations 4 fold lower than that required in  the norma l  cel ls .8s 
One trend in AO design that became evident was that the length of the AO could 
play a m ajor role in detertnining the efficacy of induced exon skipping, although this  
appears to be largely dependent upon the target exon.86 Several motifs were exami ned 
as targets for induced skipping of human dystrophin exon 1 6, in particular, a c luster of 
high-scoring potential ESE's near the donor splice site. Despite masking of high­
scoring ESE's and this donor splice motif, overlapping AOs directed at the human exon 
1 6  donor s ite were found to be ineffective� whereas a 25mer, spanning the acceptor site 
induced moderate exon 1 6  skipping. AOs with additional bases at the 5' or 3' end of the 
25mer \vere found to be about four-fold more effective than the original AO targeting 
the acceptor. Most surprisingly, a 20mer common to a l 1  three AOs was found to be 
total ly i neffective.86 Although it had been observed that a 25mer d irected at the mouse 
exon 23 donor s ite was marginally more effective than a 20mer, longer AOs (30mer) 
directed at thi s  site were consistently found to induce less exon 23 skipping than the 
shorter compounds.86 
Some dystrophin  exons were d ifficult to dis lodge from the mature dystrophin 
mRNA, and despite designing AOs across most of the exon, with either no or only very 
low l evels of skipping being induced after transfection with high AO:l ipoplex 
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concentrations. Exon 20 was one such example, in which over 20 different AOs were 
designed and evaluated, but only one compound was eventually found to induce 
moderate level s of exon 20 excision. Combinations of AOs were then evaluated and 
some, but not all AO cockta i ls} were found to be very effective i n  a clearly synergistic 
rather than cumulative manner.S3• 87 AO cocktai l  design was not as simple as combining 
the most effective AOs} as the optimal AO cocktai1  for exon 20 consisted of two 
compounds that had no effect on splicing ,vhen used individually. Replacing one of the 
AOs in this cocktai l  ·with a longer overlapping compound that did show some exon 
skipping potent ia l  when used a lone, actually lowered the efficiency of that cocktaiL 87 
In another example, very weak exon 65 skipping could be induced with one AO after 
transfect ion at a concentration of 600 nM. When this AO was combined with another 
directed at exon 65, pronounced exon skipping was evident after transfection at a 
combined AO concentration of 2 nM.87 
This raises the question of exactly how AOs influence the spl icing process. It 
had been assumed that AOs anneal to s ingle stranded motifs on the pre-mRNAj where 
SR proteins or other' spl ice factors} such as short non-coding RNAs including miRNAs 
S8 may be involved in exon recognition and definition. AO b indi ng to the appropriate 
target would render that pre-mRNA site double-stranded and presumably prevent 
correct assembly of the sp l iceosome. If this were the case, one would assume that the 
more obvious motifs involved in splicing, such as the acceptor or donor sites should 
provide reliable targets for consistent splice intervention. Th is is clearly not the case, as 
we have identified only one human dystrophin exon in which the donor spl ice s ite was 
the s ingle most amenable target for exon skipp ing.78 Although directing AOs to some 
donor spl ice s ites does induce exon skipping, there are more examples of no skipping 
whatsoever. As reported by Arechavala-Gomeza et al, 89 applying a panel of AOs to 
micro-walk across the donor spl ice s ite of human dystrophin exon 5 1 )  or using AOs of 
increased length targeting the donor s ite, failed to i nduce any substantial  exon skipping. 
It would appear that if a donor splice motif does not appear alnenable, extens ive AO 
design and man ipUlation targeting that area wBl be a futi le  exercise . 
Rather than direct ly masking motifs recognized by the various splice factors, 
perhaps the AOs bind to the pre-mRNA and alter secondary structures that are crucial in  
exon recognit ion and spl icing. -There is  mounting evidence that secondary structures 
within the pre-mRNA are involved in both constitutive and alternative spl ic ing,90>92 and 
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this may account for the observations that 2 out of 3 AOs designed and eva1uated were 
able to induce some exon skipping.77, 78 It is possible that some donor or acceptor sites 
unresponsive to AO intervention are influenced by particular splicing factors, which 
bind very strongly and/or immediately after transcription. 
Several oligomer chemistries have been identified as suitable to induce exon 
skipping. While ODNs were first used to induce exon 1 9  excision in dystrophi n  
processing,93 and later used in  the first c l inical trial involving one patient,94 there are 
several reasons why this particular chemistry should not be taken to the clinic for 
induced exon skipping. This type of ol igomer is more susceptible to nuclease 
degradation than many other chemistries and wou ld need constant re-admini stration to 
maintain therapeutic concentration. Secondly, ODNs are typically used to ind uce 
degradation of the target gene transcript by RNaseH action. Presumably if exon 
excision can occur before RNaseH degradation, the induced transcripts would then be 
resistant to degradation, unJ ike_ the intact transcript. Although ODNs \vere able to 
induce exon 19 skipping in cultured cel l s� AOs of this chemistry directed at other spl ice 
motifs did not induce exon skipping.ss Chimeric AOs consisting of a mixture of 
modified and unmodified bases demonstrated increased exon skipping efficiency, 
correlated with i ncreased content of 21-O-methyl modified bases.95 
One of the more comm�n ly used nucleotide chemistry for AOs to induce exon 
skipping are those consisting of 2'-O-methyl modified bases on a phosphorothioate 
backbone.62, 69, 71, 96 Several other AO chem istries have also been evaluated for 
induction of exon skipping, includ ing terminal ly modified 20Me AOs�97 2'�O-methoxy­
ethoxy AOs (MOE, unpublished data)� 4'-C-ethylene bridge nucleic acids (ENAs)}72, 95, 
98 locked nucleic acids (LNAs),72, 99 peptide nucleic acids (PNAs),72 and 
phosphorodiamidate morpholino oligomers (PMOS).72, 1 00 LNA, PNA, PMO, and 
20Me AOs were d irectly compared to remove exon 46 from a DMD cell line in  which 
exon 45 was deleted.72 This study found that oligomers prepared as 20Me and LNAs 
could efficiently induce exon 46 relnoval, whereas the equivalent compounds prepared 
as PMOs or PNAs were ineffective.72 These authors concluded that the 20Me 
chemistry was preferable to pursue further induced exon skipping strategies,72 and an 
AO of this chemistry has now undergone Phase I cl inical trials. I Ol, 102 
There are advantages and disadvantages to each of the AO chemistries, and 
several factors must be taken into account. The LNA compound des igned to excise 
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exon 46 was able to induce substantial exon skipping, has the additional advantages of 
increased resistance to nuclease degradation and an exceptional affinity for the target 
sequence. A 1 5mer targeting exon 46 ,vas estimated to have a Tm of 1 3 1°C,72 and it 
was the latter feature that raised concerns for potential off-target annealing� particularly 
after the authors showed that an AO with 2 m ismatches was sti l l  ab le to induce targeted 
exon skipping.72 We have shown that 20Me AOs containing several m ismatches could  
also induce targeted exon skipping in vitro, but  this was on ly  after appl ication of high 
concentrations of AO, and skipping \vas not efficient compared to opt imal ly designed 
AOs.8s 
A lthough earlier studies repotted that PNAs may be of l imited use as agents to 
induce exon skipping,72. 1 00 this may again reflect l imitations of del ivery of the PNA i nto 
the nucleus, necessary for splice intervention. Recently, a report by Yin et al. 103 
indicated that PNAs of 20 bases l ong could induce substantial exon 23 skipping in both 
mdt cel l s  in vitro and in vivo after intramuscular injection. These authors were able to 
compare efficiencies of different ol igomer chemistries and concluded that the PMOs 
were marginal ly more efficient than the PNAs. It should be noted that direct sequence 
comparisons were not repolted. 
One l imitation of the PMO chemistry is poor uptake in vitro, unless either very 
h igh concentrations were used or the cel l s  were encouraged to take up the PMO by 
scrape loading. 104 Sense strand o ligonucleotide leashes� designed to anneal to a PMO 
directed at mouse exon 23 donor, al lowed the uncharged PMO to be complexed with a 
cationic l iposome� and induced targeted exon removal at concentrations three orders of 
magnitude lower than the uncomplexed PMO in cell culture. 1 00 Once the PMOs were 
taken up by the cells, high levels of exon skipping were maintained for the l ife of the 
cultures, as these uncharged compounds are not metabol ized . The PMO chem istry does 
not sho\v any overt toxicity in vitro, even when added to cultures at concentrations of 
50JlM. More importantly, no serious drug-related adverse events have been observed in 
1 5  safety studies of 4 different PMOs, designed as anti-v iral and metabol ism modifying 
agents, involving approximately 350 individuals . lOS 
It i s  not real ist ic to consider using cat ionic l iposome preparations for repeated 
systemic del ivery, based upon cost and more imp01tantly, potentia l  toxicity. Tbe 
pluronic b lock co-polymer F 127 was shown to enhance uptake of 20Me AOs, 106, 107 and 
Wel ls et al. IOS sho\ved enhanced AO del ivelY in the mouse using electroporation. 
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However, it i s  possible that systemi c  del ivery may not be as great a chal 1enge for PMOs 
as first anticipated. In vivo adm inistrat ion of a PMO was undertaken by inj ecting a 
cat ion ic  l ipoplex composed of a PMO annealed to a sense strand leash> ( 1 -5 ug) directed 
to the donor spl ice s ite of mouse dystrophin exon 23 . As anticipated from in vitro 
studies, substantial dystrophin exon skipping was detected at the RNA and protein 
levels .  lOO Immunofluorescence indicated that the induced dystrophin was correctly 
loca l ized and the sarcolemmal complex was re-establ ished. What ,vas unexpected was 
that similar levels  of exon skipping were induced after administration of an equivalent 
amount of PMO that was not annealed to the leash. It quickly became apparent that in 
vivo PMO uptake was much more efficient  than anticipated from in vitro studies. 
Systemic stud ies fol lowed and dystrophi n  expression could be detected in a l l  t issues 
examined, except the heart. 109. 1 1 0 Further advances i n  PMO del ivery came with 
conjugation to cell penetrating peptides, and even more substantial dystrophin 
expression was induced, using even lower doses of the PMO. I I I  However, to date, the 
heart remains resistant to AO-Jnduced exon skipp ing, prompting add itional studies 
using different peptide tags and dosage regimens. 
2.9 Alternative exon skipping strategies 
Several approaches are being investigated as potential avenues to induce 
permanent exon skipping. Gene editing using chimeric RNA/DNA ol igonucleotides 
(RDOs), 1 12, 1 1 3 s ingle stranded ol igodeoxynucleotides (ODNs), 1 14 and p lasmid DNA has 
been repOlted. 1 15 If a base change could be introduced at a donor or acceptor spl ice site, 
the modified cell could maintain permanent exon skipping. Although the most common 
consequence of a spl ice site mutation is exon skipping, such as found in the canine 
model of muscular dystrophy,39 there are many instances where a donor or acceptor 
mutation has led to the act ivation of a cryptic  spl ice s ite, thereby causing intron 
retention or paltial exon loss in  the mature mRNA. We previously reported a case of 
germline mosaicism in a fami ly with a defect in the exon 26 donor spl ice s ite. 1 1 6 Thi s  
mutation d id  not lead to  loss of  exon recognition and skipping, but rather activation of  a 
cryptic splice s ite downstream, with intron retention and an in-frame stop codon now in  
the mature mRNA. I t  may be  difficult to  predict the consequences of  each spl ice  motif 
mutation unti l it has been induc-ed and val idated in human cel ls .  What i s  clear i s  that 
levels of induced gene correction repotted are generally very lo,v, and vary extensively 
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from one laboratory to another and this avenue of therapy is many years from the 
clinic: 1 7, 1 18 
Viral vectors are being developed to introduce expression cassettes that al low 
synthesis of antisense RNA sequences. 1 1 9, 120 Auxiliary sequences such as U I  and U7 
are proposed to enhance accessib i l ity of the AO to the spl ice s ite. Goyenval le  et al. 12 1  
presented e legant \vork showing long-term dystrophin expression in the mdx mouse 
after introducing a viral construct carrying sequences annealing to the branch point of 
intron 22 and donor site of exon 23, l inked to a modified U7 sequence under control of 
the U7 promoter. Dystrophin was readily detectable by western b lotting and 
immunostain ing 3 months after treatment. Should the appropl'iate construct be 
introduced into a stem or progenitor cel l , 122 prol iferation capacity could al lo\v for 
potentia l ly enhanced therapeutic  benefits. 
Autologous cel l  therapy ' i s  also being investigated to restore dystrophin. 1 23, 1 24 
Cell s  were harvested and then tl'ansfected \vith a lent iviral construct, contai ning an exon 
skipping cassette designed to constantly generate RNAs to dislodge the target exon. 
The treated autologous cel1s were evaluated for exon skipping and transplanted into the 
tibial is anterior of mdy/SCID mouse. A few dystrophi n  positive myofibres were 
detected 10 weeks after transplantjon� 123 and it appears that the low levels of dystrophin 
expression were caused by a combination of low exon skipping efficiency and poor 
v iability of transplanted cells . 
2.10 Clinical Trials 
The first clinical trial to address a DMD-causing mutation by induced exon 
skipping involved a s ingle patient with a frame-shift ing deletion of exon 20 . An 
oligomer, d irected to exon 1 9, should restore the read ing frame in thi s  individua1.94 The 
treatment consisted of an ODN administered intravenously at a dosage of 0.5  mg/kg of 
body \veight per \veek, for 4 weeks . Dystrophin protein was reportedly detected at very 
low level s  by immunostaining of sections from the patient ' s  biceps, 1 week after the last 
infusion. No western blot data, was shown and the treatment failed to reduce serum 
creatine kinase levels. Although exon skipping was demonstrated in lymphocytes after 
the third and fom1h treatments, only Iow levels of transcript missing exons 1 9  and 20 
were found in the muscle biopsy after 4 treatments. In thi s  report, precl in ical testing 
was l imited to one species, the mdx mouse, in which doses of 200 mg/kg were 
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administered by infusion. There were no adverse effects reported, but surprisingly 
neither were any exon skipping studies, s ince this particular o ligomer matched the 
mouse dystrophi n  sequence perfectly and had been shown to induce mouse exon 
skipping in vih'o. 85 Even more surprising, this  compound had previously been reported 
to i nduce exon 1 9  skipping in the mdx mouse, but only after intraperitoneal injection . 1 2 5  
Although a simi lar  infusion protocol \vas used to administer this compound to a normal 
human volunteer for safety testing, no exon skipping analysis was repotted. 
This raises one of the fundamental problems with pre-clinical testing ol igomers 
designed for dystrophin  exon skipping. If this compound had efficiently dis lodged exon 
1 9  from the dystrophin  pre-mRNA of the normal human volunteer, the reading frame 
wi l l  be d isrupted, leading to reduced dystrophin expression, and in essence i nduce 
muscular dystrophy. This aspect is d iscussed in more detai l  below. 
In add ition, highly sensitive assays could lead to m is interpretati on of exon 
skipping efficiency. Lymphocytes have been used to study i l legitimate dystrophin 
expression, 1 26 where i t  has been estimated that one copy of dystrophin gene transcript 
occurs in about one thousand ceIls. 1 27 As very sensitive assays were required to detect 
these i l legitimate transcripts, the lo\v level of exon 1 9  skipping from the muscle biopsy 
is unl ikely to reflect an accurate ratio  of rescued muscle gene transcript. Several issues 
relating to dosage and route of administration, which were not properly addressed, 
highl ight some limitations of this  clinical trial .  
A Phase I cl inical tl'ia l  in Leiden has now been completed . 1 02 A 20Me AO 
designed to induce exon 51  skipping \vas injected i nto tibialis anterior muscles of 4 
DMD patients . Exon 5 1  ,vas chosen as the target for this study as its removal would 
correct the reading frame in more DMD individuals than any other exon) accord i ng to 
the Leiden muscul ar dystrophy database (http ://www .dmd. nil) . Preexisting or fibroblast 
derived myogen ic cells from patients were used for in vih'o pre-screening of ol igomer 
PR005 1 . 102 Four weeks after 
-
four intramuscular injections of 200 Jlg of PR005 1  
o l igomer, running along a 1 .5cm measuring l i ne, muscle from the 8 to 1 2  year o ld  
participants were assessed for exon skipping at the RNA level and dystrophin 
restoration. Substantial dystrophin restoration was demonstrated in a l l  patients by both 
immunostaining and western blot analysis , 102 This is the first evidence to conclusively 
support the potential of using AOs to restore dystrophin in DMD patients . Another trial  
has recently commenced injecting patients in the United Kingdom, also with the aim of 
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i nducing exon 5 1  excision. Ho\vever, there are several differences from the above 
study, including o l i gomer sequence,89 ol igomer chemistry and dosage, and the muscle to 
be treated. lOl 
2.11 Futu re challenges 
There is considerable optimism that AO-induced exon skipping may 
substantially reduce the progression and symptoms of DMD. However, a number of 
maj or chal lenges lie ahead. First, the classification of exon skipping as a gene therapy 
is regarded differently by regulatory agencies i n  different countries. We propose that 
the use of AOs to induce exon skipping should not be regarded as a form of gene 
therapy, s ince no permanent genetic changes are induced in the recipient. These 
ol igomers cannot integrate into the DNA, and their mode of action interferes with gene 
expression, not the gene. In some respects, ol igomers inducing exon skipping should be 
viewed no differently to a compound such as PTC 1 24, which can suppress premature 
termination codons, 1 O  or any other molecule or antibody that blocks or modifies the 
function of a gene product. Upon cessation of the AO administration, the compounds 
will be either degraded by endogenous nucl eases or gradual ly c leared from the system. 
No permanent changes will have been introduced, and while this may expedite some 
regulatory aspects of the work, i t  also poses a potential l imitat ion, as the AOs wil l  need 
to be re-administered at periodic intervals to maintain therapeutic levels of the induced 
protein. 
The i nitial exon 51 skipping trials in Leiden and the United K ingdom will only 
provide proof-of-principle, with relatively l imited information on safety being 
generated, since low doses of AOs of two chemistries are administered by an 
intramuscular i njection . This mode of delivery cannot be considered to treat the entire 
body, although i t  may be possible to treat indiv idual musc les i n  the hand, wrist, and 
forearm of older boys. This may preserve what l ittle muscle is left and enhance their 
function. 
The extent of the genomic deletion causing DMD will s ignificantly influence the 
functional ity of the AO-induced dystrophin isoform. The dystrophin isoform rescued 
by skipping of exon 5 1  in a DMD individual carrying a genomic deletion of exon 50 is 
l ikely to be more functional than the isoform i nduced in a patient whose gene lesion 
extended from exon 1 3  to 5 0. Targeted excision of exon 5 1  would restore the reading 
57 
Chapter 2 Personalised genetic  intervention for DMD: Antisense oligomers and exon skipping 
frame in both deletions, but the missing cod ing region from the larger deletion would 
result in a greatly shortened dystrophin isoform. Genomic deletions in excess of 36 
exons have generally been associated with a severe phenotype, regardless of the reading 
frame. 128 It is to be expected that different BMD-like dystrophin i soforms will have 
variable function, which would in turn influence the stabi lity and rate of turn-over of the 
protein in muscle and presumably, the muscle fibres. 
Whi le different DMD patients \vith the same type of genomic mutation could be 
treated \vith the same AD preparation, the different dystrophic ind ividuals may require 
ol igomer dosage regimens that wil l  be determined by their genetic background and 
nature of the dystrophin mutation. The i nfluence of genetic backgrounds on 
manifestation of the same dystrophin  mutation within one family has been reported.5o 
Prescreening the target exons in recipients will then be essential to ensure there are no 
neutral DNA polymorphisms that could compromise AD anneal ing and hence excision 
of the targeted exon. 
The cost of bringing a single drug to the market can be hundreds of mi l lions of 
dollars. 1 29 In the case of drugs to treat common cond itions, it would be expected that 
these may be used by millions of people. In these s ituations, extensive testing is  
mandatory to identify any adverse effects, particularly considering the number of 
individuals be ing exposed . The potential cost of bringing 1 2  d ifferent ADs, which 
would treat the majority of DMD deletion patients, to the market is staggering and wil l  
be beyond the capacity of any organizations other than the largest pharmaceutical 
companies . It should be noted that the 'majority of deletion patients' would still only 
constitute about 60% of al l DN!D individuals, and a proportion of these would carry 
such large deletions, or the loss of crucial coding domains, such that exon skipping may 
not be a viable option. 
The non-deletion DMD individuals will require many different ADs to address 
their  mutations, as such lesions are scattered across the dystrophin  gene. The concept of 
developing over 1 00 antisense compounds seems ludicrous, yet thi s  must be considered 
if exon skipping is to be appl icable to a l l  amenable dystrophin mutations, especially 
since many of these defects occur in the large central rod domain .  The loss of a single 
exon in the rod domain is  expected to result in a dystrophin  isoform of near normal 
function, since this  is a variably dispensable part of the dystrophin protein. If ADs are 
to be used as a personalized genetic medic ine, some compounds may be designed to 
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treat a mutation found in only  a s ingle family. We have shown that targeting dystrophin 
pseudo-exons with AOs can block thei r  inclusion in the mature mRNA.S4, 1 30 Unl ike 
restoring the reading frame around a genomic deletion or excis ing exons canying 
nonsense mutations, AO-induced pseudo-exon suppression could lead to the production 
of a perfectly normal dystrophin. If the priority of targeted exon skipping is  only based 
upon the frequency of mutations, then pseudo-exons wou ld never be considered, despite 
being potentially the most responsive type of dystrophin gene defect. 
Several PMOs of different sequences have been tested in animals, including 
mouse, rat, dog� and non-human primate for general toxicity and s ide-effects that may 
be associated with the backbone chemistry . 105 While safety studies of ol igomers 
designed for viral gene suppression have been undertaken in normal human volunteers, 
similar safety trials cannot be considered fol' testing AVI-4658, a PMO des igned to 
excise dystrophin exon 5 1 .  Evaluat ing A VI-4658 in normal human volunteers must be 
regarded as unethical due to unacceptable r isks to the palticipants . If this compound 
works exactly as predicted, exon 5 1  would be removed from the normal dystrophin gene 
transcript, d isrupting the reading frame and potentially inducing DMD. As shown in  
Figure 2, the consequences of exon 5 1  skipping wi l l  vary extensively between normal 
i ndividuals and different DMD patients. In what should be a most amenable mutation 
(DMD A50), A VI-4658 would restore the reading frame around this single exon 
deletion, and al low synthesis of a dystrophin  of near-norma l  length and function. The 
nature of induced dystrophin isoform will depend upon the extent of the primary gene 
deletion, hence potential benefits of exon skipping would be compromised by l arger 
gene delet ions; such as DMD .A30�50 and A 1 3-50. Thus, there is a broad spectrum of 
potentia l  consequences of administering AVJ-4658 to different individual s, ranging 
from no restoration of the reading frame in DMD patients with non-responsive 
mutations, induction of dystrophin isoforms of variable function depending upon the 
primary gene lesion, to inducing DMD in a normal individual by disrupting the 
dystrophin reading frame. 
Although non-human primate studies may be more relevant, there are 
l imitations, as there are no known primate models with dystrophin  genomic deletions 
that would be restored by exon 5 1  skipping. Similarly, removal of a dystrophin  exon 
could disrupt the reading frame and induce an adverse react ion associated \vith 
dystrophin deficiency, since the exon skipping compound would be working exactly as 
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it was designed to do. Animal testing of compounds designed for specific human 
dystrophin m utations can only supply l imited information, and should be only 
undertaken if rel evant data is  generated. 
There is currently no therapy available for DMD that addresses the missing or 
defective dystrophin. Although corticosteroids such as prednisolone or deflazacort have 
been shown a clear benefit in s lowing muscle wasting, 1 3 1- 133 mood swings, weight gain) 
stunted growth, brittle bone and cataracts h ave inevitably become acceptable side 
effects of the treatment. It i s  imperative that as many therapeutic compounds are made 
avai lable to the DMD community in shortest possible t ime frame. DMD is a relentless 
progressive muscle wasting disorder that does not wait for regulatory approval, 
challenges in ol igomer design, delivery, and production. 
For the widespread implementation of o li gomer induced spl ice intervention as a 
therapy for DMD, it may become necessary to regard induced exon skipping as a 
generic platform. If the first cl inica l  trials show safety and efficacy in restoration of 
dystrophin expression after excising exon 5 1  from some patients) there must be a move 
to systemic administration and developing therapeutic dosage regimens. This  is l ikely 
to take some considerable time, and may be confounded by the nature of the primary 
gene lesion and the genetic background of the patient. At the same t ime, additional exon 
targets must be considered to . address other DMD mutations, and in this manner} 
sufficient safety d ata would become avai lable that could a llow d ifferent ol igomer 
sequences of a particular class, for example  PMOs, to be regarded as class-specific 
compounds.  
Steroids} the current "gold standard" treatment to deJay DMD progression, exeli 
their effect through an unknown mechan ism and have been available for decades. 
Despite this, there is  stil l no consensus on the best dose and treatment regimen for 
steroids. Faced \vith the challenge of developing a persona l ized genetic intervention to 
address many different dystrophin mutations, it i s  most l ikely that establ ishing ol igomer 
dosage regimens for individual DMD patients wil l  prove to be an even greater 
chaJ Ienge. Nevertheless, upon the demonstration of one mutation being amenable to 
exon skipp ing, we must make all efforts to expedite the appl ication to as many different 
dystrophin mutations as possible. 
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Table 1 :  Some examples of BMD deletions with associated comments on phenotype 
Exonic Special comments References 
Deletion 
3-9 Playing competitive badmilltoll at age 62 1 6  
years. 
9-22 High Cx, myalgia but well developed 1 34 
nUlsclllatllre and no evidence of muscle 
weakness 
13-18 Myalgia and cramps after normal activity 1 35 
13-41 VelY mild BMD 1 36 
1 7-47 Source of the dystrophin mini-gene used in 34 
gene replacement studies 
1 7-51 Mild BMD lvith congenital cataracts 1 37 
35-44 Cramping after soccer or mountain 1 38 
climbing 
41-44 Elevated Cx, otherwise asymptomatic 1 39 
45-53 Diagnosed age 60 140 
48 Accidenta lly diagnosed ill female, four 1 4 1  
affected male members then diagnosed with 
high CK only. 
50-53 Elevated Cl( othenvise asymptomatic 1 39 
It should be noted that velY few BMD patients have been 1 42 
identified "with in-frame deletion in the central rod domain 
involving exons 33-45. 
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3. 1 Abstract 
Background Duchenne Muscular dystrophy (DMD), a severe neuromuscular disorder, 
i s  caused by protei n-truncating mutations in the dystrophin gene. A b sence of  
functional  dystroph in  renders musc le  fibres more vulnerable to damage and 
necrosis .  We report ant isense o l igomer (AD) induced exon skipping in the B6Ros.Cg­
Dmdllldr-4Cv /J (4 cv) mouse, a muscular dystrophy model aris ing from a nonsense 
mutation in dystrophi n  exon 53 .. Both exons 52 and 53 must be excised to remove the 
mutati on and maintain the reading frame. 
Materials and Methods A series of 2'-O-methyl modified ol igomers on a 
phosphorothioate backbone (20MeAOs) were designed and evaluated for the removal 
of each eXOll, and the most effective compounds were then combined to induce dual 
exon skipping in both myoblast cultures and in vivo. Exon skipping efficiency of 
20MeAOs and phosphorodiamidate morpho l ino o l igomers (PMOs) was evaluated in 
vitro and in vivo at the RNA and protein level .  
Results Compared to the original mdx mouse studies, induction of exon skipping from 
the 4cV dystrophin mRNA was far more chal lenging. PMO cocktai ls could restore 
synthesis of near-full length dy�troph in protein in  cultured 4cV myogenic cells and in 
vivo, after a single intramuscular injection. 
Discussion By-passing the protein truncating mutation in the 4cV mouse model of 
muscular dystrophy could not be achieved with s ingle ol igomers targeting both exons 
and was only achieved after the application of AO cocktails to remove exons 52 and 53 .  
As \vith previous studies, the stabi lity and efficiency of  PMOs proved superior to 
20MeAOs for consistent and susta ined protei n  induction in vivo. 
Keywords Exon skipping; B6Ros.Cg_Dmdmd-c>4CvjJ (4cv) mouse; Antisense oligomer, 
Duchenne muscular dystrophy; morpholino. 
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3.2 Introduction 
Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder 
characterised by progressive tnuscle wasting, and proximal musc1e weakness, arises 
from the absence of functional dystrophin. Dystrophin links the actin cytoskeleton to 
the extracel lu lar matrix via a complex of proteins embedded in the sarcolemma and 
plays a p ivotal role during muscle contraction (for review see 1-3). Loss of dystrophin 
renders muscle fibres vulnerable to membrane damage during contraction. Progressive 
loss of muscle fibres, \vith inflammatory ce l l  i nfiltration and fibrosis eventual ly 
overwhelms the regenerative capacity of the muscle. 
The human dystrophin gene is  the largest known, and the major muscle isoform 
consists of 79 exons, spanning 2 .4 million bp. Most mutations in DMD patients are 
i ntrage ni c  de l et ions  or d up l icat i ons,  accounting for about 60% and 8% of a l l  DMD 
patients, respectively.4-7 Point mutations, including nonsense and spl ice motif 
mutations, as wel l as smal l insertions/deletions that d isrupt the reading fralne, are 
responsible for 25 to 35% of aILcases.7, 8 DMD mutations typical ly disrupt the reading 
frame, thereby preventing synthesis of functional dystrophin. B ecker muscular 
dystrophy (BMD) is also caused by mutations in the dystrophin gene, but this mi lder 
al lelic condition is generally caused by gene defects that do not disrupt the read ing 
frame and al low production of shorter, but partially functional protein .  Depend ing upon 
the position and nature of the mutation, some cases of BMD may only be diagnosed late 
in Hfe, and present with very mild or no symptoms,9, 10 whi le others may present as 
borderl ine DMD and lose ambulation around the age of 1 5 .
1 1 , 1 2  
AO-induced exon skipping stud ies initia l ly targeted different spl ice motifs of 
exon 23 in the muscular dystrophy mouse model (mdx) , with the a im of restoring 
protein expression. 1 3. 14 The defect in the mdx mouse is a natural ly occurring 
nonsense mutation in dystrophtn exon 23 . Despite l imitations, including a mi ld 
cl inical phenotypeJ the mdx mouse has been widely used i n  developing potential 
therapies for DMD, inc luding exon skipping, 1 5.22 gene and cell replacement (for 
review see 23, 24), and premature translation termination suppression?5 
In this study, the B6Ros .Cg_Dmdmdt-4Cv/J (4cv) muscular dystrophy mouse,26 
carrying a nonsense mutation in <exon 53 of the dystrophin gene, was used to evaluate 
AO-induced dual exon skipp ing in a region of the dystrophin gene within the major 
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human dystrophin deletion hot-spot. By-passing the 4cV mutation, and maintaining 
the reading frame) requires removal of both exons 52 and 53 from the mature 
dystrophin gene transcript. A series of AOs \vere designed and evaluated for the 
remova1 of each exon, and the most effective compounds were then combined to 
induce dual exon skipping in both myoblast cultures and in vivo. AOs of two 
different chemistries, 2' -O-lnethyl modified o l igomers on a phosphorothioate 
backbone (20Me), and phosphorodiamidate morpholino oligomers (PMOs) 
conjugated to a cell-penetrating peptide (P007)27, 28 were compared. 
3.3 Materials and methods 
3.3.1 AOs and primers 
AO nomenc lature is based on that described by Mann et aI . ,  2002. 1 8 
Sequences and compos it ion of AO treatments are described in Table 1 .  20Me 
AOs were synthes ized on an Exped ite 8909 Nucle ic  Acid synthesizer using the I 
Ilmo1e thioate synthes i s  protoco l .  AOs were designed to  anneal t o  either exonic  
sequences or  exoniintron junctions of mouse dystrophin exons 52 or  53 .  PMOs 
conjugated to an argin ine-rich, cel l  penetrating peptide (P007i7, 28 were synthesized 
by A VI B ioPharma (Corva l l is ,  OR, USA) . Primers for RT�PCR and sequencing 
analysis were synthesized by Geneworks (Adelaide� Australia) and are l isted in 
supplemental information. 
3.3.2 Animals 
4CV (B6Ros.Cg�Dmdmd\'.4cv/J ) congenic m ice, obtained from the lackson 
Laboratory (Maine, USA), 'were raised and supplied by the Animal Resources Centre, 
Murdoch, Western Australia. Animal housing and transport fol lowed guidelines from 
National Health and Medical Research Counc i l  (Austral ia) .  The use of animals \vas 
approved by the Animal Ethics Committee of University of Western Austral ia (approval 
number 03/1 00/572). 
3 .3.3 Cell culture and AO transfection 
Immorta l ized mdt H2� -tsA58 mouse cells (H-2K mdx) were propagated and 
transfected as described previollsly.29 Primary myoblast cultures were prepared from 
2 to 4 days old 4cV pups and the procedure \vas  adapted from Rand o  et al .3 o 
L i m b  m u s c l e s  from 4 pups were d issected ,  homogenized, and i ncubated at 3 7° C  
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for 3 0  m i n utes  with d i ss o ciat i ng enzyme m ix c onta i n i n g  2 . 4  units/m l d i spase 
(Invitrogen, VIC,  A u stral i a) ,  5 mg/m l c o l l agenase Type n (Inv itrogen) , and 2 . 4  
mM C a C b  i n  DME M  (Inv itrogen) . A fter c e ntr i fugati o n ,  t h e  c e l l  p e l l et was 
added t o  a 7 5  c m2 t i s s u e  c u l ture fl ask with 1 0  ml of pro l i fe ra t i v e  m ed i a  and 
i n c u b ated for one h o ur .  Non·adherent cells were removed and seeded into 75 c m2 
t i s s u e  c u lture  fla s ks c o at e d  _ w ith 1 0 0 Ilg/ml m atr i ge l .  When nearly confluent, 
cell s  were seeded into 24 well-plates coated with 50 J-ig/ml poly-D-lysine solution and 
matrigel,  and i ncubated for 48 hours before transfection .  Duplicate wells were 
transfected with 20MeAO l ipoplexes using Lipofectin (lnvitrogen) at a ratio of 2: I 
Lipofect in  to AO. Briefly, Lipofectin was mixed with OptiMEM (Invitrogen) to a fi nal 
vo lume of 200 J-i l and incubated for 30 minutes at room temperature. The 20MeAO, 
whi ch h ad been di luted to 200 III in  Opti MEM , was then c ombined with 
Lipofectin : OptiMEM and the mixture incubated for a further 30 m inutes, before 
add ition of OptiMEM to a final volume of I ml and subsequent addition of 500 III 
aliquots to each welL Transfected cel ls were i ncubated for 48 hours before RNA was 
extracted for analysis .  
3.3.4 Intranluscular administration 
Oligomers, in physiological sal ine, were inj ected into tib ialis anterior (TA) 
muscles at doses indicated . Each experiment included at l east one saline only 
injection as a negative control .  The animals \vere anesthetized and sacrificed by 
cervical dislocation at indicated time points after the injection, and muscles were 
removed and snap-ft'ozen in pre-cooled isopentane, before being sect ioned and 
prepared for RNA and protein studies. 
3.3.5 RNA extraction, RT -peR analysis and DNA sequencing 
RNA was harvested from H-2K mdx cultures, 4cv cultures and frozen sections 
tissue block using Trizol (Invitrogen), according to the manufacturer's protocol .  One­
step RT-PCR was undertaken using 1 20 ng of total RNA as template, in a 1 2. 5  III 
reaction fot' 3 0  cycles of ampl ification. After the reverse transcription step for 30 
minutes at  55°C, the reaction was heated to 94° C for 2 minutes before the primary 
thermal cycl ing rounds of 94 QC for 40 seconds, 60°C for 1 m inute, and 68°C f01* 1 
minute. Nested PCR was then carried out on 1 J-il of the primary amplification reaction 
using AmpliTaQ Gold (Applied B iosystems) . Cyc l ing conditions for the secondary 
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PCR were 94°C for 6 minutes to activate the polymerase, foHowed by 20 cycles of 
94 QC for 40 seconds� 60°C for 1 minute, and 72°C for ] minute. PCR products were 
separated on 2% agarose gel s  in T AE buffer and the images captured on a 
CHEMISMART-3000 (Vi lber Lourmat, Marne-Ia-val lee, France) gel documentation 
system. Bands of interest were re-amplified directly from the agarose gel,3 1  and the 
sequencing templates were purified using UltraClean spin columns (Mobio 
Laboratories, CA, USA) and then sequenced on a 3730 ABI DNA sequencer using 
B igDye v3 . 1  terminator chemistry (Appl ied B iosystems). 
3.3.6 Western blot analysis 
Protein extracts \vere prepared as weight per volume of treatment buffer 
containing 125  mM Tris/HCI, pH 6 .8, 1 5% sodium dodecyl su lphate, 1 0% glycerol ,  0 .5 
mM pheny lmethylsulfonyl fluoride, 50  mM d ithiothreitoI, bromphenol b lue} and 
protease inhibitor cocktai l  (Sigma) to cel l  pel let or mouse muscle cryostat sect ions. 
Samples were then vOl1exed and sonicated briefly, heated at 95°C for 5 minutes, before 
electophoretic fractionation on a 4 to 1 0% SDS gradient gel at pH 8 .8  with 4% stacking 
gel� pH6.8. Densitometry of myosin bands after coomassie blue staining was 
undertaken to faci l itate equivalent protein loading. Extracts from AO treated cultures or 
muscle cryosections from treated anhnals (2.75 mg) and control muscle (0.275 mg) 
were loaded onto a second PAGE gel for Western b lotting. Proteins were transferred 
from the gel to n itroceIIulose membranes (Amel'sham B iosciences, Castle Hil l �  
Austra l ia) overnight at 1 8°Cj at 290 mA. Dystrophin was visual ised using NCL-DYS2 
mono clonal anti-dystrophin antibody (Novocastra, Newcastle-upon-Tyne, UK) as 
described previously?1 Images were captured on a Vilber Lom'mat CHEMISMART-
3000 gel documentation system. Percentage of dystrophin restoration was calculated 
according to dystrophin expression in control cell s  after normalization for myosin 
loading. 
3.3.7 Tissue preparation and immunofluorescence 
TA muscles were taken from mice and snap-frozen in isopentane, pre-cooled in 
l iquid nitrogen. Dystroph in was detected in 6 Jlm unfixed cryostat sections using NCL­
DYS2, an antibody that reacts strongly with C-tenninus of dystrophin. 
Immunofluorescence was performed using the Zenon Alexa F luor 488 labeling kit 
(Invitrogen), accord ing to protocol recommended by manufacturer, except for the init ial 
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fixation step. The primary antibody was d iluted at 1 : 10 and sections were 
counterstained with Hoechst (Sigma) at the di lution of 1 :  1 0,000 to visual ize nuclei. 
Sections were vie\ved under O
'lympus IX 70 invelied microscope and images were 
captured on an O lympus DP70 digital camera. 
3.4 Results 
3.4.1 Single exon targeting 
A pane l  of AOs was .  des i gned to anneal  to obvious  spl ic i ng mot ifs ,  
inc lud i ng the acceptor and donor splice sites, and potential exonic spl icing enhancers 
(ESEs) of both exons 52 and 53 .  Although designed to predict human ESEs, the web­
based ESE prediction prograln, ESEfinder 3 . 0,32 , 33 was used to i dentify putative ESEs 
i n  mouse dystrophin exons 52  and 5 3 .  Figure 1 shows the predicted ESEs of exons 
52 and 5 3  and the relative annealing positi ons of the AOs (sequences provided in Table 
1) des igned to induce exon removal .  S ix AOs, des igned to excise dystrophin exon 
52, \vere evaluated in it ia l ly in HM2K!'-tsA58 mdx (H-2K mdx) immortal ised 
myogen ic  cel l s .34 The use of these immortal ized ce l l s  reduced animal usage and, 
s ince the 4cv mutation in exon 53 d id not a lter dystrophi n  spl ic ing patterns, it was 
assumed that design in one mouse strai n  shou ld  be va l id for another. Subsequent 
experiments va l idated this approach . According to ESEfinder, the nonsense 
mutation in dystrophin exon 53 occurs in two pred i cted ESE motifs that are only 
just above the thresho ld :  an SF2/ASF motif (score 2 . 1 87/threshold 1 .956) and an 
SRp40 motif (score 3 .042/threshold 2 .67). 
None of the AOs targeting the acceptor or donor sites of exon 52 consistently 
induced removal of the target (Fig 2a), whereas the AOs anneal ing between the 
coordinates +] 7+5 1 efficiently excluded exon 52 from the mature dystrophin mRNA 
(Fig 2b). Subsequent titration studies comparing AOs 1 and 4 indicated the latter 
compound \vas more efficient at inducing exon 52 removal at l o\ver transfection 
concentrations} although there was l ittle exon 52 skipping induced at 25 nM (data not 
shown). Consequently} A04 was selected for further studies. 
Excision of exon 53 proved to be a greater challenge, and although nutnerous 
AOs were des igned and evaluated, no single AO tested efficiently excluded exon 53  
from the mouse dystl'ophin mRNA. Whi le  many AOs fai led to  dislodge exon 53 ,  as 
shown in Figure 2e, others removed exon 53 in addition to both exons 53+54 (Fig 2d). 
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Two AOs activated a cryptic splice s ite and resu lted in partia l exon 53 loss (Figure 2e). 
Thirteen different combinations of non-overlapping AOs were then assessed and one 
AO cocktai l  was developed to consistent ly induce specific exon 53 skipping (Fig 2t). 
3.4.2 Exon 52+53 skipping: 20Me AOs 
As the relat ive efficiencies of exc ision of the target exons d iffered, i t  was 
necessary to evaluate combinations of the optimized AOs directed to exons 52 and 53 ,  
shown in Table 2. 1 .  Four 20MeAOs (4, 8, 9, 1 3) were combined at  ratios ind icated 
(A 1 ,  A2, A3, A4, and A5) and used to transfect 4cV cultured primalY myoblasts (Fig 
3a-c) . The identity of the transcript miss ing exons 52 and 53 was confirmed by DNA 
sequencing (Fig 3d). At 2 days after transfection, the A2 and A3 cocktai ls  appeared 
marginal ly more effective at excising both exons 52 and 53 ,  as shown by the absence of 
the ful l- length product (Fig 3a-c), hence the A2 cocktai l  was selected for further 
stud ies. 
A lthough RT-PCR stud ies ind icated substantial exons 52+53 skipping at days 3 
and 5 ,  only a trace of shortened transcript could be detected at days 8 and 9 after 
treatment (data not shown). No detectable dystrophin protein was observed in treated 
cultures at any time point. RNA and protein  were analysed at day 1 4  after two 
transfections at days 0 and 9, and no exon skipping or restored dystrophin protein were 
observed (data not shown). 
A total of 1 00 J.tg of the 20MeAO A2 cocktai l ,  was complexed with F 1 27 and 
administered to 4cv mice through intramuscular or intraperitonea l  routes. Animal s  were 
sacrificed 3, 5, and ? days after injection and RNA from the diaphragm and TA muscle 
was assessed for exon skipping. Although sporadi c  exon 52 and 53 skipping was 
detected in the TA muscle, no substantial dystrophin protein restoration could  be 
demonstrated by e ither immunofluorescence or western blot analysis (data not shown). 
3.4.3 Induced exon 52 and �3 skipping with phosphorodiamidate lnorpholino 
oligomers 
We had previously found that whi le  20MeAOs \vere well sui ted for AO design 
and short-term in vitro RNA stud ies, restoration of dystrophin prote in in 20MeAO 
treated cultures was more problematic.35 AOs 4 ,  8 ,  9 and 1 3  were prepared as PMOs, 
coupled to the cell penetrating peptide POO? These ol igomers d id not induce any exon 
skipping when applied individually (data not shown). The combination was evaluated 
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in 4 cv myoblast cultures, and as with the 20Me AOs, different ratios of PMOs were 
assessed. The PMO cocktails B2, B3 and B4 induced the transcript missing both target 
exons at concentrations as low as 0.5 }1M in vih'o. The B2 and B3 PMO combinations 
comparable to th-e A2 and A3 20Me combinations appeared to be the most effect ive 
mixtures, and were selected for further study (Fig 3e-g). Both the B2 and B 3  cocktai ls  
were able to induce pronounced exon 52 and 5 3  skipping� 2 weeks after in vitro 
transfection at a concentration of 40 }1M (Fig 3h), consistent with the appearance of 
induced dystrophin, as determined by western b lotting (Fig 3i). Normalization of 
dystrophin accord ing to myosin densitrometry indicates the B2 and B3 cocktails 
induced 1 1  and 8% of normal levels of dystroph in respectively (Fig 3i and 
Supplementary data 2. 1 ). 
3.4.4 Evaluation of off-target effects 
To confirm spec ific ity of the multi-oligo cocktai l  on dystrophin expression, RT­
peR was undertaken across the dystrophin gene transcript using 5 sets of nested primer 
pairs (supplementary data) covering exons 1 3  to 70 region (Fig 4aMe). Figures 4a to e 
represented amplified segments of the dystrophin transcript. Although sporad ic 
"revertant" transcripts ,vere detected in PMO cocktai l treated cultures, the numbers of 
alternative ly spliced transcripts were not greatly different from those in 6 untreated 
cultures (Fig 5) . 
3.4.5 In vivo studies 
A single injection of 40 J.tg of each of the PMO cocktails,  at ratios shown in 
Table 2 .3 ,  was made into the T As of 4cv mice. Two weeks after injection , RT-PCR on 
RNA extracted from injected 4cv muscle demonstrated exon 52 and 53 skipping in al l  
cocktail-treated samples (Fig 6a) with western blotting indicating dystrophin express ion 
to be approximately 5 to 7%, based upon normalization of loading (supplementary 
i nformat ion). Consistent with the RNA stud ies, dystrophin immunofluorescence on 
sections from the TAs of 4cV mice treated with PMO cocktails C l  and C2, also showed 
dystrophin-posit ive fibres (Fig 7a, b). 
3 . 5  D is cuss ion 
Oligomer design, evaluat ion of different chemistries and systemic  del ivery 
protocols have been extens ively studied in the mdx mouse model of muscular 
dystrophy. 1 4, 1 8-2 1 , 36, 37 We describe the app lication of AO-induced dual exon sk ipping 
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to address the primary gene lesion in another mouse model, the 4cV mouse, whose 
nonsense mutation should be by-passed with the excision of exons 52 and 53 .  This  
model may be regarded as  of greater relevance to  the human condition, s ince the 
targeted exon skipping is induced within the lnajor hotspot for dystrophin gene 
de let ions.38 
Acceptor and donor spl ice sites \vere initia l ly considered obvious targets for 
AO-induced exon skipping} and .consistent exon 23 removal was achieved with the first 
o l igomer targeting the donor splice s ite. 14 However, a comprehensive study targeting 
all human dystrophin exons indicated donor splice s ites are rarely the optimal or 
preferred targets, and the majority of preferred targets appear to be intra-exonic 
motifs .39 Indeed, i t  appears that if a pre-mRNA s ite is not amenable  to ol igomer 
intervention, the application of a panel of oligomers to microwalk across that motif, 01' 
altering AO length or chemistry� i s  unl ikely to achieve acceptable  (or detectable) levels 
of exon exclusion.40 S imi lar trends were observed for the 4cV mouse dystroph in exons 
52 and 53 ,  where individual ol igomers annealing to either the donor or acceptor spl ices 
sites failed to induce any targeted exon skipping. Two overlapping o l igomers, AOs 1 
and 4, targeting intra-exonic motifs within exon 52, were identified that induced 
substantial skipping and titrat ion studies indicated AO 4 was sl ightly more efficient at 
lower transfect ion concentrations. 
Mouse dystrophin exon 53 proved to be much more challenging to d islodge 
from the mature mRNA. Eighteen o ligomers were designed to target acceptor and 
donor spl ice s ites} as wel l  as intra-exonic motifs pred icted by ESEfinder.32, 33 Although 
this program is based upon hum�n sequences, the strong homology between mouse and 
human dystrophin sequences was considered sufficient justification to use this program 
as a starting point in AO design. Initia l  AO design was undertaken in an immortal ized 
mdx mouse myogenic cel l  l ine, while awaiting establ ishment of the 4cV mice colony. 
The sequences of dystrophin exon 52 were i dentical in both strains, and s imilar 
identified spl ice patterns were generated \vith A04 in both cell l ines. S imilarly, AOs 
that led to exon 53 skipping in the md-r cell l ine exhibited identical patterns in cultured 
cells from the 4cV mouse . Since no aberrant spl icing was observed involving exon 53  in 
untreated 4cV cultures, i t  was presumed that the mutation did not influence spl ic ing. 
This is consistent with the mutation occurring in two putative ESEs that were just above 
the threshold for SF2/ASF and SRp40.  Once the 4cV colony was establ ished, a l l  
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subsequent experiments were undertaken in these cells. 
The majority of compounds targeting exon 53, when used individually were 
e ither ineffective, activated a cryptic splice site (loss of 7 8  bases from the end of exon 
53), or led to the production of dystrophin gene transcripts missing exons 53+54, in  
addition to  exon 53 alone (Fig 2d-f). Interestingly, AO 7, which anneals to exactly the 
same co-ordinates identified as an optimal target to d is lodge human dystroph in exon 53 ,  
induced mouse dystrophin transcripts missing exons 53+54, in  addition to  exon 53  
excision. Several other AOs overlapping AO 7 a1so induced this pattern of exon 
removal, implying that this area may be involved in coordinated processing of both 
exons during pre-mRNA spl ic ing, at least in mice. Targeting exon 5 3  for excision from 
the human dystrophin gene transcript only resulted in specific target removal ,  
highlighting some l imitations in extrapolation of o ligomer design between homologous 
genes of different species .39  The loss of an exon flanking that targeted for excision has 
been reported previously. The AO targeting the mdx mouse exon 23 for removal also 
induced dystrophin gene transcripts missing exons 22+23, an out�of-frame transcript 
that cannot lead to dystrophin production.36 Similarly, transcripts missing exons 53+54 
are out-of-frame, even \vhen exon 52 was omitted and were thus considered undesirable. 
As we had previously observed that some combinations of apparently i nactive 
AOs were able to induce highly efficient exon skipping,4 1 various AO cocktai ls 
targeting exon 53 were evaluated . A combination of AOs 8 and 9, targeting the 
acceptor and donor s ites respectively, was able to induce some exon 53 skipping, 
a lthough not at a consistent and satisfactory level .  Subsequently, AOs 8 and 9 were 
combined with other AOs (7, 1 0, 1 1 , 1 2, 1 3 ,  1 4, 1 6) to identify a cocktai l  capable of 
inducing specific exon 53 skipping. When AO 13 was combined with AOs 8 and 9, 
efficient and specific exon 53 removal could be induced after transfection at low total 
AO concentrations. The mixture of AOs 8 and 1 3  generated the same pattern induced 
by AO 1 3  alone, indicating no advantage, whi le the combination of AOs 9 and 1 3  only 
induced inconsistent exon 53 excision. This 3 AO combination was necessary for both 
efficiency and specificity of exon skipping. 
Since exon 53 was removed from the mature mRNA at a h igher efficiency than 
exon 52, attempts \vere made to balance the ratio of AO 4, targeting exon 52, with AOs 
8,  9 and 1 3, to maximize induction of in-frame transcripts. When equimolar amounts of 
all four oJ igomers were appl ied, the ful l-length transcript was observed, in addition to 
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dystrophin mRNAs missing exon 53 and 52+53 .  A ltering the composition of the 
cocktai ls  with increased proportions of AO 4 resulted in decreased amounts of ful l­
length product and a higher prop011 ion of in-frame transcripts missing both exons 
52+53 .  Transcripts missing only exon 52, another out-of-frame mRNA was also 
observed.  
Although, substantial exons 52+53 deleted transcripts were detected at  days 3 
and 5 after transfection with 20Me AOs, no detectable dystrophin was observed by 
western blot analysis (data not shown). Only trace amounts of exon skipping could be 
observed 8 -1 4  days after transfection, and this  also did not generate sufficient 
dystrophin detectable by western blotting (data not shown). It was assumed that this 
l imitation arises from the uptake and turn-over of the 20MeAOs in cel ls .  The 2'-0-
modified oligomers on phosphorothioate backbone increase the oligOlners resistance to 
nuclease degradation, but unlike PMOs which are not metabolized, 20MeAOs are 
gradually broken down by nucleases,42 This  was most apparent in a time-course of 
20MeAO-induced ex on skipping in cultured cells, where there was substantial exon 
skipping 24 hours after transfection, but this decl ined substantially over the next 9 
days.43 In contrast, substantial PMO-induced exon skipping transcript had been 
detected with less intermediate product at 1 4  days after transfection, in vitro. 44 By­
passing the dystrophin gene lesion and inducing dystrophin detectable by western 
blotting was very inconsistent in canine cultured cells from the GRMD model of 
muscular dystrophy and human dystrophic muscle explants.35, 44 However, upon the 
application of PMOs of the same sequences, efficient exon skipping could be induced 
and maintained in vitro or ex vivo to al low sufficient dystrophin synthes i s  to be readily 
detected by western blotting at 7 days after transfection.35 
The application of any ol igomer to a cell has the potential to cross react with 
other sequences and/or exert non-specific effects. The u se of AO cocktails would 
potentially increase this  r isk and although a detailed examination of other genes has not 
been unde11aken, we showed that the cocktai l  only induced targeted changes in the 
dystrophin mRNA. We had noticed in other studies that the addition of oligomers 
seems to marginal ly i ncrease the appearance of alternat ively spl iced transcripts .45 
However, the application of 4 ol igomers did not greatly alter the incidence of the 
alternative transcript in treated cells compared to untreated cultures. 
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The application of PMO.s, coupled to an arginine rich cel l-penetrating peptide, 
induced more robust exon skipping in vitro and in vivo in 4cv cells than the equivalent 
20MeAOs.  As we had previously shown that a hierarchy of exon skipping efficiency 
induced by 20MeAOs ,vas also seen when the same sequences were evaluated as 
PMOs,46 the most effective mixtures of 20Me and PMO AO appeared comparable  in 
the 4cV model, although there was a minor sh ift in  the relative proportions of exon 
excised transcripts. The optim"al 20MeAO cocktails induced removal of rough ly  
equivalent amounts of exons 52 and 52+53,  while the equiva lent PMO combinations 
generated transcripts missing exon 53 as the predominant transcript and, exons 52+53 .  
Approximately 1 0% of  restored dystrophin protein was induced according to calculation 
of band densitrometry of western blot analysis. 
PMO cocktai ls, consi sting of a total of 40 J..lg of the oligomers d i rected to exons 
52 and 53,  were administered into the TAs of 4cv m ice by a single intramuscu lar 
inject ion. T\vo weeks later, dystrophin was observed by dystrophin i mmuno­
fluorescence after C l ,  C2, or C3 treatment. Calcu lation of band densitometry from 
Western blot analysis  demonstrated approximately 5 - 1 0% of restored dystrophin protein 
after C l ,  C2, or C3 treatment. Further studies in  this area may provide add itional 
information to understand and to refine more efficient combinations for AO-induced 
dual exon skipping. 
In summary, there still appears to be no consistent pattern in AO design for 
targeted exon skipping. Masking an obvious spl ice motif, such as the donor splice s ite 
that proved so effective in the mdx mouse, was ineffective in excising different exons in 
another mouse model of muscular dystrophy. AO cocktails were essential for by­
passing the mutation in the 4cV mouse in terms of both specificity and efficient exon 
removal .  Consistent with other studies, the PMOs appeared superior to 20MeAOs, 
especially in vivo. Long-term systemic treatment of the 4cV mouse is now underway to 
establ ish an appropriate del ivery regimen that would be best suited for dual exon 
skipping, in a region of the dystl'ophin gene located within the human d�letion hotspot. 
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Figure 1 :  Dlagramatlc presentation of predicted ESEsj (a) mouse exons 62; and (b) 63. 
Relalive annealing coordinates of oIlgomers are Indicated. Vertical bars indicate the fIVe ESEs predicted (0 be 
binding sites of SR proteins (viz. S F2IASF (red), SF2IASF (lgM-BRCA1) (pInk), SC35 (navy blue). SR�40 (light 
green) and SRp55 (yeIIOYI}). Threshold scores Vlere set at default values as specified In ESe finder.3 . 33 
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FIgure 2: Induced sTngle exon skipping in H·2K mdx cells. 
(a) Transcripts resulting after transfeclion with AO 2 (typical of that obtained after transfection .. lith AOs 3,5,6); (b) Transcripts 
fesu lling after transfecUon vJith AO 4 and AO 1; (c) Transcripts resulting after transfection with AD 8 (typical of that obtained 
after Iransfection v,rith AOs 9.14.15,1 S, 19-24); Cd) Transcripts resulting after fransfecfion with AO 7 (typical of that obtained after 
transfection IfJith AOs 7,10-13); (e) Transcripts resulting after transfecticn vlith AO 1 7; (0 Transcripts resulting after Iransfection 
INilh cocktail AOs 8+9+13. 
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Figure 3: Induced exon skipping In 4CVcells after tranlfedkm With 20MeAO cocktails. 
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resulting after transfedlon with (8) 81 ; (f. h) B2; (0, h) B3 in 4CV cullures ; (i) \Nestem blot analysis from �v cu Hu res 
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Figure 5: RT-PCR analysis of dystrophin transerlpts in untreated and PMO treated 4CVcultures across exons 20-35 indicating alternatively spliced dystrophln transcripts. 
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Figure 7: Dystrophfn Immunofluorescence on muscle cryoseetlon from 4CVmlce treated with cocktails (a) C1 ; Cb) C2; (e) ca; 
(d) C4; (e) CS; (I) saline; and (g) untreated c61BU10ScSn 
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Table 1 : The lengths, annealing coordinates, sequences and GC content (number and %) of the 24 selected AOs targeting exons 52 and 53. 
length (bp) Annealing exon number sequences GC content 
eoordinates (bp) % 
25 M52A+ 1 7+41 52 5 '  uec aau ugg ggg cgu cue ugu uee a 3' 1 4  56 
30 M52Aw1 5+1 5 52 5' aue uug eag ug u uge cug aaa gaa aaa aaa 3' 1 0  33 
30 M52D+ 1 5-1 5 52 5' eau uaa gag aeu uae uue gau cag uaa uga 3' 1 0  33 
30 M 52A+22+51 52 5' aau gag uuc uue eaa uug ggg geg ueu cug 3' 1 5  50 
30 M52A+32+61 52 5' ggg cag cag uaa uga guu euu eea auu ggg 3' 1 5  50 
30 M 52A+42+71 52 5' uue aaa uuc ugg gea gca gua aug 8g U ucu 3' 1 2  40 
31  M53A+39+69 53 5' eau uea aeu g uu Gue uee ugu ueu gea g eu 9 3' 1 5  48 
30 M 53A-1 5+1 5  53 5' ucu gaa uuc uuu caa eug gaa uaa aaa uaa 3' 7 23 
30 M53D+ 1 5-1 5 53 5' aug euu gac aeu aae euu ggu uue ugu gau 3' 1 2  40 
30 M53A+29+58 53 5 '  ugu eue eug uue uge age ugu ueu uga aee 3' 1 5  50 
30 M53A+49+78 53 5' uua aea uuu eau uea aeu guu g ue uec ugu 3' 1 0  33 
30 M53A+59+88 53 5 '  guu gaa uee uuu aac auu uea uue aae ugu 31  9 30 
30 M5SA+69+98 53 5' cag eca uug ug u uga aue cuu uaa cau uue S' 1 1  37 
30 M53A+ 1 9+48 53 5' ueu gea geu g u u  cuu gaa eeu eau ece aeu 3' 1 5  50 
30 M53A-25+5 53 5' uue aac ugg aau aaa aau aag aau aaa gaa 3' 6 20 
30 M53A+ 12 9+1 58 53 5' eca uga gue aag cuu gee ucu gac cug uec 3' 1 7  57 
30 M53A+ 1 5 1  +1 80 53 5' cua eug ugu gag gae euu cuu uee aug agu 3' 1 4  47 
30 M53A+ 1 76+205 53 5' ueu gug aue uuc uuu ugg a u u  g ea ueu acu 3' 1 1  37 
30 M53D+5-25 53 5' uuu uaa aga uau geu uga eae u aa eeu ugg 3' 1 0  33 
25 M53A�25-1 53 5' cug gaa uaa aaa uaa gaa uaa aga a 3' 5 20 
25 M 53A-20+5 53 5' u ue aac ugg aau aaa aau aag aau a 3' 5 20 
25 M 53A+69+93 53 5' auu g u g  uug aau eeu uua aea uuu c 3'  7 28 
25 M53A+74+98 53 5' cag eea uug ug u uga a ue cuu uaa e 3' 1 0  40 
25 M5SA+99+1 23 53 5' ccu guu egg euu cuu ecu uag cuu c S' 1 3  52 
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Table 2.1 : 20Ma cocklail composition for in vitro studies. 
cocktail Ai A2 A3 A4 A5 
20Me AO 1 :3 1 .66: 1 3 . 33 : 1 6.66: 1 1 2 .33:1  
4 1 50 375 460 520 555 
8 1 50 75 46 26 1 5  
9 1 50 75 46 26 1 5  
1 3  1 50 75 46 26 1 5  
total 600 600 600 600 600 
concentration {nM }  (nM) (nM) (nM) (nM )  
Table 2.2 : PMO cocktails composition for In vitro studies. 
cocktai l  B 1  B2 B3 84 8 5  
POO7-PMO 1 : 3 1 .66: 1 3.33: 1 6.66: 1 1 2 .33: 1 
4 2.5 6 .25 7.7 8.8 9.25 
8 2 .5  1 .25 0.77 0.44 0.25 
9 2 . 5  1 .25 0.77 0.44 0 .25 
1 3  2 . 5  1 .25 0.77 0 .44 0 .25 
total 1 0  1 0  1 0  1 0  1 0  
concentration (�lM) ( �lM) (�tM) (�lM) (� lM) 
Table 2.3: PMO cocklails composition for In vivo studies. 
cocktail C 1  C 2  C 3  C4 C 5  
POO7-PMO 1 :3 1 .66: 1  3 .33 : 1  6.66: 1 1 2. 33 : 1  
4 1 0  25 30 35 37 
8 1 0  5 3 . 3  1 .8 1 
9 1 0  5 3 .3 1 .8 1 
1 3  1 0  5 3.3 1 .8 1 
total 40 40 40 40 40 
amount ( �tg) ( �lg) (�lg ) ( �lg ) ().lg) 
102 
Chapter 3 - By-passing the nonsense mutation in the 4cv mouse by induced eXOll skipping 
Table 3 :Primers used for RNA studies and sequenclng. 
Primers for primary PCR Seq uences (51 _ _ >3t) 
1 3Fa TGC TTC MG AAG ATC TAG AAC AGG AGC 
27Ra CTA TTT ACA GTC TCA GTA AGG 
1 3Fb CTC G CT CAC TCA CAT GGT AGT AGT G 
26Rb CCT GCC TTT MG GCT TCC TT 
20Fa CAG AAT TCT GCC AAT TGC TGA G 
35Ra GGT GAC AGC TAT CCA GTT ACT GTT CAG 
20Fb CCC AGT CTA CCA CCC TAT CAG AGC 
3SRb GCC CM CAC CAT TIT CAA AGA CTe TCC 
37Fa CCA AAG GTG GAG TCC ACA CGT G 
SORa CCA GTC GTG CTC AGT CCA GGG 
37Fb GAG CCC CAA ATG TCT GAG CTe 
SORb GGT TT A CAG CCT cce ACT CAG 
48 Fa GAT TTT AGG CAG CTT GM GAG 
58Ra TTC CAA AGT GCT GAG CTT AT A AG 
48Fb eTT CTG TGG CTe TCT CCT ATT AG 
S8Rb eTC CTG GTA GAG TTT eTC TAG 
58Fa GGG CCT TCA AGA GGG AA T TG 
70Ra CCT eT A AeA CAG TCT GCA CTG G 
58Fb CT A MG MC CTG T AA TCA TG 
70Rb GCG AAG TCG CGA ACA TGT TGT GGG 
50Fa GTT AGA AGA TCT GAG GTC TGA GTG 
55Ra GAG TCT TCT AGG AGC TTC TCC TTA 
50Fb CTG T AA ACC A TT TAC TTC GGG AGC 
55Rb GTG TAG GAG ATT GGG AGT TGT TTC 
1 03 
Chapter 4 - Enhanced exon skipping in the 4cI' mouse through refined oligomer design 
CHAPTER 4 
Enhan ced exon skipping in the 4cV dystrophic mouse mode1 of 
muscular dystrophy through refined oligomer design 
Chalermchai MitrpantlJ 2, Sue. Fletcher\ Gavin Pinniger3, Patrick L Iversen4 and 
Steve D Wilton1t'V. 
l Centre for Neuromuscular and Neuro logical D isorders, The University of Western 
Australia, QE II Med ical Centre, Nedlands, Western Austral ia, 6009, Australia . 
2Department of B iochemistry, Faculty of Medicine, Siriraj Hospital , Mahidol 
University, Bangkoknoi, Bangkok, 1 0700, Thai l and . 
30epartment of Physiology, School of B iomedical ,  B iomo lecular & Chemical Sciences, 
The University of Western Austral ia, WA, 6009, Austral i a  
4AV1 B iopharma Inc, Corval l is, Oregon, USA. 
\j!Correspondence to: 
Steve D Wiltoo:, Centre for Neuromuscular and Neuro logical Disorders, The Un iversity 
of Western Austral ia, QE I I  Medical Centre, Ned lands, Western Austral ia, 6009, 
Australia . 
emai l :  swil ton@meddent.uwa .edu .au 
Telephone: (+6 1 )  8 9346 3967 
Facsimile: (+6 1 )  8 9346 3487 
1 04 
Chapter 4 - Enhanced exon skipping in the 4 cv mouse through refined oligomer design 
4.1  Abstract 
Antisense oligomer (AO) induced dual skipping of the dystrophin gene was 
stud ied in  the B6Ros.Cg_Dmdmdx.4cv/J (4cv) mouse, an estab l ished mouse model of 
muscular dystrophy. We previously reported by-passing the protein-truncating mutation 
in exon 53 in this mouse by AO-induced skipping of exons 52 and 53 .  However, 
d ifferences in the efficiency of removal of exons 52 and 53 led to a m ixture of 
transcripts, with some missing only exon 53 and others missing both exons. We have 
developed d ifferent AO preparations and report a more efficient combination of AOs 
that induced almost exclusive expression of the des ired transcript m issing both exons, 
first in vitro and then in vivo. Both intramuscular and intraperitoneal administration of 
an AO-cockta il preferentially induced the in-frame dystrophin transcript missing both 
exons and paltial1y restored dystrophin protein expression in vivo. The ol igotner 
cocktail  also restored assembly of the dystrophin-associated protein complex (DAPC) 
demonstrated by express ion and local isation of DAPC component proteins, and showed 
some evidence of improving muscle functionality. 
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4.2 Introduction 
Duchenne muscular dystrophy (DMD) is the most common and serious 
neuromuscular d isorder in young adults, affecting about one in  3 ,500 newborn males. 
In DMD, the ablation of functional dystrophin leads to loss of the dystrophin-associated 
protein complex (DAPe), a complex l inking the actin cytoske leton to extracel lular 
matrix, thereby rendering muscle more susceptible to membrane damage. Proximal 
tTIuscle weakness becomes evident when muscle regeneration is overwhelmed by 
increased rates of muscle degeneration. DMD patients commonly suffer from 
cardiovascular and respiratory failure i n  their late twenties (for rev iew seel-3 ) .  
Most DMD mutations result in  d isruption of the reading frame of the dystrophin 
transcript, thus lead ing to prematurely truncated non-functional dystrophin.4, 5 Becker 
muscular dystrophy (BMD) also arises from mutations in the dystrophin gene, but these 
defects do not lead to d isruption of the reading frame, thereby allowing production of 
some part ial ly functional dystrophin. BMD phenotypes depend upon the s ize and 
position of the mutation, and the clinical presentation can vary from severe (borderl ine 
DMD) to asymptomatic.6-1 O  
Exon skipping induced by antisense oI igomers (AOs) is being investigated as a 
mechan ism to restore dystrophin protein expression in both DMD patients and an ima l 
models of muscular dystrophy. l I - 1 7  The B6Ros.Cg_Dmdmdx-4CvjJ (4cv) mouse, a model 
of muscular dystrophy, carries a nonsense mutation in dystrophin exon 5 3 . 1 8 , 1 9  
Removal of both exons 52 and 53 i s  required to address this protein-truncating 
mutation} maintai n  the reading frame and induce the expression of a functional 
dystrophin i soform. We previously reported that a cocktai l  of four AOs "vas capable of 
removing exons 52 and 53 from the mouse dystrophin transcript and restoring 
dystrophin protein expression after a s ingle intramuscular i njection in the 4CV mouse.20 
However, exons 52 and 53 \vere excised at d ifferent efficiencies by this  AO-cocktail, 
which, in turn, resulted in a predominance of transcripts miss ing exon 53, compared to 
the desired in-frame transcript lnissing both exons 52 and 5 3 .  As a consequence, 
dystrophin expression was less than 1 0% of that in the control C57BLI l OScSn mouse. 
We report fmiher oligomer optimisation experiments to remove dystrophin  
exons 52 and 53  and compare the efficiency of exon removal with that previous ly 
reported. Initial o ligomer optimisation \vas carried out with 2t-O-methyl (20Me) 
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phosphorothioate compounds, and subsequently, phosphorodiamidate morphol ino 
oJ igomers (PMOs) conjugated to a cell-penetrating peptide (P007) \vere synthesised and 
administered to 4cV mice, to assess the abi lity of AOs to i ncrease dystrophin expression 
and muscle functional ity in vivo. 
4.3 Results 
4.3 . 1  Optimising AO-induced skipping of the individual dystrophin exons 52 and 
53 
Based on our previous study,20 a panel of 20MeAOs, to anneal  to spl ice motifs 
of exons 52 and 53,  including the acceptor and donor spl ice sites, and potential exon ic 
spl icing enhancers (ESEs) of both exons 52 and 53, were selected for further study. 
Figure 1 shows the relative annealing positions of the ol igomers under investigation. 
For exon 52, a total of six o l igomers anneal ing to the acceptor (AO 2), donor 
(AO 3) and ESEs (AOs 1 ,  4, 5 and 6) were evaluated . For exon 53 ,  eleven out of 
e ighteen ol igomers were selected on the grounds that they annealed to the acceptor 
(AOs 8, 1 4, 1 6  and 1 7), donor (AOs 9 and 1 5) and ESEs (AOs 7, 1 0, 1 1 , 1 2  and 1 3).20 
The AOs selected for anneal ing to ESEs were those that bind to regions + 1 7  to +5 1 and 
+29 to +98 on exons 52 and 53, respectively, and which have been shown to 
individual ly induce exon skipping?O The AOs were combined into five cockta i ls  for 
exon 52 and fourteen combinations for exon 53  (Table 1), and exon skipping 
efficiencies were estimated after transfection into cu ltured 4cv myoblasts. 
For exon 52, combining AOs anneal ing to ESEs (AOs 1 ,  4, 5 or 6) \vith an AO 
b inding to the acceptor splicing motif (AO 2) and an AO masking the donor s ite (AO 3) 
resu lted in no improvement in the level of exon skipping� compared to treatment with 
AO 4 alone, an AO previously shown to be the most effective individual A020 (data not 
shown). However, treatment with the cocktai l of AOs 1 +6 , which combines two non­
overlapping AOs, was found to substantially increase the efficiency of exon 52 skipping 
in 4cv myoblasts, compared to AO 4 (Fig 2a, b). The efficiency was emphasised by the 
dramatic reduction in the amount of ful1-Jength gene transcript. 
For exon 53,  AOs annealing to the mouse dystrophin pre-mRNA acceptor (AOs 
8, 1 4, 1 6, or 1 7) and donor spl ice sites (AOs 9 or 1 5) were combi ned with five ESE­
masking oligomers (AOs 7, 1 0, 1 1 , 1 2, or 1 3) in foul1een different combinations. The 
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combination of AOs 8+1 3+9 was originally identified as the most efficient cocktail .20 
A cocktail of AOs 1 4+] 3+9 did not lead to any substantial  improvement, but a 
combination of AOs 8+1 3+ 1 5  was found to enhance level s  of ex on skipping (Table 1). 
Subsequently, two combinations comprising AOs masking acceptor and donor 
spl ice sites « AOs 1 4+9) and (AOs 8+ 1 5)) were combined with ESE-annea l ing AOs 
(AOs 7, 1 0, 1 1 � 1 2  or 1 3) giving ten different combinations. A cocktai l  of AOs 
8+1 3+ 1 5 was the most effective, compared to the other nine combinations (Table 1). 
F inally, interchanging of d ifferent AOs masking the acceptor splice site (AOs 16 or 1 7) 
led to no remarkable increase if! the efficiency of exon skipping (Table 1 and Fig 2c, 
d). However, there ,vas a greater consistency in the abi l ity of AOs 1 3+ 1 5  to induce 
robust exon 53 skipping. For this reason, thi s  AO combination was used in subsequent 
experiments. 
4.3.2 Optimising AD-induced dual exon skipping of dystrophin exons 52 and 53 
We then hypothesised that a 20MeAO-cocktail combining AOs ,vith proven 
efficiency in causing in vitro skipping of exon 52 (AOs 1 +6), and exon 53 (AOs 
1 3+ 1 5), \vould be effective in vivo in inducing dual exon skipp ing. As the previous 
study suggested, combining AOs targeting 2 exons at d ifferent molar ratio could 
enhance level s  of the desired transcript,20 hence this cocktai l  was eva luated at two 
d ifferent ratios ( 1 : 1 and 3 :  1 (referred to as AO-� and AO-a)) and compared with AOs 
4+8+9+ 1 3  (AO-a), the AO cocktail described previously (Table 2).20 
Both AO-f3 and AO-o were capable  of inducing predominant expression of the 
in-frame dystrophin transcript missing exons 52+53 (.L\52+53), but whi lst AO-a i nduced 
the .L\52+53 transcript, it also generated a substantial proportion of .L\53 transcripts in 
four out of five 4 cv myoblast cultures (Fig 2e-g). There were dystrophin transcripts 
missing exon 52 in AO-f3 (Fig  2t), and AO-o-treated 4cv myoblasts, but the levels were 
lower in AO-a-treated-myoblasts (Fig 2g) . 
4.3.3 III vivo efficacy of AO cocktails in  inducing exon skipping after 
intramuscular PMO admillistr.ation 
AO-a, AO-J3 and AO-o were synthesized as peptide-conjugated PMOs, and 
classified as PMO-a, PMO-J3 and PMO-a (Table 2) . Exon skipping efficiencies were 
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compared in vivo by intramuscular injection of 40 flg of each cocktai l  d irectly into 
tibialis anterior (TA) muscles of  4cV mice. Two \veeks after treatment, the Li52+53 
transcript was induced at h igh levels, compared to other dystrophin transcripts (viz. ful l ­
length, LiS2, LiS3) in TAs treated with PMO-J3 and PMO-o, wh i l e  l evels o f  the LiS3 
transcript were more pronounced in PMO-a-treated muscle (Fig 3a). In addition, 
significant leve l s  of the Li52+S3 transcript were expressed at 4, 6 and 8 weeks after 
intramuscular administration of PMO-P and PMO-o, and at two different concentrations 
(20 and 40 flg) . The fai lure to genel:ate a LiS2+53 product at the 6 week time point (40 
flg) is l ikely to be due to sampling error (Fig 3b). 
Western blotting was used to confirm dystrophin expression. At equivalent 
protein load ing, dystrophin was barely detectable after 2weeks in PMO .. a-treated 4cV 
mouse TAs, cmnpared to the C57BLIl OScSn muscle sample (Fig 3c). However, 
dystrophin was readi ly  detected within 2 weeks after intramuscular administration of 
PMO-f3 or PMO-o into treated animals. PMO-8 treatment at both 20 and 40 J..lg restored 
dystrophin protein to approximately 40% of level s  in control CS7BL/I 0ScSn mice at 4 
weeks, although thi s  reduced to 7% to 1 0% at 6 and 8 weeks after treatment (Fig 3d,  e). 
Only at a dose of 40 J..lg was PMO-P found to lead to significant levels of dystrophin 
protein (Fig 3e). 
4.3.4 III vivo efficacy of AO cocktails in inducing exon skipping after 
intraperitoneal PMO administration 
Intraperitoneal administration of PMO-J3 and PMO-o at a dosage of 40 mg/kg 
twice \veekly for 4 weeks, and" weekly thereafter unt i l  9 weeks, led to 1 00% of the 
induced .852+53 transcript in diaphragm of 4cv mice} as determined by RT-PCR. 
Similarly, RT-PCR analysi s  of RNA from TA muscles from PMO-J3 treated mice at 4 
and 8 weeks, and PMO-o-treated mice at 8 weeks showed 100% expression of the 
Li52+53 transcript (Fig 4a). No Li52+53 transcript, howevel'� was evident in cardiac 
muscle from mice treated with PMO-P or PMO-o, irrespective of the time after PMO 
treatment (Fig 4a). 
Western blot analyses of tissues from treated lnice corroborated the results of 
RT-PCR analysis, confirming the expression of dystroph in in d iaphragm from PMO-P 
and PMO-o treated mice at 4 and 8 weeks (Fig 4b).  Dystrophin immunostaining of 
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muscle cryosections from PMO--f3 and PMO*o treated mice again showed a high degree 
of consistency in the expression of dystrophin in diaphragm. However, in TA 
expression of dystrophin was less pronounced at 4 weeks in PMO-o treated m ice (Fig 
Sa). 
4.3.5 111 vivo efficacy of AO cocktails to restore DAPe and improve muscle 
functionaJity after intraperitoneal PMO administration 
The observation that PMO treatment led to re-establ ishment of dystrophin 
expression in 4cv m ice raised the question of whether PMO treatment could restore the 
DAPC and lead to improved muscle functionality. Prel iminary studies using three 
PMO-o treated mice sacrificed 8 weeks after a course of i ntraperitoneal injections, 
showed that PMO treatment restored the DAPC components, nNOS and p-dystroglycan, 
to level s  comparable to those in the C57BLI l OScSn control mouse, in both diaphragm 
and TA, albeit to a greater degree in d iaphragm (Fig 5b, c) . 
PMO-o treatment also led to some restoration of functional ity i n  diaphragm (Fig 
6a)j but not extensor digitorum longus (EDL) (Fig 6b), based on the extent (%) of 
damage fol lowing an eccentric contraction (5 stretches at  1 0% optimum muscle length) 
(Fig 6a). Other measures of functionality (viz. twitch force after fatigue, tetani c  force 
and fatigue recovery time), however, showed no significant restoration after PMO 
treatment (Fig Gb, c). 
4.4 Discussion 
As in our previous study of AO-induced dual exon skipping, we explored the 
use of ol igomer cockta i l s  to excise exons 52 and 53 from the dystrophin gene transcript 
in the 4cv mouse model of muscular dystrophy.2o We showed that combining selected 
AOs that when used ind iv idually were inefficient, could induce robust exon skipp ing. 
Ho\vever, not all AO combinatio'ns resulted in enhanced exon skipping. 
For exon 52, changing the components of the AO cocktai ls  to include AOs 
anneal ing to both acceptor and donor spli cing motifs resulted in  no great improvement 
in exon skipping efficiency. However, individual AOs masking ESEs (SF2/ASF (IgM­
BRCAI ), SC35,  SRp40 and SRp55) (AO 6) induced inconsistent patterns of exon 52 
skipping,20 but using this AO together with a non-overlapping AO anneal ing to ESEs 
(SC35 ,  SF2/ASF and SF2/ASF (IgM-BRCAl )  (AO 1 ), increased the efficiency of exon 
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5 2  skipping i n  4cv myoblasts . 
Excision of exon 5 3  also required an AO-cockta i l .  A 3-AO cocktai l  (AOs 
8+ 1 3+9) comprising AOs targeting acceptor and donor spl ice s ites and ESEs, was 
original ly identified as the most active preparation.2° Substitution of different AOs 
annealing to the donor spl ic in g  m otif led to greater levels of exon skipping, whereas 
changing the composition of AO cocktails to mask the acceptor splice s ite caused no 
obv ious improvement in AO-induced exon skipping. AO 1 3  anneal ing to ESEs (SC35 
a nd SRp40), as in our previous study, appeared to be the best of the ESE-masking AOs 
when combi ned in a cockta i l ,  compared to other ESE-anneaI ing AOs. A lthough 
masking both obvious spl ice s ite and ESEs did not enhance efficiency of exon 5 2  
removal , optimising the a nnealing coord inates o f  the donor spl ice site A O  seemed to 
improve the efficiency of exon 5 3  skipping?O The most effective AO-cocktai ls  
targeting exon 5 3  a l J  included AOs 1 3+ 1 5, subsequently these two compounds were 
evaluated and found to be of simi lar efficiency to the 3-AO cocktai l  in inducing exon 
skipping. Consequently, th is 2-AO cocktai l was selected for further studies. 
AOs with proven efficiency in inducing in vitro skipping of exon 52 (AOs 1 +6) 
and exon 53 (AOs 1 3+ 1 5) were combined at two different molar ratios ( l : l  a nd 3: 1 
(referred to as AO-J3 and AO-B» because of the relative d ifferences i n  exons 52 and 5 3  
removal, demonstrated b y  intermediate products. These cocktai ls  i nduced expression of 
the i n-frame dystrophin transcript m issing exons 5 2+53 (Llexons 5 2+53) as the 
predominant transcript i n  cultured 4cV myoblasts. 
These in vitro studies on cultured 4cv mouse myoblasts provided the basis for 
subsequent in vivo studies using either i ntramuscular or i ntraperitoneal administration of 
peptide-conjugated PMOs, PMO-f3 and PMO-o. The efficacy of induced dual exon 
skipping by these PMO cocktails was compared with that of the cockta i l  (PMO-a) 
reported in our previous study?O 
A single intramuscular injection of PMO- J3 or PMO-o directly i nto the TA of 4cv 
mice resulted i n  very efficient dual exon skipping, with the .152+53 transcript observed 
two weeks after PMO administration. There was s ignificant expression of the Ll52+53 
transcript at 4, 6 and 8 weeks, peaking at 4 weeks after PMO-J3 and PMO-o 
administration, and thereafter decl ining to approximately 1 0% by 6 and 8 weeks. 
Western blotting estimated that PMO-o, and to a l esser extent PMO-f3, restored 
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dystrophin protein levels to approximately 40% of that in control C57BL/I 0ScSn mice. 
S imilarly, intraperitoneal administration of PMO- f3  or PMO-8 for 4 and 8 weeks led to 
1 00% expression (relative to total dystrophin transcript product) of the A52+53 
transcript in diaphragm and to lesser extent in TA from 4cV mice, as detennined by RT­
PCR. The expression of the A52+53 transcript in PMO-P and PMO-o treated mice was 
accompanied by expression of the dystrophin protein in diaphragm muscle and at a 
lesser extent in  TA muscle� as determined by western b lotting and immunofluorescence 
using anti-dystrophin antibody. 
No exon skipping effect was observed in cardiac t issue foHowing PMO-f) or 
PMO-8 treatment; ,ve now know that this is due to the nature of the P007 peptide tag 
conjugated to the PMOs. No induced dystrophin was detected in cardiac t issues after 
treatment of another PMO with the same P007 peptide tag masking donor spl ice s ite of 
mouse dystrophi n  exon 23 in mC/x mice. 12, 13 Most recently, it has been shown that the 
PMO M23D(+7- 1 8)  conjugated to peptide B was able to i nduce robust dystrophin 
expression in cardiac tissue.2 1 -23 
The finding that PMO-P or PMO-o treatment led to predominant induction of 
the A52+53 transcript and dystrophin protein expression in the 4cv mice prompted us  to 
confirm that these dystrophin changes at the molecular level s  led to restored assembly 
of components of the DAPC and, u ltimately, to improved muscle functional ity . One of 
the key roles of dystrophin is to stabi l ise DAPC, which plays a pivota l role in muscJe by 
l inking the cytoskeleton to extracel lular matricesl ,  24, The DAPC also mediates 
intracel lular s ignal s  via nNOS and other components25• 26 . Our pre l iminary studies 
confirmed assembly of the DAPC and improved muscle functionality, and are h ighly 
encouraging. Levels of the DAPC components, nNOS and l3-dystroglycan� were 
comparable to those in the C57BL/ l 0ScSn control mouse. Moreover, PMO-b 
treatment was shown to also lead to some improvement in the extent of damage 
fol lo\ving eccentric contraction in the d iaphragm, but not extensor digitorum longus 
(EDL) muscles . The l imited .EDL response, based on the extent (%) of damage 
fol lowing an eccentric contraction, is most probably due to insufficient restoration of 
dystfophin expression in this muscle .  Other measures of functional ity (viz. twitch force 
after fatigue, tetanic force and fatigue recovery time) showed no significant restoration 
after PMO treatment, which demands that further studies be carried out. 
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The implications of the these studies for the management of muscular dystrophy 
i n  humans are potentially far reach ing, given that they confirm that PMO-induced dual 
exon skipping can lead to substantial dystrophin  protein expression, restored assembly 
ofDAPC, and based on pre l iminary studies, some restoration of muscle functional ity .  
4.5 Materials and methods 
4.5.1 AOs and primers 
The sequences of the AOs employed in thi s  study were as reported by 
Mitrpant et al., 2008.2° The nomenclature adopted for o l igomers is based on that 
described by Mann et aI ., 2002.�7 20MeAOs were synthesised on an Expedite 8909 
Nucleic Acid Synthesiser (Applied B iosystem� Forster, CA, USA.), and PMOs 
conj ugated to an arginine-rich, cell-penetrating peptide (P007i8, 29 were synthes ised 
by A VI B ioPharma (Corval l i s, OR, USA) . Primers for RT-PCR and sequencing 
analysis were synthesised by Geneworks (Adelaide, Australia) and are reported 
elsewhere.2o 
4.5.2 Animals 
4CV (B6Ros.Cg_Dmdmdx-4cvjJ ) congenic mice, housed and suppl ied by the 
Anima l  Resources Centre, Murdoch University, Western Australia, were used for in 
vivo studies .  Procedures for animal housing and transport complied with the guidel ines 
of the National Health and Med ica l Research Counci l  (Austral ia) .  Experimenta l 
protocol s  using animals were approved by the Animal Ethics Committee of the 
University of Western Austral ia (Approval Number 03/1 00/572) . 
4.5.3 Cell culture and AO transfection 
Primary myoblast cultures of 4cv m ice  were prepared from 2-4 day-old 
pups by the protoco l descr ibed e l sewhere . 2 o, 3 0  20MeAOs complexed on a 1 :2 
basis (w/w) with Lipofectin (Invitrogen, VIC, Australia) were incubated with 4cv 
myo b l asts ,  as reported by M i trpant  et al. 2 00 8 . 20 Transfected myoblasts were 
i ncubated for 48 hours before RNA \vas extracted for analys is. 
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4.5.4 Intramuscular administration 
PMOs, prepared in physiological 0.9% (w/v) saline, were injected i nto mouse 
TA muscles in vivo at the doses indicated in the text. Each experiment included at 
least one saHne-only treated mouse as a negative contro l .  TAs were removed from 
animals anaesthetised and sacrificed by cervical dislocation at the indicated t ime 
points after i njection, and snap-frozen in pre-cooled isopentane. TAs were then 
clyosectioned and prepared for RNA and protein  analysis. 
4.5.5 Intraperitoneal administration 
PMO cocktai ls, prepared in 50 JlI of 0.9% (w/v) normal sal ine, were injected 
i nto the peritoneal cavity of mice at day 7 after bhih. PMO cocktails were 
administered twice a week for 4 weeks, and once a week from weeks 6 to 9. Animals 
administered saline alone served as contro ls. PMO-treated and saline-injected animals 
were anesthetised and sacrifi ced by cervical dislocation at the indicated time points 
after i njection. Muscles and other t issues were removed , snap-frozen in pre-cooled 
i sopentane. Tissues were then cryosectioned and prepared for RNA and protein 
analysis. 
4.5.6 RNA extraction, RT-PGR analysis, and DNA sequencing 
RNA ,vas harvested from 4cv cultural myoblasts and tissue cryosections using 
Trizol (Invitrogen), according to the manufacturer's protoco1 . One-step RT-PCR 
followed by nested peR was undertaken according to protocols described e lsewhere.2o 
peR products were separated on 2% agarose gel s  in T AE buffer, pH 8.3 and images 
captured on a Vi lber LoUt'mat CHEMISMART-3000 gel documentation system (Vi lbel' 
Low'mat, Marne-Ia-vallee, France) . peR products were re-ampl ified and identified by 
DNA sequencing fo l lowing protocols reported else\vhere.3 1  
4.5.7 Western blot analysis 
Mouse muscle  cryosections were homogenised in treatment buffer (4 .5 mg 
tissue per 1 00 �l buffer) as described in Mitrpant et al., 2008?O Protein extracts were 
fractionated by e lectophoresi s  on a 4- 1 0% SDS gradient gel at pH 8 . 8  with a 4% 
stacking gel ,  pH 6.8 .  Densitometry of myosin bands aftet' coomassie blue staining was 
undertaken to ensure equivalent l evels  of protein l oading. Proteins were transferred 
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from the gel to nitrocel lu lose membranes (Amersham Biosciences, Cast le Hi 1 1 ,  
Austra lia) overnight at 1 8°Cj at 290mA. Dystrophin \vas visuali sed using NCL-DYS2 
monoclonal anti-dystrophin antibody (Novocastra, Ne\vca stle-upon-Tyne, UK) as 
described previously.2o Images were captured on a Vilber Lourmat Chemi-Smalt 3000 
gel documentation system (Vi lber Lourmat). 
4.5.8 Tissue preparation and immunofluorescence 
Oystrophin was detected on unfixed cryosections using NCL-DYS2, an antibody 
that reacts strongly with the C-terminus of dystrophin .  Immunofluorescence was 
performed using a Zenon Alexa F luor 488 l abell ing kit (Invitrogen), according to the 
protocol recommended by manufacturer, except that fixation was delayed unt i l  after 
staining. The primary antibody yvas d i luted 1 :  I 0 and sections were counterstained with 
Hoechst (Sigma-Aldrich, St. Louise, MO, USA) at a di lution of 1 :  1 0,000 to visualise 
nuclei .  Sections were viewed under an Olympus IX 70 inverted microscope and images 
captured on an Olympus DP70 d igital camera. 
4.5.9 Functional testing of isolated diaphragm strips and EDLs 
The entire diaphragm muscle and surrounding ribcage, were excised and pJ aced in a 
d i sh containing oxygenated physiological sal ine solut ion containing l OmM sodium 
pyruvate and 1 % foetal bovine serum. Diaphragm strips and extensor digitorum longus 
(EDLs) \vere dissected and tied with surgical s i lk at the central tendon and at the distal 
end. D iaphragm strips and EDLs were then transferred to a muscle test chamber 
containing physiological saline maintained at 25°C continuously bubbl ed with 95% 02, 
5% C02. The contractile  properties of the muscles were evaluated using an in vitro 
muscle test system (Aurora Scientific Inc. ,  Milford, PA, USA) to determine the 
max imum isometric  twitch force (Pt)� lnaximum isometric tetanic force (po) and the 
frequency force relationship (20 to 1 50 Hz). After determination of their i sometric 
contracti le properties, muscles were subjected to an eccentric contraction protoco l to 
determ ine susceptibil ity to stretch-induced muscle damage. After functional  testing, the 
muscle mass, fibre length, and Po were recorded to calculate the specific force relative 
to muscle fibre cross-sectional area (kN/m2). 
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Figure 1 :  Annealing positions of selected AOs targeting exons 62 and 53. 
Diagrammatic representation of the predicted ESEs in exons 52 and 53 and the 
relative annealing coordinates of the selected ADs. Vertical bars indicate the fIVe 
ESEs predicted to be binding sites of SR proteins (viz. SF2fAS F (red) , SF2IASF 
(lgM-BRCA1) (pink), SC35 (navy blue). SRp40 (Iighl green) and SRpSS (yellow». 
Threshold scores were set al default values as. specified io ESE finder,32. 33 
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Figure 2: RT-PCR analysis of extracts of 4cv myoblasts after treatment with 
different concentrations of the A()..cocktalls. 
(a) AO 4; (b) AOs 1+6; (c) AOs 8+13+9; (d) AOs 13+15; (0) 20MeAO-a. (AOs 4+ 
8+9+ 13); (f) 20MeA()..13 (ADs 1 +6+13+15); and (g) 20MeAO-8 (ADs 1 +6+ 1 3+ 
15) compared to untreated 4cv myoblasts and saline-only negative controls, The 
full.length transcript (FL) are shown as well as transcripts missing axon S2 (A52), 
exon 53 (A53) ,  and both e)(ons 52 and 53 (A521S3). The size of transcripts was 
determined by comparison to molecular weight markers. and confirmed bV DNA 
sequenclng, 
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Figure 3: (a and b) RT-PCR The full-length transcript (FLI transcripts mlsslng 
exon 52 (.0.62), exon 53 (A53), and both exons 52 and 53 (A52I53) are indicated. 
The size of transcripts was determined by comparison to mole�ular weight markers; 
(0 and d) W&stem bioi analysis. Semi-qusnlirlCSlion of restored dystrophio was 
determined by densitometric analysis of western blots of samples from treated 
mice relative (%) lo dystrophin protein levels in C57BLl1OScSn conttrol mice: and 
(e) semi-quantir�ion of restored dystoprun protein in TAs of the 4 mice which 
ware inlramuscuiarly injected with PMO-<x., PMO-� and PMO-S. 
(a) 
PMo..l3 
FIgure 4: Levels of (a) dystIophin RNA and (b) protein In diaphragm 
Md TA muscles derived from the 4cv mice lntraperltonea"v lnIeded 
with PMo-l3 and PMQ.O as determined by RT-PCR and western blot 
analysis, respectively, 
The levels of rull .. length transcript (FL) erc shown 9S well as Iovels of the 
transcripts missing axon 52 (.0.52), emn 53 (.o.53}, and both exons S2 
and 53 (.0.52/53). The size of transcripts was determined by comparison 
to molecular weight markers. 
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Figure 5! Immunofluorescence of (a) dyslrophln, (b) neuronal nitric oxide synthase (nNOS) and (c) �-dystroglycan In diaphragm 
and TA muscle cryosectlons (rom PMO..p and PMO-o treated 4cv mice. 
O;strophln Immunofluorescence was examined at 4 and 8 weeks after intraperitoneal PMO injection In 4cv mice and compared to that on 
cryoseclions from C57BU1OScSn and untreated 4cv mice. oNOS and p..dysttogiycan lmmunostalning was examined al 8 weeks after 
PMO...s treatmeni and compared to C57BU10ScSn and untreated 4cv mk:e. {bar=1 OOJ-lm) . 
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Figure 6: Contractile properties of (a and e� diaphragm; and (b) extensor dfgitorum 
longus (EOL) mUKles derived from the 4C mice Intrapertoneally treated with 
PMO-o for 8 weeks. 
Four EDLs and three diaphragms from PMO..5 tWtated 4 mice ",./ere included. whereas 
four EDLs and fyJO diaphragms from untreated 4cV mice were used in the study. 
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Table 1 :  The compoSlUon of the AO-eocktalls to remove etther exons 52 or 63. 
The compositions of the different AO-cocIdal1s tested fargeting axons 52 and 53 and their elllclency In causing axon skippilg (as scored 
subjectively on a 4·point scale by visual analysis of >2 separate RT-PCR gels). 
compositions of exoo skipping 
effK:iene)' 
AOs 1+6 +++ 
AOs 2+1 +3 + +  
A Os  2+4+3 + + 
AOs 2+5+3 + 
A0s 2+6t3 + 
A0 4 tt 
A0s 8+ 1 3+9 +++ 
A0s 8+1+15 ++ 
AOs S+10+ 1 5  + +  
AOs 8+11 + 1 5  +++ 
A0$ 8+1 2+ 1 5  ++ +  
A0s 8+13+ 1 5  +++ .. 
AO$ 1 4+7+9 ++ 
AOs 1 4+10+9 ++ 
AOs 1 4+1 1+9 +++ 
AOs 1 4+ 12+9 +++ 
AOs 1 4+13+9 +++ 
AOs 1 4+ 1 3+ 15 ++++ 
AOs 16+ 1 3+ 15 ++ ++ 
AOs 1 7+ 1 3+ 15 ++++ 
AOs 1 3+ 1 5  ++++ 
Table2: The composition of the selected cocktails to remove exons 52+63 and theIr efflclency In causing Ixon skipping. 
The compositions of the three selected AO-cocktails largelilg both exons 52 and 53 and their efficiency In causing sklpplng of both exons, 
based on levels of dyslrophln protein. determined by densitometr1c analysis of Yleslem blots and expressed (%) relative to dyslrophln 
protein levels In control C57BU1OScSn mice. 
compositions molar ratios Percentage of AOs 20MeAO PMO of rescued of selected targeting cocktails cocktails dystrophin cocktails exons 52:53 protein 
ADs 4+8+9+1 3 1 .66:1 20MeAO-u PMO"'t1. 7% 
AOs 1 +6+1 3+1 5 1 : 1  20MeAO-� PMO-� 40% 
AOs 1 +6+ 1 3+1 5 3:1 20MeAO-i) PMO-S 40% 
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5.1 Abs tract 
Duchenne muscular dystrophy (DMD), the most severe neuromuscular d isorder 
of childhood, is caused by the absence of a functional dystrophin. Antisense ol igomer 
induced exon skipping is being investigated to restore functional dystrophin expression 
in models of muscular dystrophy and DMD patients. One of the major chal lenges will 
be the development of cl inically relevant oligomers and exon skipping strategies to 
address many different mutations. Various models, including cell-free extracts, cel l s  
transfected \vith artificial constructs, o r  mice with a human transgene., have been 
proposed as tools to facilitate ol igomer design. Despite strong sequence homology 
between the human and mouse dystrophin  genes, d irecting an ol igomer to the same 
motifs in both species does not always induce comparable exon skipping. We report 
substantially d ifferent levels of exon skipping induced in normal and dystrophic human 
myogenic ceH l ines and propose that animal models 01' artificial assay systems usefu l  in 
initial studies may be of l imited relevance in designing the most efficient compounds to 
induce targeted skipping of human dystrophin exons for therapeutic outcomes. 
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5.2 Introduction 
Duchenne muscular dystrophy (DMD), the most severe neuromuscular disorder 
of childhood, is caused by the absence of a functional dystrophin, I with patients 
suffering from progressive muscle weakness and severe respiratory and cardiac 
complications by the second and third decades of l ife.2, 3 Becker muscular dystrophy 
(BMD) also arises from mutations i n  the dystroph in  gene, but these lesions are such that 
some functional protein can be generated, albeit of reduced quantity and/or quality. 
Splice intervention using antisense ol igomers (AOs) is being developed as a 
potential  molecular therapy for DMD. AO intervention during dystrophin  pre-mRNA 
processing a ims to exclude on� or more exons associated with the primary DMD­
causing mutation, whi le  maintaining or restoring the dystrophin reading frame. A 
clinical trial of AO induced exon skipping in DMD patients has demonstrated proof of 
principle that th is  antisense strategy can restore some dystrophin expression in DMD 
muscle.4 
One of the major challe�ges to oligomer induced gene transcript manipu lation 
for therapeutic purposes, wi11 be the design and development of c l in ically relevant 
o l igomers. Various models, includ ing cel l-free extracts, cells transfected with artificial 
constructs, mice with a human transgene, and in silieo predictions, have been proposed 
as too l s  to faci l itate ol igOJner design for splice manipulation .5-7 The highly coord inated 
nature of gene expression leads to reduced efficiency of processing when cell-free 
extracts are used to assay spl icin-g. Within a nucleus, introns  are removed an estimated 
forty times faster than in vitro processing of synthetic pre-mRNA transcripts.8 Normal  
gene  expression appears precariously balanced when one considers minor base changes 
can lead to activation of cryptic spl ice sites} pseudo-exon inclusion or some other form 
of aberrant splic ing.9, 10 Hence, i nsertion of any test exon with some arbitrarily selected 
flanking intronic sequences into .a spl ice repOliel' system may allow some assesslnent of 
ol igomer induced redirection of spl ic ing patterns in transfected cells. However, such a 
system wil l  not directly reflect processing of that exon \vhen it is under control of the 
ful l  complement of t issue specific cis- and trans- spl icing motifs and factors. F inally, 
transcription-coupled processing d iffers from uncoupled processing in that the nascent 
pre-mRNA is a growi ng strand that is constant ly folding into new structures and 
associating with protein-RNA
' 
and protein-protein  complexes within the IImRNA 
factory". 1 1 The majority of in silteD predictions are the result of analysi s  of imported 
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sequences of arbitrari ly selected length. 
We consider normal human Inyogenic cel1s appropriate for AO design and 
optimisation, and reported an ini�ial draft of AOs targeting human dystrophin exons 2 to 
78 . 12 Despite strong homology benveen the mouse and human dystrophin genes, we 
found variation in exon skipping efficiency and patterns of exon removal  in these 
transcripts . For some exons, d irecting oligomers to the same target motifs induced 
s imilar exon skipping patterns. In contrast, ol igomers targeting other exons generated 
different dystrophin splice isoforms in the two species. We report substantial ly 
different levels of exon skipping induced in normal and dystrophic human myogenic 
cell l ines, and propose that animal models  or artificial assay systems useful in some 
studies may be of l imited relevance in designing the most efficient compounds to 
induce targeted skipping of human dystrophin exons. 
5.3 Results 
5.3.1 Splice site and auxiliary motif predictions 
Acceptor and donor spl ice site scores for exons under investigation, as 
calcu l ated by the web-based program, MaxEntScan are shown in Table 1, along with 
details of exon and flanking intron lengths. Although there was some variation in the 
mean donor splice site strength of those exons under investigation, there was no 
obvious trend where strong or ·weak donor splice sites were found to be more 
responsive as targets for spl ice intervention. S imilarly, the score for the acceptor spl ice 
s ites d id not offer any ind ication as to the suitability of the sites for AO induced exon 
skipping. It is of interest that the mouse dystrophin exon 23 acceptor spl ice site, 
predicted to be very weak, has previously been shown to be unresponsive as a target for 
exon removal . 13 
Exons and l imited flanking intronic sequences were anaJysed for Exonic Splice 
Enhancers (ESEs), using two programs: ESEfinder 3.0 predicts motifs responsive to the 
human SR proteins SF2! ASP, SC35� SRp40 or SRp55, 1 4, 15 and RESCUE-ESE al lows 
identification of putative ESEs for human and mouse . 1 6, 17 AO sequences designed to 
excise selected exons, and pred icted ESEs, within these annealing sites are described in 
Table 2. The distribution of spl ice motifs predicted by RESCUE-ESE, relat ive AO 
anneal ing, and induced exon skipping patterns for both human and mouse dystrophin 
exons under investigation are shown in Figures la-e. The most effective AOs appear 
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to preferentially  target predicted SF2/ASF (IgM-BRCA I )  (25%) or S C3 5  (28%) motifs, 
compared to 22%, 1 7% and 8% targeting SF2/A SF, SRp40, SRp55} respectively. 
5.3.2 AD design and evaluation 
A direct comparison of relative AD induced skipping of the sam e  exon in 
immortalized mdt mouse and human myogeni c  cells was undertaken to establ ish if  
annealing coord inates for one species could be directly appl ied to the other. 
Immortal ized mdx cells ,vere assessed as removal of exon 23 would by-pass the 
nonsense mutation, and exon 23 skipped transcripts woul d  no longer be subjected to 
n onsen se mediated decay, unl i ke the intact, ful l�length transcript. Removal of other 
exons from the mdx dystrophin gene transcript \vould n ot remove the premature stop 
codon, hence both fu l l  length and skipped transcripts shou l d  be subj ected to equal rates 
of nonsense mediated decay. Exclusion of selected exons from the normal dystrophin 
gene transcript wil l ,  in many cases, disrupt the reading frame and render the induced 
transcript subj ect to nonsense-mediated decay . In most experiments, dose responses of 
exon skipping with varying o l igomer concentration were used to rank o l i gomer 
efficiency for that exon. A comprehensive series of AOs has been d eveloped to excise 
each exon from the human dystrophin  gene transcript. 12, 1 8, 1 9 O li gomer induced exon 
skipping of several mouse dystrophin  exons has been exami ned i n  normal and 
dystrophi c  mice, and is  a n  on�going process of refinement.20• 2 1 
In three of 1 0  exons u nder investigation, optimal anneal ing co-ord inates for 
induction of exon skipping were identical in human and mouse� indicating that transfer 
of AD design between human and mouse dystrophin exons 1 9, 2 1  and 25 was possib le  
(data not  shown). As s hown i n  Table 1�  the calcul ated acceptor splice s ite scores for 
exon 1 9  was h igh (9.07-9.24), ,vhi le  the donor splice s ite scores were moderate (5 .07� 
6.49) . In contrast, the scores for exon 21 acceptor (4.63-6. 1 4) were much weaker than 
the donor (9. 07- 1 0.08), whereas the acceptor and donor site scores of exon 25 were of 
i ntermediate values (4.36-7.46 and 7.25·9.46, respectively) . 
Exons 1 9, 2 1  and 25 were removed by single ADs, as were exons 22 and 23, 
a lthough in  the latter cases there were substantial  differences in exon skipping 
efficiency and spl ic ing patterns between the species. For both mouse exons 22 and 23,  
the donor spl ice sites 'were original ly identified as amenabl e  targets for exon excis ion, 
however, ,vhen these coordinates were targeted in the human dystrophin pre-mRNA, 
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there was no detectable exon skipping (Figs la, b). Targeting intra�exonic  motifs in 
human dystrophin exons 22 and 23 induced substantial exon skipping, and directing 
AOs to these coordinates in the mouse dystrophin pre-mRNA also resulted in efficient 
exon excis ion. Indeed� it would appear that directing an oligomer to the corresponding 
mouse intra-exonic motif identified in human dystrophin exon 22 was equal ly effective 
at excising the target exon, as the oligomer anneal ing to the donor spl ice site. The 
induced splic ing patterns for exon 23 also differed between human and mousei in that 
whi le  human exon 23 removal was specific (1 2 1 6 bp), transcripts missing exons 22 and 
23 Cl 070 bp) \vere readi ly detected in the treated mouse cells� in addition to specific 
exon 23 skipping. This dual exon skipping was more pronounced when the mouse exon 
23 donor site was targeted, and it wou ld appear that directing an oligomer to the intra­
exonic motif may result in more spec ific exon 23 skipping. 
Human exon 24 could be excised with a s ingle AO} H24A(+5 1 +73) (1 309 bp), 
but RT-PCR also revealed the presence of transcripts m issing exons 24+25 ( 1 087 bp). 
Targeting the equivalent mouse coordinates resu lted in  lower levels of exon 24 skipping 
in an apparent non-dose dependant manner. More efficient and specific mouse exon 24 
skipping was induced using a combination of two AOs. The appl ication of an AO 
cocktai l  targeting the equivalent coordinates induced skipping of human exon 24, but 
transcripts missing exon 24 and 25 were sti l l  evident (Fig le) .  
Two of the 10 human exons (20� 65) ,  and 4 of the 10 mouse exons (20, 24, 52}  53) 
were only efficiently dislodged by the application of combinations of AOs. There was 
pa11ial overlap in AO anneal ing coordinates for the cocktai l s  that excised exon 20 from 
both the human (H20A(+44+7 1 )  and H20A(+ 1 47+ 1 68)) and mouse ((M20A(+23+47) 
and M20A(+ 1 40+ 1 64)) dystrophin gene transcripts (Table 2) . 12, 2 t ,  22 The human and 
mouse AO cocktails appeared equally efficient when used in mice, but when the 
optimal mouse coordinates were directed to the human dystrophin pre-m RNA , there 
was a sl ight, but reproducible decl ine in efficiency of exon removal, most noticeable at 
lower transfection concentrat ions (Fig ld). 
A single AO, H52A(+ 1 2+4 1 )  was found to efficiently remove human exon 52 
from the mature dystrophin transcript, with greater than 30% exon skipping being 
induced after transfection at l O.O nM. 12  Directing an oligomer to the corresponding 
mouse coordinates induced substantial exon skipping, but the application of the cocktail 
M52A(+17+4 1 )  and M52A(+42+7 1 )  resulted in  four-fold more exon exclusion (data 
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not shown}. 
Directing AOs to hum�n and mouse dystrophin exons 53 resulted in the 
generation of the most d ist inct patterns of exon excision observed to date. A s ingle AO, 
H53A( + 39+69)� was able to induce efficient and specific exon skipping from the human 
dystrophin gene transcript (Fig le) .  Upon targeting the same coordinates in the mouse 
dystrophi n  pre-mRNA, some transcripts missing exon 53 (700 bp) were detected., as 
well as a substantial proportion of transcripts missing both exons 53 and 54 (545 bp) . 
The shorter transcript is out-of frame and was never detected after transfecting human 
cells \vith this AO, or any of the other 1 8  ADs designed to excise human exon 53 .20 
Specific mouse exon 53  skipping could be induced using a combination of nvo mouse­
specific AOs (Fig le). However, \vhen the same anneal ing coordinates were targeted in 
the human dystroph in gene transcript, on ly low level s  of exon 53 skipping were 
detected (Fig le).  
Two additional ADs (M53A(+1 5 1+ 1 80) and M53A(+1 76+205)), w ith 
overlapping annealing sites, were found to induce cryptic splicing in mouse exon 53 ,  
which l ed  to the loss of  78 bases of  coding sequence from 3 '  end of  the exon (Fig 2a).  
The activated mouse cryptic donor spl ice s ite was identified by DNA sequencing (Fig 
2b), and calculated to have a. spl ice site score of 7.4 1 17.26 (Fig 2e). Directing 
o l igomers to th i s  region of the human gene transcript resulted in low level s  of 
inconsistent exon 53 skipping, with no evidence of cryptic spl ice s ite activation (data 
not shown). 
Human dystrophin exon 65 could only be efficiently removed using a 
combination of two AOS,22 whel�eas a s ingle AO, M65A(- 1 1 + 1 4), annealing to the same 
acceptor sp l ice s ite coordinates as one of the human cocktail components was able to 
induce exon skipp ing from the mouse dystrophin pre-mRNA after transfect ion at 
concentrations as low as 50 nM. Another o l igomer targeting mouse exon 65, 
M65A( +63+87) (shown in Table 2), was found to induce more robust exon skipp ing, 
but l ike the two compounds in the optimised human exon 65 cocktail, this oligomer did 
not induce human exon 65 skipping when applied individually (data not shown.) 
5.3.3 Induced exon 16 skipping in normal and dystrophic human myogenic cel J s  
Two AOs, H 1 6A( - 1 2+ 19)12. 23 and H 1 6A( + 1 1  + 35i3, previously designed to 
exci se exon 1 6  from the mature human dystrophin mRNA, could be readi ly 
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distinguished in their abi l ity to excise the target exon (Figs 3a, b). H 1 6A(- 1 2+ 1 9), 
targeting the exon 1 6  acceptor site could induce pronounced exon excision at a 
concentration of 1 0  nM, \vhi l e H1 6A(+1 1 +35) induced weaker exon 1 6  skipping after 
transfection at 25 nM in normal human myogenic cells .  However, when these 
compounds were transfected into myogenic cells from a DMD patient with a G>T 
substitution of the first base of intron 1 6  (IVS1 6+ IG>T; c. 1 992+1 G>T), both AOs 
induced robust exon skipping and could not be readi ly d iscriminated (Figs 3c, d) . RT­
peR on RNA extracted from the untreated DMD cells did not y ield a consistent pattern, 
with sporadic generat ion of shorter than normal transcripts m issing exons 1 3  - 1 5, 1 4- 1 6, 
1 4+ 1 6  (exon 1 5  present) and 1 6, and less abundant, near-norma], or larger than 
expected products. Some of the products of abnormal s ize were identified by DNA 
sequencing as having arisen from displacement of the exon 1 6  donor spl ice site by one 
base upstream, or pseudo-exon inclusion of 89 bases from intron 1 6  (data not shown). 
5.4 Discussion 
Pre-mRNA splicing, the process of joining exons and removing intervening 
sequences, is t ightly control led by complex interactions between cis-elements and more 
than 1 50 trans-factors24-27 involved in recognition of exon boundaries and subsequent 
incorporation into the mature transcript. F our c lassical c is-elements; the 5' and 3 '  
spl ice s ite, the polypyrjmid ine tract, and branch point are primary binding sites for 
snRNPs and other proteins involved i n  defining exon/intron boundaries. In addition to 
the obvious spl ice motifs, exon .recognition and spl icing also depends upon the nature, 
position and combination of auxi l iary splice motifs that modu late s ignals determining 
exon incorporation, presumably by recruiting trans-factors that regulate exon 
selection.28, 29 
The high degree of conservation at the ends of the introns \vould suggest that the 
acceptor and donor spl ice s ites are obvious and preferable targets for AO induced exon 
skipping. Since a l l  dystrophin exons are constitutively expressed in the predominant 
427 kDa skeletal muscle isoform, spl ice site scores are somewhat redundant, but may 
provide an indication of amenable targets to redirect pre-mRNA spl icing. However, 
considering the 1 0  exons examined in thi s  report, there was no obvious correlation 
between predicted splice site score, and optimal AO target. Donor splice s ites seemed 
to be the least preferred human targets, although these motifs were amenable targets in  
skipping 3 of  the 10  mouse exons. 
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AO-induced exon skipping requ ires appropriately designed AOs to specifical ly  
mask motifs involved in  the exon recognition and splicing process� by either rendering 
the s ingle stranded motifs double-stranded or a lter ing the secondary structures essential 
for normal exon recognition ana processing. Robust and consistent exon skipp ing is 
essentia l  if o l igomers are to be cl i nically app licable.  If it  is  necessary to use large 
amounts of an o l igomer to excise a target exon, this  may be difficult to achi eve in a 
c linical  setting, andlor lead to non-antisense effects . Although 1 2  oligomers may be 
capable of restoring the dystrophin readi ng frame in DMD ind ividuals with exon 
d eletions in the mutati on hotsPQts,30 it will  be essential to extend this therapy to many 
different amenable  mutations across the gene transcript. 
Subtle DNA changes in the dystrophin gene (m icro-insertion/deletion, nonsense, 
spl ice site m utations) represent an estimated 3 0% of DMD cases.  These mutations 
cannot be ignored based only upon incidence, especially since the gene is largely  intact 
and in most of these cases, spli�e intervention should result in a dystrophin i soform of 
near-normal function. Furthermore, protein-truncating mutations in the exons encoding 
the rod domain could be considered most amenable to exon skipping. The maj ority of 
exons in this region are in-frame and hence removal of a nonsense mutat ion/micro­
insel1ion/deletion would  only requi re excis ion of a single exon. In-frame deletions 
within this region are not commonly repot1ed, possi bly because many of these cases are 
not recognised due to a mi l d ' phenotype.3) Indeed, it has been reported that an 
ind ividual missing exon 1 6  had no c l inical symptoms and normal serum creatine kinase 
levels, a sens itive marker of lnuscle damage.32 
The 45 AOs evaluated for both human and mouse dystrophin pre-mRNA 
annealed to a total of 1 74 predicted ESEs. SF2/ASF (JgM-BRCA) and SC3 5 were 
found to be more common targets for the optimized AO-induced skipping of these 
dystrophi n  exons, consistent with other reports.22, 33 The high propOl1ion of A Os 
capable of red irecting splic ing suppo11s the concept that many pre-mRNA motifs are 
involved in exon defin ition and splicing (for review see t l , 34, 35) .  It is possible that the 
i mpot1ance of some motifs in pre·mRNA processing is reflected by the levels of 
induced shortened transcripts. I� should a lso be noted that no s ingle motif is  a universal 
optimal target. Mouse exons 22 and 23 were efficiently excised by targeting two 
d i sti nct domains, the donor splice s ites and intra-exonic motifs, which were identified 
during a study of the human gene transcript. The human dystrophin gene transcript 
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only responded to AOs directed at intra-exonic targets for these exons. 
Although some AO coordinates appeared to be equal ly amenable i n  the two 
species, there were differences, some subtle and others more pronounced, that must 
raise questions regarding the accuracy and validity of AO desi gn in non-homologous or 
artificial systems . Directing an AO at coordinates found to efficiently excise exon 53 
from the human dystrophi n  mRNA, induced dystrophin gene transcripts missing exons 53 
and 53+54 when appl ied to mouse cells .  There are several cases where a single AO can 
excise two exons at a time, presumably reflecting c losely coordinated processing.30• 36, 37 
Targeting human exon 5 3  resulted in only the loss of that exon from the mature 
dystrophin  transcript) but interestingly, directing an AO to human dystrophin exon 54 led 
to removal of both exons 54+55. 12 An AO designed to excise mouse exon 54 resulted i n  
specific removal of that targeted exon (unpub1 ished data). A lthough shni larities i n  human 
and mouse dystrophin splice motif usage were predicted to be as high as 90% i n  
constitutive spl icing,38-40 differences in genetic background and splice motif usage must 
be considered when extrapolating transcript manipulat ion from one model to another. 
During initial optimisation studies to induce mouse exon 53 skipping! two 
overlapping AOs were found to activate a cryptic donor spl ice site in that exon, which 
led to the loss of 78 bases of coding sequence. The activated mouse exon 53 cryptic 
sp lice s ite was calcul ated to have a spl ice s ite score s imilar to the wild type donor site. 
When targeting the same coordinates in the human dystrophin transcript, activation of 
cryptic spl icing was never detected. A 'T' (mouse) and 'e'  (human) difference allowed 
activat ion of a clyptic donor spl ice site only in the mouse transcript, thereby 
demonstrating that species-specific variat ion, even when not d irectly affecting AO 
annealing, can have indirect and unexpected consequences on gene expression. 
We consider it important to initial ly optimize AO design in myogeni c  cel ls  
expressing a normal dystrophin gene transcript, even though protein studies are  not 
possible. Induced exon removal from the intact dystrophin  mRNA would ensure that 
the intervention was possible if! the presence of all normal transcription and splicing 
cis·elem ents and splicing machinery! thus setting a h igh standard in AO design. 
Exonic deletions that disrupt the reading frame and lead to DMD would compromise 
pre-mRNA processing to some extent, because of the l oss of splice motifs in the del eted 
region. A deletion of exon 50 and flanking intronic sequences wil l  bring together exons 
49 and 5 1  that should not be in direct communication in the context of normal 
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dystrophi n  transcript processing. FU11hermore, a normal dystrophin gene transcript 
\vould not be subjected to nonsense-mediated-decay, unl i ke i nduced transcripts in 
which exon removal causes a frame-shift.34 
We previously reported optimisation of AOs to excise exon 1 6  from the human 
gene transcript.23 The addition of 5 nucleotides to the AO was found to increase 
efficiency of target exon skipping by approximately forty-fo ld, more than j ustifying a 
20% increase i n  the length of the ol igomer. The exon 1 6  donor spJ ice s ite mutation d id 
not lead to a single aberrant gene transcript, but a mixture of products, including shorter 
i n�frame transcripts that should have m itigated severity of the d isease . S i nce the 
d iagnosis of DMD had been confirmed clinical ly, it  is  most l ikely  that the in�frame 
products represent very l ow abundance mRNAs that had escaped NMD and ·were hence 
detected by RT-PCR. A nonsense mutation in the muscle glycogen phosphorylase gene 
was repo11ed to result in 7 different gene transcripts generated by altered spli c ing.41 
Whi l e  it appears that the exon 1 6  dystrophin donor splice site mutation generated 
mUltiple d isease-associ ated transcripts, the AO that excised exon 1 6  restored apparently 
normal l evels  of a s ingle i n-frame transcript. 
The evidence that s ingle base variation between mouse :human or human:human 
dystrophin genes can influence splice manipUl ation must cast some doubts on assays 
that do not assess dystrophin spl ice manipUlation in the appropriate environment. There 
is  no doubt that in vitro gene expression d iffers from that in equivalent cel ls in vivo. 
However, dystrophin processing- in  cultured myogen ic cel ls  is likely to be more rel evant 
than an at1ificial system exam ining transgene expression in a cell  l ine transfected with a 
plasmid construct containing only a portion of the dystrophin gene taken out of context. 
Goren et al.4o demonstrated that the same auxil iary spl ice motif could  direct e ither exon 
inclusion or exclusion from d ifferent mini-genes, depending on the location of splice 
motifs in the constIuct. When sequences flanking splice regulatory motifs are 
manipulated� splicing is modified.4o In such an artificial system, irrelevant intron s ize and 
sequences must be a major concern for AO design and optimization. 
In summarYj the design and evaluation of AOs to induce human dystrophin exon 
skipping should be undertaken in human myogenic cu ltures, whereas a study of exon 
excision from the mouse dystrophin gene transcript should be undet1aken in murine 
cells. Despite strong homology between the human and mouse (and canine) dystrophi n  
genes, there are many differences and some� as described i n  this  report, influence RNA 
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processing. When deveJ oping exon skipping strategies for non-deletion DMD patients, 
AOs designed according to the normal dystrophin gene may not be ideal . The disease­
causing base change, l oss or , inse11ion m ay occur at the AO anneal ing s ite and 
compromise its ability to excise that exon.  A lthough it is possible that the change may 
alter a spl ice motif and enhance exon recognition and strengthen splicing, it  is  more 
probable that most changes in a gene would weaken exon recognition and splicing. 
Regardless of the predicted consequences of a change in dystrophi n  splicing, testing 
should be undertaken in myogenic cel ls, then dystrophi c  cells carrying the mutation 
under examination, and u l timately the patient. 
5.5 Materials and methods 
5.5.1 Splice site scoring  and prediction of ESEs motifs 
Acceptor and donor splice site sores for all exons under analysis were 
determined using two different ,algorithms; the maximu m  entropy model  (MEM) and 
the F irst-order Markov model (MM) . B oth a lgorithms were computed on the web­
based program, MaxEntScan (http://genes .mit.edu/burge1ab/maxentlXmaxent.html), 
which allows the calcul ation of strength of both acceptor and d onor spl i ce s ite scores.  
MaxEntScan requires 20 bases upstream of the 3 f spl ice site and the first 3 bases after 
the acceptor to perform 3 '  splice s ite scoring. Three bases upstream and 6 bases 
downstream of the donor splice' s ite were included to evaluate 5 '  splice s ite scoring.42 
Exonic sequence \vith 25 bases of flanking intron from 1 0  human and mouse exons 
were analysed to identity putative ESEs, using ESEsfinder3 ,Ol4, 1 5 for human exons, and 
human and mouse ESE motifs were predicted by RESCUE-ESE, 16, 1 7 
5.5.2 AO synthesis, design and nomenclature 
2t�O-methyl modified AOs on a phosphorothioate backbone were designed to 
anneal to motifs pred icted to be involved in pre-mRNA spl ici ng, and synthesized in­
house on and Expedite 8909 Nucleic Acid Synthesizer (Appl ied B iosystems FOl'stet', 
CA) using the 1 J.lmol thioate synthesis protocoL Nomencl ature was based upon that 
described by M ann et 01.,37 where the first letter designates the species (H: human, M :  
mouse), the number refers t o  the exon, the second letter indicates Acceptor o r  Donor 
Splice site and the " _ "  and 11+" specifies intron or exon bases, respectively . 
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5.5.3 Myoblast culture and t�ansfection 
Normal and dystrophic human myogenic cells were prepared by a modification 
of the protocol described by Rando et al.43 Myogenic cel ls  were transfected with AOs 
at concentrations of 25 to 600 nM . Lipofectamine 2000 (Invitrogen, Melbourne, 
Austral ia) and Lipofectin (Invitrogen) were employed as transfection reagents for 
human myogenic cel ls and H2K mdt cells ,  respectively, described previously. l s  
5.5.4 RNA extraction and RT -peR analysis 
RNA was harvested from the cell cultures 24 hours after transfection using 
Trizol (Invitrogen), according to the manufacturer's protocol. One step RT-PCR was 
undertaken using 1 00 ng of total RNA as template in a 1 2.5  III reaction for 30 cycles 
using 1 U of Superscript III (Inyitrogen) . Nested peR ,vas carded out for 3 0  cycles 
using AmpIiTaQ Gold (Applied Biosystems, Melbourne, Australia) . PCR cycl ing 
condit ions were performed as described by McClorey et a1 2006.36 PCR products were 
separated on 2% agarose gels in T AE buffer and the images were captured on a 
CHEMISMART-3000 gel documentation system (Vi lber Lourmat, Marne-la-vallee, 
France) . 
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Figure 1 :  Patlerns of dystrophln exon skIpping Induced by AOs targeting 5 exons «a) 22 ; (b) 23; (cl 24; (d) 20; (e) 53) after 
transfection Into normal human and mdK mouse myogenic cells. 
Annealing coordinates relative to predicted ESEs are shO'tm, as are the sizes of full-length and induced transcript products. 
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a b Exon 53 54 
-0 � lI.J 
Q. :E :;. :E m � c. .Q c: c: c: � � 8 8 0 � g f5 0 ..- � :::> z .,.. 
c 
Human dystrophin exon 53 
.0.3$13.32 8.5417.21 
CAGGTC'l'l'AGGACAGC-o:::f>..G.I\GC'::-AAGCTlGJI.GTCATGGAf.GGP-.GJGTCCC'fA'l'AC'J\GTAGATGCA.1',.'iCCPJ>.Ajl.G.r...�r...TCACAGA.r..ACq;::"AGlgt tagtl 
M53A(+1 51 +180) 
M53A(+1 76+205) 
CAGGTCA'i' AGGrlcA':¥ICAGtEGcAAGCTiGACTCATGGAAAGAAGG TCCl'CACACAGIAGA7:GCAA'iCCl>.AA.I\GA.ll.GATCACAGM.i\I�q:"AG 19t t a g  t I 
7.41n.26 8.54n.Zl 
Mouse dystrophin exon 53 
Figure 2: A04nduced cryptic splicing of mouse dystrophln exon 63. 
(a) Dyslrophin transcript products inAO·treated mdX cunures; (b) Nucleolide sequences at the novel junction arising from activation 
of the axon 53 ayptlo donor splioe site identified l7j DNA sequenclng; (0) Partial sequence of human and mouse dystrophin axon 53 
shCNling mouse cryptic donor spflC8 site and AO anoealng coordinates. Differences In nucleotide sequences are Indicated in bold 
type. 
Figure 3: 'U-PCR analysis of AO titration In (a and b) normal myogenic cellsj and lc and d) cells from a DMO patient with 
a mutation (IVS16+1G>T; c.1992+1G>T) In dystrophln exon 16. 
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Table 1; Predicted acceptor and donor splice site scores showing length of exon and flanking introns for exons investigated. 
exons preceding exon length 
intron len th 
H 1 9  1 6. 1 65 88 
M 1 9  1 7035 
H2O 1 0 ,236 242 
M20 8906 
H21 6 , 1 77 1 81 
M21 4365 
H22 1 2.609 1 46 
M22 1 5930 
H23 3 ,453 2 1 3 
M23 91 3 
______ ·_·,_'O_,· ____ _____ �_· 
H24 3 ,798 1 1 4 
M24 2606 
- -- ------------- ,  .. -. 
H25 991 1 56 
M25 1 096 
H52 44 ,21 1  1 1 8  
M52 57507 
H53 50,044 2 1 2  
M53 43,569 
H65 1 3 , 347 202 
M65 1 5253 
following 
intron len th 
1 0,236 
8906 
6 , 1 77 
4365 
1 2,609 
1 5930 
3,453 
91 3 
3,798 
2606 
......  -�,-�-...... .,.,�-
991 
1 096 
" ","--- .� ....... "�,. 
8,606 
5983 
50,044 
43,569 
21 .230 
23 , 325 
2,830 
2234 
3'SS 
t c t t t gc t c t cat g c t g ca gGCC 
�,��!_�� <:::_�C:::�.C,C:�5I<:::.�_�,��.9�,�,� _ _  ,
aat t a t t t t t t t c t t t ct a gAGG 
t a t t t t g g t t t t ct t t g t a gAGG __ ._w. __ "............... . . . . .. __ ...... . .  , 
t t c c at a c t c t a t ggcacagGAT 
t a c t c t ga a t t at g a t gcagGAT 
t t t t t t c c ct t t t ga t a a a gTTT 
t a t a a cg g gt c t c g t t t ca gAAT 
�E..�_�,�g c��.�.�� t a  �.��ca9.�� __ . 
a a a t t ga t t t a t t t t c t t a g CT T  
a ct a t gca t t g t t t c c a t agCTT 
agggat at t t gt t c t t acagGCA 
a t t t t t t t tt t t t c t t t c agGCA 
t a t t t t t c c t t t t a t t ct a gT T G  
a t t t t a t t t g t t t t tt g c a gTGG 
t t g t g t g gt c t t t t t t gcagTGG 
a MEM and MM are Maximum Entropy Model and Fi rst--order Markov Model, respec1ively. 
M EM3 MM a 5'SS 
9 . 1  9.24 AT G g t a a t t  
9. 1 6  9.07 
8.65 1 1 .04 AAG g t a a g a  
7.82 1 0. 5 1  .�G.9.t a a99 _ _  
4.63 6 . 1 4  CAAgt a a g t  
5 .28 5.8 CAAgt a a gt 
4.79 5.43 CAGgt c t g t  
8.91 9.05 CAGgt c t gt 
• .  ____ . _  .... v._. _____ ••• 'Wo 
7.97 , 7.42 CAGgt aa t t  
1 .94 0 .92 
_-o ..... _ ..... ... � 
8.84 6.45 
7.56 1 0  
4.36 5.32 CAGg t a t ag 
7. 1 6  7.46 CAGgt a t ga 
6.66 5.58 GAAgt aa gt 
1 1 .71  1 3.43 GAAgt aagt 
8.55 1 1 .07 AAGg t t a gt 
7.81 1 0.24 
8.77 1 1 . 1 4  TAC g t a c gt 
8.37 1 0.48 TACg t aa g t  
MEMa MM a 
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6.84 6 . 1 3  
6.84 6 . 1 3 
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9 . 88 1 1 . 1 8  
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Table 2: Nucleotide sequences of oligomers designed and evaluated for axon skipping potential. Oligomers for the human and mouse dystrophin exon are grouped by axon, 
light black lines separate individual ADs from AO-cocktail. ESE binding scores as predicted by ESE finder are shown the number. 
Exon 
H16 
HM19 
H20 
M20 
H21 
M21 
H22 
M22 
H23 
M23 
H24 
M24 
H25 
Sequence (5'->3') 
GC: DCA eca GAU caG C�G GCA u e l]  UGC AG� U 
CUG GCA. GM l'UC GAU ceA eCG G::::u CUU C 
CA3 CAG VAG VUG UCA ucu eco c 
uue; r;CA r.:,o...; uuc ucu r:CA eCG Gell GUll C 
CGG c.l\G llAG t1l1G UCA cou c 
f\C::U I\GU U::;U Ci\1J cue CM vue u 
CA,) eCA GC.'> AeA UCC cue C 
CAU eCA GKA AeA U�G Gce c 
CM uuc ece GAG oCU CUG C 
OM u uu ecc GAG vell CUC C 
UCC ACA CAt;: CUG 'JP", (lU 
]:,u;, uue A:A GAC C�JG CM QV 
CUA AUO UCA GAG GGC G:-U oue UUC GAC 
CNJ AUU ueu Gtv\ CvU GCU UUC UIJG GC e.: 
CM Ace U CC GCU VAC coe l>P.fl.. U 
r ... Cl) AAA AUC [[lG A.".U 011:::; CUG PAU 
CM GGG CAG Gce AUU CCU ecu OC 
cc.!\. GGG CAG Gce AOr) cell CUU !le 
Coordinates 
HM1 9A : .,. 35 .. 6 5 :, 
H2.0A ( -"1t,,, 7 1  
H20A I 1 4 7 '- 1 G 8 : 
)Il:: D"'' ' T � 4 + 7 1  
H20A { + 2 3 +1J 7  
H 201l ( + 1 4 0 "' 1 6 4  ) 
rQ 31\ ( +6 9 + � 8 )  
size 
31 
28 
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Table 2: Nucleotide sequencos of oligomers dosigned and evaluated for axon skipping potential. Oligomers for tha human and mouse dystrophin a)(on are grouped by axon, 
light black lines separate individual AOs from AO-cocktaiL ESE binding scores as predic1ed by ESE finder are shown the number (Continued). 
H52 ucc: /\1\('; UGG GG/I eGe cue UGU ucc i\;\ll. ucc 1-l!:.2A ': + 12 +4 1 )  30 ���<3t_ ��)- ���L_ 3.55 3.33(2) .- �.-.... -
iJCC "AU UGC CGG cct) cue ueu UCc AAA lJCU 1-:!:>2A ( + 1 2+·1 l 1  
,----_ ........... ............ .... --- ..... .. , ..... _- ._---- _."" ...  _ ..... _._.-,------_._-- �--... --.. ��� ,---...... . 
M52 ucc f�U UGC GCG CGU cue UGU UCC A H 5 2A ( + 1 '7  25 2.56 2.54(2) 3.33{3) 
U 'JC AAA !JUC UGC GCP, CCA GUA AUG AGU UC'.I [4521'1 ( +4 2 +7 1 ) 30 2.73(2) 2.91 (2) 4.92 3.02 .- - ---:..-..- --- '-- ---_ . ..-_- ------
uec ;'';''C GGA eGC cue UCC A H 5;(A ( + 1  h� 1 1  
vue AA". OUU UGG GCA GCG GUA AUG ACV UCU H 5 2i\ ( +·1 2 +7 1 )  
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6.1 Abstract 
Spinal muscular atrophy (SMA) i s  due to a deficiency in  the survival of motor 
neuron (SMN) protein, most commonly caused by loss of the entire SMNl gene. 
Absence or reduced amounts of the SMN protei n  result i n  degeneration of the anterior 
horn cel l s  and clinically to hypotonia, symmetrical muscle weakness and atrophy, 
tremor of finger and hand, and fasciculation of the tongue muscles. Although the 
SMNl gene homologue, SMN2, is present in SMA patients, a s ingle base (CfT) 
difference at the s ixth nucleotide in  exon 7 of the SMN2 gene promotes exci s ion of that 
exon from the mature transcript, thereby dramatical ly reducing the amount of ful l-length 
SMN transcr ipt and SMN protein. The full-length SMN2 product partially compensates 
for the lack of SMN 1 protein in SMA. 
Given the molecular basis of  SMA, this paper explores whether antisense 
o ligomers (AOs) provide a way of enhancing the number of SMN transcripts containing 
exon 7 in cultured fibroblasts from an SMA patient. By masking silencing splice motifs 
and promoting exon 7 i nc lusion, the SMN 2 transcript could be translated into a 
functional protein. 
Our results suggest that masking the potential intronic s i lencing motifs, located 
in SMN2 introns 6 and 7, by the use of ADs, promotes exon inc lusion as determined by 
RT-PCR. Combining selected ol igomers into multi-AO cocktai ls  enhanced exon 7 
i nclusion in a cumulative and dose dependent manner. S im i larly> changing the 
chemistry of AOs from 2'-D-.methyl ol igomers on phosphorothioate backbone to 
phosphorodiamidate morpholino o ligomers, further enhanced AO-induced exon 
inclusion and led to SMN protein expression. Thi s  study provides additional insights 
into possible intronic spl ice s i lencing motifs, which could be targeted in combination 
with previously identified motifs, as candidates for a molecular therapeutic approach to 
SMA, and may perhaps open new avenues for the treatment of other genet ic d isorders 
where oligomers could be used to induce exon i nclusion. 
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6.2 Introduction 
Spinal muscular atrophy (SMA) is the most common autosomal recessive 
neurodegenerative d isorder in infants and chi ldren, with an incidence of 1 in  1 0,000 l ive 
births, and a carrier frequency of 1 in 40-50 in adu lts. I,  2 The disorder is  characterised 
by degeneration of the anterior horn cells lead ing to four main symptoms, hypotonia, 
symmetrical muscle weakness and atrophy, tremor of finger and hand, and fasciculation 
of the tongue Inuscles.3 
In SMA patients, the morphology and function of motor neurons sho\v s igns of 
immaturity, with a reduced number of motor neurons in the ventral horn cel l s  the most 
striking p athological finding (Fig 1) . Most surviving motor neurons exhibit  some signs 
of immaturity, including smaller s ize and l ess-developed granular endoplasmic  
reticulum (Nissl body) compared to normal individuals of comparable age. In the motor 
axons, the ventral nerve roots of SMA patients contain a relatively high proportion of 
poorly Inyel inated thin axons and multi -axonal bundles of l ow density (based on axon 
per mm2).  Axons in peripheral nerves show extended latency to electrical stimulation 
and reduced conduction velocities (for revie\v see4, 5) .  
Spinal muscular atrophy arises from a deficit in the survival of motor neuron 
(SMN) protein, which in most patients is caused by mutations in the SMNl gene.6, 7 
Deletions, point mutations, and . gene conversion in both alleles of the survivor motor 
neuron 1 gene (SMNl)  are responsible for more than 94% cases of SMA w ith 
drastical ly reduced levels of SMN protein.8, 9 There are two copies of the SMN gene, 
SMN I (telomeric SMN) and SMN2 (centromeric SMN)6 (Fig 2), but l ittle SMN protein 
is  produced by SMN2. A single base (efT) difference at the sixth nucleotide i n  exon 7 
of the human SMN2 gene is  known to cause exon 7 skipping, thereby drastical ly 
reduci ng the amount of SMN pr�tein. l0 The T base of SMN2 has been proposed either 
to cause d isruption of an exonic splice enhancer (ESE) or create a novel spl ice s i lencing 
motif (Fig 3). The fuU- length product transcribed from SMN2 partly compensates for 
lack of the SMNl gene product in mi lder forms of SMA (SMA types II and Ill) . 
Whi le there is  sti l l  some debate about ho\v reduced amount of SMN protein  
leads to the pathophysiology of  SMA 1 1 , several mechanisms have been proposed. One 
mechanism is believed to involve a deficit in snRNP biosynthesi s  of the SMN protein. 
SMN protein  is an important component of the SMN complex,12 where assembly of the 
snRNAs and common core proteins of the snRNP complex (Sm protein) occurs ,  This  
complex also has a role in ensuring the authenticity of snRNA binding to the Srn protein 
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allowing the formation of the snRNP complex to proceed. 1 3  A lack of the SMN protein 
causes tissue-specific perturbation in  the expression of snRNAs and gene mis�splicing. 
A second mechanism has been postulated from the observation that SMA i s  
associated with the predominant expression of  a truncated SMN transcript containing no 
exon 7. The absence of exon 7 from the SMN transcript encoding a domain critical to 
normal SMN function not only results in the degradation of the truncated SMN protein, 
but may also confer pro-apoptotic activity. 14 
A third proposed mechan ism put forward to explain d isease pathophys iology i s  
that a lack of SMN protein leads to  drastic loss of  motor neurons and a defect of  
axonogenesis. The lethality of most SMN knockout and knockdown animal models 
suggests that the SMN protein complex i s  critical to normal development. iS- } 7 Recently, 
under non-lethal knockdown conditions, zebrafish embryos were shown to undergo 
development but exhibited dramatic SMA-l ike motor axon degeneration. 18 
Furthermore, the injection of purified spl iceosomal U snRNPs into SMN-deficient 
embryos forestalled developmental arrest in Xenopus and prevented motor neuron 
degeneration in zebrafish. 1 8  These findings add weight to the critical importance of 
defective axonogenesis in disease pathophysiology. 
Depend ing upon the onset and severity of disease, patients \vith SMA are 
classified as SMA types I, II or Il l .  SMA type I is the most severe form, resulting in  
death in infancy, whi lst the mi lder forms, SMA types Il and III are associated with extra 
copies of the SMN2 gene. 1 9, 20 The disease phenotype is now recognised to be 
dependent on the levels of full-length SMN protein. An approach aimed at enhancing 
SMN2 expression has been pursued as a genetic treatment for SMA patients) albeit w ith 
l imited success? 1 -25 
The use of antisense oligomers (AO) as a genetic intervention for SMA has been 
pursued as another way of enhancing the number of SMN2 transcripts containing exon 
7. Theoretically, by masking silencing splice motifs or strengthening exon 7 
recognition, the SMN 2 transcript should be translated i nto a functional protein if exon 7 
forms part of the mature transcript. Several studies have sought to identify those 
s i lencing splice motifs, where binding of AOs can promote exon 7 inclusion and SMN 
protein, and ultimately be cl inically beneficial to SMA patients . t • 26-29 Here, we 
examine the effect of masking potential intronic s ilencing motifs by the use of AOs in  
cultured fibroblasts from an  S:rvt;A patient. As  combinations of ol igomers were shown 
to synergisticaJ Jy induce exon skipping in human and mouse dystrophin gene 
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transcripts,30-32 AO-cocktai ls were investigated with the goal of maximis ing the 
effic iency of eXon 7 inclusion. Studies on the effects of exon inclusion after using AOs 
with d ifferent backbone chemistries are also reported. 
6.3 Results 
6.3. 1 Preliminary evaluation of AO-induced exon inclusion 
Two exonic and one intronic si lencing motifs on SMN2 pre�mRNA have been 
previous ly i dent ified as potential target regions capable of enhancing production of the 
ful l- length SMN2 transcript. I, 29 AOs a2B, f1 and gl targeting these motifs were 
evaluated for their abi l ity to induce exon 7 inclusion i n  cultured fibroblasts from an 
SMA patient. Only AO-a (SMN20- 1 0-29) was shown to substantially induce exon 7 
inclusion at the RNA level} as determined by RT-PCR analysis (Fig 4a, b) . An array of 
22-mer-AOs (AOs b, c, d and e), designed to anneal to d ifferentia l  positions in  the 
vic inity of - 1 0  to -29 on the exon 7 donor spl ice s ite on pre-mRNA of SMN2} was 
evaluated to establish \vhether the efficiency of exon 7 inclusion could be improved by 
targeting different s ites. However, use of these AOs led to no detectable improvement 
i n  exon 7 inclusion compared to AO-a. 
6.3.2 Optimising AO- induced exon inclusion 
S ixteen ol igomers were designed to target motifs within either intron 6 or 7 
adjacent to either acceptor (A I -AS) or donor (O I -DS) spl i ce sites, with the goal of 
masking any potential intronic splice si lencers and inducing expression of SMN2 
transcript containing exon 7 .  The effects of these AOs were compared with that of AO .. 
a, \vhich were previously reported by Singh et al.,29 in cultured SMA fibroblasts. 
Whereas AO-a treatment caused >90% exon inclusion, transfection of cu1tured 
fibroblasts with AOs A3� AS, A6� D3 , D4, D6 or D7 promoted exon 7 inclusion, albeit 
to less than 80%. On1y in the case of treatment with AOs A3, AS or A6 \vas the effect 
dose dependent (Fig 5). Other oligomers led to either minimally induced exon inclusion 
or exon skipping (Fig 5). 
Three regions to which bind ing of AOs (A3,  AS, A6, D3, DS or D6) resu1ted in 
substantial exon 7 inclusion \vere selected for further optimisation. These were {3I (-90 
to �5 1 upstream from acceptor site of exon 7), f32 (-75 to -94 downstream from donor 
splice s ite of exon 7) and 133 (- 1 35 to - 1 74 downstream from donor spl ice s ite of exon 7) 
(Fig 6a) . 
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Three 25mers (AOs 1 0, 1 1  and 1 2), designed to anneal to the PI  region on pre-
mRNA of SMN2 \vere found to be less active in inducing exon 7 inclus ion compared to 
A6 treatment (Fig 6). Evaluating AOs of variable length led to differences in inclusion 
of exon 7, with two 25mers (A9 and A I D) being less effective than A6 (20mer) (Fig 6). 
In the p2 region, five nucleotide extension of D3 at either the 5' or 3' end induced exon 
7 inclusion as efficiently as in D3 transfected cultures (Fig 6), however, for the p3 
region, additional bases at either end of D6 led to reduced exon 7 inclusion compared to 
D6- treated SMA-fibroblasts (Fig 6) . The D7 ol igomer was found to be more efficient 
compared to the derived 30mer (0 1 3) and 25mer (D 1 4). 
6.3.3 Optimising AO-cocktail induced exon 7 inclusion 
Two oligomers target ing intron 6 and three oligomers anneal ing to intron 7 \vere 
selected to evaluate whether a combination of AOs at different concentrations ( 1 5 0, 300 
and 600 nM) can further enhance exon 7 inclusion (Fig 7). A number of two-AO 
cocktails were shown to lead to substantial exon 7 inclusion in a concentration-
dependent manner. The two-AO cocktails (A6+D3, A6+D6, A6+D7, D3+D6, D3+D7, 
D6+D7 and A3+D3) were found to be marginal ly superior to the combinations (A3+D6 
and A3+D7) (Fig 7). The combination of A6+06 led to cumulative exon inclusion 
compared to individual treatment of fibroblasts with A6 and D6 (Fig 7). Treatment of 
fibroblasts with three-AO cocktails (A3+D3+D6, A3+D3+D7 and A3+D6+D7) resulted 
in comparable levels of exon inclusion compared to the A6+D6 cocktai l .  
6.3.4 Effects of different backbone chemistries on AO induced cxon 7 inclusion 
PMO-a., conjugated to ceU penetrating peptide (P007), was synthesised with the 
same nucleotide sequence as AO-a., and its efficiency in inducing exon 7 inclusion 
compared with that of AO-a., complexed with cationic l iposome, in  cultured SMA 
fibroblasts. Based on RT-PCR and densitometric of the products, 200 nM of AO-a. 
induced exon 7 inclusion in approximately 70% of the SMN transcripts by day 5 (Fig 
8a and b) . However, at day 7 post AO-a. transfection, the l evel of induction of SMN 
transcripts containing exon 7 was no greater than that of untreated SMA fibroblasts (Fig 
8a and b) . Treatment with PMO-a. at 1 IlM, by contrast, led to 1 00% exon inclusion at 
day 7 after treatment (Fig 8a) . SMN transcripts were not detectable at day 1 0  after AO­
a. transfection due to poor cell viabi l ity (Fig 8a) . PMO-a. treatment led to a 2-fo ld 
increase in the level of SMN protein by day 7, as determined by densitrometric analysis 
of western b lots (Fig 8e and d) . In contrast, no increase in SMN protein compared to 
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untreated fibroblasts was observed at day 5 after AO-a treatment (Fig Se). 
6.4 Discussion 
Several studies aimed at identifying exonic and i ntronic spl ice motifs on the pre­
mRNA of the SMN gene have been reported, where the goals  were ( i) understandi ng of 
the complex regulatory interplay between eis-acting elements and (rans-factors, and (H) 
devel oping a molecular treatment for SMA patients. I, 28, 29, 33 The CfT nucl eotide 
transition has been the main focus for studies seeking to understand why SMN2 pre­
mRNA does not predominantly produce futI-Iength transcripts containing exon 7. Two 
different spl ice motifs, an ESE on SMN1 34 and an ESS on SMN235 have been identified 
and proposed as reasons for d ifferences in the level s  of fuU-length transcripts between 
SMNl and SMN2 products. Intronic s ilencing motifs have also been identified using 
mutagenesis of an artificial  SMN construct.29 
In the present study, two exonic and one i ntronic s i lencing motifs, which have 
been previously rep0l1ed as possible targets for enhanci ng production of the ful l- length 
SMN2 transcript 1 ,  29, were used as the initial targeted regions for i nvestigation of exon 
inclusion. Targeti ng the two exonic s ilencers led to no change i n  exon 7 inclusion in 
cultured fibroblasts from an SMA patient. Based upon RT-PCR analysis, 37.5- 1 50 nM 
AO-a (SMN2D- I O-29) was shown to induce substantial  exon 7 incl us ion at the RNA 
l eveL The use of an array of ol igomers (AOs b, c, d and e) anneal ing to adjacent 
positions a long intron 7, starting from 1 0  nucleotides downstream of the exon 7 donor 
splice site on SMN2 pre-mRNA. led to no improvement in exon inclusion, compared to 
AO-a. 
Human and mouse regulatory spl ice motifs are conserved to some degree/6-38 
and are fou nd close to the splice junction and up to 200 nucleotides away.39 W e  
explored the potential intronic splice si lencing motifs in  regions with i n  200 nucleotides 
either upstream or downstream from the acceptor or donor m otifs of exon 7 on SMN2 
pre-mRNA. Sixteen ol igomers were designed to target e ither intron 6 or 7 at l ocations 
adj acent to either acceptor (A l -A8) or donor (D l -D8) motifs .  Whereas AOya treatment 
caused >90% exon inclusion at 1 50 nM, transfection of cultured fibroblasts with several 
AOs (A3 ,  A5, A6, D3, D6 or D7) at 1 50 nM caused exon i nc lusion between 70 to 80%. 
Other o l igomers led to either minimal ly induced exon inclusion or even promoted exon 
exclusion. The effi ciency of AOs targeting the newly identified intronic splice s i lencing 
motifs was no greater than that of AO-a in induc ing exon 7 inclusion. 
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Three targeted regions PI  (-90 to -5 1 upstream from the acceptor site of exon 7), 
P2 (-75 to -94 downstream from donor splice s ite of exon 7) and t33 (- ] 35  to - 1 74 
downstream from donor splice s ite of exon 7) were selected on the grounds of their 
efficiency in promoting exon 7 inclusion. Modifying AOs by size extension) either at 
the 5 1� 3' or both ends of ol igomers targeting the three selected regions (PI ,  P2 and P3), 
l ed to no marked change in the efficiency of AO-induced exon 7 inclusion. 
Although, binding of hnRNP Al to either exonic or intronic c is-elements was 
reported to cause exon 7 skipping in the SMN 2 gene transcript,35 of five AOs (AOs f, 
A6, A7, D4 or D7) masking the· hnRNP A l  spJ ice silencing moti f  (UAGNNAIU), only 
two AOs (A6 or D7) increased ful l - length SMN transcripts. A retrospective study using 
the putative exonic splicing enhancers/s i lencers program40 revealed thit1een splice 
si lencing motifs, located in introns 6 and 7 and exon 7 of human SMN 2 pre-mRNA, 
however these did not correlate with AO efficiency. As shown in Table 1, there is also 
no obvious difference in  the percentage of GC content and melting temperature (Tm) of 
effective AOs compared to those that were inefficient. 
Two oligomers targeting intron 6 and three ol igomers annealing to intron 7 were 
se lected for evaluation in combinations, to determine whether AO-cocktai ls  could 
further enhance exon 7 inclusion. Combining A6 and D6 enhanced exon inclus ion 7, 
compared to individual treatment of fibroblasts with either A6 or D6. Most two-AO 
cocktai ls  (A6+D6, A3+D3, A6+D3} A6+D7, D3+D6, D3+D7 and A6+D7) caused 
substantial  exon 7 inclusion in a concentration· dependent manner. 
It has been proposed that two hnRNP Al s promote ' looping out' in pre-mRNA 
structure and cooperatively induce exon exc1usion from the mature mRNA.4 1 A 
cocktail of AOs A6+D7, masking two hnRNP Al bindi ng motifs flanking exon 7 ,  
resulted in  equivalent levels of  exon 7 inclusion in  SMN 2 gene transcript compared to 
most two-AO cocktails .  
Treatment of SMA fibroblasts with three-AO cocktails (A3+D3+D6, 
A3+D3+D7 and A3+D6+D7) resulted in comparable levels of exon inclusion, 
compared to the A6+D6 cocktai l .  Ho\vever, both two- and three-AO cockta i l s  resulted 
in approximately 85% exon inclusion at a combined concentration of 1 50 nM, whereas 
treatment with AO-a led to 95% exon i nclusion at an equivaJent concentration.  
In addition to optimising the composition of AO-cocktai ls, we also investigated 
whether changing the ol igomer backbone chemistry affects the level of AO-induced 
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protein expression, by comparing the effect of 20MeAO (AO-a) with that of PMO-u. 
AO-a induced exen inclusion p�aked at day 2 (90%) and thereafter decl ined to 70% at 
day 5 and to level s  no greater than those of untreated SMA fibroblasts by day 7 .  No 
SMN transcripts were detectable at day 1 0  after AO- a transfection. This  pattern i s  
simi lar to previous reports from this laboratory on the effects of 20MeAO in inducing 
exon skipping� where l evels  were highest at 24-48 hours after transfection� but were 
greatly reduced over the next 9 days.42 This  is most l ikely due to nuclease degradation 
of the 20MeAO.43 
Treatment with PMO-a at 1 �M, by contrast) resulted in 1 00% of ful l- length 
SMN transcripts containing exon 7, and increased levels  of SMN protein at day 7 after 
treatment> whi le AO-a treatment of cultured fibroblasts led to no increase in the l evel of 
SMN protein compared to untreated fibrob1asts. Likewise, there was a h igh degree of 
variabi lity in the inductions of dystrophin protein in canine cultured cells from the 
Golden Retriever model of muscular dystrophy and in human dystrophi c  muscle 
explants,44, 45 whereas use of PMOs with the same nucleotide sequences led to highly 
consistent dystrophin protein expression at 7 days after transfection .45 PMOs appear to 
be the compounds of choice for clinical tria ls to treat DMD patients because of thei r  
long half- life and rel atively apparent lo\v toxic.46, 47 
In summary, selected ol igomers were shown in this study to be capable of 
increasing SMN2 exon 7 inclusion, at least in cultured fibroblasts ft'om an SMA patient. 
Moreover, combining AOs into cocktails enhanced levels of the ful l - length SMN 
transcript, containing exon 7 in a cumulative and dose-dependent manner, However 
AO-cocktai l s  induced exon 7 inclusion to a l esser degree than AO-a. Final ly, changing 
the backbone chemistry of o ligomers by using PMOs further enhanced exen 7 inclusion 
and led to substantial SMN protein expression. Unlike 20MeAOs, PMOs are not 
subjected to nuclease degradation, and do not require a l ipid carrier, which may cause 
cellular toxi city. Moreover, conjugation of a PMO with cel l  penetrating peptide tags 
fac i litates o l igomer delivery. Summation of these advantages contributes to 
enhancement of exon 7 inclusion in PMO-treated SMA cel ls .  In conclusion, this study 
provides additiona l information about possible intronic splice s ilencing motifs, ,vhich 
could  be used in combination with previously identified motifs, as sites for a molecular 
therapeutic approach to SMA, and may perhaps open up new avenues for the treatment 
for other genetic disorders where ol igomers could be used to induce exon inclusion. 
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6.5 Materials and methods 
6.5.1  ADs and primers 
The sequences of the AOs used and thei r  relative coordinates are shown i n  
Table 1 .  20MeAOs were synthesised on a n  Expedite 8909 Nucle ic Acid 
synthesizer using the 1 Jlmol e - thioate synthes i s  protocoL AOs were designed to 
anneal to either putative i ntronic or exonic spl ice si lencer motifs of human SMN2 
pre-mRNA exon 7. PMOs conjugated to an arginine-rich, cell penetrati ng peptide 
(p007)48. 49 were synthesized by A VI BioPharma Inc . (CorvaHis, OR, USA). Primers 
for RT -PCR and sequencing analysis were synthesised by Geneworks (Adela ide�  
Austral ia) and are l isted i n  supplemental information. 
6.5.2 Cell culture and AD transfection 
Cultured fibroblasts from an SMA type I patient were seeded and prol iferated 
into 7 5  cm2 t i ssue cu l ture  flasks .  When nearly confluent, cells were seeded into 24 
wel l·plates and incubated for 24 hours before transfection. Duplicate weBs were 
transfected with 20MeAO IipopJexes using Lipofectamine (lnvitrogen) at an equivalent 
amount of L ipofectamine to AO. Briefly, Lipofectamine was mixed \vith DMEM 
(Invitrogen) to a final volume of 200 III and incubated for 1 0  m inutes at room 
temperature. The 20MeAO-, which had been prepared in 200 JlI DMEM, was then 
combined with Lipofectamine:DMEM and the mixture incubated for a fmiher 20 
m inutes, before addition of DMEM to a final volume of 1 ml and subsequent addition of 
500 III a l iquots to each wel l .  Transfected cells were incubated for 48 hours before RNA 
was extracted for analysis. 
6.5.3 RNA extraction, RT -PCR analysis, and DNA sequencing 
RNA was harvested from cultured SMA fibroblasts using Trizol  (lnvitrogen), 
according to the manufacturer's protocol . One-step RT-PCR was undertaken using 1 20 
ng of total RNA as template, i n  a 1 2 . 5  JlI reaction for 28 cycles of amplification. After 
the reverse transcription step for 30 minutes at 5 5°C, the reaction was heated to 94°C 
for 2 minutes before the primary thermal cycling rounds of 94°C for 40 seconds, 56°C 
for 1 minute, and 68°C for 1 minute. PCR products were separated on 2% agarose gels 
in TAE buffer pH 8.3, and the images captured on a CHEMISMART-3000 (Vi lber 
Lom'mat, Marne-Ia-vallee, France) gel documentation system. Bands of i nterest were 
re-ampl ified directly from the agarose ge150 and the sequencing templates were purified 
using UltraClean spin  columns (Mobio Laboratories, CA, USA) and then sequenced on 
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a 3730 ABI DNA sequencer using B igDye v3 . 1  terminator chemistry (Applied 
Biosystems) .  
6.5.4 Western blot analysis 
Protein extracts were prepared by adding an equal volume (w/v) of treatment 
buffer containing 125 mM Tris-HC I , pH 6.8, 1 5% sodium dodecyl sulphate, 1 0% 
glycerol ,  0.5 mM phenylmethylsulfonyl fluoride, 50 mM dithiothreitol ,  bromphenol 
blue, and protease inhibitor cockta i l  (Sigma) to a ceH pellet. Samples were then 
vortexed and sonicated briefly, heated at 95°C for 5 minutes, before electophoretic 
fractionation on a 4 to 1 0% SDS grad ient gel at pH 8.8 with a 4% stacking gel ,  pH 6.8.  
Densitometry of protein bands after coomassie b lue sta ining was undertaken to enable 
ca lculation of protein levels. Extracts from AO-treated cultures were loaded onto a 
second PAGE gel for \vestern blotting. Proteins were transferred from the gel to 
nitrocel lulose membranes (Amersham Biosciences, Castle Hill ,  Austra l ia) for 4 hours at 
1 8°C at 290 mA . SMN was visual ised us ing anti-SMN polyclonal antibody (Santacruz, 
UKil . Images were captured on a Vi lbel' Lourmat CHEMISMART-3000 gel 
documentation system. Levels (%) of SMN were calculated relative to those in 
untreated cel ls  after normal isation for total protein  loading. 
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SMA Normal 
Figure 1: HistopathologY' of spinal muscular atrophy. 
Normally, neuronal signals are transmitted from tha molor cartel( 10 muscle fibres through a-motor neu rons . The green 9rrOll'l in (A) shows 
an (I.-motor neuron In a spinat cord section from a normal human . Motor stim uli are not 1ransmlttable to muscle flbres In SMApallents 
because of a tack of «-motor neurons as shown In  a spinal cord section from an SMA pall en! (8). Hypertrophic fibres (shovm by a hollOYI 
arrowhead) surrounded by group atrophy (shown by a green arrowhead) are histopathological features of type I SMA-derived muscle sections 
stained wilh haematoxilln and eosin (see C) compared to the morphologically uniform muscle sections seen in normal hUmans (0), (modified 
from luon et aJ. 20085) 
Centromeric copy Telomeric copy 
011 t-
on 0]2 
CATT-! (MS1 CATI-l (171 AG1-CA 012 on AG1..(A (171 CATI-1 (fASt 
Cen 1 1 , ! ! , ! , ! 
GTF2Hl NAIP SMN2 SERFl SERFl SMNl NAIP GTF2H2 
----- • ..........- .......- � � III ............. 
SMA genetic map on chromosome 5q13 
Figure 2: Genetle location of the survivor motor neuron (SMN) gene. 
A defect which is responsible for spinal muscular atrophy (SMA), The rlQure ShoylS that two large inverted genomic fragments (black horizontal 
lines) on c hromosome 5q 13 are the sites of Ihe two SMN genes. The telomeric copy (SMN1) is transcribed foward the teromere 8S denoted by 
th e  red arrOYlS, vihereas al leasl one centromerlo copy of SMN2 is tra nsc ri bed toward the centromere as Indicated by the blue arrows. Other 
genes in the proximity of the SMN gene copies are shovlJ'l in black and mulliple copies of the microsatellite markers (red) are Indicated withIn 
these regions. (from Lunn et a/. 20085) 
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(A) 
SMNl 
(8) 
SMN2 
FIgure 3: Regulation of exon 7 pre-mRNA splicing of the SMN1 and SMH2 genes, 
(A) In SMN1 splicIng, stimulation of exon 7 inclusion is controlled by tvJO mechanisms, one mediated by Tra2 through Hs interaclJon 
with U2AF .rans-factor and the second by splicing factor 2 (SF2) and tha complex it forms with alternative splicing factor (SF2IASF). 
which stabilises binding of the U2 small nuclear ribonucfear protein (U2 snRNP) to pre-mRNA. Binding of two trans·factors to exonlc 
splice enhancers (ESEs) leads to exc lusive exon 7 inclusion Into the SMN mature transcript. (8) In SMN2 spl icing , approximately 
10% of the full·length transcript containing exon 7 Is transcribed from the SMN2 gene because of Ihe substitution of a cytosine with a 
thymidine at the sixth nucleotide from the accepIor of exon 7 on pre-mRNA. Two proposed models may explain why the major spliced 
product of the SN1N2 excludes axon 7. One proposal Is that this is caused by disrupting SF2IASF binding , whereas ihe second model 
suggesls lhal it is mediated by binding of heterogeneous nuclear ribonuclear protein  (hnRNP) M. which resulls In about 90% of the 
SMN2 spliced transcripts containing no axon 7. The Tra2 protein complex on axon 7 accounts for approximately 10% offull·langth 
SMN2 transcripts (modified from Luon et at 2008�. 
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f 
(C) 
UT a b c e 
Figure 4: Relative annealing coordinates 01 ollgomers to pre-mRNA of SMN2 and their efficacy to Induce exon 7 inclusion 
in cultured f1broblasts from an SMA patient. 
(A) Relative annealing coordinates of selected oligomers 10 axon 7 and the adjacent intron 7. Ollgomers a, f and 9 were previously 
identified as candidates for AO-Induced exon Inclusion. Four addillonal �mjcro-walk" oUgomers Vlere designed to establish the 
optimal annealing coordinates for axon 7 lnclusl00. (8) RT·PCR analysis 0{ cuHured fibroblasls from a SMA patient treated with the 
different ollgomem (a, b-g) al different concentrations (75, 150 and 3OOnM). Also SOO/Ill are r8Suhs from untreated patient fibroblasts 
and a negative (seUna) control. The Sl29 of the four Isoforms (viz. exons 4+5+6+ 7+8, exons 4+5+6+8, exons 4+5+ N8 a nd 
el(ons 4+5+8) of SMN2 end the two lsoforms (viz. exons 4+5+6+7+8 and axons 4+5+6+8) or SMNl were determined using molecular 
weight markers. (C) Levels 01 the full·length SMN 1 aod SMN2 transcripts conlalnlng exon 7 as determined by densilrometnc analysis 
or RT·PCR ,  relative to the levels of 1he ""10 major lsoforms (exons 4+5+6+ 7+8 and Cleons 4+5+6+8) after treatment '1roh the different 
oligomem (a, b-g) at different concentrations (15, 150 and 300 nM). 
163 
1-0 
0"1 
� 
(A) 
AS -
AS -A4 -A3 
A1 
A2 
-
(B) 
A3 A4 _ . 
AB A7 --
....... ....... � .......... ....... .......... .......... 
......... 
600, 300, 150 nM 
a 
04 
D7 .QL..... -D6 
�-
D2 D3 
-
D1 --
Flgule 5: Relative anneaUn; coordinates of ollgomers targeting Intronlc regions of SUN2 pre-mRNA and their efflcacy In lnduclng exon Inclusion. 
(A) Relative annealing coordinates of seventeen selected oIigomers on the region flanking axon 7 in the SMN2 pre--mRNA (8) Levels of fulWength SMN1 and SMN2 transcripts containing exon 7. as detennined bV 
densltromotrlc analysis of RT·PCR of cultured fibroblasls from an SMA. patient treated with oIigomars (M-AS. 01-08 or 0:.) targeting lntrons 6 and 7 at varlow concentrations (150. 300 and 6OOnM). relative to the 
levels of the two major isofonTIs (exons 4+5+6+7-1-8 and 6Xons 4+5+6+8). 
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(A) Relative annealing c:oon::Unates of selected oligomers targeting 131 (-90 to ·51 upstream from the acceptor site of mean 7). P2 (-75 to -94 downstream from the donor splice site of meon 7); and f33 (-135 to -17-4 
dov\In$t(oom from the donor splice site of exon 7), (6) levels of full-length SMN1 and SI\AN2 transcripts. containing exon 7, as determined by densitromelr.ic analysis of RT -peR on RNA from cultured flbroblas.ts 
from an SMA patient lreated with oligomars (MS, AS, A9-A 12. 06, D7. D9-D1-4 and a) targeling selected regions at different concentrations (150. 300 and SOOnM). relative to levels of the two major iSOrorm60 (exons 
4+5+6+7+8 and exons 4+5+6+8). 
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Ta ble 1 :  Size, an nealing coordinates and sequences of oligomers used in this study. 
AOs size coordinates sequences GC content melting 
(bp) % temperalure 
a 20 SM N2E70(- 10-29) 5' AUU CAe UUU CAU AAU GCU GG 3' 7 35 54 
b 22 SMN2E70{-10-31 )  5' AGA u ue ACU uue AUA AUG eUG G 3' 8 36 60 
c 22 SMN2E70(- 1 2-33) 5' UAA GAU UCA CUU UCA UM UGC U 3' 6 27 56 
d 22 SMN2E70(-1 4-35) 5' AGU MG AU U CAe U U U  eAU MU G 3' 6 27 56 
e 22 SMN2E70(-16-37) 5' AAA G UA AGA uue ACU U UC AUA A 3' 5 23 54 
f 1 5  HSMN2A(+7+21 ) 5' UUU UUG AUU UUG UCU 3' 3 20 36 
9 1 5  HSMN2A( +34+48) 5' AUU UM GGA AUG UGA 3' 4 27 38 
A1 20 HSMN2A-1 70-151  5 '  AUA GUC UUU UM UGU ACU UU 3' 4 20 48 
A2 20 HSMN2A-1 50-131  5 '  UAU GAU CAG AAA U UA AGU UG 3' 5 25 50 
A3 20 HSMN2A-130-1 1 1  5' ACU UAU U U U  AUU C M  C M  M 3' 3 1 5  46 
A4 20 HSMN2A-1 1 0-91 5' UUU GUU UCA CM GAe AU U UU 3' 5 2 5  50 
AS 20 HSMN2A-90-71 5' AUA UGG AU G UUA AM AGC AU 3' 5 2 5  50 
AB 20 HSMN2A-70-51 5' AGC UAU AUA UAG AUA GCU UU 3' 5 2 5  50 
A7 20 HSM N 2A-50-31 5' AUA GCU AUA UAG AUA UAG AU 3' 4 20 48 
A8 20 HSMN2A-30-1 1 5' MU AAA GGA AGU UM AAA AA 3' 3 1 5  46 
A9 30 HSMN2A-80-51 5' AGC UAU AUA UAG AUA GCU UUA UAU GGA UGU 3' 8 27 76 
A1 0 25 HSMN2A-75-51 5' AGC UAU AUA UAG AUA GCU UUA UAU G 6 24 62 
A1 1 2 5  HSMN2A-90-66 5' GCU UUA UAU GGA UGU UAA MA GCA U 3' 7 28 64 
A1 2 2 5  HSMN2A-82+58 5' UAU AGA UAG CUU UAU AUG GAU GUU A 3' 6 24 62 
D1 20 HSMN20-35-54 S' MC CAU AAA GUU UUA CM AA 3' 3 1 5  46 
02 20 HSMN2D-55-74 5' AAA AAC AU U UGU UUU CCA CA 3' 5 25 50 
D3 20 HSMN2D-75-94 5' UCU GM CUU U U U  AAA UGU UC 3' 5 25 50 
D4 20 HSMN20-95- 1 1 4  5 '  MC CUU UCA ACU UUC UAA CA 3' B 30 52 
D5 20 HSMN20-1 1 5-134 5' MU AUU GAU UGU UUU ACA UU 3' 3 1 5  46 
D6 20 HSMN20-1 35-154 S' UUU UGG CAU CM AAU UCU UU 3' 5 2S 50 
07 20 HSM N20(- 1 55-1 74) 5' AUU MC CUU U UA UCU MU AG 3' 4 20 4 8  
0 8  20 HSMN2D(�1 75-194) 5' GM uue UAG UAG GGA UGU AG 3' B 40 56 
D9 2 5  HSM N20( -70-94) 5' UCU GM CUU UUU AM UGU UCA AM A 3' 5 20 60 
01 0 2 5  HSMN20(�75-99) 5' UM CAU CUG MC UUU UUA MU GUU C3' B 24 62 
D1 1 2 5  HSMN2D(-130-154) 5' UUU UGG CAU CM MU UC U UUA AUA U 3' 5 20 60 
D 1 2  2 5  HSMN2D(-135-159) 5' MU AGU UUU GGC AUC AAA AUU CUU U 3' 6 24 62 
0 1 3  2 5  HSMN20(-1 50-174) 5' AUU AAC CUU U UA UCU MU AGU U UG 3' 5 20 60 
0 1 4  30 HSMN20{-145-174) s' AUU MC CUU UUA UCU AAU AGU UUU GGC AUC 3' 8 2 7  76 
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Chapter 7 
Conclusions and implications for future research 
There has been enormous progress in the field of antisense applications with 
improved methods for oligonucleotide production, leading to consistent and rel iable use 
of antisense ol igomers (AOs) agai nst a number of gene targets, through various 
mechanisms (viz. RNaseH-dependent gene knockdown, interfering splicing motifs, 
mRNA trans lation modulation and miRNA knockdown). Typical ly, DNA analogues 
were uti l ised to anneal to mRNA, thereby recruiting and act ivating RNaseH-dependent 
mRNA degradation of the target. } The use of new AO chemistries of 2'-O-methyl 
modified sugars (20Me) or 2'-O-methoxy ethyl modified sugars (MO E) on 
phosphorothioate backbones, peptide nucleic acids (PNAs), l ocked nucleic ac ids 
(LNAs) and phosphorodiamidate morpholino o l igomers (PMOs), which all  confer 
greater stability and affinity to an mRNA target, have created new generation AOs able 
to modify gene expression by mechanisms other than RNaseH-dependent mRNA 
transcript degradation? 
In fact, contl'ol of gene expression through RNA oligomers is a natural process. 
Surprisingly, 93% of investigated genomic bases are transcribed in different human 
cel ls .) Noncoding RNAs (ncRNAs) account for 5 0  to 75% of al l  transcripts in higher 
eukaryotes .4, s Although the majority of documented ncRNAs have not been studied in 
their biological roles, there is some evidence that most steps of gene express ion, 
including transcription,6 splicing7 and translation,S are controlled by natural antisense 
transcri pts. 
microRNA (miRNAs) are approximately 22-nucleotide-long untranslated RNAs, 
and act post-transcriptionally to control gene expression.9-1 1 Imperfect base pairing 
between the seed region (two to e ight nucleotides) of an miRNA and target transcripts, 
which share identical seed regions (Fig 1), allow an JniRNA to repress translation in a 
number of genes, which possibly participate in common cellu l ar processes. Chemically 
modified ol igomer analogues are unable to induce miRNA effects on target genes as 
these synthet ic  compounds do not form a complex with the argonaute protein (AGO) . 
Neveliheless, a novel AO-based i ntervention has been developed, where ' antagomirs ' , 
sequences complementary to the miRNA, have been util ised as decoys to intercept 
binding between an miRNA and the target RNA. 12 
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A Inhibition of translation elongation B Co-translational  protein degradation 
R ise Proteolysis R ise 
C Competition for the cap structure D Inhibition of ribosomal subunit lolnln g  
Figure 1 :  Possible mechanisms of mlRNA-medlated gene silencing. 
(A) miRNAs (dart red) Inhibit targeted mRNA translation by promoting premature dissociation of ribosomes; thereby Impeding translation 
elongation; (B) miRNA-associated RiSe (RNA-Induced silencing complex) activates proteases to co!ranslationally degrade the nascent 
potypepUde chain: (C-E) Three possible mechanisms of miRNA interference via Itanslation Ini1iation complex ara through a competitive 
inhibitOfY effect of Argonaule protein on the Initiation complex; (F) miRNAs trigger deadenyiation and subsequent.,. dooapping of target 
RNA. Light green rectangular boxes demonstrate miRNA seed, seven to eight nucleolides at the 5' end of an miRNA. which determine 
mlRNA speciflcfly to larget mRNA. (Modified from Eulallo et al. 2008 11 ) 
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Another possib i l ity to modulate gene expression at a d ifferent level is the use of 
AOs to induce a part icular spl ice isoform. Pioneering research on a p-globin art ificial 
construct confirmed that AOs were able to mask cryptic spl ice s ites} thereby 
normal ising an aberrant splicing pattern. 1 3 Subsequently, o l igomers were used to 
induce exon skipping of the human dystrophin exon 1 9  in  Ebstein-Ban virus 
transformed lymphoblastoid cel ls derived from a normal human donor. 14 The AOs were 
designed to target motifs predicted to be involved in exon definit ion, located in human 
dystrophi n  exon 1 9, 14 based on an intra-exonic delet ion in a DMD patient that resulted 
i n  the loss the entire exon. IS ESEs 'were subsequently postulated to be amenable targets 
for AO-induced exon skipping. 14, 1 6  
The AO-induced exon skipping approach has been embraced as  an option for the 
treatment of DMD after repolis of AO induction of near-normal dystrophi n  l evels in  
mdx mice and myoblast cultures from D M D  patients . 1 7-22 The primary feature of th is 
thes is demonstrates an AO-based approach as a targeted treatment of another mouse 
model of lTIuscular dystrophy, the 4cV 1nouse. It was originally anticipated that thi s  
would be  a relat ively s imple  task, since exon skipping was efficiently induced in the 
mdt mouse luodel after target ing the exon 23 donor spl i ce s ite/2 and the equivalent 
human exons 52 and 5 3  could be removed at h igh efficiency.23 Ho\vever, the satne 
motifs were not responsive in the 4cV model ,  and it was necessary to initiate stud ies de 
novo. 
AOs were designed to target spl ice motifs and ESEs in the mouse dystrophin  gene 
as predicted by a \veb-based program (ESEfinder 3 .0). The oligomers were then 
optimised based on their abi lity to induce exon skipping in mouse myoblasts, to ident ify 
the most active ol igomer combi nations. Although AO optimisation to d islodge mouse 
dystrophin exon 23 in the mdx: mouse was readi ly achieved, i nduction of a transcript 
missing only mouse dystrophin exon 53 proved to be more challenging. The majority 
of i nd ividual AO treatments to reluove mouse dystrophin  exon 53 were i neffective. 
Some resulted in  cryptic spl ice site activation, whi le others led to non-specific, out-of­
frame and hence undesirable  transcripts missing exons 53+54. Only the use of an AO­
cocktai l  could induce a BMD-like in-frame transcript miss ing exons 52+5 3, a lbeit at 
rel atively low l evels of expression. Further refinement of the AO target by masking 
different spl ic ing motifs resulted in more substantial l evels of exons 5 2+53 skipping, 
leading to a dramatic four-fold enhancement of dystrophin expression compared to the 
original cocktaiL  
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Theoretical ly, AO-induced exon skipping could  be of benefit in restoring the 
dystrophin reading frame in up to 90% of DMD patients.24 However, individual 
responses to the treatment of each d ifferent mutation are l ikely to vary, depend ing upon 
the nature and size of the gene lesion. Although, treatment w ith AOs to induce exon 5 1  
skipping shou ld be amenable to DMD patients with deletions of exons 1 9  to 5 0, exons 
3 5  to 50 or exon 50 only, the induced dystrophin isoforms in these three examples 
would not restore muscle functional ity to a s imilar extent, due to substanti al differences 
in the restored proteins. The clini cal benefit to DMD patients, whose mutations 
i mpinge upon regions integral to the function of dystrophi n, w iU also be min imal. 
Kno\v]edge of the extent of improvement in muscle functional ity) expected from 
an induced in-frame transcript could indicate wh ich DMD mutations might be more 
amenable to AO-induced exon skipping. One possible \vay forward would be to 
combine A Os targeting different mouse dystrophin exons into cocktai ls, and undertake 
in vivo evaluation of m ice transiently expressing induced dystrophin isoforms. Mice 
treated w ith different AO�cocktai ls  could al low us to investigate both levels of 
dystrophin expression and muscl e  functionality. The use of AO cocktai ls, as undertaken 
in this thesis to make dystroph in isoforms, could provide the basis for predicting 
funct ional consequences of dystrophin i soforms, and postul ate which DMD mutations 
in humans are l ikely to be benefit from such an approach. Such a model wi l l  be of 
particular benefit in designing s�rategies to by-pass mutations downstream of exon 62, 
\vhere very fe\v BMD-causing mutations have been rep0l1ed. This strategy i s  based 
upon assumption t hat the human and mouse dystrophins have simi lar functional ity. 
In addition, the use of cocktai ls should  a llow a standardised treatment for c lustered 
mutations . For example, induction of a consistent i soform (il45-55), which may have a 
uniform function i n  people with, different mutations, could benefit up to 63% of DMD 
with a deletion?5 As a s ingle cocktai l� regulatory authorities may regard this 
preparation as a single drug which may, in  turn, expedi te the implementation of a 
treatment to many DMD boys. 
However, removal of eleven consecutive exons (exons 45 to 55) i s  technical ly 
chal lenging at this  t ime. Individual targeted exons cou ld be thoroughly optimised to 
obtain  highly effic ient AOs in inducing single exon skipping, however, that does not 
guarantee robust mu lti-exon skipping. Combinati on of optimised AOs, in some cases, 
did not induce efficient multi-exon skipping, presumably because of interactions 
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benveen the AO-sequences, or different efficiency in exon removal (Adams, AM 
unpubl ished observations).  
To date, there are two Phase I clinical trials using oligomers to induce exon 5 1  
skipping and restore dystrophin protein i n  amenable DMD patients. In the Leiden trial, 
four 8 to 12 year old DMD patients were injected into t ibialis anterior muscles with a 
20MeAD (PROOS 1), which was designed to induce exon 5 1  skipping?6 The Leiden 
trial  was completed and dystrophin restoration was reported in all 4 patients. A dose 
escalating study is currently underway in the Un ited Kingdom with a PMD (AVI-4658), 
also inducing exon 5 1  excision.  These in it ial  two clinical trials wiJ I only provide proof­
of-princip1e of AO-induced exon skipping in DMD patients. However, s ince relatively  
low doses of o ligomer of two different chemistries were admin istered by intramuscular 
inject ion, only limited information on safety can be generated . Systemic trials  \vith 
PROD5 1 are underway, as body-wide dystrophin expression must be addressed . 
AOs} in theory, can be appl ied to many conditions modulating the level of gene 
expression, through a multipl ic ity of processes. These processes are, indeed, 
combinatorially controlled and form a regulatory network governing global gene 
expression . On a cautionary note, we need to be aware that ADs may modify gene 
expression through more than one mechanism and may indeed modify the expression of 
other genes. As a consequence, the benefits of an antisense therapy targeted to a 
specific mutation need to be balanced against possible non-antisense or non-specific 
effects, caused by interaction of ADs with other regulatory processes and other genes, 
making it necessary to weigh risk against benefit, before considering their  use in the 
treatment of patients . Assessing risk using transcriptomic and proteomic analysis on 
treated cultures or animals may ensure that anti sense therapy not only leads to the 
theoretical ly predi cted transcripts but also to the anticipated global changes in RNA and 
protein  express ion in response to synthesis  of a functional protein.  One way to 
minimise possible adverse-effects is to design the most effective compounds so that 
only low dosages, need to be appl ied. Alternatively, if some particular sequences were 
found to cause off-target effecfs� other AOs targeting d ifferent motifs could be used 
instead . 
In addition to exon skipping, the use of anti sense modulation of pre-mRNA 
splicing may potentially target splice si lencing motifs to promote exon inc lusion . AOs 
may prov ide steric h indrance, which prevents the spliceosome recognising spl ice 
s i lencing motifs, thereby enhancing incorporation of the exon into the mature transcript. 
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In the second part of this  thesis, this rationale was appl ied in the design of an array of 
o l igomers to induce exon 7 i nclusion into the human SMN2 gene transcripts i n  cultured 
fibrobJ asts from an SMA patient. The goal of the study was to develop protocoJs  to 
identify oI igomers capable of induci ng exon inclusion, which may potential ly treat 
SMA. S ince the maj ority of human gene transcripts are alternatively processed,27 the 
abi l ity to selectively incorporate or excise an exon cou1d be relevant to a number of 
other genetic d isorders. 
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Abstract: Duchenne muscular dystrophy (DMD) aril\es from protein-truncating mutations in  the large dystrophin gene that preclude syn­
thesis of a functional protein that primarily stabilizes muscle fibre membranes. The absence of dystrophin leads t o  this most common and 
serious fonn of childhood muscle-wasting. Since the identification of the dystrophin gene in 1987, cel l  and gene repair or replacement 
therapies have been evaluated for DMD treatment and onc genetic intervention, exon skipping, is now in clinical 1rials. Antisense oH­
gomers have been designed to redirect dystrophin splicing patterns so that targeted exons may be removed from a defective dystrophin 
pre-mRNA to either restore the reading frame of a deletion, or excise an in-frame exon corrupted by a nonsense mutation or micro­
insertion/deletion. This review discusses the evolution of oligomer induced exon skipping, including in vilro applications, evaluation o f  
different oligomer chemistries, the treatment o f  animal models and alternative exon skipping strategies involving viral expression cas­
settes and ex vivo manipulation of stem cells. The discussion culminates with the current clinical trials and the great challenges that lie 
ahead. The major obstacle to the implementation of personalised genetic treatments to address the many d ifferent mutations that can lead 
to DMD, are considered to be establishing effective delivery regimens for the different patients and their mutations. Furtherm ore. the 
view of regulatory authorities in  assessing preclinical data on potentially scores of different but class-specific compounds will be o f  
paramount importance in expediting the clinical application o f  exon skipping therapy for this serious and relentlessly progressive muscle 
wasting disease. 
Keyword s: Alltisense Ol igonucleotides, Exon skipping, Duchenne muscular dystrophy, Morpholino, clinical trials, dystrophin, personalized 
medicine, pre-mRNA splicing. 
INTRODUCTION 
Whcn considered individually, serious monogenic disorders are 
fortunately relatively rare, espec ially whell compared to complex 
traits such as Alzheimer's, asthma, diabetes, or acquired c{luditions, 
including pathogenic infections and cancer. The most common 
human autosomal recessive disorder, cystic fibrosis, is reported to 
occur at a frequency of about 1 in 2 l  00 in the Caucasian popu)!ltion 
Pl. However, when viewed collectivel y, single gene disorders are 
an enonnous burden to those afiected, their families, communities, 
and the health care system. 
It is no longer appropriate to consider single gene disorders as 
!!simple", p articularly s ince it is apparent that d ifferent lesions iu a 
particular  gene can result in a variety of clinically distinguishable 
conditions, with either recessive or dominant modes of transmis­
sion. Although the bF50& mutation defect accounts for about 75% 
of cystic fibrosis cases [2, 3], over 1 .000 different mutations have 
been reported and the clinical presentation can vary considerably 
from severe, with extensive lung involvement, to a very mild phe­
notype with reduced ferti lity as the predominant symptom. Simi­
larly, different mutations in the huge dystrophin gene can l ead to 
the allelic conditions, Duchcnne muscular dystrophy (DMD), 
Becker muscular dystrophy (BMD), and X-linked di lated cardio­
myopathy [4]. 
Restoration of expression of a single component to address a 
missing or defective gene product is the basis of gene replacement 
(viral and non-viral systems) or cell-based therapies. Although great 
advances arc being made in the treatment of some conditions, for 
example, gene replacement in ch ildren with X- l inked severe com­
bined immune deficiency (SCID) [5, 6}. there have also been seri­
ous adverse events and progress has not been as rapid as anticipated 
[7]. Challenges to gene and cel l  replacement therapy for DNID arise 
from the size of the gene product and/or n ature of the gene expres-
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sion. Dystrophin, the affected gene product in D1vID, is encoded by 
the largest known gene and i s  expressed as mult iple isofonns in  
different tissues, with the 427 kDa skeletal muscle protein produced 
at low amounts in about 30% ofthe human body mass [&]. 
Such challenges in gene and cel l  replacement for D1vID have 
prompted the examination of other possible therapeutic interven­
tions, including up-regUlation of a homologous protein or redircct­
ing expression, processing, or translation of the defective gene 
product (9- 1 1].  This review will consider the use of antisense oH­
gomers (AOs) to reduce the severity of D1vID, through specific 
redirection of dystrophin pre-mRNA processing to by-pass protein­
truncating mutations during mRNA maturation. The nature of this 
genetic therapy is such that specific AOs and exon skipping strate­
gies must be tailored to address d i fferent mutations .  Although this 
may sound daunting, development of personalized treatmcnts 
should not be considered unrealistic. Many compounds have now 
been optimiscd to address different dystrophill mutations in viiro, 
and two compounds are currently ill clinica l  testing to restore the 
reading frame of  a common type of  dystrophin mutation. Demon­
stration of dystrophin expression in these t rials should facilitate 
implementation of other AO strategies for different DMD patients, 
particularly ifexon skipping could be regarded as a generic therapy. 
DUCHENNE AND BECKER MUSCULAR DYSTROPHY 
DMD and BMD are allel i c  X-linked recessive cond it ions arts· 
ing from mutations in the dystrophin gene .  Onc third of cases are de 
novo and genll-line mosaicism has been reported to be as high as 
14% [ 1 2}. The tremendous size of the dystrophin gene and organ i­
zation of repeated elements within some introns in excess of200kB, 
arc thought to contribute to the high spontaneous mutation rate. 
DMD occurs at a cited incidence of 1 in 3 ,500 live male births, and 
is the most common severe muscular disorder in childhood [ 13]. 
DMD individuals appear normal at birth, but present with muscle 
weakness between the ages of  3-5 years. Muscle degeneration 
gradually overwhelms regenerative capacity in a relentlessly pro­
gressive and predictable manner. As  muscle degeneration pro­
gresses, affected individuals exhibit difficulties arising from the 
{j 2009 Bentbam Science Publishers Ltd. 
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Table 1. Some Examples of Bl\ID Deletions with Associated Comments on Phenotype 
Exonic Delelion Special comments Reference 
3-9 Playing competitive badminton at age 62 years. [ 16] 
9-22 High CK, myalgia but wel� developed musculature and no evidence of muscle weakness [134] 
13· 1 8  Myalgia and cramps after normal activity (135] 
1 3 4 1  Very mild BMD [ 136} 
1747 Source of the dystrophin mini-gene used in gene replacement studies [34] 
1 7-5 1 Mild Bl\,m \\ith congenital cataracts [ 137) 
3544 Cramping after soccer or mOWltain climbing [138] 
4 144 Elevated CK, othemise asymptomatic [139] 
45-53 Diagnosed age 60 [140J 
48 Accidentally diagnosed in female, four affected male members then diagnosed with high CK only. [141] 
50-53 Elevaled CK. otherwise asymptomatic [139] 
It should be noted that very few BMD patients have been identified with in-frame deletion in the central rod domain involving exons 3 3-45. [ 142] 
floor, climbing stairs and nllming, and eveutually lose ambulation 
before the age of 12 years. The most common causes of death are 
cardiac or respiratory complications, but improvements in heath 
care, the use of steroids and assisted ventilation have extended the 
life span of DMD patients by up to 5 0% over the last two decades 
[ l 4J. 
BMD is estimated to occur a t  one tenth the frequency of DMD 
[ 1 5]. Presenting with a spectrum of severities, BMD is clinically 
classified as an individual becoming wheelchair bound by age 1 6  
years or I
.
ater, while s0r:te �re apparently asymptomatic and may 
only be dIagnosed later ill hfe [ 1 6].  Examples of gross dystrophin 
gene deletions that have been identified in m ildly affected BMD 
patients arc shown in Tab le  1 ,  where it can be seen that over 5 0  
dystrophin exons may b e  deleted, i n  various combinations, with 
relatively minor clinical consequences. It seems probable that the 
low incidence of BMD. compared to DMD, may be due to the in­
ability to identify cases that do not present with overt symptoms. A 
mutation in the dystrophin gene was recently reported where the 
loss of ex on 16 did not raise the semm creatine kinase levels [1 7]. a 
sensitive marker ofmusc1e danlage. 
The molecular d istinction bet\'/ecn DMD and BMD ' depends 
upon the quantity and quality of dystrophin that can be synthesized 
as a consequence o f the gene l esion [ 18]. Genomic deletions of one 
or more exons. found to cluster in 2 hotspots near huge introns. are 
the most common type of dystrophin mutation and account for 
about 60% of cases. Duplications, typically involving mUltiple ex­
ons are gcneratly found in the proximal third of the gene and are 
seen in &- 1 5% of DMD cases [19-22]. Disruption o f  the reading 
frame that leads to premature tenllination of dystrophin synthesis 
results in DMD, while in-frame gene re-arrangements typically 
allow the generation o f  intemally truncated dystrophin that retains 
some biolog ical function. The variable manifestation ofBMD, from 
border-line DMD to asymptomatic, reflects the quality and/or quan­
tity o f  the internally shortened dystrophin (for review see [23-25]). 
The dystrophin gene contains 79 exons spanning approximately 
2 .4 million base pairs and encodes 3 major isofornls, which are 
expressed primarily in muscle, heart and brain. The reading frame 
organization of the 79 exons is shown in Fig. (1). 1n addition, there 
are 4 internal promoters. which encode shorter isofonns expressed 
in other tissues. Due to the catastrophic consequences of dyslrophin 
loss on muscle function and integrity, it is  presumed that the 427 
kDa skeletal muscle isofonn is most important, hence this has been 
the focus of the gene repair or replacement studies (for review sec 
[26, 27]). 
Dystrophin is thought to act much like a shock absorber l inking 
the actin cytoskeleton to a complex of proteins embedded in the 
sarcolemma. The primary actin binding domain involves dystrophin 
exons 2-8. although secondary actin binding sites have been identi­
fied [28, 29], supported by the identification of mildly affected 
BMD individuals m issing exons 3-9 [ 1 6J .  Dystroph in eXOllS 62-69 
encode U:e cysteine rich domain, which is pivotal in the linkage of 
dystrophm to p·dystroglycan, and hence to the dystrophin associ­
ated proteins and glycoproteins embedded in the sarcolemma. In 
addition to the primary structural role linking the actin cytoskeleton 
and the sarcolemma, dystrophin also anchors syntrophin, dystrobre­
vin, and localizes nNOS [25). As well as the major 427 kDa iso­
fOIms e:cp�es:ed in muscle, heart and brain, internal promoters lo­
cated wlthm mtrons 30, 45, 56 and 63 arc responsible for the pro­
duction of the shorter isofornls, DP260, DP 1 l 6, DP 140, and DP7 1 ,  
respectively. In non-muscle tissue, DPl 1 6 associates with the sar­
coglycan complex and is implicated in myelin stability in schwann 
�elts [30].. Transient expression. 
of DP140 in embryonic k idney i s  
Involved m rensl tubulogenesls [3 1 ] .  The carboxy (C)-terminal 
domain of DP7l isofoIms plays an important role in neuronal dif­
ferentiation [32J. 
The actin and j)-dystroglycan binding domains are separated b y  
2 4  spectrin-like repeats, and this rod domain is  encoded b y  about 
two thirds of the dystrophin gene transcript [33]. Portions of the ro d 
domain appear to be somewhat redundant in that substantial in­
frame deletions of rod domain generally lead only to a mild BMD 
phenotype [34] (Table 1). 
NATURAL PRECEDENTS FO R EXON EX CLUSION DUR­
ING DYSTROPHIN PRO CESSING 
There are two precedents to support the hypothesis that induced 
exon skipping could  minimise the consequences of protein­
truncating mutations in the dystrophin gene. Revertant fibres are 
dystrophin-posltive fibres that occur naturally and have been de­
tected in md..; mouse model of muscular dystrophy [35, 3 61, the 
dystrophiu-deficient muscular dystrophy canine model [37-39] and 
at least 60% of al l  DMD cases [40-43].  Another canine model, a 
Gemlan short-baired p ointer 144], in which the entire dystrophin 
gene was missing, did not contain any revertant fibres, suggesting 
that the mechanism responsible for restoring some dystrophin ex­
pression required the retention of sufi1cient coding sequences of the 
dystrophin gene. 
A
.
lthough revertant fibres are regularly detected in many dys­
trophiC tissues, the frequency is insufi1cient to be of any substantial 
clinical benefit [42] . RNA analysis and epitope mapping indicated  
the presence of multiple revertant dystrophin isofonn s  i n  human 
and mouse muscle. This suggested some natural exon skipping 
eyent led to re-arrangements [36, 45], generally excluding 20 or 
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Fig. (1). Slnlcture of the dystrophin gene transcript indicating the reading frame IInd major functional domains. Boxes represent in-frame exons whereas inter� 
locking fonvard and reverse arrows and notches indicate codons spanning the exon:exon junction. Junction codon sequences are shown above the exons. 
more exons [46]. In situ hybridization studies in the mdx mouse 
using exon 23 and flanking introni c  sequences as a genomi c  probe, 
indicated that the dystrophin gene in the majority of revertant fibres 
was structurally intact, thereby excluding secondary somatic dele­
tions in the dystrophin gene as the primary possible mechanism 
[46l The underlying basis of revertant fibres is believed to involve 
some fonn of alternative splicing [36, 47). although it is difficult to 
conceptualize a mechanism whereby 20 exons spanning hundreds 
of kilo bases of pre-mRNA are consistently excluded in one muscle 
fibre and not another. 
BMD patients typically have genomic deletions in th� dystro­
phin gene that do not disrupt the reading frame. A few point 111uta­
tions that lead to BMD h ave been identi fied, including missense 
mutations in the actin binding domain [ t S] and splice 1110tif muta­
tions that either lead to excision of an in-frame exon, or reduce the 
amount of normal dystrophin mRNA 148J. Some nonsense muta­
tions in the dystrophin gene have also been found to lead to BMD 
[49, 50], in apparent conflict 'with the reading frame hypothesis, 
which predicts that protein-truncating mutations should result in 
DMD [5 1) .  However in these m ilder than expected BMD cases, i t  
w as  found that the nonsense mutation influenced splicing patterns 
such that natural eXOll skipping excluded the exon containing the 
nonsense mutations ISO]. Comprehensive screening of -genomic 
DNA has been reported to confinn diagnosis of over 96% of DMD 
cases, whereas only 60% of BMD mutations were identified 152, 
53]. Analysis and sequencing of dystrophin cDNA from muscle i s  
often essential t o  identi fY  the consequences of less obvious gene 
mutations, where a nonsense or missense mutation/polymorphism 
may lead to exon skipping or activation of a cryptic splice site. 
Similarly, deep intronic DNA changes, sometinles kilobases away 
from the nearest dystrophin eXOll, can lead to the incorporation of 
pseudo-exons in the mature gene transcript [54]. 
ANTISENSE OLIGOMERS AND MODES OF ACTION 
An oligodeoxyribonucleotide was reported to inhibit Rous sar­
coma virus replication ill cell culture nearly three decades ago 155, 
56 J. Antisense technologies became synonymous with gene dmvll­
regulation studies, most commonly through the induction of 
RNAseH degradation of the RNA strand in the AO:RNA duplex. 
Inadequate controls con founded results of some early experiments, 
where apparent gene suppression arose from non-sequence specific 
effects, in particular the sequestration of transcription/translation 
proteins by the phosphorothioate backbone. D esp ite these early 
setbacks, which saw antisense technology regarded with a great 
deal of skepticism, there has since been great progress in temlS of 
new chemistry development and identifYing distinct mechanisms of 
altering gene expression. 
New oligomer chemistries, with modified bases andJor back· 
bones, generated compounds with greatly increased a.nnealing affm­
ity andJor enhanced resistance to nuclease degradation. Vitravene 
(fomivirsen) was the first antisense drug to achieve m arketing 
clearance in the USA to treat cytomegalovirus retinitis in people 
with AIDS [57]. In addition, new oligomer chemistries were able to 
influen ce gene expression through mechanisms other than RNaseH­
induced degradat ion. Chem ically synthesised RNA oligom ers are 
routinely used in gene silencing studies in nematodes, p lants and 
human cell s 15 8-6 1 ] .  Some second or third generation oligomers, 
which were not able to activate silencing pathways, can modifY 
gene expression at di ftcrent stages. Depending upon the target se· 
quence design, some modified oligomers can suppress translation 
by masking motifs essential for ribosomal initiation and elongation, 
while other oligomers can anneal to motifs involved in exon recog­
nition and intron removal, thereby redirecting prc·mRNA process­
ing. 
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EARLY SPLICE INTERVENTION STU DIES 
Kole and colleagues first reported the use of ADs to comect 
aberrant p-globi n  pre.mRNA splicing fifteen years ago [62] . In­
tron ic mutations in  this gene activated cryptic spl ice sites ood ac· 
count for nearly 30% of p-thalassemia cases. Despite the presence 
of intact splice donor and acceptor sites, the selection of cryptic 
splice sites led to some intron retention in the mutant 'P-globin 
mRNA. ADs consisting of 2'-D-methyl modified bases on a phos­
phorothioate backbone (2DMe) were designed to ooneal to the 
cryptic splice sites, rendering them inaccessible to the splicing m a­
chinery, which in turn defaulted to the selection of the normal 
splice s ites. A few years late r, Matsuo and col leagues were able to 
induce an abnormal dystrophin gene transcript by targeting an oH­
godeoxynucleotide on a phosphorothioate backbone (DDN) to an 
internal domain within dystrophin exon 1 9  [63]. The "Kobe" DMD 
mutation was found to arise from a 52 bp deletion within dystrophin 
exon 19 that, while leaving the donor and acceptor s ites intact, re­
sulted in the excision of the entire exolt from the gene transcript 
[64, 65]. Matsuo and colleagues hypothesized that the small intra­
exonic deletion removed crucial exon recognition motifs and re­
sulted in complete exon removal. An AD \\'8S designed to induce 
dystrophin exon 1 9  skipping in normal lymphobIastoid cells trans­
fonned with Epstein-Barr virus [63]. Hence, the first demonstration 
of exon skipping in the dystrophin gene did not rescue defective 
gene expression, but induced abnormal splicing and disrupted the 
reading frame. Nevertheless these experiments confirmed the prin­
cipl e  of targeted exon skipp ing and proposed this approach as a 
potential therapy for DMD. 
ANIi'tL\L MODELS 
The most commonly studied animal models o f dystrophin muta­
tions are the mdx mouse, which carries a nonsense mutation in ex on 
23 [35], and the Golden retriever muscular dystrophy model 
(GRMD), which was found to have a splice site mutation tllat leads 
to exon 7 exclusion and a subsequent mRNA frame-shift [39]. The 
mdt mouse model is readily avai lable, inexpensive, but su ffers fro m  
t h e  l im i tation that the dystrophin deficiency does n o t  induce a n  
overt severe dystrophic phenotype. Nevertheless, detailed examina­
tions show raised serum creatin e  kinase levels, muscle weakness 
and some muscles) in particular the diaphragm. show extensive 
fibrosis and dystrophic pathology [66] .  As these anim als age, the 
consequences of the dystrophinopathy become more obvious, but 
these ooi.1llals can voluntarily run in a manner si.milar to wild type 
animals. Another mouse model , which does show a very severe 
phenotype is the utrophin/dystrophin double knockout mouse [67J, 
although no exon skipping studies in this model have been reported 
to date. 
The canine GRMD model is much more severely affected, per­
haps more so than the human condition, and provides a more rele­
vant model in which to assess any therapies. Limitation s of the 
canine model include substantial variation in sever ity, excessive 
costs involved in maintenance and care, limited numbers available 
from each litter, and the emotive i ssu es associated with working 011 
companion animals. 
AO DESIGN AND TARGET SELECTION 
The rescue of dystrophin expression using AO-induced exon 
skipping in the md.t mouse was first reported by Dunkley and col­
leagues, who described a 20Me AD 12mer directed at the exon 23 
acceptor splice site that generated a transcript in wh ich exons 23 to 
29 had been skipped. 20Me AOs directed at the branch point or the 
donor splice site of exon 23 were not found to have any eiTect on 
the dystrophin mRNA processing [68]. In contrast, the fol lowing 
year \ve demonstrated that targeting the exon 23 donor splice site 
with a 20Me AD 20mer was able to induce precise and consistent 
Mitrpallt et al. 
exon 23 skipping, whereas a 20mer directed at the acceptor site was 
found to be ine ffective [691. Subsequent refinement s  in ADs target­
ing the dystrophin exon 23 donor splice site were reported and 
found to further enhooce the capacity of the AD to induce exon 23 
skipping pO]. Additional AD refinement at the acceptor splice s ite 
consistently failed to induce any detectable skipping [70]. 
Studies describing the app lication of AOs directed to eXOllS 
flanking frame-shifting genomic deletions in DMD patient cell lines 
were reported by van Delltekom and colleagues [7 1 J . The Leiden 
muscular dystrophy database (http://www.dmd.nll) l is t  exon 45 as 
one o f  the most commonly deleted exons in DMD, whereas the in­
frame deletion of exons 45 and 46 is associated with a mild forn} of 
BMD. van Deutekom and colleagues designed a 2DMe AD to mo­
tifs within exon 46 and conclusively demonstrated restoration of the 
reading frame in cells from DMD individuals carrying a dystroph in 
genomic deletion of exon 4S [7 1 ] . These studies were then extended 
to a variety of other mutations in  the dystrophin gene [72-74]. 
It has been prop osed that only 12 different ADs would be able 
to restore the reading fram e in the majority of DMD deletion pa­
tients, particularly s in ce  this  type of mutation is clustered in the 
minor and major dystrophin deletion hotspots [75]. Indeed, the most 
commonly deleted exons lie bcf:\veen exons 45 and 5 5, and Beroud 
and colleagues (76) reported that multip le exon skipping across  
those exons could restore some functional dystrophin expression in  
almost two thirds of all DMD patients. 
However. more than onc-third o f DMD cases do not arise from 
genomic deletions and these patients should not be excluded from 
any potential exon skipping therapy. Nonsense lllutations, splicing 
defects and micro-insertionldeletions have the potential to lead to 
premature tcnllination o f  translation, and these defects appear 
evenly distributed across the entire gene. As discussed previously, 
an apparent catastrophic DNA change such as a nonsense mutation , 
does not necessarily lead to premature tennination of translation, if  
the DNA variant compromises exon recognition and results in  vari­
able levels of natural exon skipping. Since the excluded exon is in· 
frame, a protein typical ofBMD is generated [49, 50],  again provid. 
ing evidence that exon skipping has the potential to ameliorate 
DMD progression. 
Furthermore, unlike m any genomic deletions involving multiple 
exons, the entire dystrophin coding region is present in the non­
deletion DMD p atients. The removal of one or two eXOllS to by-pass 
a protein-truncating mutation i s  unlikely to seriously compromise 
the function of the induced dystrophi n, unless the exons code for a 
crucial function al domain. A artsma-ms and colleagues [7 7] de­
scribed 1 1 4 ADs that target 35 exons for removal. In 2007, we re· 
leased the first draft of ADs targeting every exon in the dystroph i n  
pre-mRNA for excision, excluding the first and last exons [78] . 
It has been suggested that directing ADs to dystmphin donor or 
acceptor splice sites m ay lead to o ff-target effects on other splice 
sites [79}, a possibil ity which cannot be d iscounted. However, the 
invariant b ases of the acceptor and donor splice sites are only 2 
lluc1eotides long, and occur at the end and beginning of each intron 
flanking the target exon (-·-ag[EXDN]gu---). We took the approach 
that any motif involved in splicing must be regarded as a potentially 
anlenable target and evaluated the efficiency of ADs directed at 
acceptor and donor sp lice sites, as well as Exon Splicing Enhancers 
(ESE1s) as predicted by ESEFinder [80, 8 1 ] .  Although the "ag" an d 
"gu" moti fs are almost invariant at the acceptor and donor splice 
sites respectively. these two nucleotides would only constitute a 
minor proportion of the AD annealing site. It may be argued that 
targeting ESE's, where 6 or 8 con sensus nucleotide motifs are rec­
ognised by SRp55 or SC35 respectively, offers a greater chance of 
cross-transcript targeting. 
Remarkably from these two extensive reports on AD design to 
induce dystrophin eKon skipping [77, 18], about two thirds of ADs 
designed and evaluated were able to induce some l evel of targeted 
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exon exclusion. This i s  consistent with the observation that m an y  
changes i n  the protein coding region can disrupt splicing [82J. an d 
implies that many motifs are involved in exon recognition an d 
splicing. However, there are substantial variations i n  exon skipping 
efficiencies, as clearly some AOs targeted more amenable or re­
sponsive sites for induced exon skipping than others. Some exons 
were readily and efficiently removed at what was arbitrarily chosen 
an acceptable level in vitro, greater than 30% exon removal com­
pared to the intact transcript after transfection at 1 00 nM 
AO:lipoplex [781, while other exons were more difficult to dis­
lodge. Aartsma-Rus and coll eagues [831 noted that the effective 
AOs targeted significantly higher numbers of SF2/AS F, SC35 and 
SRp40 motifs than the ineffective AOs [77]. 
Our strategy for AO design h as been more empirically based . 
An initial panel of AOs were designed to target splice site junctions 
for each exon, as well as predicted ESE motifs.  Normal myogenic 
cultures were transfected and the test compounds exhibiting the 
most pronounced exon skipping efficiency were used as a template 
to design a subsequent series of overlapping AOs. The most efl1-
dent AO was defined as the compound that induced maximal exon 
excision in vitro, after transfection at concentrations over the range 
1 0  to 1 00 nM. Although the AOs designed to induce specific cxon 
skipping will ultimately be applied to cells expressing a defective 
dystrophin gene. AO development was undertaken in normal hu­
man primary myogenic cell culnlres. Designing ADs to target the 
nonnal dystrophin gene transcript places extra demands on evalua­
tion. Unlike cells expressing a defective dystrophill mRNA sub­
jected to increased turn-over through nonsense mediated decay 
[841. removal of approximately half of the exons from a normal 
dystrophin transcript m ay lead to a disruption of the reading frame. 
Hence, the normal gene transcript will be expressed at wild-type 
levels, and the induced exon deleted transcript will be subjected to 
faster turn-over though nonsense mediated decay. Consequently, 
when the appropriate therapeutic oligomer is applied to dystrophic 
cells. the effect on exon skipping should b e  more pronounced, as 
the reading franlC will have been restored and the induced transcript 
no longer subjected to nonsense med iated decay (NMD). This fea­
ture was evident in evaluating A Os to excise exon 19 from the dys­
trophin gene transcript expressed in normal and mdr murine myo­
genic cells. The md.,. dystrophin transcript would be subjected to 
NMD, as would any dystrophin transcripts missing exon 1 9. De­
spite the sam e  nucleotide sequence and splicing machinery. exon 1 9  
removal was induced i n  md'( cel l s  at  concentrations 4 fold lower 
than tbat required in the nonnal celts [85].  
One trend in AO design that became evident was that the length 
of the AO could play a major role in determining the etlicacy of 
induced exon skipping, although this appears to be largely. depend­
ent upon the target exon [86]. Several motifs were cxanlined as 
targets for induced skipping of human dystrophin exon 1 6. in par­
ticular, a cluster of high-scoring potential ESE's near the donor 
splice site. Despite masking o f  high-scoring ESE's and this donor 
splice motif. overlapping AOs directed at  the human exon 16 donor 
site were found to be ineffective, whereas a 25mer. spanning the 
acceptor site induced moderate exon 1 6  skipping. AOs with addi­
tional bases at the 5 '  or )' end of the 25mer were found to be about 
four-fold more effective than the original AO targeting the accep­
tor. Most surprisingly, a 20mer common to all three AOs was found 
to be totally ineffective [86]. Although it h ad been observed that a 
2 5mer directed at the mouse exon 23 donor site was marginally 
more effective than a 20mer, longer AOs (30mer) directed at this 
site were consistently found to  induce less exon 23 skipping than 
the shorter compounds [86l 
Some dystrophin exons were difficult to dislodge from the ma­
ture dystrophin mRNA, and despite designing AOs across most o f  
t h e  exon, with either n o  or only very low levels of skipping being 
induced after transfection with high AO:1 ipoplex concentrations. 
Exon 20 was one such example, in which over 20 different AOs 
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were designed and evaluated, but only one compound was eventu­
al ly found to induce moderate levels of exon 20 excision. Combina­
tions of AOs were then evaluated and some, but not al l  AO cock­
tails, were found to be very effective in a clearly synergistic rather 
than cumulative m anner [83, 87] . AO cocktail design was not as 
simple as combining the most effective AOs, as the optimal A O  
cocktail for exon 2 0  consisted of two compounds that h ad n o  e ffect 
on splicing when used individually. Replacing one o f  the AOs in 
this cocktail with a longer overlapping compound that d id show 
some exon skipping potential when used alone, actually lowered the 
efficiency oftbat cocktail [87]. In another example. very weak exon 
65 skipping could be induced with one AO after transfection at a 
concentration of 600 nM. When this AO was combined with an­
other directed at exon 65. pronounced eXOll skipping was evident 
after transfection at a combined AO concentration of 2 nM [87]. 
This raises the question of exactly how AOs influence the spl ic­
ing process. It h ad been assumed that AOs anneal to single stranded 
motifs on the pre-mRNA, where SR proteins or other splice factors, 
such as short non-coding RNAs including m iRNA s  [88J may b e  
involved in exon recognition and defInition. A O  bindin g  to the 
appropriate target would render that pre-mRNA site double­
stranded and presumably prevent correct assembly of the spli­
ceosome. If this were the case, one would assume that the more 
obvious motifs involved in spl icing, such as the acceptor or d onor 
sites should provide reliable targets for consistent splice interven­
tion. Thi s  is clearly not the case, as we h ave identified only one 
human dystrophin cx:on in which the donor splice site was the sin­
gle most amenable target for exon skipping [78]. A lthough direct­
ing ADs to some donor splice sites does induce exon skipping. 
there are more examples ofl1o skipping whatsoever. As reported by 
Arechavala-Gomeza et al [89] , applying a panel of AOs to m icro­
walk across the donor splice site of human dystrophin exon 5 1 ,  or 
using AOs o f  increased length targeting the donor site, failed to 
induce any substantial exon skipping. It would appear that if a do­
nor spli ce motif does not appear amenable, extensive AO design 
and manipulat ion targeting that area will b e  a futile exercise. 
Rather than directly masking motifs recognized by the various 
splice factors, perhaps the AOs b ind to the pre-mRNA and alter 
secondary structures that arc crucial in exon recognition and splic­
ing. There is mounting evidence that secondary structures within 
the pre-mRNA are involved in both constitutive and alternative 
splicing [90-92] and this may account for the observations that 2 
out of 3 AOs designed and evaluated 'were able  to induce some 
exon skipping [77, 78}. It is possible that some donor or  acceptor 
sites unresponsive to AO intervention are influenced by particular 
splicing factors, which b ind very strongly and/or immed iately after 
transcription. 
Several oligomer chemistries h ave been identified as suitable to 
induce exon skipping. While ODNs were first used to induce exon 
19 excision in dystrophin processing [93] and later used in the first 
clinical trial involving one patient [94J, there are several reasons 
why this particular chemistry should not be taken to the clinic for 
induced exon skipping. This type of oligomer is more susceptible to 
nuclease degradation than many other chemistries and would need 
constant re-administration to maintain therapeutic concentration. 
Secondly. ODNs are typically used to induce degradation of the 
target gene transcript by RNaseH action. Presumably if exon exci­
sion can occur before RNascH degradation, the induced transcripts 
would then be resistant to degradation, unlike the intact transcript. 
Although ODNs were able  to induce exon 19 skipping in cultured 
cells, AOs of this chemistry directed at other spl ice motifs did not 
induce exon skipping [85]. Chimeric AOs consisting of a mixture of 
modified and unmodified bases demonstrated increased exon skip­
ping efficiency. correlated with increased content of 2t-O-methyl 
modified bases [95]. 
One of the more commonly used nucleotide chemistry for AOs 
to induce cxon skipping are those consisting of 2'-O-methyl modi-
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fied bases on a phosphorothioate backbone [62, 69, 7 t ,  96]. Several 
other AO chemistries h ave also been evaluated for induction of 
cxon skipping, including terminally modified 20Me A Os [97], 2 '­
O-methoxy-ethoxy AOs (MOE, unpublished data), 4'-C-ethy1ene 
bridge nuclei c  acids (ENAs) [72, 95, 98], locked nucleic acids 
(LNAs) {72, 99], peptide nucleic acids (PNAs) [72], and phos­
phorodiamidate morpholino ol igomers (PMOs) [72, 1 001. LNA, 
PNA, PMO, and 20Me AOs were directly compared to remove 
exon 46 from a DMD cell line in which exon 45 was deleted [72]. 
This study found that oligomers prepared as 20Me and LNAs could 
efficiently induce exon 46 removal, whereas the equivalent com­
pounds prepared as PMOs or PNAs were inefTective [72]. These 
authors concluded that the 20Me chemistry was p referable to pur­
sue further induced exon skipping strategies [72], and an AO of this 
chemistry has now undergone Phase I clin ical trials [ 1 0 1 ,  102}. 
There are advantages and disadvantages to each of the AO 
chemistries, and several factors must be taken into account. The 
LNA compound designed to excise exon 46 was able to induce 
substantial exon skipping. has the additional advantages of in· 
creased resistance to nuclease degradation and an exceptional affm­
ity for the target sequence. A 1 5mer targeting exon 46 was esti­
mated to have a Till of 1 3 1 °C [72], and i t  was the latter feature that 
raised concerns for potential orr·target annealing, particularly after 
the authors showed that an AO with 2 mismatches was stilI able to 
induce targeted exon skipping [72]. We have shown that 20Me 
AOs containing several mismatches could also induce targeted exon 
skipping in vitro, but th is was only after application of high concen­
trations of AO, and skipping was not efficient compared to opti­
m ally designed AOs [85] .  
Although earlier studies reported that PNAs m ay be o f  limited 
use as agents to induce exon skipping [72, 1 00], th i s  m ay again 
re flec t  limitations of delivery of the PNA into the nucleus, neces­
sary for splice intervention. Recently. Cl report by Yin et al [103] 
indicated that PNAs of 20 bases long could induce substantial exon 
23 skipping in both md'( cells ill vitro and in vivo after intramuscu­
lar injection. These authors were able to compare e fficiencies of 
different oligomer chemistries and concluded that the PMOs were 
marginally more e fficient than the PNAs. It should be noted that 
direct sequence comparisons were 110t reported, 
Onc limitation of the PMO chemistry i s  poor uptake in vitro. 
unless either very h igh concentrations were used o r  the cells were 
encouraged to take up the PMO by scrape loading [ 104], Sense 
strand oligonucleotide leashes, designed to anneal to a PMO di­
rected at mOllse exon 23 donor, allowed the uncharged PMO to be 
complexed with a cationic liposome, and induced targeted exon 
removal at concentrations three orders o f  magnitude lower than the 
uncomplexed PMO in cell culture [ l OO}. Once the PMOs were 
taken up by the cells, h igh levels of exon skipping were maintained 
for the l i fe of the cultures, as these uncharged compounds are not 
metabolized. The PMO chemistry does not show any overt toxicity 
;n vitro, even when added to cultures at concentrations of 5 0JlM. 
More importantly, no serious drug-related adverse events h ave been 
observed in 15 safety studies of 4 different PMOs, designed as anti­
viral and metabolism moditying agents, involving approximately 
3 5 0  individuals [ 1 05]. 
It is not realistic to consider using cationic liposome prepara­
tions for repeated systemic delivery, based upon cost and more 
importantly. potential toxicity. The pluronic block co-polymer F l 27 
\vas shown to enhance uptake of 20Me AOs [ 1 06, 1 07} and Wells 
et af [1 08] showed enhanced AO delivery in the mouse u sing clee­
troporation. However. it is possible that systemic delivery m ay not 
be as great a challenge for PMOs as first anticipated. In vivo ad­
m inistration of a PMO was undertaken by injecting a cationic l ipo­
plex composed of a PMO annealed to a sense strand leash, ( 1 -5 ug) 
directed to the donor splice site of mouse dystrophin exon 23, As 
anticipated from in vitro studies, substantial dystrophin exon skip-
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ping was detected at the RNA and protein levels [ lOO]. Im­
munofluorescence indicated that the induced dystrophin was cor­
rectly localized and the sarcolemmal complex was re-established. 
What was unexpected was that similar levels of exon skipping were 
induced after administration of an equivalent amount of PMO that 
was not annealed to the leash. It quickly became apparent that ;n 
vivo PMO uptake was much more efficient than anticipated from in 
vitro studies. Systemic studies followed and dystrophin expression 
could be detected in  all tissues examined, except the heart [1 09, 
1 10]. Further advances in PMO delivery canle with conjugation to 
cell penetrating peptides, and even more substantial dystrophin 
expression was induced, using even lower doses o f  the PMO f I l l 1. 
However, to date, the heart remains resistant to AO·induced exon 
skipping, prompting additional studies using different peptide tags 
and dosage regimens. 
ALTERNATIVE EXON SKIPPING STRATEGIES 
Several approaches are being investigated as potential avenues 
to induce pennanent exon skipping. Gcne editing using chimeric 
RNAlDNA oligonuclcotides (RDOs) { 1 1 2. 1 1 3]. s ingle stranded 
oligodeoxynuc1eotides (ODNs) 1 1 1 41. and plasmid DNA I l l S] has 
been reported. If a base change coul d  be introduced at a donor or 
acceptor spl ice site, the modified cell could maintain pennancnt 
exon skipping. Although, the most common consequence o f  a splice 
site mutation is exon skipping, such as found in the c anine model o f  
muscular dystrophy [39J. there are many instances where a donor o r  
acceptor mutation has l e d  to  th e activation o f  a cryptic splice site, 
thereby C<'lusing intron retention or  partial exon loss ill the mature 
mRNA. We previously reported a case of germlinc mosaicism in a 
fanlily with a defect in the exon 26 donor splice s i te [ 1 1 6]. This 
mutation did not lead to loss o f  exon recognition and skipping, but 
rather activation of a cryptic splice site dov.'llstream, 'with intron 
retention and an in-frame stop codon now in the m ature mRNA. It 
may be difficult to predict the consequences of each splice motif 
mutation until it has been induced and validated i n  human cells. 
What is  clear is  that levels of induced gene correction reported are 
generally very low, and vary extensively from one laboratory to 
another and this aven'lle of therapy is  m any years fro m  the clinic 
[ 1 1 7, 1 1 8] .  
Viral vectors are being developed to introduce expression cas­
settes that al low synthesis of anti sense RNA sequences [ 1 1 9, 1 20]. 
Auxiliary sequences such as U l  and D7 are proposed to enhance 
accessibility of the AO to the splice site. Goyenvallc et al I l 2 1 ] 
presented elegant work showing long-term dystrophin expression in 
the md-.: mouse after introducing a viral construct carrying se­
quences annealing to the branch point of intron 2 2  and donor site of 
exon 23. linked t o  a modified U7 sequence under control o f  the U7 
promoter. Dystrophin was readily detectable by western blotting 
and itnmunostaining 3 months after treatment. Should the appropri­
ate construct be introduced into a stem or progenitor cel l [ l 22], pro­
liferation capacity coul d  allow for potentially enhanced therapeutic 
benefits. 
Autologous cel l  therapy is  also heing investigated to restore 
dystrophin [123, 124]. Cells were harvested and then transfected 
with a lentiviral construct, containing an ex on skipping cassette 
designed to constantly generate RNAs to dislodge the target exon. 
The treated autologous cel ls were evaluated for exon skipping and 
transplanted into the tibial is anterior of mdx/SCID mouse. A few 
dystrophin positive myofibres were detected 10 weeks after trans­
plantion [ 1 23], and it appears that the lo\-v levels of dystrophin ex­
pression was caused by a combination of low exon skipping effi­
ciency and poor viability of transplanted cel ls. 
CLINICA L TRIALS 
The first clinical trial to address a DMD-causing mutation by 
induced exon skipping involved a single patient with a frame-
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shifting deletion o f  exon 20. An ol igomer, directed to exon 1 9, 
should restore the reading frame in this individual 194J, The treat­
ment con sisted of an ODN administered intravenously at a dosage 
of 0.5 mglkg of body weight per week, for 4 weeks . Dystrophin 
protein was reportedly detected at very low levels by immunostain­
ing of sections from the patient's biceps, 1 week after the last infu­
s ion. No westem blot data was shown and the treatment failed to 
reduce scrum creatine kinase levels. Although exon skipping was 
demonstrated in lymph ocytes  after the third and fourth treatments, 
only low levels of transcrip t missing exons 1 9  and 20 were found in 
the muscle b iopsy after 4 treatments. In thi s report, preclinical test­
ing was linlited to one species, the mdx mouse, in which doses of 
200mglkg were admin istered by infusion . There were no adverse 
e ffects reported, bu t surprisingly neither were any exon skipping 
studies, since this particular oligomer matched the mous� dystro­
ph in sequence perfectly and had been shown to induce mouse exon 
sk ipp ing in vitro 185]. Even more surprising, th is compound h ad 
previously been reported to induce ex on 19 skipping in the mc/.r 
mouse, but only after intraperitoneal injection [1 25]. Although a 
similar in fusion protocol was used to administer thi s compound to a 
110nnal human volunteer for safety testing, no exon ski pping analy­
sis was reported. 
This raises one of the fundamental problem s with pre-cl inical 
te sting o ligo mers des igned for dystrophin exon skipping. If this 
compound had efficiently dislodged eXOll 19 from the dystrophin 
pre-mRNA of the normal human volunteer, the re ading frame will 
be disrupted, leading to reduced dystrophin expression , wId in es· 
sence induce muscular dystrophy. This aspect i s  more discussed in 
detail below. 
I n  addition, h ighly sensitive assays could lead to m isinterpreta­
tion of exon skipping efficiency. Lymphocytes have been used to 
study illegitimate dystrophin expression [ 1 26], where it has been 
estimated that one copy of dystroph in gene transcript occurs i n  
about o n e  thousand cells [ 1 27]. As very sensit ive assays were re­
quired to detect these illegitimate transcripts, the low level of exon 
1 9  sk ipp ing from the muscle b iopsy is unl ikely to reflect an accu­
rate ratio of rescued muscle gene transcript. Several issues relating 
to dosage and route of adm inistration, which were not 'properly 
addressed , highlight some limitations of this clin ica l trial. 
A Phase I clinical trial in Leidcn has now been completed 
[ l 02]. A 20Me AO designed to induce exon 5 1  skipping was in­
jected into tibialis anterior muscles of 4 DMD patients. Exon 5 ]  
was chosen as the target for thi s  study as its removal would correct 
the reading frame in more DMD ind ividuals t han any other exon. 
accord ing to th e Leidcn muscular dystrophy database 
(http://\\'\vw. dmd.l1l/). Preexisting or fibroblast derived myogen ic 
cells from patients were used for in vitro pre-screening of oligomer 
PRODS ] [102]. Four weeks after four intramuscular injections of 
200 Ilg of PR005 1 oligomer, running along a 1 .5cm measuring 
line, muscle from th e 8 to 12 year old part icipants were assessed for 
exon skippin g  at the RNA level and dystrophin restoration. Sub­
stantial dystrophin restoration was demonstrated in all patients by 
both immunostaining and western blot analys is [ 1 02]. This is the 
first evidence to conclusively support the potential of using AOs to 
restore dystroph in in DMD patients. Another trial has recently 
commenced injecting p atients in the United Kin gdom, also with the 
aim of inducing exon 5 1  excision. However, there are several d if.. 
ferences from the above study, including oligomer sequence [89], 
ol igomer chem istry and dosage, and tbe muscle to be treated [ 1 0  I J. 
FUTURE CHALLENGES 
There is  considerable optimism that A O-induccd exon skipping 
may substantially reduce the progression and symptoms of DMD. 
However, a number of major challenges l ie ahead. First, the classi­
fication of exon skipping as a gene therapy is regarded differently 
by re gul atory agenc ies in different countries. We propose that the 
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use of AOs to induce exon skipping should not be regarded as a 
form of gene therap y. since n o  perm anent genetic changes are in­
duced in the recipient. These oligomers cannot integrate into the 
DNA, and their mode o f  action interferes with gene expres sion, not 
the gene. In some respects, o ligomers inducing exon skippin g  
should be viewed no differently t o  a compound such a s  PTC 124, 
which can suppress premature termination codons fI O], or any other 
molecule or antibody that blocks or modifies the function of a gene 
product. Upon cessation of the AO administration, the compounds 
will be either degraded by endogenous nucleases or gradually 
cleared from the system. No pennanent changes will have been 
introduced, and while this may expedite some regulatory aspects o f  
the work, it also poses a potential limitation, as the AOs wil l need 
to be re-adm inistered at period ic intervals to maintain therapeutic 
levels of the induced protein. 
The in itial exon 51 skipping trials in Le iden and the United 
Kingdom will on ly provide proof- of..principle, with rel atively lim­
ited information on safety being generated, since low doses of AOs 
of two chemistries are administered by an intramuscular injection. 
This mode of del ivery cannot be considered to treat the entire body, 
although it may be p ossible to treat indiv idual muscles in t he hand, 
wrist, and foream\ of older boys. This m ay preserve what l ittle 
muscle is left and enhance their function. 
The extent o f  the genomic deletion causing DMD will signifi­
cantly influence the functionality of the AO�induced dystroph i n 
isoform. The dystrophin isoform rescued by skippin g  of exon 5 1  in 
a DMD indiv idual carrying a genomic deletion of exon 50 is likely 
to be more functional than the i50fon11 induced in a patien t  whose 
gene lesion extended from exon 1 3  to 50. Targeted excision of exon 5 1  would restore the reading frame in both deletions, but the miss­
ing co ding re gio n  from the larger deletion would result in a greatly 
shortened dystrophul isofonn. Genomic deletion s  in excess of 3 6  
exons have generally been associated with a sev ere phenotype, 
regardless of the reading frame II 28]. It  is  to be expected that dif­
ferent BMD-like dystrophin isoforms will have variable function, 
which would in tum influence the stability and rate of t1.lm-over o f  
the protein in muscle and presumably, the muscle fibres. 
While different DMD patients with the same type of genomic 
mutation cou ld be treated with the same AO preparation , the d i ffer­
ent dystrophic indiv iduals may requ ire oligomer dosage regimen s 
that will be determined by the ir genetic background and n ature o f  
the dystrophin mutation. The i nfluence o f  genet ic backgrounds on 
man ifestation of the sanlC dystrophin mutat ion within one fami ly 
has been reported ISO]. Prescreening the target exons in recip ients 
will then be essential to ensure there are no nClltral DNA polymor­
pili5111S that coul d comprom ise AO annealing and hence excision o f  
the taIgeted exol1. 
The cost of bring ing a single drug to  the market can be hun­
dreds of millions of dollars [ 129J. In the case of drugs to treat 
common conditions, it would be expected that these m ay be used b y  
mill ions o f people. I n  these situations, exten sive testing is manda­
tory to identify any adverse e ffects, particul arly considering the 
number ofindividuals being exposed. The potential cost of bringing 
12 different AOs, wh ich would treat the m ajority o f DMD deletion 
pat ien ts. to the market is staggering and will be beyond the capacity 
of any organ izations other than the l argest pharmaceutical compa­
n ies. It should be noted that the 'majority of de letion pat ients ' 
wo uld still only constitute about 60% of all DMD ind ividua ls, and a 
proportion of these would carry such large deletions, or the loss o f  
cmdal coding domains, such that exoll skipping may not b e  a vi­
able option . 
The non-deletion DMD indivi duals will require many diHerent 
AOs to address their mutations, as such lesions are scattered across 
the dystroph in gene. The concept of developing over 1 00 antisense 
compounds seems ludicrous, yet this must be con s idered if exon 
sk ipping is to be applicable to all amenable dystrophin mutation s, 
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especial ly since many of these defects occur in the large central rod 
domain . The loss of a single exon in the rod domain is expected to 
result in a dystrophin isofonn of near nonnal function, since this is  
a variably dispensable part of th e dystrophin protein . I f  ADs are to 
be used as a personal ized genetic medi cine, some compounds may 
be designed to treat a mutation found in only a single family. We 
have shown that targeting dystroph in pseudo-exons with ADs can 
block their inclusion in the m ature mRNA [54, 1 30]. Unlike restor­
ing the reading frame around a genomic deletion or excising exons 
carrying nonsellse mutations, AO-induced pscudo-exon suppression 
could lead to the production of a perfectly nonoal dystrophin. If the 
priority of targeted exon skip ping is only based upon the frequency 
of mutations, then pseudo-exons would never be considered, de­
spite being potentially the most responsive type of dystroph in gene 
defect. 
Several PMDs of different sequences h ave been tested in ani­
mals, including mouse, rat, dog, and non-human primate for general 
toxicity and side-effects that may be associated with the backbone 
chemistry [ 1 05]. While safety studies of oligomers designed for 
viral gene suppress ion have been undertaken in nonnal human vol­
unteers, similar safety trials cannot be considered fo r testing AVI-
4658, a PMO designed to excise dystrophin exon 5 1 . Eyaluating 
AVI-465 & in llonnal human volunte ers must be regarded as unethi­
cal due to unacceptable risks to the partic ipants. If this compound 
works exactly as predicted, exon 5 1  would be removed from the 
llonnal dys trophin gene transcript, disrupting the reading frame and 
potentially inducing D:MD. As shown in F ig. (2), the consequences 
of exon 51 skipping will vary extensively between nonnal individu­
als and different DMD patients. In what shou ld be a most amenable 
mutat ion (DMD A50), AVI-4658 wou ld restore the reading frame 
around this single  exon deletion, and allow synthesi s  of a dystro­
ph in of near-nornlal length and function. The nature of induced 
dystrophin isofonn will depend upon the extent o f  the primary gene 
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deletion, hence potential benefits of exon skipping \\'ould be com­
promise d  by larger gene deletions; such as DMD A30·50 and A 1 3-
50. Thus, there is a broad spectrum of potential consequences of 
admini stering AVI-4658 to different individuals, ranging from n o  
restoration o f  the reading frame in DMD patients with non· 
responsive mutations, induction of dystroph in isoforms of variable 
function depending upon the primary gene lesion, to inducing DMD 
in a normal individual by disrupting the dystro phin reading frame. 
Although non-human prim ate studies may be more relevant, 
there are lim itations, as there are no known primate models with 
dystroph in genomic deletions that would be restored by exon 5 1  
skipping . Similarly, removal o f  a dystroph in exon could disrupt the 
reading frame and induce an adverse reaction associated with dys­
troph in deficiency, since the exon skipping compound would be 
working exactly as it was designed to do. Animal testing of com­
pounds designed for specific human dystrophin mutations can only 
supply limited information, and should be only undertaken if rele­
vant data is generated . 
There is currently 110 therapy available for DMD that addresses 
the m issing or defective dystrophin. Although corticostero ids such 
as prednisolone or deflazacort h ave been shown a clear benefit in 
slowing muscle wasting [13 1 - 1 33], mood swings, weight ga in, 
snmted gro\\1h , brittle bone and cataracts have inevitably become 
acceptable side cffects of the treatment. It is imperative that as 
many therapeutic compounds are made available to the DMD 
commun ity in shortest possible tinle fram e. D:MD is a relentless 
progressive muscle wasting disorder that does not wait for regu la­
tory approval, challenges in ol igomer design, del ivery, and produc­
tion. 
For the widespread implementation of oligomer induced splice 
intervention as a therapy for D:tvID, it may become necessary to 
regard induced exon skipping as a generic platform. If the first 
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clinical trials show safety and efficacy in restoration of dystrophin 
expression after excising exon 5 1  from some patients, there must be 
a move to systemic administration and developing therapeutic dos­
age regimens. This is likely to take some considerable time, and 
may be confounded by the nature of the primary gene lesion and the 
genetic background of the patient At the same time, additional 
exon targets must be considered to address other DMD mutations, 
and in this manner, sufficient safety data would become available 
that eould allow difterent oligomer sequences of a particular class, 
for example PMOs. to be regarded as class-specific compounds. 
Steroids, the current "gold standard!' treatment to delay DMD 
progression, exert their effect through an unkno\\'n mechanism and 
have been available for decades. Despite this, there is still no COJl­
sensus on the best dose and treatment regimen for steroids. Faced 
with the challenge of developing a personalized genetic interven­
tion to address many different dystrophin mutations, it . is  most 
likely that establ ishing oligomer dosage regimens for individual 
DMD patients will prove to be an even greater challenge. Neverthe­
less, upon the demonstration of one mutation being amenable to 
exon skipping, we m\lst make all efforts to expedite the application 
to as many different dystrophin mutations as possible. 
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Abstract 
Background Duchenne muscular dystrophy (DMD), a severe neuromus­
cular disorder) is caused by protein-truncating mutations in the dystrophin 
gene . Absence of functional dystrophin renders muscle fibres more vulnerable 
to damage and necrosis. We report anti sense oligomer (AD) induced exon 
skipping in the B6Ros.Cg-Dmdmdx-4CV /J (4cv) mouse, a muscular dystrophy 
model arising from a nonsense mutation in dystrophin exon 53. Both exons 
52 and 53 must be excised to remove the mutation and maintain the reading 
frame . 
Methods A series of 2'-O-methyl mod ified oligomers on a phosphorothioate 
backbone (2DMeAOs) were designed and evaluated for the removal of each 
exon, and the most effective compounds were then combined to induce dual 
exon skipping in both myoblast cultures and in vivo. Exon skipping efficiency 
of 20MeADs and phosphorodiamidate morpholino oligomers (PMOs) was 
evaluated both in vitro and in vivo at the RNA and protein levels. 
Results Compared to the original mdx mouse studies, induction of exon 
skipping from the 4cv dystrophin mRNA was far more challenging. PMO 
cocktails could restore synthesis of near-full length dystTophin protein in 
cultured 4cv myogenic cells and in vivo, after a single intramuscular injection. 
Conclusions By-passing the protein-truncating mutation in the 4GV mouse 
model of muscular dystrophy could not be achieved with single oligomers 
targeting both exons and was only achieved after the application of AD 
cocktails to remove exons 52 and 53.  As in previous studies, the stability and 
efficiency of PMDs proved superior to 20MeAOs for consistent and sustained 
protein induction in vivo. Copyright © 2008 John WHey & Sons, Ltd. 
Keywords antisense oligomer; B6Ros.Cg-Dmdmdx-4CV /J (4cv) mouse; Duchenne 
muscular dystrophy; exon skipping; morpholino 
I ntroduction 
Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder 
characterized by progressive muscle wasting} and proximal muscle weakness, 
arises from the absence of functional dystrophin. Dystrophin links the actin 
cytoskeleton to the extracellular matrix via a complex of proteins embedded 
in the sarcolemma and plays a pivotal role during muscle contraction [1-3J .  
Loss of dystrophin renders muscle fibres vulnerable to membrane damage 
4CV mouse m odel of muscular dystrophy 
during contraction. Progressive loss of muscle fibres, 
with inflammatory cell infiltration and fibrosis eventually 
overwhelms the regenerative capacity of the muscle. 
The human dystrophin gene is the largest known, and 
the major muscle isoform consists of 79 exons, spanning 
2.4 million bp. Most mutations in DMD patients are intra­
genic deletions or duplications, accounting for approx­
imately 60% and 8% of all DMD patients, respectively 
[4-7] . Point mutations, including nonsense and splice 
motif mutations, as well as small insertions/deletions that 
disrupt the reading frame, are responsible for 25-35% 
of all cases [7,8J .  DMD mutations typically disrupt the 
reading frame, thereby preventing synthesis of functional 
dystrophin. Becker muscular dystrophy (BMD) is also 
caused by mutations in the dystrophin gene but this milder 
allelic condition is generally caused by gene defects that 
do not disrupt the reading frame and allow production of 
shorter, but partially functional, protein. Depending upon 
the position and nature of the mutation, some caSES of 
BMD may only be diagnosed late in life, and present with 
very mild or no symptoms [9,10] ,  whereas others may 
present as borderline DMD and lose ambulation around 
the age of 15 years [11,12] . 
AO-induced exon skipping studies initially targeted 
different splice motifs of exon 23 in the muscular 
dystrophy mouse model (md.x:), with the aim of restoring 
protein expression [13,14] .  The defect in the mdx mouse 
is a naturally occurring nonsense mutation in dystrophin 
exon 23. Despite limitations, including a mild clinical 
phenotype, the mdx mouse has been widely used in 
developing potential therapies for DMD, including exon 
skipping [1 5-22] , gene and cell replacement [23,24J , 
and premature translation termination suppression T25] . 
In the present study, the B6Ros.Cg-Dmdmdx-4Cv / J (4GV) 
muscular dystrophy mouse [26]t carrying a nonsense 
mutation in exon 53 of the dystrophin gene, was used to 
evaluate AO-induced dual exon skipping in a region of 
the dystrophin gene within the major human dystrophin 
deletion hot-spot. By-passing the 4GV mutation, and 
maintaining the reading frame, requires removal of 
both exons 52 and 53 from the mature dystrophin 
gene transcript. A series of AOs were designed and 
evaluated for the removal of each exon, and the most 
effective compounds were then combined to induce dual 
exon skipping in both myoblast cultures and in vivo. 
AOs of two different chemistries, 2'-O-methyl modified 
oligomers on a phosphorothioate backbone (20MeAOs), 
and phosphorodiamidate morpholino oligomers (PMOs) 
conjugated to a cell-penetrating peptide (P007) [27,28] 
were compared. 
Materials and methods 
AOs and primers 
AO nomenclature is based on that described by Mann 
et at [18] . Sequences and composition of AO treatments 
are described in Table 1. 20MeAOs were synthesized 
Copyright :9 2008 John Wiley & SOM, Ltd. 
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on an Expedite 8909 Nucleic Acid synthesizer (Applied 
Biosystems, Foster City, CA, USA) using the 1 J..lmol 
thioate synthesis protocol. AOs were designed to anneal 
to either exonic sequences or exon/intron junctions of 
mouse dystrophin exons 52 or 53. PMOs conjugated to 
an arginine-rich, cell penetrating peptide (P007) [27,28] 
were synthesized by A VI BioPharma (Corvallis, OR, 
USA) . Primers for RT-PCR and sequencing analysis were 
synthesized by Geneworks (Adelaidet Australia) and are 
listed in the Supporting information (Table SI) .  
Animals 
4CV (B6Ros.Cg-Dmdmdx-4Cv/J) congenic mice, obtained 
from the Jackson Laboratory (Bar Harbor, ME, USA), 
were raised and supplied by the Animal Resources 
Centre, Murdoch, Western Australia. Animal housing 
and transport followed guidelines from National Health 
and Medical Research Council (Australia) . The use of 
animals was approved by the Animal Ethics Committee 
of University of Western Australia (approval number 
03/100/572). 
Cell culture and AO transfection 
Immortalized mdx H2Kb -tsA58 mouse cells CH-2K mdx) 
were propagated and transfected as described previously 
[29] . Primary myoblast cultures were prepared from 
2-4-day-old 4GV pups and the procedure was adapted 
from Rando et al. [30] . Limb muscles from four 
pups were dissected, homogenized, and incubated 
at 3 7 °C for 30 min with dissociating enzyme mix 
containing 2.4 units/m! dispase (I nvitrogen , Victoria, 
Australia), 5 mg/ml collagenase Type II (Invitrogen), and 
2.4 mM CaCh in Dulbecco's modified Eagle's medium 
(Invitrogen) . After centrifugation, the cell pellet was 
added to a 75-cm2 tissue culture flask with 10 ml of 
proliferative media and incubated for 1 h. Non-adherent 
cells were removed and seeded into 75-cm2 tissue 
culture flasks coated with 100 1lg/ml matrigeL When 
nearly confluent, cells were seeded into 24-well plates 
coated with 50 llg/m1 poly n-lysine solution and matrigel, 
and incubated for 48 h before transfection. Duplicate 
wells were transfected with 20MeAO lipoplexes using 
Lipofectin (Invitrogen) at a ratio of 2 : 1 Upofectin to AO. 
Briefly, Lipofectin was mixed with OptiMEM (Invitrogen) 
to a final volume of 200 Jll and incubated for 30 min 
at room temperature. The 20MeAO, which had been 
diluted to 200 III in OptiMEM, was then combined with 
Lipofectin : OptiMEM and the mixture incubated for a 
further 30 min, before addition of OptiMEM to a final 
volume of 1 ml and subsequent addition of 500 IJI aliquots 
to each welL Transfected cells were incubated for 48 h 
before RNA was extracted for analysis. 
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Intramuscular administration 
Oligomers, in physiological saline, were injected into 
tibialis anterior (TA) muscles at doses indicated. Each 
experiment included at least one saline only injection as 
a negative control. The animals were anaesthetized and 
sacrificed by cervical dislocation at indicated time points 
after the injection, and muscles were removed and snap­
frozen in pre-cooled isopentane, before being sectioned 
and prepared for RNA and protein studies. 
RNA extraction, reverse 
transcriptase-polymerase chain 
reaction (RT-PCR) analysis, and DNA 
sequencing 
RNA was harvested from H-2K md."( culturesj 4cv 
cultures and frozen sections tissue blocks using Trizol 
(Invitrogen), according to the manufacturer's protocol. 
One-step RT-PCR was undertaken using 120 ng of total 
RNA as template, in a 12.5 J-ll reaction for 30 cycles 
of amplification. After the reverse transcription step for 
3 0  min at 55 QC, the reaction was heated to 94 QC for 
2 min before the primary thermal cycling rounds of 
94°C for 40 s, 60 °C for 1 min, and 68 QC for 1 min. 
Nested PCR was then carried out on 1 J-ll of the primary 
amplification reaction using AmpliTaQ Gold (Applied 
Biosystems, Foster City, CA, USA) . Cycling conditions 
for the secondary PCR were 94 °C for 6 min to activate 
the polymerase, followed by 20 cycles of 94 QC for 40 s, 
60 °C for 1 min, and 72 QC for 1 min. PCR products 
were separated on 2% agarose gels in TAE buffer and 
the images captured on a CHEMISMART-3000 (Vilber 
Lourmat, Marne-La-Vallee, France) gel documentation 
system. Bands of interest were re-amplified directly from 
the agarose gel [31] and the sequencing templates 
were purified using UltraClean spin columns (Mobio 
Laboratories, Carlsbad, CA, USA) and then sequenced 
on an ABI 377 automated sequencer using BigDye v3 .1 
terminator chemistry (Applied Biosystems) . 
Western blot analysis 
Protein extracts were prepared as weight per volume of 
treatment buffer containing 1 25 mM Tris/HCI, pH 6.8, 
15% sodium dodecyl sulphate, 1 0% glycerol, 0.5 mM 
phenylmethylsulfonyl fluoride, 50 mM dithiothreitol, 
bromphenol blue, and protease inhibitor cocktail (Sigma, 
St Louis, MO, USA) to cell pellet or mouse muscle 
cryostat sections. Samples were then vortexed and 
sonicated briefly, heated at 95 °C for 5 min, before 
electophoretic fractionation on a 4- 10% sodium dodecyl 
sulphate gradient gel at pH B.8 with 4% stacking 
gel, pH 6.8. Densitometry of myosin bands , after 
coomassie blue staining was undertaken to facilitate 
equivalent protein loading. Extracts from AO treated 
cultures or muscle cryosections from treated animals 
Copyright � 2008 John Wiley & Sons, Ltd. 
C. Mltrpant et al. 
(2.75 mg) and control muscle (0.275 mg) were loaded 
onto a second polyacrylamide gel electrophoresis gel 
for western blotting. Proteins were transferred from the 
gel to nitrocellulose membranes (Amersham Biosciences, 
Castle HilI, Australia) overnight at 18 °C, at 290 mA. 
Dystrophin was visualised using NCL-DYS2 monoclonal 
anti·dystrophin antibody (Novocastra, Newcastle-upon­
Tyne, UK) as described previously [21J . Images were 
captured on a Vilber Lourmat CHEMISMART-3000 gel 
documentation system. The percentage of dystrophin 
restoration was calculated according to dystrophin 
expression in control cells after normalization for myosin 
loading. 
Tissue preparation and 
immunofluorescence 
TA muscles were taken from mice and snap-frozen in 
isopentane, pre·cooled in liquid nitrogen. Dystrophin was 
detected in 6 �m unfixed cryostat sections using NCL­
DYS2, an antibody that reacts strongly with C-terminus 
of dystrophin. Immunofluorescence was performed using 
the Zenon Alexa Fluor 488 labelling kit (Invitrogen) 
according to the manufacturer's protocol, except for the 
initial fixation step. The primary antibody was diluted 
at 1 : 1 0  and sections were counterstained with Hoechst 
(Sigma) at the dilution of 1 : 1 0  000 to visualize nuclei. 
Sections were viewed under Olympus IX 70 inverted 
microscope (Olympus, Tokyo, Japan) and images were 
captured on an Olympus DP70 digital camera. 
Results 
Single exon targeting 
A panel of ADs was designed to anneal to obvious 
splicing motifs, including the acceptor and donor splice 
sites, and potential exonic splicing enhancers (ESEs) of 
both exons 52 and 53. Although designed to predict 
human ESEs, the web-based ESE prediction program, 
ESEfinder 3.0 [32,33] , was used to identify putative ESEs 
in mouse dystrophin exons 52 and 53. Figure 1 shows 
the predicted ESEs of exons 52 and 53 and the relative 
annealing positions of the AOs (sequences are provided 
in Table 1) designed to induce exon removal. Six AOs, 
des igned to excise dystrophin exon 52, were evaluated 
initially in H-2Kb-tsAS8 mdx (H-2K mdx) immortalised 
myogenic cells [34] . The use of these immortalized cells 
reduced animal usage and, because the 4GV mutation 
in exon 53 did not alter dystrophin splicing patterns, it 
was assumed that design in one mouse strain should be 
valid for another. Subsequent experiments validated this 
approach. According to ESEfinder, the nonsense mutation 
in dystrophin exon 53 occurs in two predicted ESE motifs 
that are only jus t  above the threshold : an SF2/ASF motif 
(score = 2.1 87/threshold = 1.956) and an SRp40 motif 
(score = 3 .042/threshold = 2.67) . 
J Gene Med 2009; 1 1: 46-56. 
DOl: lO.1002/jgm 
4CV mouse model of muscular dystrophy 49 
(a} 
5_._ 
2 
(I» 
18 
_
_ _ 
1 9  
Figure 1. Diagrammatic presentation of predicted ESEs [32.33Jj (a) mouse exons 52 a n d  (b) exon 53.  Relative annealing coordinates 
of oligomers are indicated 
Table 1. Sequences, annealing coordinates, length and GC content of all AOs targeting exons 52 and 53 
Length Annea ling Exon GC content 
AO (bp) coordinates number Sequences (bp) % 
1 2 5  M52A + 1 7 + 41 52 S/-UCC MU UGG GGG CGU CUC UGU uce A-3' 1 4  56 
2 3 0  M52A - 1 5 + 1 5  52 5'  -Aue U UG CAG UGU UGC CUG AAA GM AAA AAA-3' t o  3 3  
3 30 M52D + 1 5 - 1 5 52 5�  -CAU UM GAG ACU UAC uue GAU CAG UM UGA-3' 1 0 33 
4 3 0  M52A + 22 +  5i 52 5/·MU GAG uue UUC CM UUG GGG GCG UCU (UG-3' 1 5 5 0  
5 3 0  M 52A + 3 2 + 6 1 52 S'-GGG CAG CAG UAA UGA GUU CUU CCA AUU GGG·3' 1 5 50 
6 30 MS2A + 42 + 71 52 SI -UUC AAA UUC UGG GCA GCA GUA AUG AGU ueU-3' 1 2  40 
7 3 1  M53A + 39 +  69 53 5'-CAU UCA ACU GUU Gue UCC UGU UCU GCA GCU G-3' 1 5  48 
8 3 0  M53A - 1 5 +  1 5  53 5'-ueu GM UUC U U U  CM eUG GAA UAA AAA UAA·3' 7 23 
9 3 0  M53D + 1 5 - 1 5  53 5'-AUG CUU GAC ACU AAC CUU GGU UUC UGU GAU-3' 1 2  40 
1 0  30 M53A + 29 + 58 53 5'-UGU cue CUG UUC UGC AGC UGU ueu UGA Ace-3' 1 5  50 
1 1  30 M 53A + 49 + 78 S3 5'·UUA ACA UUU CAU UCA ACU GUU Gue uce UGU-3' 1 0  33 
1 2  30 M S3A + 59 + 88 53 5'-GUU GM uec UUU MC AUU UCA uue MC UGU-3' 9 30 
1 3  3 0  M53A + 69 + 9 8  53 S'·CAG eCA UUG UGU UGA AUC euu UAA CAU UUC-3' 1 1  37 
1 4  3 0  M53A + 1 9 + 48 53 5'-UCU GCA GCU GUU CUU GM CCU CAU CCC ACU-3' 1 5  50 
1 5  30 MS3A - 25 + 5 S3 5'-uue AAC UGG MU AAA MU AAG MU AAA GM-3' 6 20 
1 6  30 M53A + 1 29 +  l SB 53 51-CCA UGA GUC AAG CUU Gec UCU GAC CUG UCC-3' 1 7  57 
1 7  3 0  M53A + 1 51 + 1 80 53 5'-CUA CUG UGU GAG GAC (UU CUU UCC AUG AGU·3' 1 4  47 
1 8 30 M53A + 1 76 +  205 53 5'·UCU GUG AUC uue UUU UGG AUU GCA UCU ACU-3' 1 1  3 7  
1 9  30 M53D + 5 25  53 5'-UUU UAA AGA UAU GCU UGA CAC UAA CCU UGG-3' 1 0  33 
20 2 5  M53A - 25 - 1  53 S'·CUG GM UAA AAA UAA GAA UAA AGA A-3' 5 20 
2 1  25 M53A - 20 + 5 53 5/-uue AAC UGG MU AAA AAU MG AAU A-3' 5 20 
22 25 M53A + 69 + 93 53 S'·AUU GUG UUG MU CCU U UA ACA UUU C-3' 7 28 
23 25 M53A + 74 + 98 53  5'·CAG CCA UUG UGU UGA AUC CUU UAA C-3' 1 0 40 
24 25 M53A + 99 + 1 23 53 5'-CCU GUU CGG CUU CUU CCU UAG CUU C-3' 1 3 5 2  
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Figure 2. Induced single exon skipping in H·2K mdx ceUs; (a) Transcripts resulting after transfection with AD 2 (typical of that 
obtained after transfection with ADs 3, 5 and 6); (b) Transcripts resulting after transfection with AD 4 and AD 1 ;  (c) Transcripts 
resulting after transfection with AD 8 (typical of that obtained after transfection withAOs 9, 1 4, 15. 16 and 19-24); (d) Transcripts 
resulting after transfection with AD 7 (typical of that obtained after transfection with ADs 7 and 10- 1 3); (e) Transcripts resulting 
after transfection with AD 1 7; (t) Transcripts resulting after transfection with cocktail ADs 8, 9 and 13 
None of the AOs targeting the acceptor or donor sites 
of exon 52 consistently induced removal of the target 
(Figure 2a), whereas the AOs annealing between the 
coordinates +17 + 51 efficiently excluded exon 52 from 
the mature dystrophin mRNA (Figure 2b) . Subsequent 
titration studies comparing AOs 1 and 4 indicated that 
the latter compound was more efficient at inducing exon 
52 removal at lower transfection concentrations, although 
there was little exon 52 skipping induced at 25 nM (data 
not shown) . Consequently, AO 4 was selected for further 
studies. 
Excision of exon 53 proved to be a greater challenge, 
and although numerous AOs were designed and evalu­
ated, no single AO tested efficiently excluded exon 53 
from the mouse dystrophin mRNA. Although many AOs 
failed to dislodge exon 53, as shown in Figure 2c, oth­
ers removed exon 53 in addition to both exons 53 and 
54 (Figure 2d) . Two AOs activated a cryptic splice site 
and resulted in partial exon 53 loss (Figure 2e) . Thir­
teen different combinations of non-overlapping AOs were 
then assessed and one AO cocktail was develop.ed to 
consistently induce specific exon 53 skipping (Figure 2f). 
Copyright © 2008 John Wiley &: Sons, Ltd. 
Exon 52 and 53 skipping: 20MeAOs 
As the relative effidencies of excision of the target exons 
differed, it was necessary to evaluate combinations of the 
optimized AOs directed to exons S2 and 53 (Table 2) . 
Four 20MeAOs (4, 8, 9 and 13) were combined at ratios 
indicated (Al. A2, A3, A4 and AS) and used to transfect 
4cv cultured primary myoblasts (Figures 3a to 3 e) .  The 
identity of the transcript missing exons 52 and 53 was 
confirmed by DNA sequencing (Figure 3d) . At 2 days after 
transfection, the A2 and A3 cocktails appeared marginally 
more effective at excising both exons 52 and 53, as shown 
by the absence of the full·length product (Figures 3a 
to 3c); hence, the A2 cocktail was selected for further 
studies. 
Although RT·PCR studies indicated substantial exons 
52 and 53 skipping at days 3 and 5, only a trace 
of shortened transcript could be detected at days 8 
and 9 after treatment (data not shown) . No detectable 
dystrophin protein was observed in treated cultures at any 
time point. RNA and protein were analysed at day 14 after 
two transfections at days 0 and 9, and no exon skipping 
J Gene Med 2009; 11 :  46-56. 
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studies, restoration of dystrophin protein in 20MeAO 
treated cultures was more problematic [35] . AOs 4, 
8, 9 and 1 3  were prepared as PMOs, coupled to the 
cell penetrating peptide P007. These oligomers did not 
induce any exon skipping when applied individually 
(data not shown) . The combination was evaluated in 4cv 
myoblast cultures and, as with the 20Me AOs, different 
ratios of PMOs were assessed. The PMO cocktails B2, 
B3 and B4 induced the transcript missing both target 
exons at concentrations as Iow as 0.5 IlM in vitro. The 
B2 and B3 PMO combinations comparable to the A2 
and A3 20Me combinations appeared to be the most 
effective mixtures, and were selected for further .study 
(Figures 3e to 3g) .  Both the B2 and B3 cocktails were 
able to induce pronounced exon 52 and 53 skipping, 
2 weeks after in vitro transfection at a concentration of 
40 JlM (Figure 3h), consistent with the appearance of 
induced dystrophin, as determined by western blotting 
(Figure 3i) .  Normalization of dystrophin according to 
myosin densitrometry indicates the B2 and B3 cocktails 
induced 1 1 %  and 8% of normal levels of dystrophin, 
respectively (Figure 3i; see also Supporting information, 
Table S2) . 
. 
Evaluation off-target effects 
To confirm specificity of the multi-oligo cocktail on 
dystrophin expression, RT-PCR was undertaken across the 
dystrophin gene transcript using five sets of nested primer 
pairs (see Supporting information) covering exons 13 -70 
region (Figures 4a to 4e) . Figures 4a to 4e rep�esent 
amplified segments of the dystrophin transcript. Although 
sporadic Irevertane transcripts were detected in PMO 
cocktail treated cultures, the numbers of alternatively 
spliced transcripts were not greatly different from those 
in six untreated cultures (Figure 5) . 
In vivo studies 
A single injection of 40 Mg of each of the PMO cocktails, 
at ratios shown in Table 2, was made into the TAs 
C. M ltrpant et 01. 
of 4cv mice. Two weeks after injection, RT-PCR on 
RNA extracted from injected 4cv muscle demonstrated 
exon 52 and 53 skipping in all cocktail-treated samples 
(Figure 6a) with western blotting indicating dystrophin 
expression to be approximately 5-7%, based upon 
normalization of loading (see Supporting information, 
Table S2). Consistent with the RNA studies, dystrophin 
immunofluorescence on sections from the TAs of 4cv 
mice treated with PMO cocktails Cl and C2 also showed 
dystrophin-positive fibres (Figures 7a and 7b) . 
Discussion 
Oligomer design, evaluation of  different chemistries 
and systemic delivery protocols have been extensively 
studied in the mdx mouse model of muscular dystrophy 
[14,18-21,36,37] . The present study describes the 
application of AO-induced dual exon skipping to address 
the primary gene lesion in another mouse model, the 4cv 
mouse, whose nonsense mutation should be by-passed 
with the excision of exons 52 and 53. This model may be 
regarded as of greater relevance to the human condition 
because the targeted exon skipping is induced within the 
major hotspot for dystrophin gene deletions [3 8] . 
Acceptor and donor splice sites were initially considered 
obvious targets for AO-induced exon skipping, and 
consistent exon 23 removal was achieved with the first 
PMO I(�ated untreated 
Figure 5. RT-PCR analysis of dystrophin transcripts in untreated 
and PMO treated 4cv cultures across exons 20-35 indicating 
alternatively spJiced dystrophin transcripts 
(a) E 1 3·26 (b) [37·50  (c) ES8-70 
- -
(d) E20·35 
Figure 4. RT·PCR analysis of dystrophin transcripts in untreated and PMO treated 4cv cultures across (a) exons 13-26, (b) exons 
37-50, (c) exons 58-70, (d) exons 20-35 and (e) exons 48-58 
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4CV mouse model of muscular dystrophy 
Table 2. Composition of AO cocktail: in vitro studies (20MeAO 
and PMO) and In vivo studies (PMO) 
or restored dystrophin protein were observed (data not 
shown). 
Cocktail 
2 0 Me AO 
Al A2 A3 A4 AS A total of lOO llg of the 20MeAO A2 cocktail, was 
complexed with F127 and administered to 4c,v mice 
through intramuscular or intraperitoneal routes. Animals 
were sacrificed 3, 5 and 7 days after injection and RNA 
from the diaphragm and TA muscle was assessed for exon 
skipping. Although sporadic exon S2 and 53 skipping was 
detected in the TA muscle, no substantial dystrophin 
protein restoration could be demonstrated by either 
immunofluorescence or western blot analysis (data not 
shown) . 
1 : 3 1 .66 : 1 3.33 : 1 6 .66 : 1 1 2.33 : 1 
4 1 50 
8 1 50 
9 1 50 
1 3  1 5 0  
Total concentration (mM) 600 
Cocktail 8 1  
P007·PMO 1 :  3 
4 2 . 5  
8 2 5  
9 2.5 
1 3  2 .5  
Total concentration (j.tM) 1 0  
Cocktail Cl  
P007·PMO 1 :  3 
4 1 0  
8 1 0  
9 1 0  
1 3  1 0  
Total amount {j.tg) 40 
375 
75 
75 
75 
600 
B2 
1 .66 : 1 
460 
46 
46 
46 
600 
83 
3.33 : 1 
520 555 
2 6  l S  
2 6  1 5  
2 6  1 5  
600 600 
B4 BS 
6.66 : 1 1 2.33 : 1 
6 .25 
1 .2 5  
1 .25 
1 .2 5  
1 0  
Cl 
1 .66 : 1 
2 5  
5 
5 
5 
7.7 
0.77 
0.77 
0.77 
1 0  
C3 
3 .33 : 1 
3 0  
3 . 3  
3 .3 
3 .3 
8.8 
0.44 
0.44 
0.44 
1 0  
(4 
6.66 : 1 
3 5  
1 .8 
1 .8 
1 .8 
9.25 
0.25 
0.25 
0 ,25  
1 0  
CS 
12.33 : 1 
37 
1 
1 
1 
Induced exon 52 and 53 skipping with 
phosphorodiamidate morpholino 
oligomers 
40 40 40 40 
We had previously found that, although 20MeAOs were 
well suited for AO design and short-tenn in vitro RNA 
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Figure 3. Induced exon skipping in 4cv cells after transfcction with 20MeAO cocktails (a) AI, (b) A2 and (c) A3; (d) DNA sequencing 
chromatogram confirming precise splicing of exons 5 1-54. Transcripts resulting after transfection with (e) B1, (f, h) B2 and (g, h) 
B3 in 4cv cultures; (i) western blot analysis from 4cv cultures treated with B2 and B3 PMO cocktails 
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Figure 6. (a) RNA studies; and (b) western blot analysis of muscle extracts from the 4CV mice injected (IM) with PMO cocktails (Cl 
to C5) 
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(e) (f) (9) 
Figure 7. Dystrophin immunofluorescence o n  muscle cryosections from 4cv mice treated with cocktails Ca) Cll (b) C2, (c) C3, 
(d) C4. (e) cs and (f) saline; (g) untreated C57 
oligomer targeting the donor splice site [14] . However, 
a comprehensive study targeting all human dystrophin 
exons indicated donor splice sites are rarely the optimal 
or preferred targets, and the majority of preferred 
targets appear to be intra-exonic motifs [39] . Indeed, 
it appears that if a pre-mRNA site is not amenable 
to oligomer intervention, the application of a panel of 
oligomers to micro walk across that motif, or altering AO 
length or chemistry) is unlikely to achieve acceptable (or 
detectable) levels of exon exclusion [40]. Similar trends 
were observed for the 4GV mouse dystrophin exons 52 
and 53, where individual oligomers annealing to either 
the donor or acceptor splices sites failed to induce any 
targeted exon skipping. Two overlapping oligomers, AOs 1 
and 4, targeting intra-exonic motifs within exon 52, were 
identified that induced substantial skipping and titration 
Copyright © 2008 John Wiley & Sons, Ltd. 
studies indicated AO 4 was slightly more efficient at lower 
transfection concentrations .  
Mouse dystrophin exon 53 proved to be much more 
challenging to dislodge from the mature mRNA. Eighteen 
oligomers were designed to target acceptor and donor 
splice sites, as well as intra-exonic motifs predicted 
by ESEfinder [32, 33]. A1though this program is based 
upon human sequences, the strong homology between 
mouse and human dystrophin sequences was considered 
sufficient justification to use this program as a starting 
point in AO design. Initial AO design was undertaken 
in an immortalized mdx mouse myogenic cell line, 
while awaiting establishment of the 4cv mice colony. 
The sequences of dystrophin exon 52 were identical in 
both strains, and similar identified splice patterns were 
generated with AO 4 in both cell lines. Similarly, AOs 
J Gene Med 2009; 11: 46-56. 
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that led to exon 53 skipping in the mdx cell line exhibited 
identical patterns in cultured cells from the 4cv mouse. 
Because no aberrant splicing was observed involving exon 
53 in untreated 4cv cultures, it was presumed that the 
mutation did not influence splicing. This is consisten
'
t with 
the mutation occurring in two putative ESEs that were just 
above the threshold for SF2/ ASF and SRp40. Once the 
4cv colony was established) all subsequent experiments 
were undertaken in these cells. 
The majority of compounds targeting exon 53, when 
used individually were either ineffective. activated a 
cryptic splice site (a loss of 78 bases from the end of 
exon 53) or led to the production of dystrophin gene 
transcripts missing exons 53 and 54, in addition to exon 
53 alone (Figures 2d to 20. Interestingly. AO 7, which 
anneals to exactly the same coordinates identified as an 
optimal target to dislodge human dystrophin exon 53, 
induced mouse dystrophin transcripts missing exons 53 
and 54, in addition to exon 53 excision. Several other 
AOs overlapping AO 7 also induced this pattern of exon 
removal, implying that this area may be involved in 
coordinated processing of both exons during pre-mRNA 
splicing) at least in mice. Targeting exon 53 for excision 
from the human dystrophin gene transcript only resulted 
in specific target removal, highlighting some limitations 
in extrapolation of oligomer design between homologous 
genes of different species [39J . The loss of an exon 
flanking that targeted for excision has been reported 
previously. The AO targeting the mdx mouse exon 23 
for removal also induced dystrophin gene transcripts 
missing exons 22 and 23, an out-of-frame transcript that 
cannot lead to dystrophin production (36] .  Similarly, 
transcripts missing exons 53 and 54 are out-of-frame, 
even when exon 52 was omitted and were thus considered 
undesirable. 
Because we had previously observed that some 
combinations of apparently inactive AOs were able to 
induce highly efficient exon skipping [41], various AO 
cocktails targeting exon 53 were evaluated. A combination 
of AOs 8 and 9, targeting the acceptor and donor sites, 
respectively. was able to induce some exon 53 skipping) 
although not at a consistent and satisfactory level. 
Subsequently, AOs 8 and 9 were combined with - other 
AOs (7, 10, 1 1, 12, 13, 14 and 16) to identify a cocktail 
capable of inducing specific exon 53 skipping. When AO 
13 was combined with AOs 8 and 9, efficient and specific 
exon 53 removal could be induced after transfection at 
low total AO concentrations. The mixture of AOs 8 and 
13 generated the same pattern induced by AO 13 alone, 
indicating no advantage, whereas the combination of AOs 
9 and 13 only induced inconsistent exon 53 excision. This 
three-AO combination was necessary for both efficiency 
and specificity of exon skipping. 
Because exon 53 was removed from the mature mRNA 
at a higher efficiency than exon 52, attempts were made 
to balance the ratio of AO 4, targeting exon 52, with 
AOs 8, 9 and 1 3, to maximize induction of in-frame 
transcripts. When equimolar amounts of all four oligomers 
were applied, the full-length transcript was observed, in 
Copyright f) 2008 John Wiley & Sons, Ltd. 
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addition to dystrophin mRNAs missing exon 53 and exons 
52 and 53.  Altering the composition of the cocktails 
with increased proportions of AO 4 resulted in decreased 
amounts of full·length product and a higher proportion 
of in-frame transcripts missing both exons 52 and 53. 
Transcripts missing only exon 52, another out-of-frame 
mRNA were also observed. 
Although a substantial amount of exon 52 and 53 
deleted transcripts were detected at days 3 and 5 after 
transfection with 20MeAOs. no detectable amount of 
dystrophin was observed by western blot analysis (data 
not shown) . Only trace amounts of exon skipping could 
be observed 8-14 days after transfection, and this also 
did not generate sufficient dystrophin detectable by 
western blotting (data not shown). It was assumed that 
this limitation arises from the uptake and turn-over 
of the 20MeAOs in cells. The 2'-O·modified oligomers 
on phosphorothioate backbone increase the oligomers 
resistance to nuclease degradation but, unlike PMOs, 
which are not metabolized, 20MeAOs are gradually 
broken down by nucIeases [42] . This was most apparent 
in a time·course of 20MeAO-induced exon skipping in 
cultured cells, where there was substantial exon skipping 
24 h after transfection but this declined substantially 
over the next 9 days [43J . By contrast, substantial PMO­
induced exon skipping transcript had been detected with 
less intermediate product at 14 days after transfection, 
in vitro [44J . By-passing the dystrophin gene lesion 
and inducing dystrophin detectable by western blotting 
was very inconsistent in canine cultured cells from the 
golden retriever muscular dystrophy model of muscular 
dystrophy and human dystrophic muscle explants [35,44] . 
However, upon the application of PMOs of the same 
sequences, efficient exon skipping could be induced 
and maintained in vitro or ex vivo to anow sufficient 
dystrophin synthesis to be readily detected by western 
blotting at 7 days after transfection [35] . 
The application of any oligomer to a cell has the 
potential to cross react with other sequences and/or 
exert nonspecific effects. The use of AO cocktails would 
potentially increase this risk and, although a detailed 
examination of other gene has not been undertaken, we 
showed that the cocktail only induced targeted changes 
in the dystrophin mRNA. We had noticed in other studies 
that the addition of oligomers appears to marginally 
increase the appearance of alternatively spliced transcripts 
(45] . However, the application of four oligomers did not 
greatly alter the incidence of the alternative transcript in 
treated cells compared to untreated cultures. 
The application of PMOs, coupled to an arginine 
rich cell-penetrating peptide, induced more robust exon 
skipping in vitro and in vivo in 4cv cells than the 
equivalent 20MeAOs. As we had previously shown that 
a hierarchy of exon skipping efficiency induced by 
20MeAOs was also seen when the same sequences were 
evaluated as PMOs [46], the most effective mixtures of 
20Me and PMO AO appeared comparable in the 4cv 
model, although there was a minor shift in the relative 
proportions of exon excised transcripts. The optimal 
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20MeAO cocktails induced removal of approximately 
equivalent amounts of exons 52 and 52 and 53, whereas 
the equivalent PMO combinations generated transcripts 
missing exon 53 as the predominant transcript and exons 
52 and 53. Approximately 10% of restored dystrophin 
protein was induced according to calculation of band 
densitrometry of western blot analysis. 
PMO cocktails, consisting of a total of 40 Jig of the 
oligomers directed to exons 52 and 53 .. were administered 
into the TAs of 4cv mice by a single intramuscular 
injection. Two weeks later, dystrophin was observed 
by dystrophin immunofluorescence after Cl, C2 or C3 
treatment. Calculation of band densitometry from western 
blot analysis demonstrated approximately 5-10% of 
restored dystrophin protein after Cl, C2 or C3 treatment. 
Further studies in this area may provide additional 
information to understand and to refine more efficient 
combinations for AO-induced dual exon skipping. 
In summary, there still appears to be no consistent 
pattern in AO design for targeted exon skipping. Masking 
an obvious splice motif, such as the donor splice site that 
proved so effective in the mdx mouse, was ineffective 
in excising different exons in another mouse model of 
muscular dystrophy. AO cocktails were essential for by­
passing the mutation in the 4cv mouse in terms of 
both specificity and efficient exon removal. Consistent 
with other studies, the PMOs appeared to be superior 
to 20MeAOs, especially in vivD. Long-term systemic 
treatment of the 4cv mouse is now underway to establish 
an appropriate delivery regimen that would be best suited 
for dual exon skipping in a region of the dystrophin gene 
located within the human deletion hotspot. 
Supporting Information 
Supporting information may be found in the online 
version of this article. 
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Rational Desig n of Antisense Oligomers to I nduce 
Dystroph in Exon Skipping 
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and Steve 0 Wi lton1 
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Duchenne muscular dystrophy (DMD), one of the most 
severe neurom uscular disorders of chi ldhood, is  caused 
by the absence of a functional  dystrophin. Antisense 
ol igomer (AO) induced exon skipping is being inves­
tigated to restore functional  dystrophin expression in  
mode ls  of  muscu lar  dystrop hy a n d  DMD patients.  One 
of  the major chal lenges will be  i n  the development of 
c l inica l ly relevant ol igomers and exon ski pping strategies 
to address many d ifferent mutations. Various models, 
includ ing cell-free extracts, cel ls transfected with artifi­
cial  constructs, or mice with a human tra nsgene, have 
been pro posed as tools to facilitate o l igomer desig n.  
Despite strong sequence h omology between the human 
and m o use dystrophin genes, directing a n  ol igom�r to 
the same motifs in both species does not always i nd uce 
comparab le  exo n  skipping.  We report substantial ly dif­
ferent levels of exon skipping induced in norma l a nd 
dystro p h ic h uman myogenic cel l  l ines and propose that 
an ima l  models or a rtif icial  assay systems useful in  i nitial 
studies may be of l i mited relevance in designing the 
most efficient compounds to i n duce targeted skipp ing 
of h u m a n  dystrop h i n  exons for thera peutic outcomes. 
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publication 1 7  March 2009. doio' 1 0. 1  038/mt.2009.4 9 
. 
INTRODUCTION 
Duchenne muscular dystrophy (DMD), one of the most  severe 
neuromuscular disorders of childhood, is caused by the absence 
of a functional dystrophin, I with patients suflering from progres­
sive muscle weakness and severe respiratory and cardiac compli­
cations by the second and third decades of l ife. 23 Becker muscular 
dystrophy also arises from mutations in dystropltill, but these 
lesions are such that some fu nctional protein can be generated, 
albeit of reduced quantity and/or quality. 
Splice intervention using antisense oligomers (AOs) is being 
developed as a pote ntial molecular therapy for DMD. AD inter­
vention d uring dystrophin pre-rnRNA processing aims to exclude 
one or more eXOllS associated with the primary DMD-causing 
mutation, while maintaining or restoring the dystrophin m RNA 
reading frame. A clinical trial of AD-induced exon skipping in 
DMD patients has demonstrated proof of principle that this 
antisense strategy can restore some dyst rophi n expression in 
DMD musde.� 
One of the major challenges to oligomer-induced gene tran­
script manipulation for therapeutic p urposes will be in the design 
and development of cli nically relevant oligomers. Various luodels. 
including cell-free extracts, cells transfected wit h  artificial con­
s tructs. mice with a human transgene, and in silico predictions. 
have been proposed as tools to facilitate oligomer design for spl ice 
manipulation.5--7 TIle highly coordinated nature of gene expression 
leads to reduced efikiency of processing when cell-free extracts are 
used to assay splicing. Within a nucleus, introns are removed a n  
estimated 4 0  times faster than ill vitro processing of synthetic pre­
mRNA transcripts.s Normal gene expression appears precariously 
balanced when one considers m inor base  changes can lead to acti­
vation of cryptic splice sites. pseudoexon inclusion, or some other 
form of aberrant splicing.9•IO Hence, insertion of any test exon v,rUh 
some arbitrarily selected flanking intron ic sequences into a splice 
reporter system may allow some assessment of oligomer-induced 
redirection of splicing patterns in transfected ceUs. However, such 
a system will not direc tly reflect processing of that cxon when it 
is under control of the ful l  complement of tissue specific cis.- and 
tram-splicing motifs and factors. Finally, transcription-coupled 
processing differs from uncoupled processing in that the nascent 
pre-mRNA is a growing strand that is constantly foldi ng into new 
structures and associating with protein-RNA and protein-protein 
complexes within the ltmRNA factory:>1I 
'We consider normal human myogenic cells appropriate for 
AD design and optimization, and reported an ini t ial draft of AOs 
targeting human dystrophi n exons 2 -78. 11 D espite strong homol­
ogy between mouse and human dystrophin. \",e fou nd variation 
in ex on skipping efitciency and p atterns of exon removal in these 
transcripts. For some exons) directin g  oligomers to the same tar­
get motifs induced similar eXOll skipping patterns. In contrast, 
oligomers targeting other exons generated different dystrophin 
splice isoforms in the two species. \Ve report substantially  d if­
ferent levels of exon skipping i nduced i n  normal and dystrophic 
human myogenic cell lines. and propose that ani mal models or 
art ificial assay systems, useful in some studies, may he of limited 
relevance in designing the most effic ient compounds to induce 
targeted skipping o f hurnan dystrophin exom. 
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RES U LTS 
Spl ice s ite and auxil iary motif predictions 
Acceptor and donor spike site scores for exons under investiga­
tion. as calculated by the web-based program, MaxEntScan are 
shown in Table 1, along with details of exon and flanking intran 
lengths. Although there was some variation in the mean donor 
splice site strength of those exons under investigation, there was no 
obvious trend where strong or weak donor splice sites were found 
to be more responsive as targets for splice intervention. Similarly, 
the score for the acceptor splice sites did not offer any i ndication 
as to the suitability of the sites for AO -induced eXOIl skipping. It 
is of interest that the mouse dystrophin exon 23 acceptor splice 
site, predicted to be very ''teak, has previously been shown to be 
unresponsive as a target for exon removal.13 
Exons and limited flanking intronic sequences were analyzed 
for exonic splice enh'lncers (ESEs). using two programs: ESEfinder 
3.0 predicts moti fs responsive to the human SR proteins SF2/ASFj 
SC35. SRp40, or SRp55,H.15 and RESCUE-ESE allows identifica­
tion of putat ive ESEs for human and mouse. 1t\ 17  AO sequences 
designed to excise selected exons, and predicted ESEs. within 
these annea1 ing sites are described in TabJe 2. 1bc distribution of 
splice motifs predicted by RESCUE-ESE, relative AO annealing, 
and induced exon skipping patterns for both human and mouse 
dystrophi n  eXOllS under investigation are shown in Figure .l a-c. 
TIle most effective AOs appear to preferentially target predicted 
SF2/ASF (IgM- BRCA l )  (25%) or SC35 (28%) motifs. compared 
to 22. 17. �md 896 targeting SF2/ASF, SRp40, and SRpSS, respec­
tively. 111cse percentages are calculated from the Humber of ESE 
© The Arncric.1n Society of Gene Tl1el<lpy 
motifs, either completely or partially occurring within the oli­
gomer annealing site, divided by the total number of ESE motifs 
within the target exons . 
AO desig n and evaluation 
A direct comparison of relative AO-induced skipping of the same 
exon in immortal ized mdx mouse and human myogenic cells was 
undertaken to establish, if annealing coordinates for one species 
could be directly appl ied to the other. Immortal ized mdx cells were 
assessed as removal of exon 23 would bypass the nonsense muta­
t ion, and exon 23 ski pped transcripts would no longer be sub­
jecte d to nonsense-mediated decay, unlike the intact. full-length 
transcript. Removal of other exons from the mdx dystrophin gene 
transcript woul d  not remove the premature stop codon, hence 
both full-length and skipped transcripts should be subjected to 
equal rates of n onsense-mediated decay. Exclusion of selected 
exons from the normal d}'strophin gene transcript will, in many 
cases, d isrupt the reading frame and render the induced transcript 
subject to nonsense-mediated decay. In most experiments. dose 
responses of exon skipping with varying oligomer conce ntrat ion 
were used to rank oligomer efficiency for that exon. A comprehen­
sive series of AOs has been developed to excise each exon from 
the human dystrophi n gene transcript.12•1S•1'l Oligomer-induced 
ex on skipping of several mouse dystrophin exons has been exam­
ined in normal and dystroph ic m ice, and is an on -going process 
of reiinement.20)1 
In 3 of 10 exons u nder invest igation, op timal annealing coor­
dinates for i nduction of exon skipping were identical in human 
Table 1 Predicted acceptor and donor spl ice sI te scores showing length of exon and flanking introns 
Exons site MEMa MM' 5 '  site MEM' MM" 
H 1 9  1 6, 1 65 88 10,236 tctttgctct�atgctgcagGCC 9.1 9.24 ATGgtaatt 6,49 5.07 
M 1 9  17,035 8,906 cctttgctctcatgctgcagGCC 9. 1 6  9.07 ATGgtaatt 6.49 5.07 
H2O 1 0,236 242 6, 1 77 aattatttttttctttctagAGG 8.65 1 1 .04 AAGgtaaga 1 0.57 1 0.55 
M20 8,906 4,365 tattllggttttctttgtagAGG 7.82 1 0.5 1 AAGgtaagg 10.5 1 1 0.49 
H 2 1  6, 1 77 1 8 1  1 2,609 ItccatactctatggcacagGAT 4.63 6.1 4  CAAglaagt 1 0.08 9.07 
M 2 1  4,365 1 5.930 tactctgaattatgatgcagGAT 5.18 5.8 CAAgtaagt 1 0.08 9.07 
H 2 2  1 2.609 1 46 3,453 ttttttccctttI gat<'laagTTT 4.79 S,43 CAGgletgt 6.84 6. 1 3  
;\-122 1 5.930 9 1 3  tgttattctctttctttaagTTT 8.9 1 9.05 CAGgtctgt 6.84 6.13 
H23 3,453 2 13 3,798 Ittaaaaaa�1gttttttagGLl 7.97 7.42 CAGgtaatt 8.55 7.72 
j\'123 9 13 2,606 aacttctatttaa ttugagGCr 1.94 0.92 CAGgtaagc 9.88 1 1 . 1 8  
H2'1 3,798 1 14 991  tataacgggtctcgtttcagAAT 8.84 6.45 AGAgtaaga 5.73 5.95 
M24 2,606 1,096 atattgcttttttal tceagAAT 7.56 10 AGAgtaaga 5.73 5.95 
H25 991 1 56 8.606 aaattgatttattt lcUagCTT 4.36 5.32 CAGgtatag 8.73 7.25 
M25 1,096 5,983 actatgcattgtttccalagCTT 7.16 7..16 CAGgtatga 9.46 8.96 
H52 44.2 1 1  l IB 50,044 aggsatattlgttcttacagGCA 6.66 5.58 GAAgtaagt 9.82 8.09 
M52 57.507 43,569 attttttttttttctttcagGCA 1 1 . 7 1  13.43 GAAgtaagt 9.82 8.09 
H53 50,044 2 1 2  2 1 ,230 tatttttccttttattctagTTG 855 l I .0 7  AAGgttagt 8.54 7.2 1 
�[53 43.569 23,325 tattcttattt ttattccag'fTG 7.8 1 1 0.2>1 AAGgttagt 8.54 7.2 1 
H65 1 3,347 202 2,830 attttatttgttllltgcagTGG 8.77 l Ll 4 TACgtacgt 6.81 6. 1 9  
�'f65 2 ,234 8.37 1 0.48 9.27 6.9J 
'MEM and MM are maximum entropy model and first-order Markov model, respectively. 
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Table 2 Nucleotide sequences of ollgomers desig ned and evaluated for exon skipping potential 
hon Coordinates Size SF2/ASF SF2/ASF 5C35 
H 1 6  
. � • � • • • • • • • • . . . .  _ _  • _ _  . _ _ _ _ _ • _ • • • • • • . • • • •  _ _ _  . _ . _ _  • • • • .  � � ��5 -: �::-!?� . . . . . . . . .  � !  . . . . . �: l.�(�� • _ • • • • •  _ . • • • 2:1? . . . .  4:��(3) • •  !:O?_ • • .  
GAU UGC U U U  UUC UUU UCU AGA UCC G 2 5  
Hr.tl9 GCC UGA GCU GAU CUG CUG GCA UCU UGC AGU U HM19A(+35+65) 3 1  2.82{2} 3.34(3) 
H20 CUG GCA GAA UUC GAU CCA CCG GCU GUU C H20A(+44+71) 2 8  4.62(2) 4.18(3) 
������ .l.!�� �l.!9. �.�� _l.!�.��<:!1.� . . . . . .  _ _ _ _  . _ _ _ _  . _ _ _  ����S!��:!��� . . _ .  _ _ _ _ �� _ _  . _ _  !:�� _ _ _ _ _ �·:51S�! 
UUG GCA GAA UUC UGU CCA CCG GCU GUU C M20A(+44+71) 
CGG CAG UAG UUG UCA UCU GU U C M20A( 147+1 68) 
2.40(2) 2.77 
4.09(4) 2.83 
3.63(3) 457(2) 
- . - - - - - - - - - - - - - - - - �  
� - - - - - - - - - - - - � - - - - - - - - - - - - - - - - - - - - - - . - - - - - - - - - - - - - - - - - - - - � - - � � . - - - - - - - - - - - - - - - - - - - - - - - . - �  . .  - - - - - - - - - - - - - - - - - - - - - - - - - - -
�120 GUU CAG UUG UUC UGA AGC UUG UCU G . M20A(+23+47) 25 4.62(2) 4.17(2) 2 .68 3.88{2) 
����.��. ���_��:.: ::l.!9_ ���_��� �l!��_ .  _ _ _ _ _  . . . .  _ _  !�t3��(:!"_1��:!"_1��! _ _ _ _ _ _  . �? _ _ _  . �:�:{�! _ _ _  �:.l�S�� . _ .�.�!�! _ _  4.:��(3) _ _ _ _ _ _ _  . .  
G U U  CAG UUG UUC UGA G G C  U U G  UUU G H20A(+23+47) 
AGU AGU UGU CAU CUG CUC CAA UUG U 
H21  �l!� ::�l!.��� 9.'?:"-:.\::� 5!�� 9.l!�_ � _ _ _ _ _ _ . _ _  . . . . . .  _ _ _ _ ��!�\5 !���}??! . .  _ _  . _ .  _ ��. _ _ _ _  !:��(:L _ _  �:.2�!�! _ _  �.����� _ _  3.:�? _ • . .  �:3� _ _  . .  
Nll l CUG CAU CCA GAA ACA UUG GCC C 3.25 4 .35 
H22 CUG CAA UUC CCC GAG UCU CUG C H22A(+ 1 2S+146) 22 2.23 2.6 1 (2) 4.21 (2) 3.90(2) 2.95 
. - - - - - � + � - - - � - - - - - - - - - - - - � . - - - - - - - - - - - - - - - - - - � � - � - - - - - - - - - - - - - - - - � � �  . .  - . .  - - - - - - - - - - - - - - - - . .  + . � - - - - - - - - - - - - - - - - - - - - - - - - - - -
CUG UAA U U U  CCC G A G  U C U  C U C  C }'f22A{+ 1 2S+ (46) 
. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - � - - - - - - - - - - - - - - - - - - � - � - . - - - - - - - - - - - - - - - - - - . - . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - .  
1\-122 AUG UCC ACA GAC CUG UAA UU M22D(+08- 12) 20 2 .68(2) 2.72 4 .2 1  6.0 1 (2) 3.41 
. - - * . - � - - - - - - - - - - - - - - - - - . .  - . - - - - - - - - - - - - - - + + - - � - - - - - - - - - - - - - - . � . � . - � - - � - - - - - - - - - - - - - - - . .  - �  . .  - - - - - - - - - - - - - . - - � . - -
AUA UUC ACA GAC CUG CAA UU 
H23 CGG CUA AUU UCA GAG GGC GCU U UC UUC GAC H23A(+69+98) 30 2.04 2.32(3) 3.66 
� - - - - - . . � - - - � - - - - - - - - - - - - - - . - . - � - - - - - - - - - - - - - . - - - - - - � - - - - - - - - - . .  - . .  - - - - � - - - - - - - - - - - - - - - . - . - . - - - - - - - - - - - * - - . . - - - - - - - -
UGG CAU AUU UCU GAA GGU GCU UUC U UG GCC M23A( +69+98) 
. - - - - - - - - - - - - � - - - - - - - � - - - - - - - - - - - - . - - - - - - - - - - - - - � - - . - - - . - - - - - - - - - - - - - - - � � - - - - - - - - - - - - - - - - - - - � - - - - - - - - - - - - - - - - - � � - - - - - -
11.'12.3 GGC CAA ACC UCG GCU UAC CUG AAA U M23D(+07- 18) 25 3.66(2) 3.9 4.97 
. - - - - - - - - - - - . � - . . - - - - - - - - - - - - - . « . - - - - - - - - - - - - - . - . - - - - - - - - - - - - - - - - - - - _  . . - - - - - - - - - - - - - - - _  . . . . - - - - - - - - - - - - - - - _  . . .  - - - - - - - - - � �  
AGU AAA UC UUG AAU UAC CUG AAU U 
H24 CAA GGG CAG GCC AUU CCU ceu uc 
CCA GGG CAG GCe AUU CCU CUU ue :M14A(+Sl+73) 
. - - - - - - - - - - - � - - - - - -
- - - - - - - � - . - - - - - - - - -
- - � - + - - - - - - - - - - - - - -
- - - - � - - - - - - - - - - - - - .
- � . - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - ¥ �
- - - - - -
1\124 CAA eUU CAG CCA UCC AUU UCU GUA A M24A{+ 1 6+40) 25 2.34 2,45 3.02 3.63 3.74 
GAG CUG UUD UUU CAG GAU UUC AGC A M24A(+7B+I02) 25 4.31 (2} 
• _ _ _  � _ _ _ _ _ _  • _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ � � _ � _ �  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  M _ _  • _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  � � .  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  . �  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  _ 
CAA CUU CAG CCA UCC AUU UCU UCA G H24A(-t 1 6+40) 
CAG CUG CUU UUU UAG AAU UUC UGA A 
H25 UUG AGU UCU GUC UCA AGU CUC GAA G H25A(+95+1 19)  25 2 .29  3 . 16(2)  3.83 
• _ _ _ _ _ _ _  � _ _ _ _ _ _ _ _ _ _ _ _ _  � �  _ _ _ _ _ _ _ _ _ _ _  � _ � _ _ _ _ _ _ _ _ _ _ _  . _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  � _ _ _ _ _ _ _ _ _ _ _  . _ . _ .  _ _ _ _ _ _ _ _ _ _ _ _ _ _  • . _ .  _ _ _ _ _ _ _ _ _ _  L 
CUA AGU UCU GUC UCC AGU CUG GAU G 2.94 3.02 4.2 1 5.53 
H52 UCC AAC UGG GGA CGC CUC UGU UCC AAA UCC H52A(+1 2+4 1 )  3 0  3.53(2) 2 .74 (4) 4.78(3) 355 3.33(2) 
- - - - - - - - - - � - - - - - - - - - - - - �  
- - - - - - - - - - - - - � - - - - - - - - - - - - - - � - - - - - - - - - - - - - - � . - - - - - - - - - - - - - - - - - � - - - - - - - - - - - - - - �  � - - - - - - - - � � - - .  
UCC AAU UGG GGG CGU CUC UGU UCC AAA UCU M52A(+1 2+4 1 }  
MS2 UCC AAU UGG G G G  CGU cue UGU UCC A M52A( + I 7+-1 1 )  25 2.56 2 .54(2) 3..33(3) 
.l!l!.� ��:\ �_�� _l.l9_� ?�!'. 9�� _'?�� �.l!,?_':9_� _l!�!-: . _ .  _ _  :':1��!'.(;�t.2::.7.1} _ _ _ _ _ _ _ _ _ �� _ _ _  • •  _ .  _ _  • _ _ _ _  �?:.(�� . . . 2:?! ��� . _<t.:�� _ . • .  !:O.2 . . . .  
U C C  AAC UG G G G A  C G C  C U C  U G U  U C C  A H52A(+ L7+4 1 }  
uue A A A  U U U  UGG GCA GCG GUA A U G  A G U  UCU 
H53 CAU UCA ACU GUU GCC UCC GGU UCU GAA GG U G H53A( +39+69) 31  3.08(2) 3.69 3. 1 9 
MS3 
. - - - - - � � � - - - - - - - - - - - - -
� - - � - � - - - - - - - - - � � - - - - -
- - - - - - - - - � - - . - - - - - - - - -
- - - - - - - - - - - - - - - - - - - � - . . � - - - - - - - - - - - - - - -
CAU UCA ACU GUU G UC UCC UGU UCU GCA GCU G 1>.J53A(+39+69) 
.. - . - - - - - - - - - - - - - . - � - - - - - - - - - - - . . .  - - - - - - - - - - - - . .  - - - - - - - - - - - - - � - . .  « - - - - - - - - - - - - - * - - - - - - - - - - - - - - - - - - . . .  - - - - - -
CAG CCA UUG UGU UGA AUC CUU UAA CAU UUC 
UUU UAA AGA UAU GCU U G A  CAC UAA CCU UGG 
U UA AAA AGG UAU CUU UGA UAC UAA CCU UGG 
H1fS3A( +69+98) 
MS3D{+OS-2S) 
H53D(+05-25) 
30 
30 2 52 
2.94(2) 3.46(2) 
4.26 3.89 
CUA CUG UGU GAG GAC CUU CUU UCC AUG AGU MS3A(+ 1 5 1+180) 30 3.86(3) 3.65(3) 4.58(2) 3.64(3) 
3.28(2)  
. * - - - - - - - - - - - - - - - - - - -
- - - - - - - - . � - . - - - - - - - - -
- - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - � � - - - - - -
- - - - - - - - - - � � - - - - - - - - -
- - - - - - - - - - -
UCU GUG AUC UUC UUU UGG AUU GCA UCU ACU 30 3.4 1 3.4 1 4.03 2.91 
H65 GCU CM GAG AUC CAC UGC AAA AAA C H65A(-1 1 + 14) 25 3.29 3.] 5  2.52(2) 3.0 1 
G UU GUG CUG GUC CAA GGC AUC ACA U H65A(+26+S0) 25 3.61 4.35 3 .76 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  � _ _ _ _ _ _ _ _ _ _  . � �  _ _ _ _ _ _ _ _ _ _ _ _ _ _  * _ . M _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  . _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  . _ _ _ _ _ _ _ _ _ _ _ _ _ _  _ 
GCU CM GAG AUC CAC UGC AAA AAA G .M6SA(-1 1 +14) 
��� �l!� �_��. ?��.CA� 9?'�_��.� �c:.�_,=, _ . . . . . . .  _ .  _ _ _  :�1��!,J:.2�.+�_O) • •  _ _ _ _ _ _ _  • • • •  _ .  _ _ _ _ _  • _ _  . _ _ _  • • • •  _ _ _ _  . •  _ _ _ _ • •  _ .  _ _ _ _  • . .  _ _ _  . 
Hl\I65 UCU GCA GGA UAU CCA UGG GCU G GU C 25 2.77 3.20 4 .35 
Dlig omers for the human and mouse dystrophin pre·mRNA are grouped by exon, dotted l ines separate individual antisense oligomers (ADs) (rom AD cocktails. 
Maximum exonic splice enhancer (£SE) binding scores, as predicted by £SE finder, are shown wilh the number 01 ESEs above the threshold occurring within tile AD 
annealing site indicated in brackets. SF2/ASF and SF2/ASF(lgM·BRCA1) predictions are based upon functional SElEX experiments to examine effects of sequence 
context on motif derivatio n .  1 4  
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Figure 1 Comparison of exon skipping induced in h um,m and mOllse myo gen ic (ells. Patterns of dystrophin exon skipping induced by antisense 
ol igomers (AOs) targeting 5 exons [(a) 22; (b) 23; Cc) 24; (d) 20; (e) 53] after transfection into normal human a nd mdx mouse myogenic cel ls .  
Annealing coordinates relative to predicted exonic splice enh ancers are shown/ as are the sizes of full- leng th and Induced transcript products. UT, 
Lipo, or L2K refer to  untreated cel ls, or cells  treated with Upofectin, o r  lipofectamine 2000, respectively. 
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bp 
c Human dystrophin exon 53 
--{),3513.32 8.54/7,21 
CAGGTCTTAG GA�CCAAGCTIGAGTCATGGAAGGAGGGTCCCTATACAGTAGATGCAATCCA.AAAGAA.A.A.TCACAGAAA�ill@iJ 
M5�A(+ 15H180) 
M 53A!+ , 76, 205) 
CAGGTCATAGG,«!IiGprcMfhGCMGCTIGACTCATGGAAAGAAGGTCCTCACACAGTAGAfGCAATCCAAAAGMGATCACAGAAACqgajfj!ffi90 
7.4117.26 8.5417.21 
Mouse dyslrophln axon 53 
Figure 2 Antisen se oligomer (AO)-induced oyptk spiking of mouse dystrophin exon 53 .  (a) Dystrophin transcript products in AO-treated mdx 
culturesj (b) nucleotide sequences at the novel junction arising from activation of the exon 53 ciyptic don o r  splice site identified by DNA sequendng; 
Cc) partial seque nce of human and mouse dystrophin exon 53 showing mouse cryptic donor splice site and AO annealing coordinates. Differences in 
nucleotide sequences are indicated in  bold type. 
and mouse, indicat ing that transfer of AO design between huma n  
and mouse dystrophin exons 19, 2 1 .  and 2 5  was possible (data not 
shown), As shown in Table I )  the calculated acceptor spl ice site 
scores for exon 19 was high (9.07-9.24), while the donor spl ice site 
scores were moderate (5.07-6.49), In contrast, the scores for exon 
21 acceptor (4.63-6. 14) were much weaker than the donor (9,07-
1 0.08), \· ... hereas the acceptor and donor site scores of exon 25 were 
of intermediate values (4.36-7.46 and 7.25 -9.46, respectively) . 
Exons 19, 2 1 ,  and 25 were removed by single AOs, as were 
exons 22 and 23, although in the latter cases there wefe substan ­
tial differences in eXOll skipping efliciency and sp licing patterns 
between the species. For both mOllse exons 22 and 23, the donor 
splice sites were originally identilietl us amenable targets for exon 
excision, hov.,rever. when these coordinates were targeted ill the 
human dystroph in pre-mRNA, there was no detectable exon 
skipping (Figure In,b). Ta rget ing intraexonic motifs in human 
dystrophin exons 22 and 23 induced substantial exon skipping, 
and directing AOs to these coordinates in the mouse dystro­
phin pre-mRNA also resulted in efficient eXOll exci sion. Indeed, 
it would appear that d irecting an ol igomer to the corresponding 
mouse intraexonic motif identified in human dystrophill cxon 22 
was equally effective at excising the target exon, as the oligomer 
annealing to the donor splice site. 'The induced spli cing pallerns 
for exon 23 also differed between h u man and mouse, in that when 
human exon 23 removal was specific ( 1 .216 bp), transcripts miss­
ing exons 22 and 23 ( 1 ,070 bp) 'were readily detected in the treated 
lllOuse cells, in addition to specific exon 23 skipping. This dual 
exon skipping was more pronounced when the mouse exon 23 
donor site was targeted, and it would aJ'pear that direct ing an oli­
gomer to the i n traexonic motif may resul t in more speci fic ' exon 
23 skipping. 
Human exon 24 could be excised with a single AO, 
H24A(+S l +73) ( l ,309 bp), but feverse transcription-PeR 
(RT-PCR) also revealed t he presence of transcripts missing 
exon s 24+25 ( l ,087 bp) . Targeting the equivalent mouse coordi­
nates resulted in lower levels of exon 24 skipping in an apparent 
Molewfal" TIterapy 
nondose-dependant manner. More efficient and specific mouse 
exon 24 skipping was induced using a combinat ion of two AOs. 
The app lication of an AO coc1.'t aH target ing the equivalent coordi­
nates i nduced skipping of hllman exon 24, but transcripts missing 
exon 24 and 25 were still evident (Figure le). 
Two of the la human exons (20 and 65)2l and 4 of the 10 mouse 
exons (20, 24/1 52, and 532{)) were only efficiently dislodged by the 
application of combinations of AOs. '{here was partial overlap in 
AO anneal ing coord inates for the cocktails that exc ised exon 20 
from both the human [H20A(+44+7 I )  and H20A (+ 1 47+ 168)] 
and mouse [(M20A( +23+47) and M20A(+ 1 40+ 1 64)] dystrophin 
gene transc ripts (Table 2).11.11.22 TI1e human and mouse AO cock­
tails appeared equally efficient when llsed in mice, but when the 
optimal mouse coordinates were directed to the human dystro� 
phin pre-mRNA, there was a slight, but reproduc ible decline in 
efficiency of eXOl1 removal, most noticeable at lower transfection 
concentrations (Figure Id). 
A Single AO, H52A(+12+4 I ) , was found to eflkie ntly remove 
human exon 52 from the mature dystroph in transcript, with >30% 
exon skipping being i nduced after transfection at 100 nmo1!1.12 
Directing an oligomer to the corresponding mouse coordinates 
induced substantial exon skipping, but the application of the 
cockta il M52A(+ 17+4 1) and 11.'152 A(+42+7 1 )  resulted in two- to 
threefold more exon exclusion (Supplementary Figure S I ) . 
Directing AOs to human and mouse dystrophin exon s 53 
resulted in the ge neration of the most distinct patterns of exon 
exc ision observed to date. A single AO, H53A (+39+ 69), was able 
to induce efficient and specific exon skipping from the h uman 
dystrophin gene transcript (Figure l e).  Upon targeting the same 
coordinates in the mouse dystrophin pre-mRNA. some transcripts 
missing exon S3 (700 bp) were detected, as well as a substantial 
proportion of transcripts missing both exons 53 and 54 (545 bp). 
The shorter transcript is out-of-irame and was never de tected after 
transfecting human cells with this AO or any of the other 18 AOs, 
designed to excise human exon 53.liJ Specific mouse exon 53 �kip­
ping could be induced using a combination of two mouse-specific 
5 
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Ffgure 3 Compil rison of exon sldppfng induced in norma l and p il t ient myogenk cells. Reverse transcription-peR analysis of two oligomers to 
induce exo n 1 6  skipping i n  normal myogenic cells (a and b); and cells from a Duchenne muscular dystrophy patient with a mutation (lVS 1 6+ 1 G>T; 
c.1 992+ 1 G> T) in dystfophin exon 1 6  (c and d). UT or L2K r€fer to untreated cells, or cells treated with lipofectamine 2000. 
AOs (Figure le). However, when the same annealing coordinates 
were targeted in the human dystrophin gene transcript, only low 
levels of exon 53 skippi ng were detected (Figure le). 
Two additional ADs, [M53A( + 151 + 1 80) and �vIS3A( + 176+ 
205)] ,  with overlapping annealing sites, were found to induce 
cryptic spl icing in mouse exon 53, which led to the loss of 78 
bases of coding sequence from 3' end of the exon (Figure 2a). The 
activated mOllse cryptic donor splice site was identified hy DNA 
sequendng (Figure 2b), and calculated to have a spl ice site score 
of 7.4117.26 (Figure 2e). Directing oligomers to this region <:f the 
human gene transcript resulted in low levels of inconsistent exon 
53 skipping, with no evi dence of cryptic splice site activation (data 
not shown). 
Human dysLrophin exon 6S could only he efficiently removed 
using a co mbination of two AOs,21 whereas AOs, 1\'165A( - 1 1  + 14) 
and 1165A( +26+S0}, anneal i ng to the same coordinates as the 
human cocktail components were able to  induce robust exon skip­
ping from the mouse dystrophin prc-m RNA, after transfection 
at concentrations of 300 nmo llt but efficiency decli ned at lower 
concentrations (Supplementary Figure 82). Another oligomer 
targeting mouse exon 65. M65A(+63+87) (shown in Table 2), 
was found to induce more robust exon skipping (Supplementary 
Figure 52). However, direct in g  an ol igome r to the co rresponding 
coordinates in the human dys trophin pre-mRNA did not induce 
skipping of the target eXOll, when appli ed individuallyY 
Induced exon 1 6  skipping in normal and dystrophk 
human myogenic celJs 
Two AOs, H16A(- 1 2+ 19)12,� and H 1 6A(+1 l +35),23 previously 
designed to excise exon J 6 from the mature human dystr�phin 
mRNA. cDllld be readily distinguished in their ability to exci se the 
target exon (Figure 3a�b). H 1 6A(- I 2+ 1 9) ,  targeting the exon 16 
acceptor site could induce pronounced exon excision at a concen­
tration of 1 0 nmoVl, 'while H 1 6A(+ 1 l+35) induced weaker exon 
1 6  skipping after transfect ion at 25 mno1l1 in n orm al human myo­
genic cells, However, when these compound s  were transfected 
into myogenic cells from a DMD patient with a G> T substitution 
of the first base of intron 16 (IVS 1 6+ 1 G>T; c. 1 992+1G>'1'), both 
ADs in duced robust exon skippi ng and could not be readily dis­
criminated (Figure 3c)d), RT-PCR on RNA extracted from the 
6 
untreated DMD cells did not yield a consistent pattern. with spo­
radic  generation of shorter than normal transcripts m issing exons 
13-15, 14-16. 1 4+ 1 6  (exon 1 5  present), and 16, and less abu n­
dant. near-normal, or larger than expected products. Some of the 
products of abnormal size were identified by DNA sequenc ing as 
having arisen from displacernent of the exon 16 donor splice site 
by one base upstream, or pseudocxon inclusion of 89 bases froOl 
intron 1 6  (dat a not shown) ,  
DISCUSS ION 
Pre-m RNA splicing. the process of join ing exons and removing 
intervening sequences, is tigh tly controlled by complex interac­
tions between eis-el ements and > 1 50 tmns-factors21-27 involved 
in recognition of exon boundaries and subsequent incorporation 
into the mature transcript. Four classical eis-elements; the 5' and 3' 
spIke site, the polypyrimidille tract. and branch point are primary 
binding sites for snRNPs and other pro teins involved in defining 
exonli ntron boundaries. In addit ion to the obvious splice motifs, 
exon recognition and splicing also depe nds up on the nature, posi­
t ion. and combination of auxiliary splice motifs that modulate 
Signals determining exon incorporation. presumably by recru it­
ing tram-factors that regulate exon selection.l,�.29 
TIle high degree of conservation at the ends of the intron� 
would suggest that t he acceptor and donor splice sites are 
obvious and preferable targets for AO -induced eXOll skipping. 
As an dystrophin exons are constitutively expressed in the pre­
dom inant 427 kd skeletal muscle isofonn, splice site scores are 
somewhat redundant, but may provide an i ndication of amenable 
targets to redirect pre-mRNA spli ci ng, However, considering 
the 10 exons exam ined in this report. there was no obvious 
correlation between predicted splice site score a nd opt im al AO 
target. Donor spl i ce sites seemed to be the least preferred human 
targets, although these motifs were amenable targets in skipping 
3 of the 10 mouse exollS. 
AO-induced exon skipping requires approprintel)' designed 
AOs to specifically mask motifs involved in the exon recogni­
tion and splicing process, by either rendering the single-stranded 
motifs double-stranded or altering the secondary struc tures essen­
tial for normal exon recognition and processing. Robust and con­
s istent exon skipping is essential if oligomers are to be clin ically 
\\·wlV.molec"lartllerapy.org 
appl icable. If it is necessary to use large amounts of an oligomer 
to excise a target exon , this may be difticult to achieve in a clin ical 
setting, andlor lead to nonantisense effects. Although 1 2  oligom­
ers ma}' be capable of restoring the dystroph in reading frame in 
DMD tndividuals with exon deletions in the mutation hotspots ,3I.l 
it wilt be essential to extend this therapy lo mallY difi'eren l  ame­
nable mutations across the gene transcript. 
Subtle DNA changes in dystrophill (microinsertion/deletioJ1, 
nonsense, splice site mutations) represent an estimated 30% of 
DMD cases. These mutations cannot be ignored based only upon 
incidence, especi al ly because th e gene is largely intact and in most 
of these cases splice intenrention would result in a dystrophill iso­
form of near-normal function. Furthermore, protein -truncati ng 
mutat ions in the exons encoding the rod domain could be. con� 
sidered most amenable to exon skipping. Ihe majority of exons 
in th is region are in�fra me and h e nce removal of a nonsense 
mutationlm kroinsertion/deletioll would only require excision of 
a single exon. In-frame delet ions within this region are not com­
monly reported, possibly because many of these cases are not rec­
ognized due to a lnHd phenotype.31 Indeed, it has been reported 
that an individual missing exon 16 had no c1inica1 symptoms and 
normal serum creatine kinase levels, a sensitive marker of muscle 
da mage.·n 
'The 45 AOs evaluated for both human and mouse dystrophin 
pre-mRNA annealed to a total of 1 74 predicted ESEs. SF2/ASF 
(IgM-BRCA) and SC35 were found to be more common targets 
for the optimized A 0-induced skipping of these dystrophin eXOllS, 
consistent with other reports.l1•3J The high proportion of AOs 
capable of redirecting splicing supports the concept that  many 
pre-mRNA motifs are involved in exon definition and spIk ing 
(for review see refs. 1 1 ,34,35). It is possible that the importance 
of some motifs in pre-mRNA processing is rcnected by the lev­
els of induced shortened transcripts. It shoul d also be noted that 
no single m otif is a universal optimal target. Monse exons 22 and 
23 were efficiently excised by targeting two distinct domains, the 
donor sp lice sites and intraexonic motifs, which were identified 
during a study of the human gene transcript . Although the human 
dystrophin gene transcript only responded to AOs directed at  
intraexonic targets for t hese exons, i t  is  importa nt that, i n  the 
event of sequence-specific effects with one compound, another 
ol igomer may be available. In addition, if poiymorphisms or dis­
ease-causing mutations compromise annealing of one oligomer, i t  
will be  necessary to have identified an alte rnative compound. 
Although some AO coordinates appeared to be equa lly amena­
ble in th e two species, there were diflerences, some subtle and others 
more pronounced, that might raise quest ions regarding the accuracy 
and validity of AO design in nonhomologous or artificial systems. 
Directing an AO at coordinates fou nd to efficiently excise exon 53 
from the human dystrophin mRNA induced dystroph in gene tran­
scripts missing exons 53 and 53 + 54 when applied to mouse cells. 
'nIere are several cases where a single AO can excise two exons at 
a time, presumably reflecting closely coordinated processing� 3-0,36.37 
Targeting human exon 53 resulted in only the loss of that exon from 
the mature dystrophin transcript, but interestingly, directing an AO 
to human dystrophin exon 54 led to removal of both exons 54 + 
55. 12 An AO designed to exci�e mouse eXOll 54 resulted in specific 
removal of that targeted cxon (c. Mitrpant, S. Fletcher, and S.D. 
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vViltol1, unpubl ished results), A lthough similarities in human and 
mouse dystrophin splice motif usage were predicted to be as h igh as 
90% in constitutive splicing,�-j(J differences in genetic background 
and splice motif usage must be considered ".'hen extrapolating 
transcript manipu1ation from one model to another. 
During initial optimization studies to induce mOllse exon 53 
skipping, two overlapping AOs were found to activa te a cryptic 
donor spl ice site in that exon, which led to the loss of 78 bases of 
coding sequence. The activated mouse exon 53 cryptic splice site 
was calculated to h ave a splice site score similar to the Wild- type 
donor site. When targeting the same coordinates in the human 
dystrophin transcript, activation of cryptic spl ic ing was n ever 
detected. A (fT> (mouse) and "C, (human) difference allowed acti­
vation of a cryptic donor splice site on ly in the mouse transcript, 
thereby demonstrating that species-specific variation, even when 
not directly affec ting AO an nealing, can have i ndirect and unex­
pected consequences on gene express ion. 
"Ve consider it important to in itially optimize AO design in 
myogenic cells expressing a normal dystrophin  gene transcript, 
even though protein stud ies arc not possible . Induced exon 
removal from the i ntact dystrophin mRNA would ensure that the 
intervent ion was possible in the presence of aB normal transcrip­
tion and sp l icing eis-elements and spl icing mach inery. thus setting 
a high standard in AO design . Exonic deletions that d isrupt the 
reading frame and lead to DMD would compromise pre-mRNA 
processing to some extent, because of the loss of spli ce motifs in 
the deleted region. A deletion of exon 50 a nd flanking intronic 
sequences will bring together exons 49 and 51 that should not be 
in direct com munication in the context of normal dystrophin tran­
script processing. Furthermore, a normal dystrophin gene tran­
script would not be subjected to nonsense-med iate d decay> unlike 
induced transcripts in which exon removal causes a framcshift.-l-I 
We previously reported optimization of AOs to excise eXOl1 1 6  
from the hu man gene transcriptY The addition o f  five nudeotides 
to the A () was found to increase efficiency of target exon skipping 
by .... 40-fold, more than justifying a 20% increase in the length of 
t h e  ol igomer. The exon 16 donor splice site mutation did not lead 
to a single aberrant gene transcr ipt, but a mixture of products, 
including shorter in-frame transcripts that should have m itigated 
severity of the disease. Since the diagnOSis of Dl'v{D had been 
confirmed clinically. i t  is most likely that the in-frame products 
represent very low abundance mRNAs that had escaped N.ivlD 
and were, hence, detected by RT-PC R. A nonsense m utatjon in 
t he muscle glycogen phosphorylase gene \"\'as repor ted to result 
in seven different gene transcripts generated by altered splicingY 
vVhHe it appears that the exon 1 6  dystrophin donor spl ice site 
mutat ion genera ted multiple disease-associated tnUlscripts, the 
AO that excised exon 1 6  res tored apparently normal levels of a 
single in-fram e  transcript . 
The evidence that single base variat ion between mouse:human 
or h uman:human dystrophins can influence splice manipulation 
must cast some doubts on assays that do not assess dystrophin splic­
ing in the appropriate environment. It is unreasonable  to assume 
that in vitro gene expression in a monolayer of cultured myogenic 
cells will exactl}' reflect ill vil'o gene expression, especia lly consid­
ering liber-type differences, muscle archilecture, innervation, and 
degree of pathology in dystrophic muscle. However, d ystroph in 
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processing in cultured myogenic cells is likely to be more relevant 
than an artificial system. examining t ransgene expression in a cell 
line transfected with a plasm id construct containing on ly a portion 
of dystrophirl taken out of context. Goren et al.4I:! demonstrated that 
the same auxiliary splice motif could direct either exon inclusion 
or exclusion from different mini genes, depending on the location 
of splice motirs in the construct. When sequences flanking splice 
regulatory moti fs are manipulated, splicing is modified. In such 
an art ificial system, irrelevant i ntron size and sequences must be a 
major concern for AO design and optimization. 
In summary, the design and evaluation of AOs to induce 
human dystrophin exon skipping sh ould be undertaken i n  
human myogenic cultures. whereas a study of exon excision from 
the mouse dystrophi n  gene transcript should be undertaken in 
murine cells. Despite st rong h omology between the human and 
m ouse (an d  canine) dystrophiu, there are many differences and 
some, as described in this report, influence RNA processing. 
\.vhen developing exon skipping strategies for non deletion DMD 
pat ie nts , AOs designed according to the normal dystrophin lllay 
not he ideal. The disease-causing base change, loss, or insertio n 
may occur at the AO a nnealing site and compromi se i ts  ability 
to excise that exon. Although it is possible that the change 
may alter a splice motif and enhance exon recognit ion and 
strengthen splicing, it is more probable that most changes in a 
gene ,votIld ,,,'eaken exon recognition and sp1idng . Regardless of 
the predicted consequences of a change in dystrophin splicing, 
t esting should be u ndertaken in myogen ic cells, t hen dystroph ic 
cells carrying the mutation under examination, and ultimately 
the pat ien t . 
MATER IALS AND M ETHO D S  
Splice site scoring and prediction o f  £SE! motifs. Acceptor and donor 
splice site scores for all exons und er analysis were determined using h ...  o 
difierent algorithms; the ma,(jmum entropy model and the first-order 
1\Jarkov model. Both a lgorithms were computed on the web-based pro­
gram, MaxEntScan (http://genes.mit.edu/burgelab/maxent/Xma.xent. 
html), which allows the calculation of strength of bo th acceptor and 
donor splice site scores. MaxEntScan requires 20 bases upstream of the 
3' splice site and the first three bases after the acceptor lo perform 3' 
spl ice sile scoring. 1hree bases upstream and six bases downstream of the 
donor splice site were included to eva luate 5' splice site scoring.4! Exonic 
sequence with 25 bases of flanking intron from 10 human and mouse 
exons were analyzed to identify putative ESEs, using ESEsfindcr3.014•ls 
for human exons, and human and mouse ESE motifs were predicted by 
RESCUE-ESE.'�,17 
AO synthesl5J design and nomenclature, 2' -O-methyl-modified AOs on 
a phosphorothioate backbone were designed to anneal to motifs predicted 
to be involved in pre-mRNA splicing, and synthesized in-house on and 
Expedite 8909 Nucleic Add Synthesizer (Applied Biosystems, Foster City. 
CA), using the 1 flmol thioate synthesis protocol. Nomenclature w,u based 
on that described by Mann et nU' where tht' first letter designates the spe­
cies (H: human. M: mouse), the number refers to the ex-on, the second 
letter indicates Acceptor or Donor Splice s ite and the U_" and "+" specifies 
intron or exon bases. respectiye\y, 
Myoblast wlture and transfectlon. Normal and dystrophic human myo­
genic cells were preparl?d hy a modification of the protocol describe!l by 
Rando and Blall . .n Myogenic cells were transfected with AOs at concen­
trations of 25-600 nmol/I. Lipofectmnine 2000 (Invitrogen, Melbourne, 
Australia) and Lipofectin (Invitrogen) were employed as transfection 
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reagents for human myogenic cells and H-2K mdx ceUs, respectively. as 
described previouslyP 
RNA extraction and RT-PCR analYSiS, RNA was harvested from the cell 
cultures 24 hours after transfection, u sing Trizol (Invitrogen). according 
to th e manufacturer's protocoL One-step RT-PCR was undertaken, l.1sing 
l OOng of total RNA as temp late in a 12,5 �l reaction for 30 cycles, using 1 U 
of Superscript III (Invitrogen). Nested PCR was carried out for 30 C)'eles, 
u sing AmpIiTaQ Gold (Applied Biosystems, iVlelbourne, Austral ia). PCR 
cycling conditions were performed. as described by McClorey et ol.16 PCR 
products were separated on 2% agarose gels in Tris-acelate-EDTA bulfer 
and the were captured 011 a CH EM fSMART-3000 gel documenta­
tion system (VHber lourmat. Marne-Ia-Vallee. France), 
S UP PLEM E NTARY MATE R IAL 
Figure Sl. Ca) Exon 52 skipping induced by M52A(+ 1 2+41) and a n  
AO cockta i l  of M52A(+ 1 7+41 ) &: M S 2A(+4 2+71 ) a t  different concen­
trations in H-2K mdx myoblasts; and (b) the eHiciency of exon ski pping 
as determined by densitrometrk ana lysis of RT- PCR .  
Figu re S2. Exon 6 5  s kip ping induced by M65A(+63+87) a n d  a n  AO 
cocktail of M65A(-1 1 + 1 4) &. M6SA(+26+50) at d ifferent concentra­
tions in H·2K mdx myoblasts. 
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